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Abstract 
 
This thesis describes the synthesis of a unique library of novel analogues as potent 
and selective DYRK1A inhibitors based on the lead 7-azaindole scaffold. 
 
DYRK1A is a dual-specificity protein kinase that catalyses not only 
autophosphorylation on its tyrosine residue but the phosphorylation of serine and 
threonine residues in its substrates. DYRK1A has been shown to be important for 
phosphorylation of tau protein and has also been identified as a Down syndrome 
candidate gene.  Overexpression of DYRK1A results in cognitive deficits and 
impairments in memory, and has been proposed as a significant contributor to the 
underlying neurodevelopmental abnormalities associated with Down syndrome and 
Alzheimer’s disease. DYRK1A overexpression has also been found in cancer cells, 
particularly in glioblastoma, which represents 15% of brain tumours. The increased 
phosphorylation of sprouty2 mediated by DYRK1A blocks the EGFR degradation as 
a result of overexpression of EGFR in the cell surface, and the enhanced EGFR 
signalling eventually leads to tumour survival. On the contrary, DYRK1A inhibition 
has been found to promote EGFR degradation in glioblastoma cells by triggering the 
endocytosis and lysosomal degradation, thus reducing the self-renewal ability of 
tumourigenic cells. Development of small molecule inhibitors of DYRK1A therefore 
provides attractive treatment strategies. 
 
Despite decades of investigation, the majority of promising DYRK1A inhibitors have 
not successfully entered clinical trials due to unexpected side effects and 
pharmacokinetic issues. A recently discovered lead compound, DANDY represents 
one chemotype of the most potent DYRK1A inhibitors. The work in this thesis 
explores the importance of the 7-azaindole skeleton to DYRK1A inhibition through 
the systematic modification to structural features of DANDY. The sequential 
selectivity of promising inhibitors over other off-targets such as DYRK1B, DYRK2 
and CLK1, as well as the functional activity against glioblastoma cells has also been 
explored.  
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Preliminary kinase inhibition assays together with cell viability assays have shown 
promising trends towards the correlation between DYRK1A inhibition activities and 
cellular efficacies in vitro. In this thesis, several promising compounds have shown 
inhibition for DYRK1A with IC50 values being < 50 nM. These compounds have also 
played effective roles for the in vitro treatment of glioblastoma cell viability assays. 
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Chapter 1 - Introduction 
1.1 CNS diseases and DYRK1A 
1.1.1 Down syndrome and DYRK1A 
 
In 1866, John Langdon Down1 first described patients with facial anomalies and 
mental retardation leading to what is now known as Down syndrome (DS). DS was 
later recognised by Lejeune et al2 as a chromosomal disorder resulting from partial or 
complete trisomy of human chromosome 21, thus DS is the most prevalent 
intellectual disability arising from a genetic disorder.3 Statistical studies4-5 showed 
that DS occurs in approximately 0.1% of populations in European countries and the 
United States. Patients with DS generally exhibit language and learning weakness,6-7 
abnormal motor skills,8-10 and short-term and long-term memory deficits.11-13 With 
aging, many patients with DS are prone to developing the symptoms of Alzheimer’s 
disease (AD), like dementia.14-15 
 
Evidence16-17 has shown that cognitive impairments and developmental deficits 
observed in patients with DS resulted from various pathophysiological changes in the 
brain. These include changes in brain sizes, reduced neuron numbers,18-19 reduced 
cerebellar volumes,20 increased spines on dentrites with augmented spine density21 
and grey matter density abnormalities.22 Since DS has been shown23 to be attributed to 
the overexpression of a large number of trisomic genes, among which, dual-
specificity tyrosine phosphorylation-related kinase 1A (DYRK1A) is located within 
the Down syndrome critical region (DSCR) of chromosome 21.24-25 It has also been 
found to be overexpressed in DS patients.26 Previous studies showed that DYRK1A as 
the dosage sensitive gene on DSCR is responsible for many features of DS including 
mental retardation and neurodegradation.27 Overexpression of DYRK1A leads to the 
hyperphosphorylation of microtubule-associated tau protein, which further 
destabilises microtubules, resulting in the release of soluble tau protein. Tau protein 
eventually forms neurofibrillary tangles (NFTs) by a series of polymerisation and 
assembly of paired helical filaments (PHFs), which eventually results in 
neurodegradation  (Figure 1). Alternatively, the increased phosphorylation of ASF 
(alternative splicing factor) by DYRK1A alters the balance between 3R-tau and 4R-
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tau distribution, eventually causing neural death, neurodegradation and mental 
retardation.28-32   
 
 
 
Figure 1. The proposed contribution of DYRK1A to the mechanism of the formation 
of Neurofibrillary tangles (NFTs) in AD.33 
 
1.1.2 Alzheimer’s disease and DYRK1A 
 
AD is the main cause of dementia.34 An estimated 40 million people worldwide have 
dementia, most of whom are aged over 60.35 Generally, AD was thought to result 
from the aggregates of abnormal beta-Amyloid (Aβ) peptide and NFTs caused by tau 
protein hyperphosphorylation.36-37 Early studies showed that increased 
phosphorylation of tau by DYRK1A reduced the stabilisation of microtubules, 
resulting in the release of soluble tau. Subsequent tau dimerisation and polymerisation 
led to the aggregation of NFTs, which is one of the hallmarks of AD (Figure 1). More 
recent studies have also indicated that NFTs and Aβ are linked by a key kinase—
DYRK1A.38 For example, Aβ loading was proven to induce an increased protein 
Tau hyperphosphorylation 
by DYRK1A 
Soluble Tau 
Tau dimerisation 
Tau polymerisation 
Tau dimer Tau oligomers Tau protomers 
Tau aggregation 
Paired helical filaments 
 (PHFs) 
PHFs assembly 
Neurofibrillary tangles 
 (NFTs) 
Microtubule destabilisation 
Tau associated microtubule 
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DYRK1A level in neuroblastoma cells, which resulted in tau aggregation.39 In the 
other pathway, the Aβ precursor protein (APP) gene is also located within human 
chromosome 21, overexpression of which has caused the increase of Aβ aggregates.40 
Mechanistic study indicated that overexpression of APP itself failed to show AD-like 
pathology.41 Only the phosphorylation of APP by DYRK1A at Thr668 residue in vitro 
and mammalian cells could significantly increase Aβ production in DS and early-
onset of AD.42 These results have provided evidence that DYRK1A is a genetic factor 
for AD.39,43 Additionally, emerging evidence has indicated that DYRK1A exists in 
much lower plasma concentrations in patients with AD than that in non-AD patients, 
hinting at its potential as an efficient biomarker for the diagnosis of AD and the 
development of future therapeutics.44  
 
1.1.3 Other CNS diseases and DYRK1A 
 
Other CNS diseases have been also reported to be associated with the level of 
DYRK1A expression, such as Parkinson’s Disease (PD).45 PD is a movement disorder 
or motor syndrome.46-47 The presence of Lewy bodies (intracellular protein 
aggregates) is one of the hallmarks of PD.48-49 α-Synuclein is the main component of 
Lewy bodies, and evidence shows that DYRK1A could be potentially correlated with 
PD by phosphorylating α-synuclein in vitro at Ser87 residue.45 The regulation of 
cytoplasmic α-synuclein inclusion or formation can potentially result in cell 
apoptosis.45 DYRK1A was also found to directly phosphorylate the causative protein 
parkin for PD at Ser131, resulting in the loss of its neuroprotective functions.50 
 
Huntington’s disease (HD) is a fatal genetic brain disorder characterised by 
uncontrolled motor function, general motor impairments and dementia.51-52 A 
correlation between DYRK1A binding and direct phosphorylation of huntingtin 
interacting protein-1 (Hip-1) has been demonstrated in HD. Phosphorylated Hip-1 
mediates neuronal differentiation and blockade of cell death in embryonic 
hippocampal neuroprogenitor (H19-7) cells.53 
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DYRK1A has also been implicated with many other diseases, such as Pick disease,54 
diabetes,55 HIV-1 disease,56 and Autism spectrum disorder (ASD).57 Therefore, the 
normalisation of DYRK1A activity appears to be crucial to improve abnormal 
phenotypes observed in patients. 
1.2 DYRK1A and its family members 
 
DYRKs belong to the CMGC group (named after the initials of some kinase 
members), which includes other kinases, such as CDKs (cyclin dependent kinases), 
CDKLs (CDK-like kinases), CK2 (casein kinase 2), CLKs (CDC-like kinases), GSKs 
(glycogen synthase kinases) and MAPKs (mitogen-activated protein kinases).58 
Among them, CDKs, CKs and MAPK families have been well investigated in terms 
of their functions in transcription, DNA damage repair, protein degradation and 
neuronalgenesis.59-64 In contrast, the functional roles of DYRKs and CLKs in the 
signalling pathways of human tissues are currently less clear.65-70 DYRKs consist of 5 
isoforms including DYRK1A, DYRK1B, DYRK2, DYRK3 and DYRK4,71 which are 
subdivided into two classes based on their subcellular localisation. DYRK1A/B 
belong to class 1, while DYRK2, DYRK3 and DYRK4 are categorised as class 2,72 
and they all possess a kinase domain shown in Figure 2. The CLKs contain CLK1, 
CLK2, CLK3 and CLK4 in human cells, and all of these members have been found to 
phosphorylate alternative splicing factors and consequently regulate splicing.73-75 
Specifically, more details about DYRKs and CLK1 will be reviewed and studied in 
this thesis. 
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Figure 2. Domain structure of DYRKs family members.54 NLS: nuclear localisation 
signal; KINASE: kinase domain; PEST: (Pro, Glu, Ser, Thr)-rich domain; His: 13-
consecutive-histidine repeat; S/T: (Ser, Thr)-rich region. 
 
 
As for substrate specificities, DYRKs were originally believed to be proline-directed 
within a consensus phosphorylation sequence PX(S/T)P, where X is a variable amino 
acid and S/T (serine/threonine) represents the site of phosphorylation (called P-site) 
with proline at both P+1 (the first position after P-site in the sequences) and P-1 (the 
last position before P-site in the sequences) sites.76 However, more recent studies have 
suggested that DYRKs also require an arginine N-terminal to the target site for more 
efficient phosphorylation.77 Therefore, the most preferred consensus sequence for 
DYRK1A has been reported to be RPX(S/T)P, although proline at P+1 position can 
be replaced by valine or alanine as well. DYRK1A has preference to recognise serine 
over threonine,78 and phosphorylation on tyrosine was not detectable in exogenous 
substrates.79 In other studies, however, substrates with no proline at P+1 position or 
arginine at P-2 could be also recognised by DYRK1A. α-Synuclein, mentioned above 
(Section 1.1.3), does not contain the specificity determinants, but can be 
phosphorylated by DYRK1A at the Ser87 residue.45 Similarly, DYRK1B only 
phosphorylates at serine/threonine residues but not at tyrosine in exogenous 
substrates. However, the substrate sites of DYRK1B were not found to correspond 
very closely with the phosphorylation preferences for DYRK1A as described 
previously. The sequence for DYRK2 and DYRK3 has been subsequently reported as 
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RXX(S/T)P.79 Generally, an efficient substrate for phosphorylation is realised through 
a binding cavity utilisation of protein kinases to specifically recognise complementary 
charged and/or hydrophobic residues in the substrates.80 However, CLKs lack such 
docking grooves in their kinase domains. Rather, the N-terminus attached to CLKl has 
been suggested to induce its oligomerisation and thus facilitate its specificity and 
binding affinity with the RS (arginine-serine-rich) domains of SR proteins (splicing 
factor containing a C-terminal RS domain).80 This kinase-substrate combined 
recognition has been employed to favour highly productive interaction with each 
other and then facilitate phosphorylation preferences. 
 
1.2.1 DYRK1A 
 
The DYRK1A gene is the only DYRK member located on 21q22.2 of human 
chromosome 21,81 which encodes more than 300 annotated genes, one third of which 
are overexpressed in DS.27 DYRK1A is a nuclear protein,72 which contains nuclear 
localisation signal (NLS) capable of targeting the proteins to the nucleus (Figure 2). 
However, increased DYRK1A immunoreactivity has also been found in the 
cytoplasm, which could phosphorylate cytoplasmic protein eIF2B at Ser539 residue in 
its ε-subunit.32 DYRK1A also catalyses the phosphorylation of CDKL5 at Ser308 
resulting in a site-directed location for subcellular distribution, which facilitates a 
cytoplasmic location rather than a nuclear location.82 Furthermore, the kinase domain 
of DYRK1A incorporates a catalytic domain with its autophosphorylation at the 
Tyr321 residue, and DYRK1A does not share significant homology sequences with 
other DYRK2−4 family members outside the kinase domain. DYRK1A also contains 
a PEST (Pro, Glu, Ser, Thr)-rich domain which is responsible for protein degradation, 
a repeat of 13 histidine and subsequent serine/threonine residues with functions not 
yet identified (See Figure 2).83 
 
DYRK1A, dual-specificity tyrosine phosphorylation-regulated kinase 1A, as its name 
implies, has dual specificities. In the kinase domain, DYRK1A can not only catalyse 
intramolecular tyrosine autophosphorylation (transitional intermediate), but it can also 
phosphorylate over 20 target substrates at serine/threonine residues (mature active 
site) in an intermolecular fashion (Figure 3). Therefore, DYRK1A could be targeted 
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in two approaches by inhibitors: the first approach through inhibiting its 
autophosphorylation at tyrosine 321 residue during the formation of mature 
DYRK1A, and the second by targeting the ATP-binding site of mature DYRK1A 
during the phosphorylation of its substrates at serine/threonine residues. Therefore, 
dual inhibitor sensitivity is another concept of DYRK1A.84  
 
 
 
Figure 3. Mechanism of DYRK1A autophosphorylation and mature DYRK1A 
formation.84 As DYRK1A mRNA is translated, the N-terminal polypeptide forms 
secondary and tertiary structure (I), then polypeptide folding leads to a subsequent 
intermediate (II) formation with the activation loop as the first substrate, which 
possesses the tyrosine-kinase activity, the phosphorylated intermediate III at the 
activation loop is therefore formed and fully translated in its mature formation (IV). 
 
1.2.2 DYRK1B 
 
DYRK1B, a highly conserved homolog of DYRK1A, is mapped to human 
chromosome 19.85 DYRK1A and DYRK1B have a high degree of similarity in the N-
terminal region and catalytic domain with 84% identical sequences (Figure 2), in 
which they harbour a conserved nuclear localisation signal. However, DYRK1A and 
DYRK1B do not show extended sequence similarity in the C-terminal region 
indicating a different role in functional specialisation. More specifically, DYRK1A is 
ubiquitously expressed in human and rat tissues, whereas DYRK1B is predominantly 
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expressed in testes and muscles.85 Overall, there are fewer than five amino acids 
variations in the ATP-binding site between DYRK1A and DYRK1B, thus rendering it 
extremely challenging to identify highly selective inhibitors, especially ATP-
competitive inhibitors. 
 
DYRK1B has been found to be overexpressed in several different types of cancer 
mediating anti-apoptotic functions.86-87 For example, DYRK1B is a positive regulator 
of Hedgehog (HH)/Gli signalling, which plays a causal role in tumour initiation and 
growth in cancers of the brain, skin and gastrointestinal tract, among others. 
DYRK1B inhibition has been shown to significantly reduce tumour growth of Gli1-
dependent cancer cells such as pancreatic cancer cells with smoothened inhibitor 
resistance.88 Furthermore, up-regulation of DYRK1B expression was also found in 
high-risk human papillomavirus (hr-HPV)-expressing cells,89 which contributed to 
HPV E7 cell proliferation by phosphorylating p27 (cyclin-dependent kinase inhibitor 
1B) at Ser10 and Thr198. Additional evidence for DYRK1B as a therapeutic target in 
HPV-associated cancers was also provided.89  
 
1.2.3 DYRK2 
 
DYRK2 is another member of DYRK family, predominantly expressed in the 
cytoplasm.72 Genetic studies indicated that DYRK2 was overexpressed in all of the 
tumours showing gene amplification,90-91 but the role of DYRK2 in cancer is still 
controversial.92 Recent studies demonstrated that DYRK2 induced p53-dependent 
apoptotic cell death by direct phosphorylation of p53 at Ser46 residue.93 It also plays a 
crucial role as a tumour suppressor in human non-small cell lung cancer, and is 
potentially a predictive marker for chemotherapy.94 
 
1.2.4 DYRK3 
 
DYRK3, closely related to DYRK2, is also cytoplasmic,72,95 containing 54% 
homology in comparison to DYRK1A.96 Together with DYRK1A, DYRK3 was 
demonstrated to promote cell survival through direct phosphorylation and activation 
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of SIRT1.97 On the contrary, knockdown of DYRK3 could in turn activate p53 (also 
called as tumour protein p53) and thus induce cell death in response to genotoxic 
stress. Furthermore, DYRK3 was shown to attenuate apoptosis in response to 
cytokine withdrawal.98  
 
1.2.5 DYRK4 
 
In contrast to other family members, data for DYRK4 is barely known. Recently, 
DYRK4 was identified as a testis-specific kinase with highly restricted testicular 
expression in spermiogenesis.99 Further studies are necessary to obtain further insight 
into DYRK4 cellular functions. 
 
1.2.6 CLK1 
 
CLK1 is a nuclear protein kinase and structurally related to DYRK1A with over 30% 
similarity. CLK1 was found to regulate ASF (alternative splicing factor) by 
phosphorylating SR proteins (splicing factor containing a C-terminal RS domain) 
more specifically in the RS (arginine-serine-rich) domains except for the serine-
proline recognition site.80 Increased CLK1 levels significantly enhance the 
phosphorylation of ASF resulting in the mislocalisation of splicing factors from the 
nucleus,100-101 and the increased expression of splicing factors has been found in 
numerous carcinomas, such as ovarian cancer.102 Analysis of cancer transcriptomes by 
EST (expressed-sequence-tag) libraries from a wide variety of cancer types has 
suggested that the cancer cells have “noisier” splicing than that in normal tissue 
counterparts.103-104 These studies indirectly provided the correlation between CLK1 
activity and tumour growth. Additionally, CLK1 overexpression in tumours was also 
detected, and inhibition of CLK1 contributes to cell death in cancer by controlling 
periodic alternative splicing.105-106 A recent report has pointed out that overexpression 
of CLK1 has strong effect on HIV-1 replication by increasing HIV-1 Gag RNA levels 
and thus virus production.107 
 
Since CLK1 phosphorylates SR proteins at serine residues, it is involved in the 
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pathophysiology of AD resulting from the increased release of SR proteins in the 
nucleoplasm from the nuclear speckles.104,108-109 Thus the role of CLK1 appears 
crucial in the development and discovery of therapeutic potential drug for AD as well. 
 
In summary, DYRK1A has been implicated in the phosphorylation of more than 20 
substrates involved in cellular and neuronal process, as well as the regulation of 
cytoskeletal and synaptic proteins.110 Normalisation of DYRK1A expression level 
appears to be essential. It is for this reason that DYRK1A is the main target of this 
thesis.  
 
1.3 Regulation of DYRK1A expression 
 
DYRK1A is a dosage sensitive gene − dosage imbalance of DYRK1A expression 
drastically affects brain function and structure. For example, mice with lower levels of 
DYRK1A expression produced similar phenotypic effects to those overexpressing 
DYRK1A.111 Evidence suggests that haploinsufficiency of DYRK1A might be 
responsible for the cognitive phenotypes of monosomy 21, thereby leading to 
autosomal dominant mental retardation.112 Therefore, low or high expression of 
DYRK1A could cause a series of abnormalities. This poses two important questions: 
1) what regulates expression level of DYRK1A? 2) How does DYRK1A expression 
affect diseases?  
 
1.3.1 Factors affecting DYRK1A expression levels 
 
DYRK1A expression is regulated by many factors, including transcriptional factors, 
tumour suppressor factors, neurogenic factors as well as protein-protein interactions. 
Emerging studies suggest that the protein-protein interactions could maintain the 
regulation of DYRK1A. For example, the catalytic activity of DYRK1A is regulated 
by autophosphorylation at Ser520 via an intramolecular mechanism.  
Autophosphorylation triggers interactions of DYRK1A with 14-3-3β protein that 
belongs to 14-3-3 protein family. This family is correlated with activation or 
inactivation of catalytic activities, the formation of macromolecular complexes, 
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modulation of protein localisation and/or stabilisation.  Therefore inducing the 
conformational changes results in increased catalytic activities of DYRK1A.113  
 
HAN11, the human homologue of AN11, encodes HAN11 protein, which interacts 
directly with DYRK1A to regulate expression levels. AN11 is predominantly in the 
cytoplasm, whereas DYRK1A is predominantly in the nuclear, yet binding between 
the two has been validated in previous studies.114 Later reports provided consistent 
results that HAN11 exists in both the cytoplasm and nucleus, when activated by 
mDia1, which is a cytoskeletal regulator as a binding partner of HAN11.115 Therefore, 
the interaction between DYRK1A with HAN11 in the cytoplasm is increased by 
moving from the nucleus to the cytoplasm. As a result, Gli1-dependent gene 
transcription activity regulated by DYRK1A is decreased by changing the level of 
nuclear Gli1. 
 
Transcriptional activity of nuclear factor of activated T-cells (NFATs) is negatively 
regulated by DYRK1A.116 Phosphorylation of NFAT by the nuclear DYRK1A 
induces its exit into the cytoplasm, resulting in the loss of transcriptional activity. 
NFATs stimulate the expression of DYRK1A in both osteoclast precursors and 
osteoclasts,117 which in turn reduces the activity of NFATs by increased DYRK1A 
expression. This discovery suggested a negative feedback mechanism for DYRK1A-
NFATs regulation, and thus predicted a therapeutic strategy for bone homeostasis and 
bone-destructive diseases. Furthermore, emerging evidence shows that normalisation 
of DYRK1A expression through MicroRNAs-199b (miR-199b) inhibition by 
antagomirs could decrease dysregulated vertebrate development, such as vascular 
defects and heart failure by promoting calcineurin/NFAT signaling.118  
 
Another transcriptional factor, E2F1, was also indicated to regulate DYRK1A mRNA 
level. It was suggested that overexpression of E2F1 enhanced the activity of 
DYRK1A promoter by increasing DYRK1A mRNA level in phoenix cells, which 
provided additional evidence that DYRK1A plays a crucial role in cell cycle 
regulation.119 Activator protein 4 (AP4) negatively regulated the transcription of 
DYRK1A in nonneuronal cells as a putative repressive element-binding transcription 
factor. This occurs by forming a functional complex with corepressor geminin as a 
repressor complex, indicating that reduced expression of the AP4 repressor complex 
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contributes to the premature overexpression of DYRK1A in foetal brain.120  
 
P53, a tumour suppressor factor, has been reported to reduce the level of DYRK1A 
expression through the induction of miR-1246, overexpression of which reduced 
DYRK1A levels, resulting in the nuclear retention of NFATc1 and induction of 
apoptosis.121 On the other hand, DYRK1A phosphorylates p53 at Ser15 residue in 
vitro, which results in an impairment of G1/G0 phase transition attenuated H19-7 
cells and embryonic neural cells proliferation. This provided evidence that 
upregulation of DYRK1A makes a contribution to neural proliferation alteration in 
DS.122  
 
In the cultured neuroblastoma cell line SH-SY5Y and transgenic mice, an increase in 
DYRK1A mRNA (transcription) was detected as a result of Aβ loading (SH-SY5Y 
cells were incubated with Aβ peptide). This led to hyperphosphorylation of tau at 
Thr212 residue, further contributing to AD pathology, which was described 
previously (Section 1.1.2).39 Furthermore, DYRK1A activity was markedly induced 
by neurogenic factor basic fibroblast growth factor (bFGF), resulting in an increased 
specific binding between DYRK1A and active site of CREB (cAMP response 
element-binding) leading to subsequent transcription in neuronal differentiation.123  
 
1.3.2 How does DYRK1A expression affect diseases? 
 
DYRK1A has been found to affect multiple signalling processes by activating or 
inactivating signals of other factors, such as transcriptional factors, translation factors, 
splicing factors and miscellaneous proteins including glycogen synthase, caspase-9 
and Notch, as well as synaptic proteins phosphorylation. 
 
1.3.2.1 DYRK1A activates transcriptional factors 
 
DYRK1A was suggested to comprise part of RNAPII (Polymerase II)-containing 
complexes in vivo. Studies showed that RNAPII CTD (C-terminal repeated domain), 
which is responsible for ‘paused’ or ‘elongating’ phase of the transcription cycle, is 
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also a substrate for phosphorylation at Ser2 and Ser5 residues by DYRK1A. Low 
levels of DYRK1A expression led to reduced RNAPII association in the targeting 
regions and increased CTD phosphorylation. In this case, DYRK1A is likely acting as 
a transcriptional regulator.124  
 
Multiple data sources indicate that the DYRK family is a key protein regulating 
NFAT1 phosphorylation. DYRKs 2−4 maintain the phosphorylation status of 
cytoplasmic NFAT in resting cells, whereas DYRK1A re-phosphorylates nuclear 
NFAT and thus promotes nuclear export in terms of their particular locations 
(cytoplasm or nucleus). Moreover, DYRK1A-mediated phosphorylation of the 
conserved serine-proline repeat 3 (SP-3) motif of the NFAT-regulatory domain 
primes for further phosphorylation of SP-2 and serine-rich region 1 (SRR-1) motifs by 
CK1 and GSK, thus deactivating NFAT1 by facilitating complete phosphorylation.125 
Overdosage of DYRK1A associated with DSCR1 was reported to lead to reduced 
NFATc activity in immune response.116  
 
Sprouty2, as a modulator of tyrosine kinase receptor signalling capable of enhancing 
EGF-dependent signalling, was suggested to be phosphorylated by DYRK1A, thus 
blocking epidermal growth factor receptor (EGFR) degradation.126 Furthermore, 
phosphorylation of sprouty2 at Thr75 by DYRK1A was found to positively affect 
FGF-induced mitogen-activated protein kinase activation.127  
 
DYRK1A was reported as a regulator of the DREAM complex, which is a multi-
subunit complex that regulates gene expression during quiescence. Phosphorylation of 
DREAM subunit LIN52 by DYRK1A at Ser28 was found to regulate the complex 
formation of the G0 phase. Inhibition of DYRK1A by inhibitors such as INDY led to 
quiescence inhibition and significantly increased the imatinib-induced gastrointestinal 
stromal tumour (GIST) cell apoptosis, thereby increasing anti-tumour efficacy.128  
 
DYRK1A also has the capacity to activate CREB, a transcriptional factor implicated 
in the formation of learning and memory. Phosphorylation and subsequent stimulated 
CRE-mediated gene transcription in neuronal differentiation resulted in neurite 
outgrowth.123 Additionally, DYRK1A was demonstrated to activate transcriptional 
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factor FKHR (forkhead in rhabdomyosarcoma) by phosphorylating FKHR at Ser329 
specifically in vivo. This has been implicated in the control of gene expression by 
insulin and regulation of apoptosis. The increased DYRK1A levels also made a 
contribution to FKHR cellular localisation.129 
 
STAT (signal transducer and activator of transcription protein), a transcriptional 
factor critical for astrogliogenesis, is another factor activated by DYRK1A. 
Overexpression of DYRK1A enhanced the phosphorylation and activity of STAT3 at 
Ser727 residue, a regulatory site that activates STAT3 activity, and in turn, the 
elevated STAT3 activity increases the differentiation of progenitor cells into 
astrocytes in vitro and in vivo. However, the knockdown of DYRK1A has no 
significant effects on STAT3 phosphorylation at Ser727, nor differentiation into 
astrocytes.130 These studies suggested that the DYRK1A-STAT signalling pathway is 
an implication for the anomalies in DS brain development, since DS is associated with 
the increased generation of astrocytes resulting from the increased progenitor cells 
differentiation into astrocytes.131 
 
Tau itself is a poor substrate for GSK3 (glycogen synthase kinase-3), whose 
phosphorylation by GSK3 could only occur after a first phosphorylation of serine or 
threonine by other protein kinases like DYRK1A in vitro.32 For example, 
phosphorylation of RCAN1 (Regulator of Calcineurin 1, which is also located in 
chromosome 21) by DYRK1A at the Ser112 residue primes protein phosphorylation 
of Ser108 by GSK3β.132 Phosphorylation by DYRK1A at tau Thr212 residue primes 
tau phosphorylation by GSK3 at the Ser208 residue, and thus resulting in the 
accumulation increase of neurofibrillary tangles, which, according to in vitro kinase 
assay, exists in the brain of AD patients.133 DYRK1A, as one of the clock-regulated 
protein kinases, catalyses priming phosphorylation of CRY2 (crystal like protein 2) at 
Ser557, and this leads to secondary phosphorylation of CRY2 at Ser553 by GSK-3β, 
thereby leading to CRY2 degradation.134 Moreover, DYRK1A priming 
phosphorylated GSK-3β at Ser539 in its ε-subunit permits GSK3 to phosphorylate 
translation factor eIF2Bε at Ser535 in vitro, and thus suggests that DYRK1A 
indirectly activated eIF2Bε.32 As a result, increased DYRK1A immunoreactivity was 
found in the cytoplasm, which provides further evidence that DYRK1A plays an 
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essential role in the cytoplasm as well, even though its localisation is in the nucleus. 
 
In addition, DYRK1A stimulates the activity of transcriptional factor Gli1 resulting in 
more efficient association with other transcriptional factors and thus delaying its 
nucleus export.135  
 
1.3.2.2 DYRK1A activates splicing factors 
 
DYRK1A has the capacity to activate splicing factors. For example, DYRK1A 
phosphorylated ASF at Ser227, Ser234 and Ser238 in vitro, and its overexpression 
altered the nuclear distribution of ASF into nuclear speckles, which affected the tau 
transcript. The resulting imbalance of 3R/4R tau in the DS brain further accelerated 
neurofibrillary degeneration, this represents a novel mechanism of neurofibrillary 
degeneration.136  
 
DYRK1A is currently the only DYRK family member that has been found to be 
involved in the regulation of Cyclin D1 turnover in RG (radial glio) progenitors.137 
Evidence showed that high-level phosphorylation of Cyclin D1 by DYRK1A at the 
Thr286 residue might induce proteolytic degeneration of Cyclin D1 in RG progenitors 
in vivo, and this process subsequently caused a steep increase in G1 phase duration of 
the cell cycle.138 This is consistent with previous studies that suggested that the 
premature neuronal differentiation of neural progenitor cells was caused by Cyclin 
D1.139 In contrast, reduced DYRK1A activity increases Cyclin D1 expression, and the 
resulting increased expression of the CDK inhibitor p21 causes a competition between 
Cyclin D1 and p21 expression level, and then controls the cell fate.138  
 
1.3.2.3 DYRK1A activates miscellaneous proteins and synaptic proteins 
 
Notch proteins are a family of transmemberane proteins. Notch signalling regulates 
interactions between physically adjacent cells, and it is controlled by several kinases 
in the nucleus by inducing phosphorylation of the Notch intracellular domain (NICD). 
DYRK1A has been implied to attenuate Notch signalling in neural cells both in 
culture and in vivo. The interaction between DYRK1A and NICD promotes its 
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phosphorylation in the ankyrin domain and induces transcription termination.140 
DYRK1A plays a critical role in maintaining the normal function of the retina − a 
dosage change of the DYRK1A gene leads to severe alterations in retinal cellularity 
and the changes in retina cell numbers. Evidence has shown that DYRK1A 
phosphorylates caspase-9 at the Thr125 residue, and the activation of caspase-9 is 
associated with apoptosis.141 Therefore, correct DYRK1A gene dosage is essential for 
the survival of retina cells during their development.142  
 
It has been identified that DYRK1A, together with other DYRKs, causes the 
phosphorylation of GSK3 at the Ser640 residue. This protein-protein interaction 
subsequently leads to the inactivation of glycogen synthase, a key enzyme in the 
regulation of glycogen synthesis by insulin. This finding has provided a new 
mechanism for the regulation of glycogen synthase by DYRK1A.114  
 
Dynamin 1 was suggested143-144 as one of the substrates acted upon by DYRK1A as it 
was directly phosphorylated by DYRK1A mainly at Ser857 in its native state. 
Phosphorylation of Dynamin 1 resulted in the reduced binding affinity of dynamin to 
amphiphysin 1, an enzyme involved in endocytosis. In most case, DYRK1A may just 
function as a regulator controlling the synaptic vesicle recycling, but later studies 
demonstrated that DYRK1A also directly phosphorylated amphiphysin 1 at Ser293 
during the regulation of endocytosis at synapses.145 
 
1.3.2.4 Other substrates activated by DYRK1A 
 
DYRK1A is a critical kinase for the regulation of beta cell growth. DYRK1A-
haploinsufficient mice showed severe glucose intolerance and reduction in mass and 
proliferation of beta cells, eventually causing diabetes.146 Upregulation of DYRK1A 
in beta cells was found to significantly enhance this phenomenon.147 However, recent 
studies148 have presented different conclusions concerning the correlation between 
DYRK1A and beta cell proliferation. For example, DYRK1A inhibition by the 
adenosine kinase inhibitor steeply stimulated human beta cell proliferation in vitro 
and in vivo, as reported in previous parallel studies.149-151 Such different results can be 
explained by the large variance between rodent and human and beta cell replication. 
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Accumulating studies showed that DYRK1A, together with DYRK3, promoted cell 
survival and resulted in deacetylation of p53. SIRT1 (Sirtuin 1, also known as NAD-
dependent deacetylase sirtuin 1), in this process, acts as the p53 deacetylase, resulting 
from the phosphorylation and activation directly by DYRK1A at the Thr522 residue. 
This essential deacetylation is involved in multiple physiological processes including 
stress response and energy metabolism. On the contrary, knockdown of DYRK1A and 
DYRK3 activated p53 and induced cell death in response to genotoxic stress.152 The 
increased SIRT1 activation by DYRK1A activated FOXO (forkhead box O) 
transcriptional factor, and turned on the expression of sNPF/NPY (short neuropeptide 
F/neuropeptide Y) target gene, as a result, increased food intake in fruit flies and mice 
was observed.153  
 
DYRK1A also specifically binds to Hip-1, which is known to be associated with the 
pathogenesis of HD described previously (Section 1.1.3). High affinity and 
hyperphosphorylation of Hip-1 by DYRK1A resulted in Hip-1-mediated neuronal 
differentiation and blockade of cell death in H19-7 cells.154 DYRK1A directly 
phosphorylated the GTPase-binding domain of neural Wiskott-Aldrich syndrome 
protein (NWASP) at the threonine residue, and knockdown of the DYRK1A gene can 
promote actin filament polymerisation, which is associated with cell migration and 
endocytosis in cellular process.155  
 
Normalising the level of DYRK1A expression rescued the skeletal alterations in DS 
Ts65Dn mice, including reduction of bone mineral density and changes of facial 
features.156 DYRK1A also catalyses the phosphorylation of CDKL5 at the Ser308 
residue, subcellular distribution is then altered to facilitate a cytoplasmic location in 
response to some stimulation in hippocampal neurons.82  
 
In summary, hyperphosphorylation mediated by DYRK1A overexpression is 
associated with multiple pathologenetic differentiations in the development of brain 
diseases, especially in DS and AD. Therefore, it is necessary to investigate DYRK1A 
as a novel target for exploration of treatments of abnormal phenotypes in DS or AD 
patients. 
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1.4 Roles of DYRK1A in tumours 
 
In DS patients, about 1.5 fold DYRK1A overexpression has been detected resulting 
from the extra copy of human chromosome 21. However, multiple studies have 
suggested that patients with DS have a much lower risk of all common tumour types 
and several malignancies (except testicular cancers and leukaemia) in either females 
or males at all ages.157 Such a low cancer risk can be explained by a slower rate of 
replication and/or higher possibility of apoptosis resulting from the tumour suppressor 
genes location on human chromosome 21 as described before (Section 1.3.2.2),158 the 
hyperphosphorylation of cyclin D1 or NFAT mediated by DYRK1A overexpression 
could be linked to these anti-cancer effects.138 
 
Overexpression of DYRK1A has been found in several tumours. For example, up-
regulated DYRK1A in HPV16 infected keratinocyte cells has been identified,159 
although it was not detected in primary keratinocytes. Increased DYRK1A induced 
tumour formation and growth by triggering cell anti-apoptosis resulting from the 
mislocalisation of FKHR mentioned above (Section 1.3.2.1).129 In cervical lesions,160 
higher DYRK1A levels have been observed compared with those in normal tissues.161 
In gastrointestinal stromal tumour, studies indicated that perturbations in the 
quiescence regulation by a regulator − DREAM complex contributes to the increased 
mitotic gene expression levels which are frequently detected in cancers, and 
DYRK1A inhibition was found to eliminate the DREAM complex and thus enhance 
imatinib-induced apoptosis.162 
 
Studies have shown that DYRK1A is upregulated in glioblastoma cells, which 
represent approximately 15% of brain tumours.163 The role of DYRK1A has also been 
established in the same studies. The increased phosphorylation of sprouty2 mediated 
by DYRK1A (Section 1.3.2.1) blocks the EGFR degradation as a result of 
overexpression of EGFR in the cell surface (Figure 4), and the enhanced EGFR 
signalling eventually leads to tumour survival. On the contrary, DYRK1A inhibition 
has been found to promote EGFR degradation in glioblastoma cells by triggering the 
endocytosis and lysosomal degradation, thus reducing the self-renewal ability of 
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tumourigenic cells.163 Therefore, DYRK1A as a novel target in EGFR-dependent 
glioblastoma represents a promising strategy for cancer therapy. 
 
 
 
Figure 4. DYRK1A-mediated EGFR degradation or recycling.65 
 
1.5 DYRK1A inhibitors 
 
Recently, researchers have endeavoured to modulate DYRK1A expression to 
ameliorate DYRK1A-associated memory deficits and mental retardation. Several 
approaches have been investigated, such as natural products and derivatives, synthetic 
inhibitors or shRNAs (short hairpin ribonucleic acids ).164-165 Generally, small-
molecules act as a scaffold for protein-protein interactions, whereas if treated by 
shRNAs, proteins may lose activities in other biological functions. Therefore, small, 
cell-permeable and blood-brain barrier (BBB)-permeable inhibitors of DYRK1A are 
important tools for investigating effective solutions to counteract alterations in the 
brain as a therapeutic strategy.  
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1.5.1 Natural compounds and derivatives 
 
Several compounds with inhibitory activity against DYRK1A have been isolated from 
natural sources.166-167 For example harmine (1a) (Figure 5), a β-carboline alkaloid 
with a pyrido[3,4-b] indole ring structure, was first isolated from medical herbs " the 
South American vine Banisteriopsis caapi, which was first used to treat Parkinsonism 
in 1928.167 Harmine was later identified as a CDK inhibitor in an ATP-competitive 
manner and displayed a strong inhibitory activity against cell growth and 
proliferation.151,168 Recently, harmine has been shown to be an ATP-competitive, 
potent and relatively selective inhibitor of DYRK1A in vitro,169-170 with 5-fold more 
inhibitory activity against DYRK1A (IC50 = 33 nM) over DYRK1B (IC50 = 166 nM), 
and much more potent than other DYRK family members. Studies have shown that 
harmine inhibited substrate phosphorylation by DYRK1A more potently than that at 
tyrosine autophosphorylation of the translational intermediate of DYRK1A (IC50 = 
1.9 µM). Inhibition of substrate phosphorylation by DYRK1A is therefore considered 
to be the major mode of action.170 Moreover, harmine and other β-carboline analogues 
were demonstrated to inhibit DYRK1A-dependent phosphorylation of tau at multiple 
sites associated with tau pathology like NFTs in DS and AD.171  
 
Harmine, a β-carboline analogue, has shown additional properties, such as inhibition 
of monoamine oxidase A (MOA-A) (IC50 = 5.3 nM), a target for depression.172 
Recently, by evaluating the characteristic features of the binding pockets of MOA-A 
and DYRK1A, the reduction of MOA inhibition, whilst maintaining DYRK1A 
inhibition has been achieved.173 In comparison (Figure 6), the methoxy group of 
harmine does not interact with MAO-A, whereas it does interact with the backbone 
NH group of hinge residue Leu241 in DYRK1A.174 Despite this, the central ring NH 
group of harmine is essential for MAO-A, but not essential for DYRK1A binding 
(Figure 5).175 Therefore, to improve DYRK1A selectivity, modifications were 
focused on the central NH group of harmine by significantly changing the binding 
affinity with MAO-A. As expected, the harmine derivative 1b (Figure 5), with 
increased size of the substituted ethyl ester dramatically decreased its inhibitory 
potency against MAO-A (IC50 > 10000 nM), but retained binding affinity with 
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DYRK1A (IC50 = 52 nM). Surprisingly, by changing the spatial effects of the methyl 
group on the pyridine ring, the chloro derivative 1c (IC50 = 56 nM) showed similar 
potency with 1b, but it lost all the activity against MAO-A. This improvement gave us 
confidence in the investigation of potential DYRK1A inhibitors through functional 
modifications. 
 
 
Figure 5. Chemical structures of harmine and its derivatives. 
 
 
 
Figure 6. Binding pockets of MAO-A (left) and DYRK1A (right) interacting with 
harmine.174 modifications on the central NH group of harmine could significantly 
decrease the binding affinity with MAO-A, thus it imparts a greater DYRK1A 
selectivity. 
 
Epigallocatechin gallate (EGCG, 2) is a polyphenol bearing a benzopyrane scaffold 
(Figure 7). It was isolated from green tea leaves as a major catechin component.176 
EGCG has been reported by Bain and co-workers as a potent inhibitor of DYRK1A 
with an IC50 of 0.33 µM.166 However it also showed inhibitory potency against p38 
with an IC50 of 1 µM by binding to p38 at the threonine residue in the activation loop. 
As a result, p38 phosphorylation by other kinases was blocked in this case. EGCG 
was later discovered to be a non-ATP competitive inhibitor via a combination of 
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genetic and biochemical approaches.177 Research later has shown that EGCG-
activated cell death signals and induced apoptosis in cancer cells selectively, without 
effecting normal cells.178 Overexpression of DYRK1A was found to lead to neuronal 
plasticity deficits in TgDYRK1A mice model, a transgenic mouse model generated by 
the overexpression of full-length DYRK1A cDNA with similar phenotypes to DS.179 
When TgDYRK1A mice were treated with EGCG, its neurogenesis alterations could 
be significantly rescued.180-181 Furthermore, a randomised and double-blind pilot 
study has demonstrated the safety of EGCG, and its use has shown significant effects 
on improving cognitive functions in trisomic mice (TG65Dn) and TgDYRK1A 
mice.182 However, some side-effects of EGCG have been detected, such as inhibitory 
effects on cannabinoid receptor 1 (CB1).183 Unfortunately, the poor bioavailability of 
EGCG has extensively limited its use as long-term therapeutic option.184 
 
 
Figure 7. Chemical structures of DYRK1A inhibitors 2−3. 
 
Indolocarbazoles are a class of natural products isolated mainly from 
actinomycetes.185 Several indolocarbazole analogues have been applied for the 
treatment of PD in clinical trials.186 Staurosporine (3a), as a representative of this 
family, possesses an indolo[2,3-a]pyrrolo[3,4-c]carbazole ring system attached to a 
sugar moiety by bonding to both the indole nitrogen atoms. Staurosporine has 
exhibited potent inhibition against DYRK1A with an IC50 of 19 nM (Figure 7).187 
Rhamnose (3b), a carbonyl derivative of 3a, showed even stronger inhibition for 
DYRK1A (IC50 = 4 nM). However, both 3a and 3b were highly non-selective among 
a large array of kinases including JAK2 (Janus kinase 2), FTL3 (fms-like tyrosine 
kinase 3), SYK (spleen tyrosine kinase) with subnanomolar inhibition.187 These 
compounds are typically used as screening control molecules in research studies.67 
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Marine alkaloids, such as meridianins (4), meriolins (5), and variolins (6) were also 
isolated from natural sources and all exhibited DYRK1A inhibition (Figure 8).188-189 
For example, meridianin 4a displayed 30% inhibition towards DYRK1A at 0.5 µM, 
but it did not show cytotoxicity to neuroblastoma SH-SY5Y cells (IC50 > 100 µM).190 
Meridianin analogue 4b, bearing a 6-bromo substituent, showed potent inhibition 
against DYRK1A with an IC50 of 34 nM, whereas it displayed similar activity towards 
CLK1 (IC50 = 32 nM).191 Meriolins are chemical hybrids between meridianins and 
variolins, bearing the 7-azaindole scaffolds (Figure 8). Meriolin 5a, containing a 2-
aminopyrimidine substituted azaindole, was shown to be a potent inhibitor of CDKs, 
especially CDK9 (IC50 = 26 nM), and to a lesser extent, other kinases such as 
DYRK1A (IC50 of 130 nM).192 The 4-hydroxy derivative meriolin 5b has shown 
inhibitory activity against both CDK9 and DYRK1A with IC50 values of 18 and 35 
nM, respectively. Furthermore, due to their potent inhibition of CDKs resulting in cell 
cycle perturbations, meriolins have been revealed to have significant effects on 
antiproliferation of multiple cancer cell lines.192 Variolin B (6) was isolated from the 
difficult-to-access antarctic sponge Kirkpatrickia varialosa found in Antarctica, and 
represents one of the first examples of an aminopyrimidine substitute on the tricyclic 
core.193 Variolin B was identified as a CDK inhibitor and potent cytotoxic agent by 
inhibiting colony formation, resulting in cell apoptosis.194-196 Later on, variolin B was 
also demonstrated to inhibit other kinases such as DYRK1A and CK1 with IC50 values 
of 80 and 5 nM, respectively.192 However, both variolin B and its derivate deoxy-
variolin B have limited use in clinical trials due to the solubility issues and complex 
pharmacokinetic properties.196 Therefore, meriolins as synthetic hybrids between 
meridianins and variolins might be a potent inhibitory scaffold for future cancer 
therapeutics. 
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Figure 8. Chemical structures of potent DYRK1A inhibitors 4−6. 
 
The purine olomoucine (8) was first identified as a potent CDKs (especially CDK2) 
inhibitor in an ATP-competitive manner (Figure 9).197 Roscovitine (9)198 and 
purvalanol (10),199-200 two derivatives from olomoucine, were later described as more 
potent and selective inhibitors of CDK2. In 2003, Bain and co-workers first tested 
roscovitine and purvalanol against a large number of kinases including DYRK1A.201 
Purvalanol, as an ATP-competitive inhibitor, showed a more potent activity against 
DYRK1A (IC50 = 300 nM) in comparison to roscovitine (IC50 = 3.1 µM). However, 
both compounds exhibited far more inhibitory potencies against CDK2 with IC50 
values of 100 nM and 250 nM, respectively.201 
 
 
 
Figure 9. Chemical structures of DYRK1A inhibitors 8−10. 
 
Leucettamine B (11a), another natural compound bearing an imidazole scaffold, was 
isolated from the marine sponge leucetta microraphis in 1993 (Figure 10).202 The 
biological activity of 11a reported by Debdab and co-workers203 displayed potent 
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inhibition against CLK1 (IC50 = 400 nM), and to lesser extent, it also exhibited 
inhibition against DYRK1A with an IC50 value of 2.8 µM. Additionally, its derivative 
leucettineL41 (11b) has dramatically increased its inhibitory potency against DYRK1A 
(IC50 = 40 nM), although it inhibited DYRK2 and CLK1 even more potently with IC50 
values of 35 and 15 nM, respectively.203 Specifically, 11b has also displayed 
neuroprotective effects on glutamate-induced HT22 cell and APP-induced cell 
death.204 
 
 
 
Figur 10. Chemical structure of DYRK1A inhibitors 11. 
 
1.5.2 Synthetic inhibitors 
 
As described previously, DYRK1A cannot only catalyse autophosphorylation on its 
tyrosine 321 residue, but also phosphorylates substrates on serine/threonine residues. 
Therefore, two targeted approaches to inhibiting DYRK1A may be considered 
promising, but require different binding modes. The inhibition of DYRK1A 
autophosphorylation can generally be realised by using small molecules to induce a 
conformational change, resulting in the loss of DYRK1A function. These inhibitors 
are classed as type II inhibitors, and might offer new avenues for developing more 
specific therapeutics.68 However, the major problem that exists with this approach is 
that excessive mutation of DYRK1A itself would cause long term function loss in 
other biological signalling pathways. Therefore, in most cases, inhibition of specific 
substrate-phosphorylation may have more benefits than targeting DYRK1A 
autophosphorylation. Many synthetic inhibitors of DYRK1A that have been 
developed to date possess higher inhibitory potency against substrate phosphorylation 
than against tyrosine autophosphorylation.84,205 For example, harmine as noted before, 
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inhibits DYRK1A substrates phosphorylation with an IC50 value of 33 nM, but its 
inhibitory activity against tyrosine autophosphorylation is much weaker with an IC50 
value of 1.9 µM. Such substantial differences indicate that inhibition of substrate 
phosphorylation and autophosphorylation of DYRK1A have markedly different SAR 
(structure-activity relationship) profiles. Inhibitors targeting the ATP binding site of 
DYRK1A are termed type I inhibitors, or ATP competitive inhibitors in an ATP-
competitive manner.68 
 
Ogawa and co-workers have developed a novel DYRK1A inhibitor INDY (12a) − a 
benzothiazole derivative structurally related to Tg003 (12b) (Figure 11, top).206 
Tg003, was initially identified as a potent CLK inhibitor (especially CLK1 and 
CLK4),100 but was later recognised as DYRK1A inhibitor with IC50 value of 93 
nM.206-207 Strikingly, INDY displayed nearly 3-fold greater inhibitory activity against 
DYRK1A (IC50 = 240 nM) compared with Tg003 in an ATP-competitive manner. 
Furthermore, INDY also inhibited other DYRK family members. DYRK1B, as the 
most closely related member to DYRK1A, was inhibited by INDY with comparable 
potency (IC50 = 230 nM).206 Additionally, the co-crystal structure of DYRK1A/INDY 
complex was also reported in this study (Figure 11, bottom). INDY binds the active 
site of DYRK1A where the hydroxyl oxygen appears to hydrogen bond to the hinge 
backbone amide NH of Leu241, while the carbonyl oxygen is anchored through 
engagement with the side-chain amino group of conserved Lys188. The biological 
activity of INDY in cells was also confirmed in this study, in which near total 
inhibition of tau phosphorylation by INDY was observed at 30 µM, and the 
calcineurin/NFAT signalling could be partially ameliorated in the INDY-treated 
HEK293 cells. Moreover, a novel in vivo assay was also employed to evaluate the 
effects of INDY in X.laevis embryo, which is an ideal platform to observe general 
effects caused by DYRK1A overexpression. However, deformities were observed in 
morphological aspects including the eyes and head of tadpoles. To rescue these side 
effects, pro-INDY (12c) was developed with acetyl group attached (Figure 11, top). 
Encouragingly, pro-INDY has successfully rescued the morphological changes while 
maintaining cellular activity similar to that of INDY.206 
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Figure 11. Chemical structures of DYRK1A inhibitors 12 (top) and crystal structure 
of DYRK1A/INDY complex (bottom).206 
 
CX-4945 (13, Figure 12) was originally reported as a potent and selective inhibitor of 
CK2 through blocking CK2-dependent HIF-1α transcription in cancer cells. It is 
currently undergoing clinical trials for cancer treatments as an orally bioavailable 
molecule.208 In 2014, CX-4945 was described as a potent CLK inhibitor, especially 
for CLK2 in an ATP competitive manner to regulate alternative splicing.209 As noted 
previously, many CLK inhibitors also exhibited similar inhibitory potencies against 
DYRKs because of the high degree conservation between DYRKs and CLKs inside 
the phylogenetic system.58 In 2016, the inhibitory activity of CX-4945 against 
DYRK1A was investigated by Kim and co-workers.210 Intriguingly, CX-4945 was 
found to be an even more potent inhibitor of DYRK1A than harmine, INDY or 
proINDY, with an IC50 value of up to 6.8 nM. It was evaluated to effectively rescue 
the abnormal phosphorylation of tau and APP in mammalian cells and living 
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organisms, and significantly ameliorate neurological and phenotypic defects.210 
 
 
 
Figure 12. Chemical structure of DYRK1A inhibitor 13. 
 
More interestingly, it was proposed that the interactions of CX-4945 with DYRK1A 
may display a similar binding mode with that of harmine with DYRK1A, indicating 
that the tricyclic appendage was a major reason for the enhanced the inhibitory 
activity. However, as mentioned before, harmine also showed strong inhibition to 
MAO-A, so determining the effects of CX-4945 on MAO-A is necessary.210 
 
Labrière and co-workers have recently mimicked the fused tricyclic skeleton of 
harmine to explore more rigid analogues such as 14a−b (Figure 13).211 Interestingly, 
analogue 14a without substitution at the 2-position showed potent inhibition against 
DYRK1A, DYRK1B, CLK1 and CLK4 (DYRK1A: IC50 = 25 nM; DYRK1B: IC50 = 
34 nM; CLK1: IC50 = 23 nM; CLK4: IC50 = 33 nM). This can be contrasted with 
harmine, which showed inhibition against DYRK1A and CLK1 with IC50 values of 29 
nM and 26 nM, respectively. 14b, possessing a 2-methoxy group (mimicking the 2-
methyl group of harmine), showed improved inhibitory potency and selectivity 
against DYRKs and CLKs (DYRK1A: IC50 = 18 nM; DYRK1B: IC50 = 42 nM; 
CLK1: IC50 = 23 nM; CLK4: IC50 = 30 nM).211 
 
 
Figure 13. Chemical structures of DYRK1A inhibitors 14 versus harmine. 
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Quinazolines represent one class of compounds that possess a chemical structure 
closely related to the adenine nucleus. NGCG (15a−c) have been evaluated as 
DYRK1A and CLK inhibitors in an ATP competitive manner (Figure 14).207,212 
Within a comprehensive kinome scan, 15a−c all possess activities versus CLK1, 
CLK4 and DYRK1A below 100 nM through binding at the kinase hinge regions. In 
particular, 15c was evaluated to have the highest selectivity for DYRK1A over other 
kinases (DYRK1A: IC50 = 27 nM; DYRK1B: IC50 = 734 nM; CLK4: IC50 = 30 
nM).212  
 
 
 
Figure 14. Chemical structures of DYRK1A inhibitors 15. 
 
In 2013, Gerard Rosse developed a novel class of thiazoloquinazoline compounds 
with quinazoline-amine scaffolds similar to compounds 15 (Figure 15).213 As 
exemplified by compounds 16a−e, also designated as EHT (Figure 15, Table 1),214 
these have displayed much stronger inhibition against DYRK1A and DYRK1B than 
harmine with subnanomolar IC50 concentrations.215 Previous studies have indicated 
that the EHTs series exhibited highly selective inhibition against DYRK1 over other 
DYRKs and CLKs off-targets.214-215 Additionally, EHT analogues with different di-
substitutions (see Table 1) displayed similar or improved inhibition and selectivity 
between DYRK1A and DYRK1B. For example, para-methoxy substituted 16b 
showed a better selectivity for DYRK1A over DYRK1B albeit with less potency than 
16a with para-chloro substitution. Interestingly, 16e with para-methyl substitution 
showed the best selectivity between DYRK1A and DYRK1B in comparison to 16a−d 
with nearly 3-fold more inhibitory activity against DYRK1A over DYRK1B. 
Although the co-crystal structure of the complex EHT/DYRK1A could not obtained, 
docking studies of 16a−b and DYRK1A/1B have revealed an unusual binding mode 
unlike that with harmine (see Figure 16). Compounds 16a or 16b were bound within 
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the ATP binding site, but the heterocyclic core did not adopt a strong hinge 
interaction; rather a hydrogen bonding interaction to a salt bridge lysine residue 
through the quinozaline nitrogen was observed instead. The methyl carbimidate did 
not interact strongly with hinge residue Ile193, with a distance relatively far away 
from the backbone of the Ile193 by calculation.215 Accordingly, the difference in 
charge and size of substitution on R1 or R2 has positively affected the interaction 
within the cavity as well. Previous studies have described that 16a also inhibits 
DYRK1A-induced tau phosphorylation in cellular assays and normalised Aβ 
production. Therefore, the class of compounds 16a−e as selective DYRK1A inhibitors 
warrant further investigation as effective therapeutics for AD-like diseases.214 
 
 
 
Figure 15. Chemical structures of DYRK1A inhibitors 16. R1 and R2 are clarified in 
Table 1 below, respectively. 
 
Table 1. IC50 values of 16a−e for DYRK1A/B.a 
 
Compounds R1 R2 DYRK1A DYRK1B 
16a Cl Cl 0.22 0.28 
16b F OMe 0.36 0.59 
16c F F 0.94 1.07 
16d F Cl 0.99 1.63 
16e H Me 0.98 2.83 
harmine  -  -  21.83 57.40 
     aIC50 values expressed as nM. 
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Figure 16. Docking studies of 16a (left) and 16b (right) with DYRK1A/1B.215 
 
A novel bioluminescent-eliciting assay was recently developed to evaluate more 
specific and selective DYRK1A inhibitors by Sonamoto and co-workers.216 In 
particular, CaNDY (17a) was demonstrated to be a potent inhibitor of DYRK1A with 
an IC50 value of 7.9 nM in an ATP competitive mechanism (Figure 17). INDY as a 
comparison in the same assay showed much lower potency in this assay (IC50 = 122 
nM).216 Two compounds structurally similar to CaNDY, PD0439 (17b) and PD0442 
(17c), were also tested (Figure 17). Compound 17b, with a dihydrobenzofuran 
substituent, inhibited the kinase activity of DYRK1A with an IC50 value of 16.7 nM, 
whereas 17c with an indole substituent showed much weaker inhibition against 
DYRK1A (IC50 not shown). This implies that the oxygen atom attached to the 
aromatic of CaNDY is the key pharmacophore for maintaining inhibitory effects on 
DYRK1A. CaNDY was also evaluated as a selective inhibitor of DYRK1A over other 
DYRK family members. The in vitro study showed that CaNDY possessed 3-fold 
poorer inhibitory activity against DYRK1B versus DYRK1A. Moreover, CaNDY 
selectively induced degradation of the DYRK1A molecule in cells and thus 
suppressed DYRK1A activity.216 
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Figure 17. Chemical structures of DYRK1A inhibitors 17. 
 
To date, compounds reported as DYRK-specific or CLK-specific inhibitors are rare, 
mainly due to the high conservation of ATP binding sites inside CLKs and DYRKs.68 
Bis-indoles of indirubin have attracted the interest of many researchers as a protein 
kinase inhibitory scaffold.217 In 2009, Beauchard and co-workers reported the 
synthesis of indirubin derivatives and their biological activity against CMGC kinases 
including CDKs, GSK, CK1 and DYRK1A. Although all these derivatives showed 
weak inhibition against DYRK1A (> 1 µM, data not shown here), they exhibited far 
better activity than against other kinases such as CDKs, GSK3. Researchers 
subsequently suggested that indirubin derivatives might be promising inhibitors that 
selectively inhibit DYRKs rather than other CMGC kinases.217 Encouragingly, 
Myrianthopoulos and co-workers had made great improvements by the modification 
of the bis-indole scaffold (Figure 18).218 As shown in Table 2, 18a−c all exhibited 
much higher inhibitory potencies against DYRK1A and DYRK2 versus other kinases, 
with all IC50 values in the submicromolar range. This increase in inhibitory potencies 
resulted from the combined presence of bromine and carboxylic acid substituents. 
According to the co-crystal structure of compound 18a/DYRK2 complex, the bulky 
bromine instigated a steric clash between compounds within the kinase hinge, while 
the acidic substitution established a stabilising interaction with lysine in DYRK2.218  
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Figure 18. Chemical structures of indirubin derivatives. 
 
Table 2. IC50 values of the inhibitory activity of indirubin 18a−c against selected 
CMGC kinases.a 
 
Compounds DYRK1A DYRK2 CDK5 GSK3 CK1 
18a 0.21 0.13 > 10 > 10 > 10 
18b 0.41 ND 1.60 1.20 4.20 
18c 0.60 1.70 > 10 > 10 7.40 
     aIC50 values expressed in µM. [ATP] = 7.7 µM.218 
 
Achievements in developing DYRK1A inhibitors with selectivity among the 
structurally and functionally closely related CLKs have been made as recently as 
2015.219 Kunick and co-workers219 reported a class of novel DYRK1A inhibitors 
19a−c (Figure 19), which exhibited DYRK1A inhibitory activity with IC50 values in 
double digital nanomolar concentrations (Table 3). When the chloro-substituent of 
compound 19a was substituted for bromine, the resulting analogue (19b) showed an 
improvement in the inhibition of DYRK1A (IC50 = 20 nM) but more potent activity 
against DYRK2 (IC50 = 16 nM). Interestingly, compound 19c, with an iodo 
substituent, dramatically inhibited DYRK1A with an IC50 value in a single digital 
nanomolar concentration (IC50 = 6 nM). More importantly, 19c totally lost its 
inhibitory activity against DYRK2, DYRK3 and CDK9, showing 100-fold less 
inhibition against DYRK1B, and 30-fold less inhibitory potency against CLK1 or 
CLK4 (Table 3).219 The X-ray co-crystal structures of 19a−c with DYRK1A have 
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been also determined. The halogen atom of 19a−c may act as halogen bond acceptor 
forming an analogous bond toward hinge residue Leu241, whereas the acidic 
substitution acts as a salt bridge between the carboxylate and the conserved lysine 
residue, keeping the inhibitor in position in the ATP binding site of DYRK1A.219 
However, potential issues lie in the solubility and cell permeability of potent inhibitor. 
Further studies are therefore necessary to understand the nature of the interaction 
between 19c and DYRK1A. 
 
 
 
Figure 19. Chemical structures of DYRK1A inhibitors 19a−c. 
 
Table 3. IC50 values of the inhibitory activity of 19a−c against selected CMGC 
kinases.a 
 
Kinases 19a 19b 19c 
DYRK1A 31 20 6 
DYRK1B 210 80 600 
DYRK2 40 16 > 10 
DYRK3 > 100 > 100 > 100 
CDK9 150 160 >10 
CLK1 130 32 500 
CLK4 45 35 210 
    aIC50 values expressed in nM. [ATP] = 7.7 µM. 
 
In summary, the inhibition of DYRK1A represents a new avenue to cancer treatments 
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as well as neurodegenerative pathologies in DS and AD. Natural products with highly 
potent inhibition for DYRK1A, such as harmine and EGCG, have played crucial roles 
in investigating more promising DYRK1A inhibitors. These compounds undoubtedly 
warrant further study by structural modifications aimed at diminishing the side effects 
while maintaining inhibition. To date, the most promising DYRK1A inhibitors, either 
from natural sources or synthetic compounds, have still been limited in use, in most 
cases, due to the undesirable effects on off-targets such as CDKs, CLKs and other 
members of the DYRK family. Reassuringly, more and more crystal structures of 
inhibitors within the active site of DYRK1A have been solved, providing more insight 
into the future rational design of novel, potent, and selective DYRK1A inhibitors. 
 
1.6 Project aims 
 
Undeniably, small molecules devoid of toxicological liabilities represent a new 
approach to therapeutic use as DYRK1A inhibitors. Therefore, attempts to find more 
potent and selective DYRK1A inhibitors are taking place. In 2013, a series of 
compounds based on 7-azaindole scaffolds were reported as DYRK1A inhibitors.220 
One such molecule, 20a (Figure 20, right), was reported as one of the most potent 
DYRK1A inhibitors to date, showing inhibitory activity against DYRK1A with an 
IC50 value of 23 nM,220 whereas 20a also exhibited inhibition to CLK at a similar 
concentration. According to the proposed binding mode between the 7-azaindole 
series of compounds within the active site of DYRK1A (Figure 20, left), the NH and 
N on the azaindole core displayed hydrogen bonding to the backbone amide of the 
Glu239 residue and hinge residue Leu241, respectively.220 Furthermore, substituents 
at C-3 and C-5 positions have offered stabilising interactions with conserved Lys188 
residue and Ile165, as well as Ser242.220 This proposed mechanism of binding 
provided us a further insight into potential modifications on the 7-azaindole scaffolds 
for more potent and selective DYRK1A inhibitors. 
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Figure 20. In silico 7-azaindole series compounds with active site of DYRK1A (left); 
Representative 7-azaindole (DANDY, 20a) (right).220 
 
Using in silico modelling, we were able to dock a number of potential molecules into 
the crystal structure ATP-binding site of DYRK1A (Figure 21). From the virtual 
screening studies, both molecule a (Figure 21, A) and b (Figure 21, B) have shown 
strong binding affinity within the ATP-binding site of DYRK1A by non-covalent 
interactions, such as hydrophobic interactions, electrostatic attractions and/or 
hydrogen bond interactions. The calculated Glidescore values of molecule a and b 
were found to be the same according to the classical scoring functions. However, 
when both molecules were tested in DYRK1A inhibition assay, their IC50 values were 
quite different: 6 nM and 31 nM, respectively (Figure 21). These results suggested 
that the docking approach to designing novel molecules for DYRK1A inhibition is not 
sufficiently predictive in this case when looking at low nanomolar potency. More 
complicated environment in vitro or in vivo can be very different from that in 
silico.221-222 We therefore decided to synthesise novel DYRK1A inhibitors in a 
traditional approach based on the lead compound DANDY. Novel analogues would 
be made by changing individual segments of DANDY to investigate which segment 
makes the most important contribution to maintaining DYRK1A inhibition, with the 
overall aim of accessing more potent and selective DYRK1A inhibitors. 
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  A 
 B 
Figure 21. Structure-based docking studies of molecules a (top: A) and b (bottom: B) 
within DYRK1A active site.  
 
In order to systematically explore structural features that impart DYRK1A binding 
affinity and selectivity, I sought to optimise more potent and selective DYRK1A 
inhibitors based on DANDY. Details about the modifications on the 7-azaindole 20a 
are shown in Figure 22. 
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Figure 22. Generalised scaffolds for DANDY 20a to investigate novel derivatives by 
changing 7-azaindole core (shown in the left box with outline in blue), substituents on 
the C3 and/or C5 (shown in the bottom box with outline in green) and disconnection 
of 7-azaindole ring (shown in the right and top box with outline in purple). 
 
In the subsequent chapters, I intend to address the following problems: 
 
1. How important is the 7-azaindole heterocyclic core? Dose the pyridine 
nitrogen play a key role in maintaining DYRK1A inhibition? Are the two 
nitrogen atoms in a specifically spatial arrangement necessary to contribute to 
the inhibitory potency against DYRK1A? Is the hydrogen atom of the pyrrole-
NH crucial to the binding mode? More diversified scaffolds are needed to 
answer these questions and will be addressed in Chapter 2. 
 
2. Do compounds that maintain both nitrogen atoms but possess more flexiblility 
through ring-opening exhibit more potent activity against DYRK1A? Do 
spatial distances between di-phenols contribute to DYRK1A inhibition? 
Attempts to answer these questions are the subjects of Chapter 3 (Figure 22). 
 
3. What substituents on C-3 or C-5 positions are most tolerated, and improve the 
DYRK1A inhibition and selectivity over other kinases? Does an amide linker 
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between the 7-azaindole core and aromatic substituents at C-3 or C-5 increase 
DYRK1A inhibition activity? Does the DYRK1A inhibition by potent 
inhibitors correlate with the cellular efficacies? These questions will be 
addressed in Chapter 4 (Figure 22). 
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Chapter 2 - Synthesis and biological evaluation of heterocyclic 
derivatives with diphenols 
2.1 Introductory remarks 
 
Structural modification is a popular approach to creating novel compounds from a 
starting scaffold. For example, some heterocyclic compounds were designed by 
mimicking the pyrimidine portion of ATP, thus acting as ATP competitive molecules 
to bind the adenine pocket via hydrogen bonds, hydrophobic effects and/or ionic 
interactions.223-224 Among them, the 7-azaindole core (21, Figure 23) has often been 
utilised due to the presence of both a hydrogen bond donor and acceptor.225 It is also 
advantageous for accessing diversified analogues through the installation of multiple 
substituents at the C-3 and C-5 positions.226 For example, Hong and co-workers 
designed [3,5-d]-7-azaindole analogues 22 as potent PI3K (phosphoinositide 3-
kinase) inhibitors to show strong effects on cellular proliferation and apoptosis 
(Figure 23).227 This series of analogues was found to exhibit further inhibitory 
potencies against TrK (tropomyosin receptor kinase) with anticancer and 
antiangiogenic activities.228 7-azaindole analogue 23 was designed as a potent 
inhibitor of SGK1 (serine/glucocorticoid regulated kinase 1) and was effective enough 
to be carried through in vivo testing (Figure 23).229 Gelbard and co-workers recently 
reported an orally bioavailable brain-penetrating inhibitor (24) of MLK3 (mixed-
lineage protein kinase 3) with excellent in vivo activity as a potential strategy for the 
treatment of Parkinson’s disease.230 This 7-azaindole analogue 24 bearing substitution 
at the C-3 position has also shown neuroprotective and anti-neuroinflammatory 
properties in both in vitro and in vivo assays of HIV-1-associated neurocognitive 
disorders (HAND) (Figure 23).231  
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Figure 23. Reported biologically active molecules with 7-azaindole scaffolds.  
 
Interestingly, several reported DYRK1A inhibitors are based on a 7-azaindole core as 
well, notably meriolins192 and DANDYs.220 DANDY (20a, Figure 24) was reported 
as one of the most potent DYRK1A inhibitors by Gourdain and co-workers in 2013. 
Its proposed mechanism of binding is with the ATP-binding site of DYRK1A, which 
involves hydrogen bonding between the N-H of 20a and the backbone amide of 
Glu239, and a second hydrogen bond between the nitrogen atom at the 7-position and 
the hinge residue Leu241 N-H. These interactions contribute to the excellent binding 
affinity within the active site of DYRK1A. Furthermore, diphenol substitutions at 
both C-3 and C-5 of the azaindole generate further stabilising interactions with the 
conserved residues Lys188 and Ile165. However, when testing its inhibitory activity 
against other related kinases (CLK1, DYRK2), 20a shows equipotent inhibition 
against CLK1 compared with DYRK1A, and inhibitory activity against DYRK1B 
was not disclosed in these studies. Very little investigation and exploration of the 
DANDY series of compounds has been subsequently reported. It is still unclear which 
individual segment of 20a is crucial to achieve DYRK1A inhibition: is the 7-
azaindole core really a key moiety for preserving inhibitory potency against 
DYRK1A? Do other heterocyclic cores work as well, or better? 
 
N NH
X
N NH
R1
R2
7-azaindole (21)
1
2
345
6
7
NHSO
O Ar
R
22
N NH
23
COOH
N NH
24
HN
N
N
Chapter 2 
 42 
In an attempt to answer these questions, I investigated other diverse heterocyclic 
scaffolds by maintaining the characteristics of diphenols (shown in Figure 24). 
Initially, I explored derivatives with an indole or indazole core, which differ through 
the positioning of and/or the second nitrogen atom. Furthermore, different spatial 
arrangements of two nitrogen atoms were studied by designing heterocycles such as 
benzimidazole-2-amine or 2-acetamide, pyrazole-pyridine with phenol substitution at 
the C-4 or C-5 position, bipyridine, naphthyridine, imidazole, and triazolopyrazine 
series. Additionally, the 7-membered analogue with a ring-shaped diphenol has been 
also investigated. With these novel analogues in hand, I then explored their inhibitory 
activity against DYRK1A afterwards. 
 
 
 
Figure 24. Generalised heterocyclic cores based on 7-azaindole core of DANDY. 
 
2.2 Synthesis of DANDY, indole and indazole derivatives 20b−c 
 
The lead compound 20a was synthesised by following previously reported synthetic 
routes.232 Commercially available 5-bromo-7-azaindole (25a) was treated with N-
iodosuccinimide (NIS) in the presence of KOH to afford the regioselective iodinated 
intermediate, subsequent 4-methylbenzenesulfonyl (tosyl) protection gave 26a in 
excellent yield (Scheme 1). Suzuki cross-coupling reaction was employed at both 
halide positions simultaneously to afford aryl substituted compound 27a. According 
to the palladium-catalysed cycle of Suzuki cross-coupling (Figure 25),233-234 the 
reaction follows a sequence with an initial oxidative insertion of aryl-halide to a Pd0-
ligand complex to form the Pd(II)-aryl complex intermediate. This can be selectively 
achieved with an aryl iodide over the bromo equivalent if required. Oxidative addition 
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is followed by transmetallation with an arylboronic acid, activated by the presence of 
base, and subsequent reductive elimination from the Pd(II)-diaryl complex 
intermediate to afford the corresponding biaryl products with regeneration of Pd0. The 
selectivity between the aryl iodides and aryl bromides stems from the greater 
electrophilicity of the former, therefore promoting faster oxidative addition.235-236 
Deprotection of the tosyl group was achieved under basic conditions in MeOH to 
furnish 28a, followed by demethylation by treatment with BBr3 in CH2Cl2 to afford 
lead compound 20a in moderate yield. The total yield of compound 20a was limited 
by the demethylation step with BBr3. After quenching with MeOH, thin layer 
chromatography showed a spot consistent with the desired product (Rf = 0.45, 
CH2Cl2/MeOH 20:1) and a strong baseline spot that could not be developped by any 
mobile phase. It was proposed that a boron-complex intermediate was forming and 
was relatively stable in this case. A process of quenching with MeOH, drying under 
reduced pressure, diluting with CH2Cl2, and quenching again by MeOH and repeating 
three times, allowed for more efficient isolation of compound 20a. Spectral data 
clearly matched that which had been previously reported.232  
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Scheme 1. Reagents and conditions: (a) NIS (1.0 equiv.), KOH (0.5 equiv.), CH2Cl2, 
RT, 10 h; (b) NaH (60% in mineral oil, 3.0 equiv.), TsCl (1.2 equiv.), BnEt3NCl (0.02 
equiv.), CH2Cl2, 0 °C−RT, 30 min; 80−89% over two steps; (c) arylboronic acid (2.0 
equiv.), Pd(PPh3)4 (4 mol%), aq. K2CO3 (2 M, 4.0 equiv.), toluene/ethanol 3:1, 
100 °C, 3.5 h, 84−87%; (d) KOH (5.0 equiv.), MeOH, 80 °C, 2 h, 91−95%; (e) BBr3 
(6.0 equiv.), CH2Cl2, 0 °C to RT, 15 h, 58−65%; TsCl = 4-methylbenzenesulfonyl 
chloride. 
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Figure 25. Standard catalytic cycle of Suzuki Cross-coupling.  
 
By altering the starting material, this procedure could be used to generate several 
analogues of 20a in moderate yield (Scheme 1). Firstly, the indole core 25b was 
employed instead of azaindole core to investigate the functionality requirement of the 
nitrogen atom at the 7-position. The indole-based compound 20b was obtained 
starting from 5-bromoindole (25b) following the same procedures outlined for 20a. A 
second functional modification was made, namely the indazole-based compound 25c, 
to reinstall a nitrogen atom at a different position to investigate different hydrogen 
bonding requirements. Compound 20c was prepared from 5-bromoindazole (25c) in a 
similar manner (Scheme 1). 
 
2.3 Synthesis of benzimidazole-based analogues 29 and 30 
 
I initially synthesised benzimidazole-2-amine 29 and benzimidazole-2-acetamide 30 
starting from commercially available 2-fluoroaniline (31) (Scheme 2). The selectively 
brominated intermediate 32 was achieved by treatment with N-bromosuccinimide 
(NBS) in CHCl3 in 90% yield. The aniline 32 was then oxidised to nitro compound 33 
in the presence of hydrogen peroxide in triflouroacetic acid (TFA) at 75 °C for 2 h. It 
was hoped that the subsequent neucleophilic substitution could be achieved by 
treatment with tert-butyldimethylsilyl ether (OTBS)-aniline 34a under basic 
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conditions. Unexpectedly, the desired product 35a was not obtained, and the 
byproduct 35b was produced instead. I proposed that the silicon atom in the TBS 
protecting group favoured bond formation with the fluorine atom of 33, resulting in 
the formation of a transition state (Scheme 2), and eventually producing ether 35b. 
 
 
 
Scheme 2. Reagents and conditions: (a) NBS (1.0 equiv.), CHCl3, RT, 2 h, 90%; (b) 
aq. H2O2 (30%, 5.0 equiv.), TFA, 75 °C, 2 h, 75%; (c) 34a (1.1 equiv.), K2CO3 (1.5 
equiv.), DMF, 90 °C, 3 h, 80%. 
 
Instead, the intermediate 33 was treated with 4-aminophenol and K2CO3 in dry DMF 
at 90 °C (Scheme 3), and the desired amine 35c was successfully obtained in 
moderate yield. Next nitro reduction by iron powder in AcOH was realised at room 
temperature in excellent yield. Cyclisation to intermediate 37 was achieved in the 
presence of cyanogen bromide to proceed in 78% yield at room temperature.237 The 2-
aminobenzimidazole analogue 29 was achieved using a standard Suzuki coupling 
reaction, followed by acetylation to afford the 2-acetamide benzimidazole analogue 
30 in moderate 65% yield (Scheme 3).  
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Scheme 3. Reagents and conditions: (a) 4-aminophenol (1.1 equiv.), K2CO3 (1.5 
equiv.), dry DMF, 90 °C, 3 h, 65%; (b) Fe (5.0 equiv.), acetic acid, RT, 2 h, 95%; (c)  
BrCN (5 M in CH3CN, 1.2 equiv.), MeCN-H2O, 3:1 (v/v), RT, 16 h, 78%; (d) (4-
hydroxyphenyl)boronic acid (1.5 equiv.), Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 3.0 
equiv.), 1,4-dioxane, 110 °C, 4 h, 30%; (e) Ac2O (1.1 equiv.), AcOH, 110 °C, 3 h, 
65%. 
 
However, a more expedient alternative synthesis of analogue 29 and 30 was devised 
based on literature,237 and is shown in Scheme 4. The commercially available 4-
bromobenzene-1,2-diamine (38) was treated with cyanogen bromide in a mixture 
solvent of MeOH and H2O at room temperature to furnish the cyclised intermediate 
39 in 80% yield. C-N bond formation was achieved following Chan-Lam type 
coupling reaction. This reaction was catalysed by copper acetate in the absence of any 
ligands or base, while the reaction was also open to the air.237 Regioisomers 41a and 
41b were both obtained in this case, and the confirmation of isomer 41b was 
determined by deprotection of the TBS group to furnish a compound which was 
consistent with the spectra of intermediate 37 shown in Scheme 3. The desired 
compound 41b was further treated with (4-hydroxyphenyl)boronic acid under the 
standard Suzuki coupling conditions to afford the intermediate 42, and subsequent 
deprotection of the TBS group eventually gave analogue 29. Analogue 30 was 
achieved under the same conditions described above in moderate yield. 
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Scheme 4. Reagents and conditions: (a) BrCN (5 M in CH3CN, 1.2 equiv.), MeOH-
H2O, 3:1 (v/v), RT, 12 h, 80%; (b) 40 (1.1 equiv.), Cu(OAc)2 (0.2 equiv.), air, MeOH, 
RT, 12 h, 20% (41a), 45% (42b); (c) (4-hydroxyphenyl)boronic acid (1.5 equiv.), 
Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 3.0 equiv.), 1,4-dioxane, 110 °C, 4 h, 65%; (d) 
TBAF (2.0 equiv.), THF, RT, 10 min, 95%; (e) Ac2O (1.1 equiv.), acetic acid, 110 °C, 
3 h, 40%; TBAF = tetra-n-butylammonium fluoride. 
 
2.4 Synthesis of pyrazole-pyridine-based analogues 43 and 44 
 
The synthesis of analogue 43 was initially designed to follow the retrosynthetic 
approach shown in Scheme 5 from a Suzuki coupling reaction with 5-bromo 
substituted intermediate 49. Heterocycle formation was to be derived from a 1,3-dione 
by treatment with hydrazine, and the intermediate 1,3-dione could be afforded from 
the condensation between ketone and ester. The 2-acetate pyridine could be easily 
obtained from commercially available 2,5-dibromopyridine 45. 
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Scheme 5. Retrosynthesis of analogue 43. 
 
Treatment of 2,5-dibromopyridine (45) with n-BuLi in toluene at −78 °C and 
quenching with N,N-dimethylacetamide affored acetate 46a in 80% yield (Scheme 6). 
46a was treated with methyl 4-(benzyloxy)benzoate 47a under different conditions 
(Table 4) but none of the desired 1,3-dione 48a was obtained. The byproduct benzoic 
acid (48b) was isolated when t-BuOK or NaOMe was used as base. Use of LDA led 
to a complex mixture of products observed by TLC monitoring. 
 
 
 
Scheme 6. Reagents and conditions: (a) n-BuLi (1.1 equiv.), N,N-dimethylacetamide 
(1.5 equiv.), toluene, −78 °C, 1 h, 80%; (b) see Table 4. 
 
 
 
 
 
 
 
N
HO
HN N
OH N
Br
HN N
OPG N
Br
O
OPG
O
N
Br
Br N
Br
O
OPG
O
O+
43
45 46a 47a
48a49
N
Br
Br N
Br
O
OBn
O
O+
b
N
Br
O
OBn
O
45 46a 47a 48a
a
OBn
O
HO
48b
Chapter 2 
 50 
Table 4. Conditions screened for step b in Scheme 6.238-239 
 
Base Solvent Temperature Product (%) 
t-BuOK THF 25 to 70 °C 48b (85%) 
NaOMe MeOH 25 to 80 °C 48b (80%) 
LDAa THF  -78 °C to 25 °C complex mixture 
aLDA was freshly made from n-BuLi (1.1 equiv.) and N,N-diisopropylethylamine (1.2 equiv.) at 
−78 °C. 
 
Considering the low reactivity of benzoate 47a, I elected to use benzaldehyde 47b as 
the reactant (with subsequent oxidation step) by treatment with 46a in the presence of 
LDA at −78 °C. Unfortunately, the reaction was sluggish and then yielded a complex 
mixture of products after stirring for another 12 h at room temperature (Scheme 7). 
 
 
 
Scheme 7. Reagents and conditions: (a) 46a (1.05 equiv.), 47b (1.0 equiv.), LDA (1.1 
equiv.), THF, −78 °C to RT. 
 
We assumed that the HOMO of the nucleophile 46a and the LUMO of the 
electrophile 47b might not match with each other due to the electronic effects from 
the aromatic systems. Therefore, I decided to swap the functional groups of ketone 
46a and aldehyde 47b to aldehyde 46b and ketone 47c, respectively (Scheme 8). As 
predicted, the desired aldol product 48d was successfully achieved in 78% yield by 
treatment with LDA in a similar protocol as described above.  
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Scheme 8. Functional groups of ketone 46a and aldehyde 47b to aldehyde 46b and 
ketone 47c were interchanged, respectively. Reagents and conditions: (a) 46b (1.0 
equiv.), 47c (1.05 equiv.), LDA (1.1 equiv.), THF, −78 °C to RT, 1 h, 78%. 
 
With the intermediate 48d in hand, subsequent oxidation with Dess-Martin 
periodinane (DMP) was employed to furnish 1,3-dione 48a in 95% yield (Scheme 9). 
The formation of pyrazole intermediate 49 was achieved in 75% yield by treatment 
with hydrazine monohydrate in MeOH at room temperature.240 No reaction occurred 
when this substrate was treated with (4-hydroxyphenyl)boronic acid under standard 
Suzuki coupling conditions. A proposed explanation for this lies in the formation of a 
complex between the Pd catalyst and pyridine-N and pyrazole moieties (a typical 
bidentate coordination site), thus reducing the catalytic reactivity of Pd catalyst in the 
reaction. Therefore, the pyrazole-N was protected with a carboxybenzyl (Cbz) group 
and the resulting substrate 50a was subjected to the Suzuki coupling reaction. 
Unfortunately, the Cbz protecting group was not tolerated under these conditions and 
only the Cbz-deprotected compound 49 was isolated (Scheme 9). 
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Scheme 9. Reagents and conditions: (a) DMP (1.5 equiv.), CH2Cl2, RT, 30 min, 95%; 
(b) N2H4•H2O (2.0 equiv.), MeOH, RT, 48 h, 75%; (c) benzyl carbonobromidate (1.1 
equiv.), NaH (60% in mineral oil, 2.0 equiv.), CH2Cl2, 0 °C−RT, 30 min, 90%; (d) (4-
hydroxyphenyl)boronic acid (1.5 equiv.), Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 3.0 
equiv.), 1,4-dioxane, 110 °C, 4 h. 
 
Treating the tosyl-protected analogue 50b with (4-hydroxyphenyl)boronic acid under 
the Suzuki coupling conditions finally afforded aryl-substituted compound 51b in 
85% yield (Scheme 10). Removal of the tosyl and benzyl protecting groups could be 
easily achieved in two sequential steps, and analogue 43 was eventually furnished in 
reasonable yield (Scheme 10). 
 
Scheme 10. Reagents and conditions: (a) TsCl (1.1 equiv.), NaH (60% in mineral oil, 
2.0 equiv.), CH2Cl2, 0 °C−RT, 30 min, 95%; (b) (4-hydroxyphenyl)boronic acid (1.5 
equiv.), Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 3.0 equiv.), 1,4-dioxane, 100 °C, 4 h, 
85%; (c) KOH (5.0 equiv.), MeOH, 75 °C, 1 h; (d) Pd/C (10 wt. %), H2, MeOH, RT, 
5 h, 45% over two steps. 
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Next, I explored the synthesis of the pyrazole-pyridine based analogue 44 with the 
phenol substitution at the C-4 position, which was initially designed to follow the 
retrosynthetic approach shown in Scheme 11. In a similar manner to that of analogue 
43, compound 44 could be derived from the cyclisation of a 1,3-dione, which could be 
originally achieved from the aldol condensation between aldehyde and ketone with 
the optimised conditions described above. 
 
 
 
Scheme 11. Retrosynthesis of analogue 44. 
 
In order to realise the synthesis of compound 44, I first tried to make the intermediate 
52 (Scheme 11) from 2-bromopyridine 58 (Scheme 12) using lithium- halogen 
exchange. Commercially available pyridin-4-ylboronic acid (54) was coupled with 1-
(benzyloxy)-4-bromobenzene (55) to afford 4-aryl intermediate 56 (Scheme 12). The 
oxidation of 56 was subsequently performed in order to install the bromide selectively 
at the C-2 position.241 N-oxide 57 was obtained in 80% yield through oxidation with 
hydrogen peroxide in acetic acid. Unfortunately, bromination of 57 with POBr3 in 
toluene at 110 °C for 48 h was unsuccessful. 
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Scheme 12. Reagents and conditions: (a) 54 (1.50 equiv.), 1-(benzyloxy)-4-
bromobenzene (55) (1.0 equiv.), Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 3.0 equiv.), 
1,4-dioxane, 100 °C, 4 h, 80%; (b) aq. H2O2 (30%, 5.0 equiv.), AcOH, 70 °C, 15 h, 
80%; (c) POBr3 (1.1 equiv.), toluene, 110 °C, 48 h. 
 
As an alternative approach towards synthesis of 44, 2-amino-4-bromopyridine 59 was 
then chosen as the starting material. It was first coupled with boronic acid 40 to afford 
4-aryl intermediate 60 (Scheme 13). The brominated compound 59a was sought from 
a Sandmeyer reaction by treatment with bromine and isopentyl nitrite in THF (not 
shown here), but no desired product was obtained. Instead, multiple brominated 
byproducts were observed and thought to be produced as a result of the electron rich 
2-aminopyridine ring. Therefore, multiple conditions that were devoid of electrophiles 
were screened (Table 5). CuBr was initially used as a bromide source but even 
heating in refluxing MeCN (80 °C) for 48 h no reaction occurred. No reaction was 
observed when CuBr2 or a CuBr/CuBr2 mixture was used in a similar manner. 
According to the literature,242 iodination at the C-2 position could be furnished by 
using CH2I2 as the solvent and halogen source with catalytic HI (Scheme 13). This 
was achieved to give the desired compound 59b in 25% yield. Increasing the reaction 
temperature (80 °C) or extending the reaction time failed to give 59b with an 
improved yield. According to the earlier mechanistic studies,243 this reaction does not 
proceed via the diazonium ion as in classical Sandmeyer protocols. Instead, it is 
proposed to form a diazoaminobenzene intermediate that leads to the formation of 
aryl radical in all cases, and the iodinated compound 61b was achieved through the 
radical reaction between the diazoaminobenzene intermediate and the iodo radical 
from CH2I2 (Figure 26). We assumed that the role of HI in this reaction was as a 
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radical scavenger to capture radicals such as •CH2I, thus stopping the occurrence of 
side reactions. 
 
 
 
Scheme 13. Reagents and conditions: (a) (4-((tert-
butyldimethylsilyl)oxy)phenyl)boronic acid (40) (1.5 equiv.), Pd(PPh3)4 (2 mol%), aq. 
K2CO3 (2 M, 3.0 equiv.), 1,4-dioxane, 100 °C, 4 h, 87%; (b) isopentyl nitrite (2.0 
equiv.), 48 h, see Table 5 for additional conditions; (c) isopentyl nitrite (20.0 equiv.), 
aq. HI (57%, 2 mol%), CH2I2, RT, 24 h, 25%. 
 
Table 5. The conditions screening for step b in Scheme 13. 
 
Halogen source Solvent Temperature Product 
CuBr MeCN 25 to 80 °C N/A 
CuBr2 MeCN 25 to 80 °C N/A 
CuBr/CuBr2 (1:1) MeCN 25 to 80 °C N/A 
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Figure 26. Mechanistic proposal for the transformation of 60 to 61b.243 
 
With the 2-iodinated intermediate 61b in hand, the formation of analogue 44 could be 
easily achieved in a similar synthetic approach to that of 43 (Scheme 14). The 2-
aldehyde intermediate 52 was furnished by the lithium-halogen exchange and 
quenching with DMF in a moderate 50% yield. The subsequent aldol condensation 
with 47c gave the aldol product 62 in 60% yield. Oxidation by DMP and subsequent 
pyrazole formation yielded intermediate 63 and the two sequential deprotection steps 
eventually afforded analogue 44. 
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Scheme 14. Reagents and conditions: (a) n-BuLi (1.1 equiv.), DMF (1.5 equiv.), 
toluene, −78 °C, 1 h, 50%; (b) 47c (1.05 equiv.), LDA (1.1 equiv.), THF, −78 °C to 
RT, 1 h, 60%. (c) DMP (1.5 equiv.), CH2Cl2, RT, 30 min, 75%; (d) N2H4•H2O (2.0 
equiv.), MeOH, RT, 48 h, 70%; (e) Pd/C (10 wt. %), H2, MeOH, RT, 5 h; (f) TBAF 
(2.0 equiv.), THF, RT, 30 min, 55% over two steps. 
 
2.5 Synthesis of bipyridine-based analogue 64 
 
Analogue 64 is a known compound reported by Constable and co-workers.244 I used 
2,2'-bipyridine 65 as the starting material, with initial formation of N-oxide 66. Initial 
attempts were made by treatment with the oxidant peracetic acid in acetic acid and 
stirred at 70 °C, but only the starting material 65 was recovered (Entry 1, Table 6). 
The more reactive oxidant 3-chloroperbenzoic acid (m-CPBA) was attempted and 
gave the N-oxide 66 in 20% yield, with 20% of bipyridine 65 not consumed (Entry 2, 
Table 6). The low yield also resulted from the poor recovery during work-up due to 
the strong polarity of N-oxide (Entry 2, Table 6). The highly improved yield of 66 
(90%) was achieved utilising hydrogen peroxide as the oxidant in AcOH (Entry 3, 
Table 6). This reaction not only went to completion but the work-up was easily 
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performed through precipitation after cooling to room temperature with the addition 
of acetone.245  
 
Table 6. Attempted optimisation of the formation of N-oxide 66  
 
 
 
Entries Conditions Product Yield (%) 
1 
CH3CO3H (5.0 equiv.), AcOH, 
RT to 70 °C, 15 h 
 
N/A 
2 
m-CPBA (5.0 equiv.), CHCl3,  
RT to 70 °C, 15 h 
 
20 
3 
aq. H2O2 (30%, 5.0 equiv.), 
AcOH,  
RT to 70 °C, 15 h 
90 
 
With N-oxide 66 in hand, the dinitro-substitution at the para-positions was achieved 
by treatment with a mixture of sulfuric acid and nitric acid at 100 °C (Scheme 15). 
The low yield of 20% after 20 h of heating presumably resulted from the use of the 
normal nitric acid instead of fuming nitric acid.246 The following chloro-substitution 
could be achieved by treatment with acetyl chloride in acetic acid at 100 °C to afford 
68 in good yield.246 Reduction of N-oxide 68 was performed in the presence of PCl3 to 
give 69 in excellent yield, which was further coupled with (4-hydroxyphenyl)boronic 
acid to furnish the desired compound 64 in moderate overall yield.246 
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Scheme 15. Reagents and conditions: (a) H2SO4 (21.0 equiv.), nitric acid (8.4 equiv.), 
100 °C, 20 h, 20%; (b) acetyl chloride (5.0 equiv.), AcOH, 100 °C, 12 h, 85%. (c) 
PCl3 (20.0 equiv.), 65 °C, 20 h, 95%; (d) (4-hydroxyphenyl)boronic acid (2.5 equiv.), 
PdCl2(dppf) (5 mol%), aq. K2CO3 (2 M, 5.0 equiv.), 1,4-dioxane, 110 °C, 4 h, 40%; 
dppf = 1,1′-ferrocenediyl-bis(diphenylphosphine). 
 
2.6 Synthesis of naphthyridine based analogue 70 
 
Analogue 70 was achieved through known synthetic routes.247 The regioselective 
bromination of 2-aminonicotinate 71 gave the 3-bromopyridine 72 in 90% yield,248 
and subsequent esterification under classical conditions furnished 73 in excellent yield 
(Scheme 16). The cyclisation of 73 was achieved by treatment with N,N-
dimethylformamide dimethyl acetal (DMF-DMA) in a sealed tube at high temperature 
to afford the imine intermediate, followed by the treatment with n-BuLi and MeCN at 
−78 °C and subsequent addition of acetic acid to give 74 in 35% yield in a one pot 
reaction sequence. Decyanation of 74 was performed by treatment with concentrated 
HCl at 150 °C in a sealed tube to give compound 75 in 33% yield after neutralisation 
with an ammoniacal solution. Given that triflates act as pseudohalides in coupling 
reactions,249 I initially attempted the triflation of the hydroxy group on compound 75 
(not shown here). However, the triflate intermediate appeared unstable in this 
heterocyclic system as observed by TLC monitoring. Instead, chloride installation was 
achieved by treatment with POCl3 at 105 °C in a sealed tube to give chloro-substituted 
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intermediate 76, with subsequent Suzuki coupling achieved using the more reactive 
PdCl2(dppf) catalyst and microwave irradiation at 130 °C. Thus, analogue 70 could be 
obtained in good overall yield. 
 
 
 
Scheme 16. Reagents and conditions: (a) Br2 (1.3 equiv.), AcOH, RT, 20 h, 90%; (b) 
H2SO4 (8.0 equiv.), MeOH, 80 °C, 18 h, 94%. (c) (1) DMF-DMA (10.0 equiv.), 
110 °C, 3 h; (2) n-BuLi (2.2 equiv.), MeCN (2.2 equiv.), THF, −78 °C 1 h; (3) AcOH 
(3.0 equiv.), −40 °C, 2 h, then RT, 20 h, 35% over three steps;  (d) aq. HCl (32%), 
150 °C, 3 h, 33%; (e) POCl3, 105 °C, 3 h, 93%; (f) (4-hydroxyphenyl)boronic acid 
(2.5 equiv.), PdCl2(dppf) (20 mol%), aq. K2CO3 (2 M, 6.0 equiv.), 1,4-dioxane, MW, 
130 °C, 3 h, 85%. 
 
2.7 Synthesis of imidazole-based analogue 77 
 
Imidazole-based analogue 77 could be easily obtained from imidazole 78 first by 
treatment with iodine in the presence of KI and NaOH in H2O at room temperature. 
The regioselective diiodinated intermediate 79 was acquired in excellent yield 
(Scheme 17).250 The diarylation of 79 was achieved through a double-Suzuki 
coupling reaction. I initially tried the conditions described previously by using K2CO3 
as a base, but failed to afford the desired product 77. We assumed that the strong 
basicity of imidazole combined with the addition of K2CO3 increased the pH to a 
point that was detrimental to the reaction.251 The addition of the phase transfer 
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catalyst tetra-n-butylammonium bromide (TBAB) increased the interaction between 
K2HPO4 and organic components to afford analogue 77 in 35% yield. The low yield 
resulted from poor product recovery in the work-up step because of its strong polarity. 
 
 
Scheme 17. Reagents and conditions: (a) NaOH (4 M), KI (5.0 equiv.), I2 (2.2 equiv.), 
H2O, RT, 10 h, 80%; (b) (4-hydroxyphenyl)boronic acid (3.0 equiv.), Pd(PPh3)4 (6 
mol%), K2HPO4 (3.8 equiv.), TBAB (0.1 equiv.), MeOH-H2O, 4:1 (v/v), MW, 
100 °C, 60 min, 35%.   
 
2.8 Synthesis of triazolopyrazine analogues 80a−b and 81a−b 
 
The next core under investigation was triazolopyrazine. Considering the spatial 
arrangements of diphenol substitutions on lead compound 20a, we designed 
triazolopyrazine analogues with linkers between phenols and triazolopyrazine core to 
give the optimal structural arrangements. Therefore, analogues 80a and 81a were 
proposed, in addition to meta-hydroxy-substituted 80b and 81b, in order to investigate 
more diversified analogues (see as Schemes 18 and 19).  
 
The synthesis of triazolopyrazine analogues 80a−b could be achieved from the 
commercially available 2,6-dichloropyrazine 82 shown in Scheme 18. The formation 
of hydrazone 83 was achieved in two sequential steps. Firstly, treatment of 82 with 
hydrazine monohydrate in ethanol gave the hydrazine intermediate, which was 
reacted with 4-(benzyloxy)benzaldehyde 47b to give hydrazone 83 in 70% yield over 
two steps.252 The oxidative heterocyclisation of hydrazone 83 to triazolopyrazine 
intermediate 84 was easily achieved using PhI(OAc)2 in CH2Cl2 at room temperature 
in excellent yield.253 The following nucleophilic substitution reactions with alcohols 
85a−b, using 18-crown-6 and KOH, could be achieved to give ethers 86a−b in 
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moderate yields (69−73%). Hydrogenolysis of 86a−b then gave the desired 
compounds 80a−b in reasonable yields (Scheme 18). 
 
 
 
Scheme 18. Reagents and conditions: (a) N2H4•H2O (1.1 equiv.), ethanol, 80 °C, 8 h; 
(b) 4-(benzyloxy)benzaldehyde 47b (1.1 equiv.), ethanol, 80 °C, 10 h, 70% over two 
steps. (c) PhI(OAc)2 (1.0 equiv.), CH2Cl2, RT, 12 h, 85%; (d) 85a or 85b (1.1 equiv.), 
KOH (3.0 equiv.), 18-crown-6 (0.07 equiv.), toluene, 40 °C, 4 h, 69−73%; (e) Pd/C 
(10 wt. %), H2, MeOH, RT, 2 h, 67−70%. 
 
The synthesis of triazolopyrazine analogues 81a−b could be achieved in a similar 
manner as that described above (Scheme 19). Pyrazine-2-carboxylic acid 87 was first 
oxidised to give N-oxide intermediate as reported previously.254 The subsequent 
chlorination255 was achieved by treatment with phosphorus oxychloride at high 
temperature to give the chloro-intermediate 88 in 70% yield over two steps. Amide 
formation was performed via the acetyl chloride intermediate, followed by the 
treatment with para- or meta-OTBS aniline 34a−b and triethylamine in dry CH2Cl2 to 
give the amides 89a−b in good yields (80−85%). The following reactions were 
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performed in a similar manner to those described in Scheme 18, hydrazones 91a−b 
were obtained in 78−85% yields over two steps and further converted to the cyclised 
compounds 92a−b in good yields. The deprotection of the TBS groups gave the 
desired compounds 81a−b in excellent yields.256 
 
 
 
Scheme 19. Reagents and conditions: (a) (1) Na2WO4•2H2O (0.025 equiv.), aq. H2O2 
(30%, 1.1 equiv.), H2SO4 (1 M), pH = 2, RT to 80 °C, 2 h; (2) POCl3, 120 °C, 2 h, 
70% over two steps; (b) (1) oxalyl chloride (1.5 equiv.), DMF (0.1 equiv.), CH2Cl2, 
0 °C to RT, 2 h; (2) 34a or 34b (1.0 equiv.), triethylamine (1.1 equiv.), CH2Cl2, RT, 2 
h, 80-85% over two steps; (c) N2H4•H2O (1.1 equiv.), ethanol, 80 °C, 8 h; (d) 4-((tert-
butyldimethylsilyl)oxy)benzaldehyde 90 (1.1 equiv.), ethanol, 80 °C, 10 h, 78−85% 
over two steps. (e) PhI(OAc)2 (1.0 equiv.), CH2Cl2, RT, 12 h, 80−87%; (f) TBAF (2.0 
equiv.), THF, RT, 30 min, 95−97%. 
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2.9 Synthesis of 7-membered analogue 93 
 
The synthesis of 7-membered analogue 93 could be achieved from commercially 
available starting material 94. Nucleophilic substitution with 4-methoxy-2-nitroaniline 
was unsuccessful under basic conditions at high temperatures (Scheme 20). However, 
a Buchwald-Hartwig cross coupling reaction could be utilised by first protecting the 
aldehyde 94 as the dioxolane 95, then coupling with 4-methoxy-2-nitroaniline to 
obtain the desired secondary amine 96. The following acetal deprotection was easily 
carried out by treatment with TFA in chloroform to give the desired intermediate 97 
in 90% yield. Compound 98 could be obtained from 97 in one pot via a cascade 
process. Initial reduction of the nitro moiety to the aniline was followed by 
intramolecular condensation with the aldehyde. Subsequent reduction in the presence 
of hydrogen gave 98. Finally, the 7-membered analogue 93 was successfully obtained 
after demethylation under classical conditions in reasonable yield (Scheme 20). 
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Scheme 20. Reagents and conditions: (a) NaH (60% in mineral oil, 1.5 equiv.), 4-
methoxy-2-nitroaniline (1.0 equiv.), THF, 0 to 70 °C, 24 h; (b) TsOH (0.01 equiv.), 
ethane-1,2-diol (5.0 equiv.), toluene, 125 °C, 24 h, 95%; (c) 4-methoxy-2-nitroaniline 
(1.0 equiv.), Pd(OAc)2 (10 mol%), Cs2CO3 (1.5 equiv.), toluene, 120 °C, 3 h, 89%; 
(d) TFA (6.0 equiv.), CHCl3, RT, 30 min, 90%; (e) Pd/C (10 wt. %), H2, MeOH, RT, 
4 h, 75%; (f) BBr3 (6.0 equiv.), CH2Cl2, RT, 10 h, 50%; TsOH = p-toluenesulfonic 
acid. 
 
2.10 Structure-activity relationship study 
 
With these derivatives in hand, their potency for DYRK1A inhibition was determined 
by performing a kinase assay in triplicate with Woodtide as a substrate and an ATP 
concentration of 100 µM. The lead compound 20a was confirmed to have inhibitory 
potency against DYRK1A with an IC50 of 14 nM (See Table 7). I then tested indole- 
and indazole-based analogues 20b and 20c, however, both were inactive with IC50 
values of up to 1000 nM (Entries 2−3, Table 7). This result confirmed the importance 
of the two nitrogen atoms contained within the 7-azaindole core, and their specific 
arrangements. Next, I tested the other analogues, which maintain the two nitrogen 
atoms in similar positioning to that of lead compound 20a. Again, all of these 
CHO
Br
O O
O
Br
O O
O
NH
NO2
O
O CHO
NH
NO2
O
O
N
H
NH
O O
N
H
NH
HO OH
94 95 96 97
9893
b c d
e
f
X
a
Chapter 2 
 66 
derivatives did not exhibit inhibitory potencies against DYRK1A at >1000 nM (Table 
7).  
 
Table 7. DYRK1A inhibition assay. 
 
Compounds Structures 
DYRK1A 
(IC50, nM) 
Compounds Structures 
DYRK1A 
(IC50, nM) 
20a 
 
14 64 
 
> 1000 
20b 
 
> 1000 70 
 
> 1000 
20c 
 
> 1000 77 
 
> 1000 
29 
 
> 1000 80a 
 
> 1000 
30 
 
> 1000 80b 
 
> 1000 
43 
 
> 1000 81a 
 
> 1000 
44 
 
> 1000 81b 
 
> 1000 
93 
 
> 1000      
 
Even though all these results showed poor inhibitory activities against DYRK1A, 
different potencies of all these analogues were further investigated by looking into the 
remaining activity of DYRK1A at different concentrations (1 µM vs 10 µM) compare 
with 100% activity of DYRK1A. Very useful information was provided as shown in 
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Table 8. Both indole 20b and indazole 20c displayed some inhibition against 
DYRK1A at higher concentrations (10 µM). In comparison, benzimidazole analogues 
29 or 30 showed stronger potency against DYRK1A than 20b−c, which suggested 
that N-C-NH moiety is more important than that of N-NH or NH alone. Interestingly, 
pyrazole-pyridine-based analogue 43 failed to show any inhibitory potency against 
DYRK1A even at higher concentrations. Analogue 44, with a closer distance between 
the two phenol substituents exhibited much more potent activity. DYRK1A activity 
could be reduced to 10% when the concentration of compound 44 was ramped up to 
10 µM, which suggests that the two phenols in a specific distance between each other 
may play an important role in maintaining DYRK1A inhibition. Furthermore, 
naphthyridine 70, the most structurally related compound to the lead compound 20a 
with the NH moiety replaced with N, still completely lost inhibitory potency against 
DYRK1A, highlighting the importance of the NH moiety in maintaining DYRK1A 
inhibition. Para-hydroxy analogue 80a exhibited relatively more potent activity than 
that of meta-hydroxy 80b, which is in line with results obtained with structurally 
related compounds 81a and 81b. Compound 93 with its fused ring structure showed 
very poor activity against DYRK1A even at 10 µM concentration. 
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Table 8. DYRK1A inhibition assay at different concentrations (1 µM vs 10 µM). 
 
Compounds Structures 
DYRK1A 
activity  
at 1 µM  
DYRK1A 
activity  
at 10 µM  
Compounds Structures 
DYRK1A 
activity  
at 1 µM  
DYRK1A 
activity  
at 10 µM  
20a 
 
2% 1% 64 
 
78% 85% 
20b 
 
100% 46% 70 
 
44% 20% 
20c 
 
92% 36% 77 
 
87% 68% 
29 
 
77% 42% 80a 
 
77% 89% 
30 
 
92% 78% 80b 
 
84% 77% 
43 
 
100% 100% 81a 
 
75% 87% 
44 
 
62% 10% 81b 
 
95% 88% 
93  100% 100%        
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2.11 Concluding remarks 
 
I have generated 14 novel compounds with different heterocyclic cores and then 
subjected them to DYRK1A inhibition assays. However, none of these derivatives 
showed any DYRK1A inhibition with all the IC50 values of over 1000 nM. 
Regardless, these results have provided us with the valuable knowledge that the 7-
azaindole heterocyclic core shows more potent activity against DYRK1A than other 
heterocycles, even when maintaining the diphenolic characteristics. By comparing 
analogues 43 with 44 we have shown that the distance between the two phenols has 
strong effects on the DYRK1A inhibition. Comparing analogue 70 to lead compound 
20a has hinted that the NH moiety is important, probably to act as a hydrogen bond 
donor in the binding modes. These data will be of use for designing further structure-
activity relationship studies to further improve the selective inhibition of DYRK1A. 
 
Based on the results of this chapter, further structural modification for the production 
of novel compounds will be attempted in the next chapter. As is shown in Figure 27, 
the aims could be realised by disconnecting the pyrrole ring of 20a to generate 
pyridine based diphenols 99, that have different spacing by virtue of different carbon 
linkers. Further disconnection of the pyridine ring could afford the linear analogues 
100 or 101, also with different carbon linkers between the two phenols. The 
methylated analogues would also be explored to again probe the importance of the 
NH functionality. The synthesis and screening of these analogues is described in 
Chapter 3. 
 
 
Figure 27. Further exploration for 7-azaindole core-opening derivatives 99−101.  
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Chapter 3 - Synthesis and biological evaluation of ring-opened 
analogues 
3.1 Introductory remarks 
 
As described in Chapter 2, the 7-azaindole core has provided the best potency for 
DYRK1A inhibition in comparison to a small panel of other heterocycles. In this 
chapter, again starting from 7-azaindole DANDY (20a), I chose to investigate diverse 
skeletons with disconnection of lead compound 20a, while retaining the hydrogen 
bonding characteristics to explore its inhibition potentials against DYRK1A (Figure 
28). Regardless of DYKRK1A potency, we would also test the cytotoxicity of all 
these novel compounds against cancer cells, in particular, glioblastoma cell lines, as a 
global test of non-DYRK1A potency. Glioblastoma represents the most common type 
of primary tumour in the central nervous system.257 Established A172 glioblastoma 
cell lines express higher quantities of DYRK1A than that in the patient-derived 
glioblastoma cell lines.258 As DYRK1A activity correlates with DYRK1A protein 
quantity, higher DYRK1A quantity (thus higher DYRK1A activity) in the established 
glioblastoma cells could render these cells more sensitive to DYRK1A inhibition. For 
this reason, we wanted to screen all analogues in A172 glioblastoma cells to 
investigate their functional activity in cancer cells. To that end, we first examined lead 
compound 20a, making disconnections to the 5-membered ring giving rise to the 1-
amino pyridine compounds 99 with various linker lengths (n = 0 to 3) (Figure 28). 
This was then further deconstructed, opening the pyridine ring to produce the 
secondary or tertiary chain compounds 100 or 101, respectively, again examining 
various linker lengths (n = 0 to 2). 
 
Figure 28. Design of 7-azaindole core-opening derivatives from disconnection of lead 
compound 20a. 
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3.2 Synthesis of compounds with disconnection of pyrrole ring 
 
The formation of compound 99a was initially designed to follow the retrosynthetic 
approach shown in Figure 29, starting from commercially available 102a with the 
fluoride as a good leaving group. The strategy involved nucleophilic substitution with 
an aniline to afford the corresponding secondary amine, followed by a standard 
Suzuki coupling reaction and sequential deprotection to afford 99a. However, this 
was not successful when I treated 102a with 34a under several different conditions 
(See Table 9). I first tried NaH as a base in THF, and heated to 70 °C (Entry 1, Table 
9), but no desired compound was obtained after 24 h. Then the higher boiling point 
and polarity solvent DMF was trialed, but again no product was obtained, and both 
starting materials were recovered. Finally, pyridine was used as both the base and 
solvent, and the mixture was heated to 100 °C with stirring for 24 h. These conditions 
also proved unsuccessful. 
 
 
 
Figure 29. Retrosynthesis of analogue 99a from 102a. 
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Table 9. Conditions screening for nucleophilic substitution of 102a 
 
 
 
Entries Base Solvent Temperature  Product (%) 
1 NaH THF 25 to 70 °C NR 
2 NaH DMF 25 to 100 °C NR 
3 pyridine pyridine 25 to 100 °C NR 
 
In light of these results, I chose 102b as the starting material (Scheme 21). Compound 
103 was successfully obtained by a copper-catalysed boronic acid cross-coupling 
reaction at room temperature in air in moderate yield.259 This Chan-Lam type reaction 
was realised in the absence of ligand and base, and a mechanism has been proposed in 
previous studies by Rao and co-workers (Figure 30).259 The obtained compound 103 
subsequently underwent a standard Suzuki coupling reaction with boronic acid 40 to 
furnish compound 104 in good yield (80%), followed by the deprotection of both TBS 
groups in the presence of TBAF to afford analogue 99a. 
 
 
 
Scheme 21. Reagents and conditions: (a) 40 (1.2 equiv.), Cu(OAc)2 (0.1 equiv.), 
MeOH, RT, 12 h, 60%; (b) 40 (1.2 equiv.), Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 2.0 
equiv.), 1,4-dioxane, 90 °C, 3 h, 80%; (c) TBAF (1.5 equiv.), THF, RT, 10 min, 95%.  
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Figure 30. Tentative mechanistic proposal for the transformation of 102b to 103 
catalysed by Cu(OAc)2 in the air.259 
 
Analogues 99b and 99d were both achieved from the same starting material 102b as 
used previously (Scheme 22). As for the reductive amination reaction in the step a, I 
initially tried to treat 102b with 4-hydroxybenzaldehyde in EtOH at 70 °C for 1 h, 
followed by addition of NaBH(OAc)3, but no product was obtained, which we 
assumed was due to the failure of the required imine formation. The addition of a 
catalytic amount of AcOH to this reaction was still unsuccessful. Alternatively, using 
AcOH as solvent and heating to 80 °C for 1 h before adding NaBH(OAc)3, afforded 
trace amounts of the desired product. Interestingly, when I treated 102b and 4-
hydroxybenzaldehyde with CF3CH2OH as solvent, the reaction was realised at room 
temperature to get compound 105 in moderate yield (68%).260 Similarly, I then treated 
102b with compound 106 under the same conditions to afford compound 107 in good 
yield (89%). A Suzuki coupling reaction between compounds 105 or 107 with boronic 
acid was subsequently performed to afford 99b and 108 respectively. Hydrogenolysis 
of 108 furnished the desired compound 99d in excellent yield.  
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Scheme 22. Reagents and conditions: (a) 106 or 4-hydroxybenzaldehyde (1.0 equiv.), 
NaBH(OAc)3 (1.5 equiv.), CF3CH2OH, RT, 12 h, 68−89%; (b) (4-
hydroxyphenyl)boronic acid (1.2 equiv.), Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 2.0 
equiv.), 1,4-dioxane, 90 °C, 3 h, 70−80%; (c) H2, Pd/C (10 wt. %), MeOH, RT, 2 h, 
90%.  
 
The synthesis of analogue 99c was accomplished by starting from commercially 
available 2,5-dibromopyridine (109) (Scheme 23), which was treated with 
nucleophilic p-methoxyphenyletheneamine to give intermediate 110,261 followed by a 
Suzuki cross-coupling reaction resulting in aryl-substituted pyridine 111. Subsequent 
demethylation of 111 using BBr3 afforded the final compound 99c in moderate yield 
(59%) (Scheme 23). 
 
 
 
Scheme 23. Reagents and conditions: (a) 2-(4-methoxyphenyl)ethan-1-amine (1.2 
equiv.), K2CO3 (3.0 equiv.), DMF, 120 °C, 8 h, 63%; (b) (4-methoxyphenyl)boronic 
acid (1.5 equiv.), Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 2.0 equiv.), 1,4-dioxane, 
90 °C, 5 h, 90%; (c) BBr3 (6.0 equiv.), CH2Cl2, 0 °C to RT, 15 h, 59%. 
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3.3 Synthesis of compounds with disconnection of pyridine ring 
 
Compound 100a was synthesised262 from 4-aminophenol 112a and glyoxal to give the 
corresponding Schiff base without further purification (Scheme 24), followed by the 
reduction by NaBH4 to give the secondary amine 100a in good yield. Tertiary amine 
101a could be easily obtained by reductive amination by using 37% formaldehyde 
and NaBH4 in EtOH. Similarly, condensation of p-hydroxybenzaldehyde (113) with 
ethylenediamine afforded the diimine intermediate that, following reduction, gave 
100b. An additional reductive amination of 100b produced tertiary amine 101b in 
comparable yield. 
 
 
 
Scheme 24. Reagents and conditions: (a) glyoxal (40% in ethanol, 0.9 equiv.), 
ethanol, RT, 4 h; (b) NaBH4 (1.0 equiv.), MeOH/CH2Cl2, 1:1 (v/v), 0 °C to RT, 30 
min, 86−93% over two steps; (c) (1) formaldehyde (37%, 10.0 equiv.), ethanol, RT, 
30 min; (2) NaBH4 (1.0 equiv.), RT, 30 min, 88−90% over two steps; (d) 
ethylenediamine (0.5 equiv.), toluene, 110 °C, 20 min. 
 
The synthesis of 100c and 101c initially started from commercially available 4-
methoxyphenylethylamine 114 (Scheme 25), whose treatment with diethyl oxalate 
afforded oxalamide 115 in high yield (91%).263 Subsequent reduction in the presence 
of LiAlH4 furnished secondary amine 116 in 92% yield. Demethylation of 116 was 
initially attempted by treatment with BBr3 in dry CH2Cl2, but failed to give the 
demethylated product returning unreacted starting material. Alternatively, methylated 
amine 116 was treated with concentrated HBr (48%) and stirred at 120 °C for 5 h and 
the desired compound 100c was obtained in good yield.264 Secondary amine 100c was 
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then subjected to reductive amination under standard conditions described previously 
to give tertiary amine 101c in excellent yield (90% over two steps). However, 
considering the multiple steps in this synthetic approach, the synthesis of 100c and 
101c was then devised by using a more efficient approach shown in Scheme 24. 
Compound 100c was efficiently prepared from 4-(2-aminoethyl)phenol amine 112b, 
followed by the standard reductive amination in two consecutive steps to afford 100c 
in excellent yield. An additional reductive amination of 100c successfully produced 
tertiary amine 101c in a similar manner (Scheme 24). 
 
 
 
Scheme 25. Reagents and conditions: (a) diethyl oxalate (0.55 equiv.), toluene, 
110 °C, 12 h, 91%; (b) LiAlH4 (10.0 equiv.), dry THF, 0 to 70 °C, 12 h, 92%; (c) aq. 
HBr (48%), 120 °C 5 h, 80%; (d) formaldehyde (37%, 10.0 equiv.), ethanol, RT, 30 
min; (2) NaBH4 (1.0 equiv.), RT, 30 min, 90% over two steps. 
 
3.4 Structure-activity relationship study 
 
With these derivatives in hand, potency for DYRK1A inhibition was determined by 
performing a kinase assay in triplicate with Woodtide as a substrate and an ATP 
concentration of 100 µM. The lead compound 20a was confirmed to have inhibitory 
potency against DYRK1A with an IC50 of 14 nM (See Table 10). I first tested the 
pyrrole ring opened 2-aminopyridine compounds 99a–d. The diarylamine 99a showed 
no inhibition at >1000 nM (Table 10) with a greater than 100-fold loss of potency in 
comparison to lead compound 20a. We assumed that the unreasonable distance and 
angles between the two phenols prohibited inhibitory activity. Compounds 99b–d, 
which avoided this problem by increasing the distance between the two phenols, were 
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also tested, but showed similar results, IC50 values were increased to over 1000 nM 
for all aminopyridine compounds (Table 10). 
 
Despite the undesirable results obtained, we expected that compounds 100a–c and 
101a–c, where the pyridine ring was also disconnected, would show better results, 
which was rationalised in two ways. Firstly, that these compounds were now 
symmetrical, giving greater malleability within the binding pocket. Secondly, the two 
nitrogen atoms are essential to inhibition258 and by increasing the flexibility between 
these two atoms, and not just the phenol groups, we thought ideal interactions could 
be achieved. The hydrogen bond donor/acceptor and not just acceptor was also 
explored with compounds 100 and 101, respectively. Unfortunately these 
rationalisations proved to be unfounded, as compounds 100a−c did not improve any 
inhibitory potency against DYRK1A. All IC50 values were shown to be greater than 
1000 nM (Table 10). These results were replicated with the methylated tertiary 
amines 101a−c with values also greater than 1000 nM (Table 10).   
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Table 10. Kinase inhibition assay of 20a, 99a–d, 100a–c and 101a–c. 
 
Compounds Structures 
DYRK1A 
(IC50, nM) 
Compounds Structures 
DYRK1A 
(IC50, nM) 
20a 
 
14 101a 
 
> 1000 
99a 
 
> 1000 100b 
 
> 1000 
99b 
 
> 1000 101b 
 
> 1000 
99c 
 
> 1000 100c 
 
> 1000 
99d 
 
> 1000 101c 
 
> 1000 
100a 
 
> 1000    
 
With the undesired results for DYRK1A inhibition, we next wanted to test the 
cytotoxicity of all the compounds against cancer cells, in particular, the established 
A172 glioblastoma cell lines. In our investigation, lead compound 20a was also 
tested, which showed cytotoxicity against A172 cell lines with EC50 value of 3.4 µM. 
In comparison, analogue 99d, which bears three-carbon chain linker between phenol 
amine and pyridine ring, has showed moderate cytotoxic activity despite the total loss 
of DYRK1A inhibition, although analogues 99a−c exhibited EC50 values of more than 
50 µM (Table 11). More interestingly, secondary amine 100a with disconnection of 
both the pyrrole and pyridine rings showed the best cytotoxicity potential against 
A172 cells with EC50 value of 2.4 µM. This means that while it did not show any 
inhibition against DYRK1A, it exhibited more cytotoxicity than that of lead 
compound 20a. When testing methylated tertiary amine 101a, much weaker activity 
was observed, though some moderate cytotoxicity was still observed (EC50 = 22.9 
µM). Secondary amines 100b−c or tertiary amines 101b−c with longer distance 
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totally lost their cytotoxic behaviour in this study. More interestingly, when both 100a 
and 101a were tested of their cytotoxicity in astrocyte cells (non-tumor cells), neither 
of them kills astrocytes even at extremely high concentration (up to 50 µM) (Figure 
31). 
 
Table 11. Cell viability assay of compounds 20a, 99a–d, 100a–c and 101a–c in 
glioblastoma cell lines (A172). 
 
Compounds Structures 
A172  
(EC50, µM) 
Compounds Structures 
A172  
(EC50, µM) 
20a 
 
3.4 ± 0.0 101a 
 
22.9 ± 2.8 
99a 
 
49.9 ± 0.5 100b 
 
>50 
99b 
 
>50 101b 
 
>50 
99c 
 
>50 100c 
 
>50 
99d 
 
20.2 ± 0.8 101c 
 
>50 
100a 
 
2.4  ± 0.2    
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Figure 31. Cytotoxicity of 100a and 101a in non-tumor cells (astrocytes). Columns in 
grey represent DYRK1A inhibition when treated with 100a in 0, 2.5 and 5.0 µM 
concentration; Columns in black represent DYRK1A inhibition when treated with 
101a in 0, 2.5 and 5.0 µM concentration. 
 
3.5 Concluding remarks 
 
I have generated a library of 10 novel compounds and subjected them to inhibition 
assays against DYRK1A. Unfortunately, for all the new compounds reported, 99a–d, 
100a–c and 101a–c, nanomolar potency of DYRK1A inhibition was not obtained. 
These results may implicate the importance of the 7-azaindole motif for DYRK1A 
inhibition. It is hypothesised that it is not just the positioning of two nitrogen atoms in 
a similar spatial arrangement that affords strong potency, but the importance of 
aromatic skeleton with specific spatial arrangements of the two nitrogen atoms can be 
confirmed. These data will be of use for designing further structure-activity 
relationship studies to further improve the selective inhibition of DYRK1A. 
 
Additionally, an interesting finding of this study is that although ring-opened 
compounds have completely lost inhibitory activity against our initial target 
DYRK1A, some of them exhibit markedly potent cytotoxicity against glioblastoma 
cells. In particular, analogue 100a has killed cancer cells even more potently than lead 
compound 20a with an EC50 value of 2.4 µM. More impressively, when both 100a 
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and 101a were tested of their cytotoxicity in astrocyte cells (non-tumor cells), neither 
of them kills astrocytes even at extremely high concentration (up to 50 µM) (Figure 
31), this finding has provided us with extremely important information to step further 
for the mechanism studies of their potency against tumour cells rather than non-
tumour cells.. 
 
In summary, this study has provided us more information and references for future 
studies on modifications for more novel compounds. For example, the flexible spatial 
position of two nitrogen atoms has dramatically affected the inhibitory activity against 
DYRK1A, which means that the aromaticity of the di-nitrogen arrangement is 
necessary to keep DYRK1A inhibition. Therefore, the subsequent chapter will detail 
the design and synthesis of novel analogues with diverse functional groups at the C-3 
and C-5 position of the 7-azaindole core, and their inhibition of DYRK1A and 
selectivity over other off-targets such as DYRK1B, DYRK2 and CLK1. 
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Chapter 4 - Synthesis and biological evaluation of 7-azaindole-based 
analogues 
4.1 Introductory remarks  
 
The work described within this chapter has formed the basis of a publication in The 
Journal of Medicinal Chemistry.258 
 
Glioblastomas, as very aggressive brain tumours, have been studied for decades. One 
of the therapeutic strategies involves targeting the EGFR kinase, overexpression of 
which has been found in half of glioblastoma.265 Accordingly, EGFR expression in 
glioblastoma is associated with diverse pathological and functional features, such as 
invasive behavior.266 Recent studies indicated that DYRK1A is highly expressed in 
glioblastoma, expression of which is indirectly correlated to that of EGFR. 
Furthermore, inhibition of DYRK1A expression was found to promote EGFR 
degradation in glioblastoma, resulting in the reduced number of tumourigenic cells.267 
To address the therapeutic potential of simultaneously targeting DYRKs, we 
developed a series of novel DYRK inhibitors and evaluated their efficacy, including 
DYRK1A inhibition, selectivity, cell viability, clonogenic survival and cell invasion 
in stem cell-like glioblastoma cell lines.  
 
Interestingly, DYRK1B and CLK1 are also overexpressed in glioblastoma, indicative 
of cell cycle deregulation through various signalling pathways.128,268 CLK1 is a prime 
regulator of alternative splicing. It not only increases cell proliferation,105 but also 
increases expression of anti-apoptotic proteins Bcl-XL (B-cell lymphoma-extra large) 
and Mcl-1 (induced myeloid leukemia cell differentiation protein),269 that results in 
resistance to apoptotic stimuli. DYRK1B, however, has the capacity to induce 
reversible cell arrest in a quiescent state, and its inhibition has been suggested to 
renew the cell cycle and sensitise cancer cells to chemotherapy and molecularly 
targeted therapy.88-89,270-272 Encouraged by these studies, it occurred to us that 
inhibitors targeting multiple kinases (such as DYRK1A, DYRK1B and CLK1) might 
be beneficial for treatment of a complex disease"cancer. Therefore, compounds as 
multiple kinases inhibitors against DYRK1A, DYRK1B as well as CLK1 are 
specifically explored in glioblastoma cells for their cellular efficacies in this chapter. 
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Figure 32. Potential structural modifications of DANDY (20a). 
 
According to previous studies in Chapters 2 and 3, the 7-azaindole moiety is 
important, providing not only hydrogen bond donor/acceptor groups, but also 
possessing a flat ring shape with aromatic positioning of two nitrogen atoms. Herein, 
we sought to investigate the functionality of DANDY (20a) to improve its inhibitory 
activity for DYRK1A, and also explore inhibition selectivity over other structurally 
related kinases such as DYRK1B, DYRK2 and CLK1. Two separate areas of 
functionality would be investigated: 1) different functionality at the C-3 and C-5 
positions, while maintaining the hydrogen bond donor characteristics, and 2) different 
linkages between the azaindole core and the phenol substituents (namely amide 
linkages) (Figure 32). The compounds obtained were evaluated in a glioblastoma-
relevant cell model. 
 
4.2 Synthetic route of aryl-azaindole derivatives 
 
We explored compounds with different substituents at the C-3 and C-5 positions. 
Firstly, derivatives 119a−d with varying substituents at the C-3 position were 
designed and synthesised while maintaining the phenol group at the C-5 position. 
These derivatives could be synthesised from the same intermediate 26a as employed 
in the synthesis of 20a in Chapter 2 by utilising sequential Suzuki cross-coupling 
reactions.228,273 To maximise yield, the temperature in the first Suzuki coupling 
reaction must be below 100 °C (90 °C was found to be optimal) with a slight excess 
of arylbronic acid. Under these conditions, the synthesis of compounds 117a−c 
proceeded in 78−85% yields. Electron-rich boron derivatives are more favoured in 
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transmetallation,236 thus the lowest yield was obtained with the electron-poor (4-
nitrophenyl)boronic acid (Scheme 26). 
The second cross coupling required the installation of 4-hydroxyphenyl substituent. 
Considering the low yield resulting from demethylation with BBr3, (4-
hydroxyphenyl)boronic acid was used instead of (4-methoxyphenyl)boronic acid in 
the second Suzuki coupling reaction (condition b, Scheme 26). To our delight, good 
to excellent yields were obtained with the only modification for the second step being 
a higher temperature (reflux vs 90 °C). Compound 118c was treated with TMSN3 
under microwave conditions274 to obtain the cyclised tetrazole compound 118d in 
good yield. Tosyl deprotection to afford compounds 119a−c was achieved using the 
standard procedure described previously, which typically proceeded in 90−95% yield. 
The resulting compound 119a was subsequently reduced in the presence of iron 
powder under acidic conditions to afford aniline 119d in moderate yield (Scheme 26). 
 
 
 
Scheme 26. Reagents and conditions: (a) arylboronic acid, Pd(PPh3)4 (2 mol%), aq. 
K2CO3 (2 M, 2.0 equiv.), toluene/ethanol 3:1, 90 °C, 3−5 h, 78−85%; (b) arylboronic 
acid, Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 2.0 equiv.), toluene/ethanol 3:1, 110 °C, 
3−5 h, 80−93%; (c) TBAF (1.0 equiv.), TMSN3 (10.0 equiv.), sodium ascorbate (0.2 
equiv.), CuSO4•5H2O (0.1 equiv.), t-BuOH/H2O, 1:1 (v/v), MW (100 W, 80 °C), 2 h, 
81−83%; (d) KOH (5.0 equiv.), MeOH, 80 °C, 2 h, 90−95%; (e) Fe powder (10.0 
equiv.), aq. HCl (3 M, 0.03 M), 110 °C, 3 h, 70−84%. 
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Modifications at the C-5 position were preceded by a first installation of the phenol 
group at C-3 position to afford compound 117d, again using (4-
hydroxyphenyl)boronic acid with no protection necessary (condition a, Scheme 26). 
The desired compounds 119e−h were successfully obtained over two or three steps 
from intermediate 117d with no significant decrease in yield compared to compounds 
119a−d.   
 
With compound 119h in hand, further modification of the aniline moiety was 
performed (Table 12). Selectivity for the NH2 over the indole NH or phenolic OH 
was achieved due to a greater nucleophlicity of NH2 towards the chosen electrophiles. 
Acetamide 120a (entry 1, Table 12) was obtained by acetylation275 of 119h by 
treatment with acetic anhydride in acetic acid at 110 °C. Sulfonamide derivative 120b 
was furnished in mild conditions and moderate yield by treating 119h with 
methanesulfonyl chloride (MsCl) in H2O at room temperature (entry 2, Table 12).276 
The relatively low isolated yield resulted from work-up, which was performed by 
extracting the reaction mixture with organic solvent (ethyl acetate or CH2Cl2). The 
resulting organic layers were monitored by TLC again which indicated that the 
formed sulfonamide 120b was slowly converted into the starting material 119h in 
nonacidic conditions. Compound 120b was stable to be characterised and persisted 
when kept as a solid under an inert atmosphere. However, these observations do pose 
problems for biological stability and need to be taken into account when considering 
results. Urea derivative 120c was obtained in 70% yield by using a low melting 
mixture of citric acid, urea and mannitol at 80 °C in the absence of additional 
solvent.277 Addition of I2 in this reaction has been reported278 to act as a Lewis acid to 
activate the carbonyl of urea to afford the desired compound 120c in a shorter time. In 
the absence of I2, reported procedures are quite sluggish and result in a much lower 
yield compared with that in the presence of I2. 
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Table 12. Design and synthesis of 119h derivatives 120a−c. 
 
 
 
Entries Conditions Product Yield 
1 
Ac2O (1.2 equiv.), 
AcOH, 110 °C, 5 h 
120a 77% 
2 
 
MsCl (1.5 equiv.), H2O, 
RT, 10 h  
 
120b 64% 
3 
Urea (15.0 equiv.), I2 
(0.1 equiv.), citric acid, 
mannitol, 80 °C, 6 h 
120c 70% 
 
4.2.1 Structure-activity relationship study of synthesised compounds 119b−h and 
120a−c 
 
All the novel compounds prepared above were then subjected to inhibition assays at 
DYRK1A, DYRK1B, DYRK2 and the structurally related CLK1. Kinase assays were 
performed with Woodtide as a substrate for DYRK kinases and RS peptide as a 
substrate for CLK1. ATP concentration (100 µM) was kept constant to allow for 
comparison of potencies across the kinases. In comparison, harmine (not shown in 
Table 13) and lead compound 20a inhibited DYRK1A with IC50 values of 360 and 14 
nM, respectively. Inhibitor 20a showed nearly equal potency against DYRK1B (15 
Conditions
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nM, Table 13), which had not been previously reported.220 In addition, 20a showed a 
10-fold weaker inhibitory potency against DYRK2 (166 nM, Table 13), but also 
displayed inhibitory activity at CLK1 with an IC50 value of 48 nM.  
 
Table 13. Kinase inhibition and cellular efficacy of DANDY (20a) and C3-modified 
analogues 119b−d. 
 
 
  Kinase inhibition assay (IC50, nM) Cell viability assay (EC50, µM) 
 R DYRK1A DYRK1B DYRK2 CLK1 RN1 WK1 JK2 SJH1 
20a 
 
14 
± 2 
15 
± 5 
166 
± 22 
48 
± 7 
2.0  
± 0.4 
1.1 
± 0.1 
5.1 
± 0.6 
4.1 
± 1.0 
119b 
 
169 
± 52 
83 
± 25 
571 
± 149 
117 
± 35 
5.7  
± 1.3 
6.2 
± 2.3 
6.3  
± 1.7 
2.2 
± 0.5 
119c 
 
280 
± 53 
172 
± 53 
416 
± 46 
85 
± 5 
> 50 > 50 >50 > 50 
119d 
 
>1,000 >1,000 >1,000 >1,000 > 50 > 50 >50 > 50 
 
Next, we tested how modification of the phenol at the C-3 position affects kinase 
inhibition. Bioisosteric replacement of the phenol moiety with indole (119b) resulted 
in 10-fold weaker DYRK1A inhibition (IC50 = 169 nM) and comparable loss of 
activity was observed against DYRK1B (IC50 = 83 nM), DYRK2 (IC50 = 571 nM) and 
CLK1 (IC50 = 117 nM). Substitution of phenol for a phenyltetrazole moiety at C-3 as 
seen in 119c further reduced kinase inhibition activity (85−280 nM) and the aniline 
analogue (119d) resulted in complete loss of kinase inhibition (IC50 > 1 µM) (Table 
13). 
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Compounds with differing substitution on C-5 showed interesting results (Table 14). 
Both 4-nitrophenyl (119e) and indole (119f) analogues showed weaker DYRK1A 
inhibition (212 and 204 nM, respectively), but indole-analogue 119f potently inhibited 
CLK1 (IC50 = 26 nM) and DYRK1B (IC50 = 51 nM). Analogues with phenyltetrazole 
(119g) or aniline (119h) both showed inhibitory potencies against DYRK1A, 
DYRK1B and CLK1 with IC50 range from 32 nM to 86 nM.  Interestingly, reversing 
the substitutions on C3 and C5, aniline 119h (IC50 up to 32 nM) had greater than 20-
fold higher activity than 119d (IC50 > 1000 nM) (Table 13). These results provide 
evidence that phenol substitution at the C-3 position plays a crucial role in 
maintaining potent inhibition, while greater variability was tolerated at the C5 
position. Compounds with further modifications of the aniline 119h showed excellent 
results. The sulfonamide (120b) or urea (120c) inhibited DYRK1A with IC50 values 
in double-digit nanomolar potency (31−86 nM), although comparable nanomolar 
potency was determined for these inhibitors against DYRK1B and CLK1. Selectivity 
over DYRK2 was detected with 10-fold difference between IC50 values. Whether or 
not the sulfonamide moiety in compound 120a survived the testing conditions is 
uncertain, but due to the different results compared to the aniline 119h it would 
suggest that this was indeed the case. The introduction of phenylacetamide at C-5 
(120a) led to the strongest DYRK1A inhibition (6.6 nM) with 5-fold selectivity over 
DYRK1B (38 nM) and CLK1 (35 nM), and 80-fold selectivity over DYRK2 (536 
nM). 
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Table 14. Kinase inhibition and cellular efficacy of C-5 analogues. 
 
 
  Kinase inhibition assay (IC50, nM) Cell viability assay (EC50, µM) 
 R DYRK1A DYRK1B DYRK2 CLK1 RN1 WK1 JK2 SJH1 
 
119e 
 
 
212 
± 36 
198 
± 45 
>1,000 
187 
± 27 
> 50 > 50 >50 > 50 
 
119f 
  
204 
± 46 
51 
± 8 
644 
± 99 
26 
± 6 
> 50 > 50 >50 
30 
± 5 
 
119g 
  
86 
± 17 
42 
± 6 
408 
± 60 
70 
± 9 
> 50 > 50 >50 > 50 
 
119h 
 
 
43 
± 9 
32 
± 16 
567 
± 168 
34 
± 8 
1.1  
± 0.3 
0.9 
± 0.3 
8.0  
± 0.2 
3.2 
± 0.3 
 
120a 
 
 
6.6 
± 1.2 
38 
± 15 
536 
± 108 
35 
± 3.5 
2.1  
± 0.3 
0.9 
± 0.2 
8.6  
± 1.7 
5.1 
± 0.8 
 
120b 
 
 
56 
± 17 
130 
± 37 
724 
± 153 
44 
± 14 
14 
± 4 
42 
± 5 
13 
 ± 2 
42 
± 6 
 
120c 
  
31 
± 10 
17 
± 8 
476 
± 60 
9.6 
± 1.5 
22 
± 4 
>50 >50 
28 
± 8 
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4.3 Synthesis of indole-based derivatives with selected functional groups  
 
According to the biological activities described above, 7-azaindole based analogues 
with different substituents at the C-3 or C-5 position showed variable potencies 
against DYRKs and CLK1. With these results, it is of scientific interest to incorporate 
an alternatively substituted indole in place of the azaindole in a similar manner, 
despite the loss of activity observed by the indole-based diphenol analogue 26b in 
chapter 2. Therefore, I investigated three more derivatives with selected functional 
groups (indole, tetrazole-phenyl and tetrazole) based on an indole scaffold (Scheme 
27). The synthesis of analogues 120d−e could be achieved in a similar fashion to the 
methods described in Scheme 26, starting from the key intermediate 26b mentioned 
in Chapter 2. The obtained methoxy intermediates 119i and 119j could be further 
treated with BBr3 to give demethylated compounds 120d and 120e, respectively. 
 
 
Scheme 27. Reagents and conditions: (a) arylboronic acid, Pd(PPh3)4 (2 mol%), aq. 
K2CO3 (2 M, 2.0 equiv.), toluene/ethanol 3:1, 90 °C, 3 h, 93−94%; (b) arylboronic 
acid (1.2 equiv.), Pd(PPh3)4 (2 mol%), aq. K2CO3 (2 M, 2.0 equiv.), toluene/ethanol 
3:1, 110 °C, 5 h, 87−90%; (c) TBAF (1.0 equiv.), TMSN3 (10.0 equiv.), sodium 
ascorbate (0.2 equiv.), CuSO4•5H2O (0.1 equiv.), t-BuOH/H2O, 1:1 (v/v), MW (100 
W, 80 °C), 2 h, 74%; (d) KOH, MeOH, 80 °C, 2 h, 89−94%; (e) BBr3 (6.0 equiv.), 
CH2Cl2, 0 °C to RT, 10 h, 67−70%. 
 
Analogue 120f with tetrazole substitution at the C-3 position was prepared from 
starting material 25b (Scheme 28). Cyanated compound 117g was generated by 
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cyanation at the C-3 position by treatment with chlorosulfonylisocyanate and TEA in 
acetonitrile279 and subsequent tosyl protection of indole nitrogen in moderate yield 
over two steps. The following arylation at the C-5 position was realised via a Suzuki 
coupling reaction to give compound 118l in excellent yield. Tetrazole-containing 
119k was furnished in a similar manner described above in Scheme 26, and the final 
compound 120f was eventually obtained from the demethylation of 119k by treatment 
with BBr3 in reasonable yield.  
 
 
Scheme 28: Reagents and conditions: (a) (1) chlorosulfonylisocyanate (1.1 equiv.), 
TEA (1.05 equiv.), CH3CN, 0 °C to RT; (2) NaH (60% in mineral oil, 3.0 equiv.), 
TsCl (1.2 equiv.), BnEt3NCl (0.02 equiv.), CH2Cl2, 0 °C to RT, 30 min; 72% over two 
steps; (b) (4-methoxyphenyl)boronic acid (1.5 equiv.), Pd(PPh3)4 (2 mol%), aq. 
K2CO3 (2 M, 2.0 equiv.), toluene/ethanol 3:1, 110 °C, 3 h, 92%; (c) TBAF (1.0 
equiv.), TMSN3 (10.0 equiv.), sodium ascorbate (0.2 equiv.), CuSO4•5H2O (0.1 
equiv.), t-BuOH/H2O, 1:1 (v/v), MW (100 W, 80 °C), 2 h, 77%; (d) KOH (5.0 
equiv.), MeOH, 80 °C, 2 h, 96%; (e) BBr3 (6.0 equiv.), CH2Cl2, 0 °C to RT, 10 h, 
70%. 
4.3.1 Structure-activity relationship study of synthesised compounds 120d−f 
 
With indole-based derivatives 120d−f in hand, kinases inhibition assays were 
evaluated shown in Table 15. Unfortunately, none of them showed active potency 
against either DYKRs or CLK with all IC50 values of over 1000 nM. Compound 
120d, in comparison to 119f (DYRK1A, IC50 = 204 nM, Table 14), has lost its 
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activity against DYRK1A by replacement of the 7-azaindole core with an indole core. 
This suggests that the 7-nitrogen is crucial in maintaining the kinase inhibition. 
Despite compounds 120e-f exhibiting inactivity against all the tested kinases, 
compound 119c, in comparison with the only difference in 7-position displayed 
moderate potency against DYRK1A with its IC50 value of 280 nM. This further 
confirms the importance of 7-azaindole scaffold compared with other heterocyclic 
rings. 
 
Table 15. Kinase inhibition and cellular efficacy of 120d−f. 
 
 
  Kinase inhibition assay (IC50, nM) Cell viability assay (EC50, µM) 
 R1, R2 DYRK1A DYRK1B DYRK2 CLK1 RN1 WK1 JK2 SJH1 
120d 
 
>1000 >1000 >1000 >1000 
26.9 
± 3.2 
22.1 
±1.6 
33.5 
± 4.0 
>50 
120e 
 
>1000 >1000 >1000 >1000 >50 >50 >50 >50 
120f 
 
>1000 >1000 >1000 >1000 >50 >50 >50 >50 
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4.4 Synthesis of novel derivatives with amide linker 
 
Since 7-azaindole core has been confirmed as crucial, I next investigated diverse 
skeletons with different geometries and increased spatial flexibility. The next set of 
targets therefore contained a linker between the 7-azaindole core and phenol group. 
The hydroxy position of the phenol group connected with an amide linker was 
investigated at both the para- and meta-positions of phenyl ring (Scheme 29). 5-
carboxamide derivatives 126a−b were made from starting material 25a. After 
protection with a tosyl group, the given compound 121 was transformed to carboxylic 
acid derivative 122. This was achieved by treating with freshly prepared acetic-formic 
anhydride (synthesised according to the reported routes280),281 and palladium acetate 
with dppf as the ligand. The related catalytic mechanism was proposed previously 
(Figure 33).282-283 CO was generated in situ in the presence of base, followed by the 
formation of the acylpalladium complex (RCOPdX), which subsequently reacted with 
acetate to generate the anhydride intermediate (RCOOAc) to eventually achieve the 
carboxylic acid after hydrolysis. This method allows for the safe in situ genesis of CO 
without handling toxic gases. 
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Scheme 29. Reagents and conditions: (a) TsCl (1.2 equiv.), NaH (60% in mineral oil, 
1.5 equiv.), THF, 0 °C, 1 h, 90%; (b) Pd(OAc)2 (5 mol%), dppf (10 mol%),  acetic-
formic anhydride (5.0 equiv.), i-Pr2NEt (5.0 equiv.), DMF, 110 °C, 5 h, 83%; (c) 
HBTU (1.2 equiv.), i-Pr2NEt (2.5 equiv.), aniline 34a or 34b (1.1 equiv.), DMSO, 
0 °C−RT, 2 h, 61−79%; (d) KOH (5.0 equiv.), MeOH, 80 °C, 1 h, 94−96%; (e) I2 (1.2 
equiv.), KOH (3.0 equiv.), DMF, RT, 8 h, 80−86%;  (f) arylboronic acid, Pd(PPh3)4 (2 
mol%), aq. K2CO3 (2 M, 2.0 equiv.), toluene/ethanol 3:1, 100 °C, 3−5 h, 60−65%; (g) 
trichloroacetyl chloride (1.2 equiv.), AlCl3 (2.5 equiv.), 0 °C, 3 h; (h) NaOH (3 M), 
RT, 5 h, 70% over two steps; (i) TBAF (1.5 equiv.), THF, RT, 30 min, 93−95%; 
HBTU = (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate).  
N NR
Br
N
HOOC
N
Ts
N NH
N
H
O
OH
N N
N
H
O
Ts
TBSO
HO
25a  R = H
121    R = Ts 122 123a 4-OTBS123b 3-OTBS
a
b c
e
f
N NH
COOH
Br
N NH
O NH
Br
OTBS
g, h
N NH
O NH
OTBS
HO
N NH
O NH
OH
HO
127 128a 4-OTBS
128b 3-OTBS
129a 4-OTBS
129b 3-OTBS
130a 4-OH
130b 3-OH
c d i
d
N NH
N
H
O
HO
124a 4-OH
124b 3-OH
N NH
N
H
O
HO
125a 4-OH
125b 3-OH
I
126a 4-OH
126b 3-OH
NH2
TBSO
34a 4-OTBS
34b 3-OTBS
Chapter 4 
 95 
 
 
Figure 33. Proposed mechanism of carboxylic acid formation via in situ genesis of 
CO.282 
 
With compound 122 in hand, the amide coupling was attempted by treating 122 with 
oxalyl chloride and catalytic DMF in CH2Cl2 to form the acyl chloride intermediate, 
followed by addition of aniline derivative 34a or 34b. Unfortunately, the desired 
amide compound was not successfully obtained. Neither aniline nor acid was 
consumed, so we assumed that the formation of acyl chloride intermediate was not 
successful in this case. Alternatively, the treatment of 122 with aniline derivative 34a 
or 34b in the presence of coupling reagent HBTU afforded desired compounds 
123a−b in comparable yields.284 The amides obtained were initially treated with I2 
and KOH to iodinate at the C-3 position but no reaction was observed and starting 
material was recovered. It was hypothesised that this was a result of the electron 
withdrawing tosyl group which reduced the nucleophilicity of C-3. Therefore, 
deprotection of the tosyl group was performed by KOH in MeOH under reflux. 
However, the TBS group was not tolerated under these conditions and as a result, the 
concomitant deprotection of both TBS group and tosyl group gave compounds 
124a−b.285 The following iodination286 at the C-3 position with I2 and KOH was 
successful and gave compounds 125a−b in good yields. The final compounds 126a-b 
could then be easily obtained by a standard Suzuki cross-coupling reaction described 
previously.  
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Similarly, compounds 130a−b could be obtained by again starting with 25a (Scheme 
29). The tosyl protected compound 121 was first employed in a Friedel-Crafts 
reaction by treatment with trifluoroacetic anhydride in the presence of Lewis acid 
AlCl3, but no product was obtained with starting material still present. The more 
reactive electrophile trichloroacetyl chloride was tested287 yet compound 121 again 
failed to react. Instead, the unprotected compound 25a was reacted directly. The 
trifluoroacetic anhydride method was unsuccessful but by treating 25a with 
trichloroacetyl chloride, the trichloroacetyl intermediate was obtained with all starting 
material consumed. Subsequent hydrolysis afforded the carboxylic acid 127 in 70% 
yield over two steps. Subsequent amide formation with 34a−b proceeded by using the 
optimised HBTU conditions described above to afford 128a−b. Suzuki-coupling gave 
129a−b which could be TBS deprotected with TBAF to afford final compounds 
130a−b (Scheme 29).288 
 
4.4.1 Structure-activity relationship study of amides 
 
We next explored the effect of an amide linker at position C-3 or C-5 on kinase 
inhibition (Table 16). Compounds 130a or 130b with an amide linker at the C-3 
position resulted in complete loss of kinase inhibition (IC50 > 1 µM) which was in line 
with results obtained with other C-3 modified analogues 119b−d. The same 
modification at the C-5 position was better tolerated − analogues 126a and 126b 
inhibited DYRK1A with higher IC50 values (344 and 127 nM, respectively). 
Interestingly, both 126a and 126b showed selective inhibition against CLK1 over 
DYRKs members. With these results in hand, we wanted to further investigate the 
effect of these compounds on cell viability and cell-based functional evaluation, such 
as cellular thermal shift assay, EGFR degradation, clonogenic survival, migration and 
invasion. 
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Table 16. Kinase inhibition and cellular efficacy of analogues with an amide linker. 
 
 
  
Kinase inhibition assay  
(IC50, nM) 
Cell viability assay  
(EC50, µM) 
 R1 and R2 DYRK1A DYRK1B DYRK2 CLK1 RN1 WK1 JK2 SJH1 
 
126a 
 
344 
± 84 
128 
± 31 
>1,000 
12 
± 3 
12.5 
± 2.9 
21.0 ± 
4.7 
37.8 
± 3.4 
5.2 
± 2.2 
 
126b 
 
127 
± 54 
138 
± 51 
847 
± 50 
34 
± 8 
13.8 
± 1.2 
13.2 ± 
1.2 
38.9 
± 0.1 
5.7 
± 0.1 
 
130a 
 
 
>1,000 >1,000 >1,000 >1,000 > 50 > 50 >50 > 50 
 
130b 
 
 
>1,000 >1,000 >1,000 >1,000 > 50 > 50 >50 > 50 
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4.5 Cell-based screening  
 
Glioblastoma is a heterogeneous cancer with great variability between patients and 
even within the same patient. Glioblastoma tumours have been sub-classified into four 
molecular subtypes − classical, proneural, neural and mesenchymal.289 Therefore, we 
have chosen to screen all potent inhibitors in patient-derived glioblastoma cells (RN1, 
JK2, WK1 and SJH1, respectively). These cells were grown as stem cells under 
defined conditions in order to maintain the phenotype and genotype of the primary 
resected tumours (Figure 34B).290-292 Viability of cells treated with test compounds 
was determined in the Alamar blue assay (Table 13−16).  
 
 
Figure 34. Expression of DYRK/CLK1 kinases and genotype of patient-derived 
glioblastoma cell lines. (A) Cell lysate of untreated cells were analysed with Western 
blotting using indicated antibodies (representative image of 2 independent blots).  (B) 
Subtype and genotype of patient-derived glioblastoma cell line RN1, JK2, WK1 and 
SJH1 as previously described.291-292 
 
The lead compound 20a diminishes the viability of RN1 cells with an EC50 of 2.0 µM 
with a comparable reduction in other glioblastoma cell (Table 13). Compounds 119h 
and 120a, as the two most potent kinase inhibitors developed in this study, have 
reduced classical RN1 viability with 1.1 µM and 2.1 µM potency, respectively (Table 
14). More excitingly, mesenchymal WK1 cells are the most responsive cells to these 
inhibitors (EC50 = 0.9−2.1 µM), furthermore the viability of the neural SJH1 and 
proneural JK2 cell lines were also reduced by 119h and 120a with the EC50 values 
β-actin 
DYRK1A 
DYRK1B 
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51
 A B 
Cell line  Subtype  Genotype                                    
RN1   Classical  p53wt, CDKN2A null, 
    PTENwt  
JK2   Proneural  p53 mut, CDKN2A null,  
    PTENwt  
WK1   Mesenchymal  p53 wt, CDKN2A null,  
    PTEN null  
SJH1   Neural  p53 mut, CDKN2A null,  
    PTENwt, NF1 mut 
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ranging 3.2−8.6 µM. Compounds 120b and 120c, however, were 13 times less potent 
in the cell viability assays (EC50 > 13 µM) versus 119h (EC50 = 1.1 µM). This 
reduction in efficacy could arise from the increased polarity and reduced cell 
membrane permeability, though off-target effects could also be a contributing factor. 
For the remaining compounds, cellular efficacy correlated with the potency in the 
kinase inhibition assay (see as Table 15 and 16). 
 
4.5.1 Cell-based functional evaluation  
 
To evaluate the most potent inhibitors, we further tested analogues 119h and 120a in 
cell-based assays. Analogue 119d was employed as a negative control, which lacks 
the kinase inhibition activity and was not cytotoxic to primary cells (Table 13).  
 
4.5.1.1 Cellular thermal shift assay (CETSA)  
 
To demonstrate target engagement in cells, compound 119h was assessed for its 
ability to penetrate cells and bind to DYRK1A. We used a cellular thermal shift assay 
(CETSA)293-294 to assess DYRK1A engagement in U251 cells as this cell line 
expresses high quantities of DYRK1A (See Figure 34A). The method was 
implemented as follows: U251 cells were treated with analogue 119h (10 µM) and 
cell suspensions were heated to different temperatures to induce protein denaturation. 
Soluble proteins were extracted with an aqueous buffer and analysed with Western 
blotting. Inhibitors that bind to their cognate target in cells would yield a stabilised 
protein, which will be detected at higher temperatures compared to the resultant 
denaturation profile in cells without drug treatment.  
 
As a result, 119h efficiently stabilised DYRK1A, but not the structurally unrelated 
p38α MAPK (Figure 35A−B). To investigate 119h concentration effects, we derived 
the isothermal dose-response fingerprint (ITDRFCETSA), which is a characteristic 
ligand-induced protein stabilisation at a constant temperature. Indeed, the DYRK1A 
biochemical potency of 119h (IC50 = 43 nM) translated well into its cellular target 
engagement (ITDFRCETSA = 711 nM; Figure 35C−D).  
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Figure 35. Treatment of U251 cells with inhibitor 119h stabilises DYRK1A and 
decreases cell viability. CETSA melt curves (40−67 °C) for DYRK1A and p38α (A) 
and quantification (mean ± SEM) of 3 independent experiments (B) were determined 
in intact U251 cells treated with compound 119h (1 h, 10 µM). Representative image 
(C) and quantification (mean ± SEM) of 2 independent experiments (D) of 
ITDRFCETSA in intact U251 cell treated with compound 119h (0−20 µM, 1 h) at 
54 °C.  
 
4.5.1.2 EGFR degradation 
 
To confirm DYRK1A inhibition in cells treated with 119h, we performed an EGFR 
degradation assay. Overexpression of DYRK1A has been shown to block EGFR 
degradation, resulting in reduction of cell proliferation.295 We therefore tested 119h 
for its ability to increase EGFR degradation in U251 cells. EGFR protein translation 
was blocked with cyclohexamide and EGFR degradation was induced with EGF (100 
ng/mL). Cell lysates were collected at indicated time points and the amount of non-
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degraded EGFR quantified by Western blotting (Figure 36A). Pre-treatment of cells 
with 119h (2.5 µM) reduced EGFR half-life to 11.3 ± 2.5 min in comparison to that in 
untreated U251 cells (25.6 ± 7.6 min) (Figure 36B). Importantly, a similar effect was 
observed with genetic knockdown of DYRK1A.  Using siRNA approach, we 
achieved on average 80% reduction in DYRK1A expression (Figure 36C) and this 
DYRK1A down-regulation reduced EGFR half-life to 3.3 ± 2.5 min (Figure 36D).  
 
 
 
Figure 36. DYRK1A inhibition induces EGFR degradation. (A) U251 cells were 
treated with DMSO (Ctr) or compound 119h (2.5 µM) for 4 h. Cells were incubated 
with cycloheximide (30 µg/mL; 1 h) and EGF (100 ng/mL) was added for indicated 
time points. (B) U251 cells were treated with scramble (Ctr) or DYRK1A-targeting 
siRNA for 24 h. Cells were incubated with cycloheximide (30 µg/mL; 1 h) and EGF 
(100 ng/mL) was added for indicated time points. Cell lysates were analysed by 
Western Blotting using indicated antibodies. (C−D) EGFR levels were normalised to 
loading control (β-actin) and are expressed as percentage of untreated cells (0 min).  
Half-life (t1/2) values were calculated by non-linear regression analysis and represent 
mean ± SEM from 3 independent experiments.  
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4.5.2 Clonogenic survival 
 
Based on kinase inhibition in vitro and in cells, we evaluated compounds 119h and 
120a for their ability to reduce long-term survival of glioblastoma cells. Compounds 
119h and 120a dose-dependently inhibited clonogenic survival of RN1 with EC50 
values of 0.8 and 2.1 µM (Figure 37A−B), respectively; mirroring the EC50 values 
obtained in the short-term viability assay (Table 14). Compound 119h was more 
efficacious at reducing the survival of the established U251 cell line (EC50 = 0.18 µM, 
Figure 37C).    
 
 
                         119h                                                                120a                                                            119h 
 
Figure 37. Clonogenic survival following drug treatment.  Patient-derived RN1 
glioblastoma cells were treated with 119h (A) or 120a (B) for 10 days. Established 
U251 glioblastoma cells were treated with 119h (C) for 10 days. Colonies were fixed, 
stained with Toluidine Blue and counted using the ImageJ software. Data were 
normalised to vehicle-treated controls (set as 100% survival) and EC50 values 
calculated by non-linear regression analysis. EC50 values represent mean ± SEM from 
3 independent experiments performed in duplicate. One-way ANOVA, followed by 
Dunnett’s multiple comparison test was used to determine statistical significance. (*P 
< 0.05, *** P < 0.001, ****P < 0.0001 in relation to vehicle-treated cells).  
 
4.5.3 Migration and invasion 
 
We finally assessed 119h, 120a, and the inactive analogue 119d using in vitro assays 
of cell migration and invasion (Table 17). We employed U251, A172 and RN1 cell 
lines, all of which without treatment by any compounds (Conc. = 0 µM) show high 
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basal velocity of migration and invasion (Table 17). When treated with 119h, 
migration of A172, U251 and RN1 cells were all reduced up to 75% when a 
concentration of 5 µM was reached (Table 17), and invasiveness of A172 and U251 
cells in a dose-dependent manner were also blocked (Table 17). Similar effects were 
observed across all assays with the analogue 120a, whereas the inactive analogue 
119d was not effective at all in the migration and invasion assays (Table 17).  
 
Table 17. Inhibition of migration and invasion of glioblastoma cells by CMGC 
inhibitors 119h and 120a, and inactive analogue 119d. Values represent mean ± SEM 
from 3 independent experiments. 
 
 
Conc. 
(µM) 
U251 
migration 
(ύ, µm/h) 
U251 
invasion 
(ύ, µm/h) 
A172 
migration 
(ύ, µm/h) 
A172 
invasion 
(ύ, µm/h) 
RN1 
migration 
(ύ, µm/h) 
119h 
0.0 2,163 ± 133 1,337 ± 93 3,123 ± 103 2,659 ± 674 1,174 ± 158 
1.0 1,247 ± 176 1,139 ± 112 2,828 ± 271 2,675 ± 475 355 ± 28 
5.0 127 ± 56 234 ± 22 728 ± 308 1,538 ± 696 118 ± 43 
10.0 129 ± 52 -149 ± 12 131 ± 129 714 ± 585 208 ±77 
120a 
0.0 2,159 ± 48 1,710 ± 97 2,739 ± 428 3,047 ± 506 1,115  ± 110 
1.0 1,125 ± 93 736 ± 117 2,891 ± 147 2,731 ± 431 332 ± 33 
5.0 173 ± 38 34 ± 153 2,296 ± 564 2,027 ± 419 210 ± 64 
10.0 111 ± 1 -118 ± 37 651 ± 300 1,718 ± 517 196 ± 47 
119d 
0.0 2,653 ± 395 1,151 ± 133 2,650 ± 675 2,990 ± 997 937 ± 17 
1.0 2,331 ± 143 1,451 ± 69 3,123 ± 745 2,411 ± 241 1,070 ± 246 
5.0 2,370 ± 39 1,481 ± 181 3,065 ± 718 2,232 ± 498 929 ± 253 
10.0 2,702 ± 239 1,380 ± 73 2,827 ± 709 2,707 ± 491 791 ± 236 
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4.6 Concluding remarks 
 
While others have concentrated on the development of selective DYRK1A 
inhibitors,215,296 our goal was to understand the SAR across the DYRK family and 
CLK1. In our studies, potent inhibitor 120a showed about 6-fold more potent activity 
against DYRK1A over DYRK1B, which demonstrated that selective inhibition of 
DYRK1A is possible within the CMGC family of protein kinases. The potency of 
tested analogues to inhibit DYRK1A and DYRK1B activity was comparable to the 
potency of inhibitors against CLK1; with exception of compound 126a and 126b 
which inhibited CLK1 with >10-fold higher potency than DYRK1A/B, these 
interesting results are quite significant for future design of CLK1 inhibitors. Finally, 
all compounds displayed selectivity as their inhibitory action at DYRK2 with >10-
fold higher IC50 values. After screening anti-cancer efficacy in established and stem 
cell-like glioblastoma cell lines, we found that the potent inhibitor 119h for both 
DYRK1A/DYRK1B and CLK1 (IC50 ≤ 50 nM) significantly decreased viability, 
clonogenic survival, migration and invasion of glioblastoma cells than that of the 
most potent inhibitor 120a for DYRK1A only, which demonstrated that inhibitors 
targeting multiple kinases are beneficial in the treatment of tumours. We also 
demonstrate that DYRK1A’s thermal stability in cells was increased upon compound 
treatment, confirming binding in cells by using cellular thermal shift assay.  
 
 
 
Figure 38. SAR analysis of derivatives from 20a. 
 
Accordingly, 7-azaindole based compounds, as is shown in Figure 38, have been 
further analysed in terms of their SAR. The N-C-NH as a key moiety plays an 
N NH
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important role in keeping potent inhibitory activities against DYRKs as both a 
hydrogen bond donor and acceptor. Moreover, we found that C3-modified analogues 
failed to inhibit all kinases, underlining the importance of the C-3 phenolic group 
attached to the 7-azaindole core. In particular, aniline 119d completely lost its 
inhibitory potency against DYRK1A with an IC50 value of up to 1000 nM, 
presumably its NH2 can be protonated which decreases its electrostatic interaction 
with the ammonium ion of conserved Lys188 residue. However, the reason why 
potency of other analogues such as 119b and 119c with different hydrogen bond 
donors at the C-3 position varied in kinase inhibition remains elusive. Interestingly, 
the C-5 position offered scope for improvement of activity and yielded analogues with 
low nanomolar potency. In particular, acetamide 120a has shown selectivity between 
DYRK1A and DYRK1B with a ratio of 5:1. The potency and selectivity probably 
results from several factors including, 1) the acetamide moiety acts as a hydrogen 
bond donor/acceptor; 2) it has a decreased spatial distance between 120a and Ile165 
residue compared with the hydroxy group of DANDY; 3) the methyl group of 
acetamide improves its hydrophobicity and thus increases its hydrophobic interaction 
with the hydrocarbon side chain of hinge residue Ile165. 
 
In summary, the protein kinases of the DYRK family are emerging as potential targets 
for small molecule cancer therapy. We have presented a library of novel potent and 
cell-active DYRK kinase inhibitors based on the 7-azaindole scaffold. Future work 
will be focused on the biological evaluation of these potent analogues in an in vivo 
animal model of glioblastoma, including the permeability in cells and BBB, as well as 
the tolerance abilities in the actrual environment in vivo.  
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Chapter 5 - Summary and future work 
 
5.1 Summary and conclusion 
 
In the work described in this Thesis, I have systematically generated a small library of 
compounds based on structural modifications to the lead compound DANDY (20a), 
and all of these compounds have been subjected to DYRK1A inhibition assays. In 
some instances, selectivity against other off-targets including DYRK1B, DYRK2 and 
the structurally related CLK1 has been also evaluated. Additionally, for the most 
promising compounds functional activity was investigated in glioblastoma cells, 
which have provided us relevant information for further studies in the future. 
 
The nature of the 7-azaindole core of DANDY (20a) was found to be essential for 
DYRK1A inhibition and selectivity over other off-targets. Replacement by other 
heterocyclic rings such as indole, indazole, benzimidazole, pyrazole-pyridine, 
bipyridine, naphthyridine, imidazole or triazolopyrazine has resulted in dramatic 
reduction in DYRK1A inhibition. 
 
In terms of the ring-opened analogues, investigations have revealed that relatively 
more flexible compounds failed to exhibit nanomolar potency against DYRK1A, even 
though they possess similar spatial arrangements of two nitrogen atoms mimicking 
the 7-azaindole scaffold. Interestingly, some of ring-opened compounds have showed 
markedly potent cytotoxicity against glioblastoma cells by cell viability assays. In 
particular, linear compound 100a killed cells more effectively than DANDY. Since 
these ring-opened analogues’ cell cytotoxicity was not correlated with the capacity for 
DYRK1A inhibition, the internal mechanism is still unknown, which drives us to 
further explore their mode of action. 
 
Exploration of the nature of the biaryl substitutions on C-3 or C-5 position of the 7-
azaindole core has revealed that various modifications and substituents at the C-5 
position were much more tolerated than that of the C-3 position. Analogue 120a with 
acetamide rather than hydroxy exhibited the most potent activity against DYRK1A 
with its IC50 up to 6 nM in comparison to DANDY (IC50 = 14 nM). More importantly, 
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derivative 120a has also showed improved selectivity for DYRK1A over DYRK1B 
with a ratio of 5:1 compared with DANDY with that of about 1:1. This is a big 
improvement over previous studies since DYRK1B only differs by a small number of 
amino acids in the ATP-binding site compared with DYRK1A, which makes it 
extremely difficult to design inhibitors only targeting DYRK1A. Additionally, aniline 
119h has shown a broad inhibition for DYRK1A, DYRK1B and CLK1 with all the 
IC50 values of being < 50 nM, as a result, 119h has played effective roles in targeting 
multiple kinases in the therapeutic treatment of glioblastoma in kinases inhibition 
assays and cell viability assays in vitro. 
 
Considering that 7-azaindole scaffold is essential in keeping DYRK1A inhibition, the 
introduction of an amide linkage between the phenol group at the C-3 or C-5 position 
of the 7-azaindole core has been further investigated. However, the analogues 130a−b 
have totally lost their inhibition for DYRKs and CLK1 by the addition of this amide 
linker on C-3 position. This further confirms our observation that phenol substitution 
at the C-3 position is quite essential in maintaining the activity. Interestingly, 
analogues 126a−b with the amide linker at the C-5 position have shown moderate 
potency against DYRK1A with their IC50 values in three digit nanomolar range, even 
though this does make them less effective than DANDY. More surprisingly, amide 
130a−b exhibited selective potency against CLK1 with two digit nanomolar 
concentration (12 nM and 34 nM, respectively), and in the same case, they showed 
relatively cytotoxic activity in all the subtypes of glioblastoma cells. These results 
have provided us very useful directions for our future investigations on CLKs 
inhibitors. 
 
According to the preliminary studies, potent DYRK1A inhibitors such as 119h and 
120a have displayed a very similar trend to the corresponding cellular efficacies in 
vitro assay. This indicates that these promising results warrant further exploration of 
the in vivo activity of the novel inhibitors in animal models, in the hope that these 
promising inhibitors can be utilised in clinical studies for therapeutic treatment of 
cancers. Such efforts are currently underway. 
  
Chapter 5 
 108 
5.2 Future work 
 
As mentioned above, the future work of this project will first involve further 
biological evaluation of these promising inhibitors through in vivo assays, with the 
aim of a potential use of inhibitors for targeting cancer cells. 
 
According to recent studies on DYRK1A inhibitors, Guillou and co-workers have 
reported a novel compound 131a as a potent DYRK1A inhibitor (Figure 39),297 and 
in their studies, an interesting result has been obtained when a methoxy group was 
switched from the 6-position of the 7-azaindole skeleton to the 7-position by a 
replacement of the 7-nitrogen, the resulting analogue 131b has exhibited much more 
potency against DYRK1A than 131a with its IC50 value of 18 nM. This finding has 
given us a hint in the future designs based upon DANDY shown in Figure 39 below. 
The introduction of the methoxy group at the C-6 to give compound 132a might 
provide improvement of its binding affinity within th DYRK1A active site, since 
there is still some space left between the 6-position and the hinge residue according to 
the binding mode described in Chapter 1. Additionally, a switching of the methoxy 
group from the 6-postion to the 7-position to give compound 132b might be 
worthwhile by a replacement of the 7-nitrogen. The oxygen atom of the methoxy 
group has similar properties as a hydrogen bond acceptor in binding modes with that 
of nitrogen atom. 
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Figure 39. Design for novel DYRK1A inhibitors 132a−b. 
 
In 2013, Luk and co-workers have reported a new class of DYRK1A inhibitors 
(Figure 40),298 the exemplified 133a showed very poor inhibitory activity against 
DYRK1A with its IC50 value over 1000 nM. However, with the addition of a phenyl 
group on the long carbon chain, the resulting racemic compound 133b has been 
dramatically increased for its DYRK1A inhibition with its IC50 value in single digital 
nanomolar concentration (9 nM). This interesting finding has driven us to refocus on 
our inactive compounds 99a−d described in Chapter 3 (Figure 40), which have 
totally lost DYRK1A inhibition (IC50 > 1000 nM). Similarly, it might be promising to 
install an additional phenyl group on the carbon chain, increasing π-π interactions in 
the binding modes, and eventually improving its binding affinity within the DYRK1A 
active site. Importantly, it was unknown which confirmation of 133b has made a 
bigger contribution to DYRK1A inhibition in this study. Therefore, more endeavours 
on this aspect are necessary as well in our future directions.  
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Figure 40. Design for novel DYRK1A inhibitors 134. 
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Chapter 6 - Experimental 
6.1 General details 
 
Unless noted otherwise, commercially obtained reagents were used as purchased 
without further purification. Solvents for flash chromatography were distilled prior to 
use, or used as purchased for HPLC grade, with the eluent mixture reported as the 
volume/volume ratio (v/v). Flash chromatography was performed using Merck 
Kieselgel 60 (230–400 mesh) silica gel. Analytical thin-layer chromatography (TLC) 
was performed using Merck aluminum-backed silica gel 60 F254 (0.2 mm) plates 
(Merck, Darmstadt, Germany), which were visualised using shortwave (254 nm) 
ultraviolet fluorescence. Melting points were measured with a rate of 5 °C/min and 
are uncorrected. Infrared absorption spectra were reported as vibrational frequency 
(cm–1). Nuclear magnetic resonance spectra were recorded at 300 K on Bruker 
Advance DRX200, DRX300, DRX400 or DRX500 spectrophotometers. The data are 
reported as chemical shift (δ ppm) relative to the residual protonated solvent 
resonance (CDCl3: δ 7.26, d-DMSO: δ 2.50, d-MeOD: δ 3.31, D2O: δ 4.79 and d-
acetone: δ 2.05), the carbon of the solvent resonance (CDCl3: δ 77.16, d-DMSO: δ 
39.52, d-MeOD: δ 49.00 and d-acetone: δ 29.84/206.26),299 relative integral, 
multiplicity (s = singlet, br.s = broad singlet, d = doublet, dd = doublet of doublets, t = 
triplet, m = multiplet, etc.) and coupling constants (J Hz). Low-resolution mass 
spectra (LRMS) was obtained from a ThermoQuest Finnigan LCQ Deca ion trap mass 
spectrometer with electro-spray ionisation in either positive (+ESI) or negative (-ESI) 
mode.  Data is expressed as observed mass (m/z), assignment (M = molecular ion), 
and relative intensity (%). High-resolution mass spectra (HRMS) was performed on a 
Bruker Apex Qe 7T Fourier Transform Ion Cyclotron Resonance (FTICR) mass 
spectrometer equipped with an Apollo Π ESI dual source. Samples were run with 
syringe infusion at 150 µL/hr on a Cole Palmer syringe pump into electrospray 
ionization (ESI). Atmospheric pressure chemical ionization (APCI) was performed by 
untilising MeOH. High performance liquid chromatography (HPLC) analysis of 
organic purity was conducted on a Waters Alliance 2695 instrument using a 
SunFireTM C18 column (5 µm, 2.1 x 150 mm) and detected using a Waters 2996 
photodiode array (PDA) detector set at 254 nm. Separation was achieved using water 
(solvent A) and acetonitrile (solvent B) at flow rate of 0.2 mL/min and a gradient of 
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0% B to 100% (HPLC Method A) or 0% B to 80% (HPLC Method B) or 0% B to 
40% (HPLC Method C) over 30 min. HPLC data is reported as percentage purity and 
retention time (RT) in minutes. 
 
6.2 Synthesis of compounds from Chapter 2 
 
General procedure A: synthesis of iodinated derivatives 
 
The compounds were prepared following a literature procedure.232 Step 1: To a 
solution of indole-based compound (1.0 equiv.) in CH2Cl2 (0.05 M) was added KOH 
(0.5 equiv.) at RT. After 30 min, NIS (1.0 equiv.) was added, and the mixture was 
stirred for 10 h, quenched with sat. Na2S2O3 (aq.) and extracted with CH2Cl2. The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude product was used in the next step without further purification.   
 
Step 2: To a solution of the iodinated intermediate or 5-bromo-7-azaindole or 
cyanated intermediate (1.0 equiv.) in CH2Cl2 (0.05 M) was added NaH (60% in 
mineral oil, 3.0 equiv.) and benzyltriethylammonium chloride (0.02 equiv.) under 
nitrogen at 0 °C. After 30 min, TsCl (1.2 equiv.) was added at 0 °C, and the mixture 
was allowed to warm to RT. After 2 h, H2O was added and extracted with CH2Cl2. 
The combined organic layers were dried over MgSO4 and concentrated in vacuo.  
 
5-bromo-3-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine (26a) 
 
This compound was prepared according to general procedure A by treating 25a 
(1.97 g, 10 mmol) with NIS (2.25 g, 10 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 15:1 → 10:1) to give the product as a 
white solid (3.86 g, 81% over two steps). m.p. 186−187 °C; Rf (hexane/ethyl acetate 
1) NIS, KOH, CH2Cl2
2) NaH, TsCl, BnNEt3Cl
    CH2Cl2, RT, 30 min
HetR2
N
H
R1 HetR2
N
R1
I
Ts
N N
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10:1): 0.65; 1H NMR (500 MHz, CDCl3): δ 8.44 (1H, d, J = 2.1 Hz), 8.06−8.04 (2H, 
m), 7.86 (1H, s), 7.78 (1H, d, J = 2.1 Hz), 7.29 (2H, d, J = 8.1 Hz), 2.37 (3H, s); 13C 
NMR (125 MHz, CDCl3): δ 146.7, 146.0, 144.7, 134.7, 132.5, 131.4, 130.0, 128.4, 
126.7, 116.0, 60.4, 21.8; LRMS (+ESI): m/z 499/501 (100/97, [M + Na]+). IR (neat, 
cm-1): 3138, 1619, 1371, 1167, 1140, 1015, 527. The spectroscopic data matched 
that reported in the literature.273 
 
5-bromo-3-iodo-1-tosyl-1H-indole (26b) 
 
This compound was prepared according to general procedure A by treating 25b 
(1.96 g, 10 mmol) with NIS (2.25 g, 10 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 20:1 → 10:1) to give the product as a 
white solid (4.24 g, 89% over two steps). 1H NMR (200 MHz, CDCl3): δ 7.83 (1H, d, 
J = 8.7 Hz), 7.75 (2H, d, J = 8.4 Hz), 7.68 (1H, s), 7.51 (1H, d, J = 1.7 Hz), 7.45 (1H, 
dd, J = 1.9, 8.7 Hz), 7.25 (2H, d, J = 8.0 Hz), 2.36 (3H, s); 13C NMR (50 MHz, 
CDCl3): δ 145.8, 134.8, 134.4, 133.3, 131.1, 130.3, 128.8, 127.1, 125.0, 117.7, 115.0, 
65.5, 21.8. The spectroscopic data matched that reported in the literature.300 
 
5-bromo-3-iodo-1-tosyl-1H-indazole (26c) 
 
This compound was prepared according to general procedure A by treating 25c 
(1.97 g, 10 mmol) with NIS (2.25 g, 10 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 20:1 → 10:1) to give the product as an 
off-white solid (3.82 g, 80% over two steps). m.p. 160−161 °C; Rf (hexane/ethyl 
acetate 12:1): 0.50; 1H NMR (500 MHz, CDCl3): δ 8.05 (1H, dd, J = 0.5, 8.9 Hz), 
7.86 (2H, dd, J = 1.7, 6.7 Hz), 7.69 (1H, dd, J = 1.8, 8.9 Hz), 7.60 (1H, d, J = 1.6 Hz), 
7.27 (2H, d, J = 8.1 Hz), 2.38 (3H, s); 13C NMR (125 MHz, CDCl3): δ 146.2, 139.2, 
134.1, 133.5, 131.9, 130.2, 127.9, 125.0, 118.2, 114.8, 102.4, 21.8; HRMS (ESI+) 
ν
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Calc. for C14H10N2O2BrIS [M + Na]+ 498.8583/500.8562, found 498.8579/500.8559. 
IR (neat, cm-1): 3102, 3071, 2923, 1593, 1373, 1238, 663, 531. 
 
General procedure B for di-Suzuki Coupling Reaction 
 
To a solution of 26a−c (1.0 equiv.) in toluene/ethanol 3:1 (0.02 M) was added (4-
methoxyphenyl)boronic acid (2.0 equiv.), aq. K2CO3 (2 M, 4.0 equiv.) and Pd(PPh3)4 
(4 mol%), and the reaction was heated to 110 °C for 5 h under argon. The reaction 
mixture was cooled to RT, concentrated in vacuo, and then partitioned between H2O 
and ethyl acetate. The aqueous layer was extracted with ethyl acetate, and the 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash chromatography (hexane/ethyl acetate 5:1 → 3:1) 
to give the product. 
 
3,5-bis(4-methoxyphenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (27a) 
 
This compound was prepared according to general procedure B by treating 26a 
(2.38 g, 5 mmol) with (4-methoxyphenyl)boronic acid (1.51 g, 10 mmol) to give the 
product as a white solid (2.10 g, 87%). m.p. 158−160 °C; Rf (hexane/ethyl acetate 
2:1): 0.45; 1H NMR (400 MHz, CDCl3): δ 8.64 (1H, d, J = 2.1 Hz), 8.14 (2H, d, J = 
2.0 Hz), 8.12 (1H, d, J = 1.8 Hz), 7.81 (1H, s), 7.54 (2H, dd, J = 2.2, 6.7 Hz), 7.49 
(2H, dd, J = 2.2, 6.7 Hz), 7.29 (2H, dd, J = 0.6, 8.6 Hz), 7.01 (4H, dt, J = 2.2, 8.8 Hz), 
3.87 (3H, s), 3.85 (3H, s), 2.38 (3H, s); 13C NMR (100 MHz, CDCl3): δ 159.6, 159.5, 
146.8, 145.3, 144.2, 135.7, 132.7, 131.1, 129.8, 128.9, 128.7, 128.2, 126.8, 125.3, 
ν
R1 N
R2
Br
I
Ts R1 N
R2
Ts
OMe
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122.7, 122.0, 120.4, 114.8, 114.7, 55.5 (two overlapping signals), 21.8; HRMS 
(ESI+) Calc. for C28H24N2O4S [M + H]+ 485.1529, found 485.1525. IR (neat, cm-1): 
 2920, 2836, 1596, 1381, 1173, 1157, 577. 
 
3,5-bis(4-methoxyphenyl)-1-tosyl-1H-indole (27b) 
 
This compound was prepared according to general procedure B by treating 26b 
(2.38 g, 5 mmol) with (4-methoxyphenyl)boronic acid (1.51 g, 10 mmol) to give the 
product as a white solid (2.08 g, 86%). m.p. 168−170 °C; Rf (hexane/ethyl acetate 
2:1): 0.45; 1H NMR (500 MHz, CDCl3): δ 8.08 (1H, d, J = 10.4 Hz), 7.86 (1H, s), 
7.83 (2H, d, J = 8.0 Hz), 7.64 (1H, s), 7.56−7.54 (3H, m), 7.51 (2H, d, J = 8.2 Hz), 
7.23 (2H, d, J = 8.0 Hz), 7.02 (2H, d, J = 8.2 Hz), 6.97 (2H, d, J = 8.2 Hz), 3.86 (3H, 
s), 3.84 (3H, s), 2.34 (3H, s); 13C NMR (125 MHz, CDCl3): δ 159.3, 159.1, 145.1, 
136.9, 135.3, 134.6, 134.0, 130.2, 130.0, 129.2, 128.5, 127.0, 125.6, 124.3, 124.1, 
123.0, 118.5, 114.5, 114.3, 114.1, 55.5, 55.4, 21.7; HRMS (ESI+) Calc. for 
C29H25NO4S [M + Na]+ 506.1396, found 506.1394. IR (neat, cm-1):  2954, 2932, 
2834, 1609, 1367, 1170, 835, 576. 
 
3,5-bis(4-methoxyphenyl)-1-tosyl-1H-indazole (27c) 
 
This compound was prepared according to general procedure B by treating 26c (2.38 
g, 5 mmol) with (4-methoxyphenyl)boronic acid (1.51 g, 10 mmol) to give the 
product as a white solid (2.03 g, 84%). m.p. 115−117 °C; Rf (hexane/ethyl acetate 
2:1): 0.45; 1H NMR (400 MHz, CDCl3): δ 8.27 (1H, dd, J = 0.6, 8.8 Hz), 7.98 (1H, 
ν
N
Ts
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MeO
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N
N
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dd, J = 0.7, 1.6 Hz), 7.92 (2H, dd, J = 1.7, 6.7 Hz), 7.89 (2H, dd, J = 2.1, 6.8 Hz), 
7.75 (1H, dd, J = 1.7, 8.8 Hz), 7.53 (2H, dd, J = 2.1, 6.7 Hz), 7.23 (2H, d, J = 8.0 Hz), 
7.01 (4H, ddd, J = 2.1, 6.8, 12.4 Hz), 3.87 (3H, s), 3.85 (3H, s), 2.34 (3H, s); 13C 
NMR (100 MHz, CDCl3): δ 160.9, 159.5, 151.9, 145.3, 141.1, 137.9, 134.8, 133.2, 
129.9, 129.7, 128.7, 128.6, 127.7, 125.3, 124.1, 119.3, 114.5, 114.4, 113.9, 55.5 (two 
overlapping signals), 21.7; HRMS (ESI+) Calc. for C28H24N2O4S [M + H]+ 
485.1529, found 485.1527. IR (neat, cm-1): 2934, 2836, 1609, 1303, 1274, 837, 
589, 578. 
 
General procedure C for the deprotection of tosyl group 
 
To a solution of tosyl protected substrate (1.0 equiv.) in MeOH (0.02 M) was added 
KOH (5.0 equiv.), and the reaction was heated to 70 °C for 2 h. After completion 
monitored by TLC, the solvent was removed under reduced pressure, and then 
partitioned between H2O and ethyl acetate. The aqueous layer was extracted with 
ethyl acetate, and the combined organic layers were dried over MgSO4 and 
concentrated in vacuo.  
 
3,5-bis(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine (28a)  
 
This compound was prepared according to general procedure C by treating 27a 
(2.00 g, 4 mmol) with KOH (1.12 g, 20 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 3:1 → 1:1) to give the product as a 
yellow solid (1.25 g, 95%). m.p. 193−194 °C; Rf (hexane/ethyl acetate 1:1): 0.35; 1H 
NMR (300 MHz, CDCl3): δ 11.50 (1H, s), 8.53 (1H, s), 8.37 (1H, d, J = 1.6 Hz), 
7.59−7.51 (5H, m), 7.03 (4H, d, J = 8.6 Hz), 3.87 (6H, s); 13C NMR (75 MHz, 
ν
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CDCl3): δ 159.4, 158.6, 147.3, 140.2, 131.6, 129.9, 128.6, 128.5, 127.6, 127.2, 123.0, 
119.8, 116.7, 114.6 (two overlapping signals), 55.5 (two overlapping signals). The 
spectroscopic data matched that reported in the literature.232 
 
3,5-bis(4-methoxyphenyl)-1H-indole (28b) 
 
This compound was prepared according to general procedure C by treating 27b 
(1.45 g, 3 mmol) with KOH (0.84 g, 15 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 3:1 → 1:1) to give the product as a 
yellow solid (938 mg, 95%). m.p. 153–154 °C; Rf (hexane/ethyl acetate 1:1): 0.35; 1H 
NMR (400 MHz, d-acetone): δ 10.39 (1H, bs), 8.03 (1H, t, J = 1.0 Hz), 7.67 (2H, dd, 
J = 2.2, 6.6 Hz), 7.61 (2H, dd, J = 2.2, 6.6 Hz), 7.53−7.51 (2H, m), 7.42 (1H, dd, J = 
1.8, 8.4 Hz), 7.04 (1H, d, J = 2.2 Hz), 7.02 (2H, t, J = 2.5 Hz), 7.00 (1H, d, J = 2.2 
Hz), 3.84 (3H, s), 3.83 (3H, s); 13C NMR (100 MHz, d-acetone): δ 159.6, 159.0, 
137.4, 136.2, 133.7, 129.5, 129.1, 128.9, 127.3, 123.6, 122.0, 118.1, 117.9, 115.1, 
115.0, 112.9, 55.6, 55.5; HRMS (ESI+) Calc. for C22H19NO2 [M + Na]+ 352.1308, 
found 352.1307. IR (neat, cm-1): 3401, 2953, 2834, 1503, 1273, 837. 
 
3,5-bis(4-methoxyphenyl)-1H-indazole (28c) 
 
This compound was prepared according to general procedure C by treating 27c (2.0 
g, 4 mmol) with KOH (1.12 g, 20 mmol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 3:1 → 1:1) to give the product as a pale yellow 
solid (1.20 g, 91%). m.p. 180−181 °C; Rf (hexane/ethyl acetate 2:1): 0.50; 1H NMR 
(500 MHz, d-DMSO): δ 13.13 (1H, s), 8.12 (1H, s), 7.98 (2H, d, J = 8.7 Hz), 7.66 
N
H
OMe
MeO
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(2H, d, J = 8.6 Hz), 7.63 (2H, d, J = 5.9 Hz), 7.10 (2H, d, J = 8.7 Hz), 7.03 (2H, d, J = 
8.6 Hz), 3.83 (3H, s), 3.80 (3H, s); 13C NMR (125 MHz, d-DMSO): δ 158.9, 158.5, 
143.5, 140.7, 133.4, 133.2, 128.2, 128.1, 126.3, 125.6, 120.6, 117.6, 114.3, 114.3, 
110.9, 55.1 (two overlapping signals); HRMS (ESI+) Calc. for C21H18N2O2 [M + H]+ 
331.1441, found 331.1440. IR (neat, cm-1): 3128, 3024, 2906, 1611, 1243, 804. 
 
General procedure D for demethylation 
 
To a solution of methylated substrates (1.0 equiv.) in dry CH2Cl2 (0.05 M) was 
added BBr3 (1 M, 6.0 equiv.) under nitrogen. The reaction mixture was allowed to 
warm to room temperature for 10 h, then quenched at 0 °C with MeOH and 
concentrated in vacuo.  
 
4,4'-(1H-pyrrolo[2,3-b]pyridine-3,5-diyl)diphenol (20a) 
 
This compound was prepared according to general procedure D by treating 28a (330 
mg, 1 mmol) with BBr3 (6 mL, 6 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a pale yellow 
solid (196 mg, 65%). m.p. 156−158 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H NMR 
(500 MHz, d-DMSO): δ 11.83 (1H, s), 9.69−9.23 (1H, br s), 8.47 (1H, d, J = 2.0 Hz), 
8.30 (1H, d, J = 2.0 Hz), 7.71 (1H, d, J = 2.5 Hz), 7.56 (4H, dd, J = 0.9, 8.6 Hz), 6.87 
(4H, dq, J = 2.0, 8.6 Hz), one OH signal not observed; 13C NMR (125 MHz, d-
DMSO): δ 156.8, 155.7, 147.2, 140.5, 129.5, 128.7, 128.2, 127.7, 125.6, 125.3, 123.2, 
117.9, 115.8, 115.7, 115.0; HRMS (ESI+) Calc. for C19H14N2O2 [M + H]+ 303.1128, 
found 303.1130. IR (neat, cm-1): 3107, 2943, 1611, 1249. HPLC: 98.9% (HPLC 
Method A), RT: 16.4 min. 
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4,4'-(1H-indole-3,5-diyl)diphenol (20b) 
 
This compound was prepared according to general procedure D by treating 28b (329 
mg, 1 mmol) with BBr3 (6 mL, 6 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a white solid 
(181 mg, 60%). m.p. 246−248 °C; Rf (CH2Cl2/MeOH 20:1): 0.50; 1H NMR (500 
MHz, d-MeOD): δ 7.90 (1H, d, J = 1.0 Hz), 7.48 (4H, dd, J = 8.6, 23.2 Hz), 7.42 (1H, 
d, J = 8.5 Hz), 7.35−7.33 (2H, m), 6.86 (4H, dd, J = 8.5, 14.8 Hz), NH and OH 
signals not observed; 13C NMR (125 MHz, d-MeOD): δ 157.2, 156.5, 137.6, 135.8, 
134.2, 129.4, 129.1, 129.0, 127.6, 123.1, 122.0, 118.6, 117.9, 116.5, 116.4, 112.6; 
HRMS (ESI+) Calc. for C20H15NO2 [M + Na]+ 324.0995, found 324.0998. IR (neat, 
cm-1): 3402, 3022, 1514, 1219, 1170, 798. HPLC: >99.9% (HPLC Method A), RT: 
21.7 min. 
 
4,4'-(1H-indazole-3,5-diyl)diphenol (20c) 
 
This compound was prepared according to general procedure D by treating 28c (330 
mg, 1 mmol) with BBr3 (6 mL, 6 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a white solid 
(175 mg, 58%). m.p. 251−252 °C; Rf (CH2Cl2/MeOH 20:1): 0.50; 1H NMR (500 
MHz, d-MeOD): δ 8.11 (1H, s), 7.97 (1H, d, J = 8.7 Hz), 7.82 (2H, d, J = 7.4 Hz), 
7.73 (1H, d, J = 8.7 Hz), 7.51 (2H, d, J = 7.4 Hz), 7.06 (2H, d, J = 7.4 Hz), 6.89 (2H, 
d, J = 7.2 Hz), NH and OH signals not observed; 13C NMR (125 MHz, d-MeOD): δ 
161.6, 158.7, 144.6, 141.4, 139.2, 133.2, 132.6, 131.1, 129.5, 120.3, 119.6, 119.5, 
N
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117.7, 116.9, 112.9; HRMS (ESI+) Calc. for C19H14N2O2 [M + H]+ 303.1128, found 
303.1131. IR (neat, cm-1): 3343, 2980, 1609, 1497, 1263, 1182, 809, 507. HPLC: 
98.8% (HPLC Method A), RT: 19.9 min. 
 
4-bromo-2-fluoroaniline (32) 
 
This compound was prepared following a literature procedure.301 To a suspension 
of 2-fluoroaniline 31 (2.22 g, 20 mmol) in CHCl3 (50 mL) was added NBS (3.56 g, 20 
mmol), and the resulting mixture was stirred at RT for 2 h. After completion 
monitored by TLC, the mixture was quenched with sat. Na2S2O3 (aq.) and extracted 
with CH2Cl2 (3 x 20 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1) to give the product as orange oil (3.42 g, 90%); Rf 
(hexane/ethyl acetate 6:1): 0.35; 1H NMR (300 MHz, CDCl3): δ 7.14 (1H, dd, J = 2.1, 
10.5 Hz), 7.05 (1H, d, J = 8.4 Hz), 6.65 (1H, t, J = 9.0 Hz), 3.72 (2H, br.s); 13C NMR 
(75 MHz, CDCl3): δ 151.5 (d, JCF = 241.5 Hz), 133.9 (d, JCF = 12.8 Hz), 127.5 (d, JCF 
= 3.0 Hz), 118.8 (d, JCF = 21.8 Hz), 117.9 (d, JCF = 3.8 Hz), 109.0 (d, JCF = 9.0 Hz). 
The spectroscopic data matched that reported in the literature.301 
 
4-bromo-2-fluoro-1-nitrobenzene (33) 
 
This compound was prepared following a literature procedure.301 To a solution 
of 32 (1.26 g, 6.6 mmol) in TFA (13 mL) was added aq. H2O2 (30%, 3.4 mL, 33 
mmol) dropwise over 30 min, and the resulting mixture was stirred at 75 °C for 1 h. 
After completion monitored by TLC, the mixture was poured into ice (20 mL), the 
pale yellow precipitate was obtained and filtered, washed by cold water and dried 
under reduced pressure to get the desired compound without further purification 
(1.09g, 75%). Rf (hexane/ethyl acetate 10:1): 0.45; 1H NMR (400 MHz, CDCl3): δ 
7.97 (1H, t, J = 8.0Hz), 7.50 (1H, dd, J = 2.0, 10.0 Hz), 7.47−7.44 (1H, m); 13C NMR 
(100 MHz, CDCl3): δ 155.4 (d, JCF = 268 Hz), 136.4, 129.4 (d, JCF = 9.0 Hz), 128.1 
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(d, JCF = 4.0 Hz), 127.1 (d, JCF = 2.0 Hz), 122.1 (d, JCF = 24.0 Hz). The spectroscopic 
data matched that reported in the literature.301 
 
General procedure E for the TBS protection 
 
The compounds could be prepared according to the literature.302 To a solution of 
hydroxy substrate (1.0 equiv.) in dry DMF (0.05 M) was added imidazole (2.5 or 5.0 
equiv.) at 0 °C, followed by the addition of TBSCl (1.5 or 3.5 equiv.). The reaction 
mixture was allowed to warm to RT for 12 h. After completion monitored by TLC, 
the mixture was extracted with ethyl acetate (3 x 30 mL) and H2O (50 mL), the 
organic layers were dried over MgSO4 and concentrated in vacuo. 
4-((tert-butyldimethylsilyl)oxy)aniline (34a) 
 
This compound was prepared according to general procedure E by treating 4-
aminophenol (2.18 g, 0.02 mol), imidazole (3.2 g, 0.05 mol) and TBSCl (4.53 g, 0.03 
mol). The residue was purified by flash chromatography (hexane/ethyl acetate 10:1 → 
5:1) to give the product as pale yellow oil (4.0 g, 87%). Rf (hexane/ethyl acetate 2:1): 
0.45; 1H NMR (300 MHz, d-DMSO): δ 6.53 (2H, d, J = 8.7 Hz), 8.46 (2H, d, J = 8.7 
Hz), 4.59 (2H, s), 0.93 (9H, s), 0.11 (6H, s); 13C NMR (75 MHz, d-DMSO): δ 145.5, 
142.8, 119.9, 114.9, 25.6, 17.8, −4.6. The spectroscopic data matched that reported in 
the literature.303 
 
4-(5-bromo-2-nitrophenoxy)aniline (35b) 
 
To a solution of 33 (220 mg, 1 mmol) in DMF (10 mL) was added K2CO3 (207 mg, 
1.5 mmol), followed by the addition of 4-((tert-butyldimethylsilyl)oxy)aniline 34a 
(245 mg, 1.1 mmol). The resulting mixture was heated to 90 °C and stirred for 3 h. 
After completion monitored by TLC, the mixture was extracted with ethyl acetate (3 x 
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10 mL) and H2O. The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 5:1 → 2:1) to give the product as a pale yellow semisolid (247 
mg, 80%); Rf (hexane/ethyl acetate 4:1): 0.25; 1H NMR (400 MHz, d-DMSO): δ 7.96 
(1H, d, J = 8.8 Hz), 7.42 (1H, dd, J = 2.0, 8.8 Hz), 6.96 (1H, d, J = 2.0 Hz), 6.88 (2H, 
dd, J = 2.0, 10.8 Hz), 6.65 (2H, dd, J = 2.0, 10.8 Hz), 5.26 (2H, br.s); 13C NMR (100 
MHz, d-DMSO): δ 152.6, 146.7, 143.6, 138.8, 127.4, 127.2, 125.1, 121.1, 120.3, 
115.0; HRMS (ESI+) Calc. for C12H9N2O3Br [M + Na]+ 330.9689/332.9668, found 
330.9691/332.9670. IR (neat, cm-1):  3475, 3385, 3098, 3085, 1615, 1505, 1466, 
1231, 824, 528. 
 
4-((5-bromo-2-nitrophenyl)amino)phenol (35c) 
 
To a solution of 33 (220 mg, 1 mmol) in dry DMF (10 mL) was added K2CO3 (207 
mg, 1.5 mmol), followed by the addition of 4-aminophenol (120 mg, 1.1 mmol). The 
resulting mixture was heated to 90 °C and stirred for 3 h. After completion monitored 
by TLC, the mixture was extracted with ethyl acetate (3 x 10 mL) and H2O. The 
combined organic layer was dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash chromatography (hexane/ethyl acetate 10:1 → 4:1) to 
give the product as a pale orange solid (201 mg, 65%); m.p. 151−152 °C; Rf 
(hexane/ethyl acetate 4:1): 0.30; 1H NMR (300 MHz, d-DMSO): δ 9.65 (1H, br.s), 
9.40 (1H, br.s), 8.02 (1H, d, J = 9.0 Hz), 7.14 (2H, d, J = 8.1 Hz), 6.92−6.84 (4H, m); 
13C NMR (75 MHz, d-DMSO): δ 156.1, 145.0, 131.0, 130.2, 129.0, 128.2, 127.7, 
119.4, 117.7, 116.3; HRMS (ESI+) Calc. for C12H9N2O3Br [M + Na]+ 
330.9689/332.9668, found 330.9692/332.9672. IR (neat, cm-1):  3349, 3089, 1602, 
1556, 1475, 1241, 1198, 747, 531. 
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4-((2-amino-5-bromophenyl)amino)phenol (36) 
 
To a solution of 35c (308 mg, 1 mmol) in acetic acid (15 mL) was added iron powder 
(280 mg, 5 mmol), and the resulting mixture was stirred at RT for 12 h. After 
completion monitored by TLC, the volatile was removed under reduced pressure and 
the residue was washed with sat. NaHCO3 (aq.) and extracted with ethyl acetate (3 x 
15 mL). The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by flash chromatography (CH2Cl2/MeOH 
100:1) to give the product as a brown solid (265 mg, 95%); m.p. 145−147 °C; Rf 
(hexane/ethyl acetate 1:1): 0.25; 1H NMR (400 MHz, d-DMSO): δ 6.91 (1H, dd, J = 
2.4, 8.4 Hz), 6.75 (2H, dd, J = 2.4, 6.8 Hz), 6.68 (1H, d, J = 8.4 Hz), 6.59 (2H, dd, J = 
2.4, 6.8 Hz), 6.55 (1H, d, J = 2.4 Hz), 5.08 (2H, br.s), 4.97 (1H, br.s); 13C NMR (100 
MHz, d-DMSO): δ 146.1, 145.7, 145.3, 138.4, 125.1, 120.2, 118.4, 116.2, 114.8, 
105.5; HRMS (ESI+) Calc. for C12H11BrN2O [M + H]+ 279.0128/281.0107, found 
279.0125/281.0104. IR (neat, cm-1):  3500, 3400, 2896, 1610, 1598, 1510, 1220, 
756, 520. 
 
4-(2-amino-6-bromo-1H-benzo[d]imidazol-1-yl)phenol (37) 
 
This compound was prepared following a literature procedure.237 To a solution of 36 
(200 mg, 0.72 mmol) in the mixture solvent of MeCN-H2O (4:1 (v/v), 10 mL) was 
added cyanogen bromide (158 µL, 0.79 mmol, 5 M in MeCN) at 0 °C. and the 
resulting mixture was allowed to warm to RT for 16 h. After completion monitored by 
TLC, the mixture was treated with sat. NaHCO3 (aq.) (10 mL) and extracted with 
ethyl acetate (3 x 15 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography 
(CH2Cl2/MeOH 100:1 → 20:1) to give the product as a pale pink solid (171 mg, 
78%); m.p. 273−274 °C; Rf (CH2Cl2/MeOH 15:1): 0.20; 1H NMR (400 MHz, d-
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DMSO): δ 9.98 (1H, s), 7.24 (2H, dd, J = 2.0, 6.4 Hz), 7.14 (1H, dd, J = 0.4, 8.4 Hz), 
7.11 (1H, dd, J = 1.6, 8.4 Hz), 6.96 (2H, dd, J = 2.0, 6.4 Hz), 6.81 (1H, dd, J = 0.4, 
1.6 Hz), 6.35 (2H, s); 13C NMR (100 MHz, d-DMSO): δ 157.8, 155.3, 141.6, 136.8, 
128.5, 125.0, 123.8, 116.8, 116.4, 110.4, 110.3; HRMS (ESI+) Calc. for 
C13H10BrN3O [M + H]+ 304.0080/304.0059, found 304.0083/306.0062. IR (neat, cm-
1):  3330, 3205, 1647, 1514, 1449, 1272, 1247, 1122, 800, 727, 586, 432. 
 
General procedure F for mono-Suzuki Coupling Reaction 
 
To a solution of aryl-halide (1.0 equiv.) in toluene/ethanol 3:1 or 1,4-dixoane (0.02 
M) was added arylboronic acid (1.2 equiv.), aq. K2CO3 (2 M, 2.0 equiv.), and 
Pd(PPh3)4 (2 mol%), and the reaction was heated to 90−110 °C for 4 h under argon. 
After completion monitored by TLC, the reaction mixture was cooled to RT, solvent 
was removed under reduce pressure, and then partitioned between H2O and ethyl 
acetate. The aqueous layer was extracted with ethyl acetate, and the combined organic 
layers were dried over MgSO4 and concentrated in vacuo. 
 
4,4'-(2-amino-1H-benzo[d]imidazole-1,6-diyl)diphenol (29) 
 
This compound was prepared according to general procedure F by treating 37 (61 
mg, 0.2 mmol) with (4-hydroxyphenyl)boronic acid (33 mg, 0.24 mmol) in 1,4-
dioxane at 110 °C. The residue was purified by flash column chromatography 
(CH2Cl2: MeOH = 50:1 → 10:1) to afford the product as a pale yellow solid (10 mg, 
30%). m.p. 249−250 °C; Rf (CH2Cl2/MeOH 10:1): 0.35; 1H NMR (400 MHz, d-
DMSO): δ 9.85 (1H, br.s), 9.36 (1H, s), 7.42 (2H, dd, J = 2.0, 6.4 Hz), 7.35 (1H, d, J 
= 1.6 Hz), 7.26 (2H, dd, J = 2.0, 6.8 Hz), 7.06 (1H, dd, J = 1.6, 8.0 Hz), 6.97 (2H, dd, 
J = 2.0, 6.8 Hz), 6.82 (2H, dd, J = 2.0, 6.4 Hz), 6.79 (1H, d, J = 8.0 Hz), 6.14 (2H, 
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br.s); 13C NMR (100 MHz, d-DMSO): δ 157.3, 156.2, 154.9, 143.4, 134.5, 133.8, 
132.6, 128.1, 127.5, 125.8, 117.1, 116.5, 115.5, 112.6, 107.6; HRMS (ESI+) Calc. for 
C19H15N3O2 [M + H]+ 318.1237, found 318.1241. IR (neat, cm-1):  3337, 3135, 
2954, 2921, 2852, 1633, 1608, 1540, 1513, 1459, 1218, 1170, 1101, 835, 801, 513. 
HPLC: 96.0% (HPLC Method A), RT: 16.8 min. 
 
N-(1,6-bis(4-hydroxyphenyl)-1H-benzo[d]imidazol-2-yl)acetamide (30) 
 
To a solution of 29 (30 mg, 0.10 mmol) in acetic acid (1 mL) was added acetic 
anhydride (10 µL, 0.11 mmol) at RT. And the resulting mixture was stirred at 110 °C 
for 3 h. After completion monitored by TLC, the solvent was removed under reduced 
pressure and the residue was neutralised with sat. NaHCO3 (aq.) and extracted with 
ethyl acetate (3 x 15 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography 
(CH2Cl2: MeOH = 50:1 → 10:1) to afford the product as a pale yellow solid (25 mg, 
38%). m.p. 207−209 °C; Rf (CH2Cl2/MeOH 10:1): 0.25; 1H NMR (400 MHz, d-
DMSO): δ 10.28 (1H, br.s), 9.86 (1H, s), 9.45 (1H, s), 7.77 (1H, s), 7.50 (2H, d, J = 
8.4 Hz), 7.43 (1H, d, J = 8.0 Hz), 7.24 (2H, d, J = 8.0 Hz), 7.16 (1H, d, J = 8.4 Hz), 
6.93 (2H, d, J = 8.4 Hz), 6.85 (2H, d, J = 8.4 Hz), 1.95 (3H, s); 13C NMR (100 MHz, 
d-DMSO): δ 170.3, 157.9, 157.1, 141.7, 141.6, 135.6, 134.6, 132.2, 128.3, 128.0, 
126.5, 122.0, 116.5, 116.4, 116.2, 110.7, 23.0; HRMS (ESI+) Calc. for C21H17N3O3 
[M + H]+ 360.1343, found 360.1346. IR (neat, cm-1):  3274, 2953, 2921, 2852, 
1587, 1550, 1513, 1366, 1203, 834, 808, 560. HPLC: 96.6% (HPLC Method A), RT: 
16.6 min. 
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6-bromo-1H-benzo[d]imidazol-2-amine (39) 
 
This compound was prepared following a literature procedure.237 To a solution of 4-
bromobenzene-1,2-diamine 38 (206 mg, 1.1 mmol) in the mixture solvent of MeCN-
H2O (4:1 (v/v), 10 mL) was added cyanogen bromide (240 µL, 1.2 mmol, 5M in 
MeCN) at 0 °C. and the resulting mixture was allowed to warm to RT for 16 h. After 
completion monitored by TLC, the mixture was treated with sat. NaHCO3 (aq.) (10 
mL) and extracted with ethyl acetate (3 x 15 mL). The combined organic layers were 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 10:1) to give the product as a tannish solid 
(186 mg, 80%); Rf (CH2Cl2/MeOH 10:1): 0.20; 1H NMR (400 MHz, d-DMSO): δ 
7.24 (1H, d, J = 2.0 Hz), 7.04 (1H, d, J = 8.4 Hz), 6.97 (1H, dd, J = 2.0, 8.4 Hz), 6.39 
(2H, br.s); 13C NMR (100 MHz, d-DMSO): δ 156.2, 141.2, 137.1, 121.3, 114.4, 
112.5, 111.1. The spectroscopic data matched that reported in the literature.304 
 
(4-((tert-butyldimethylsilyl)oxy)phenyl)boronic acid (40) 
 
This compound was prepared according to general procedure E by treating (4-
hydroxyphenyl)boronic acid (1.38 g, 0.01 mol) with imidazole (3.2 g, 0.05 mol) and 
TBSCl (5.29 g, 0.035 mol). The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1 → 3:1) to give the product as a white solid (2.27 g, 90%). 
Rf (hexane/ethyl acetate 1:1): 0.30; 1H NMR (300 MHz, CDCl3): δ 8.11 (2H, d, J = 
8.4 Hz), 6.96 (2H, d, J = 8.4 Hz), 1.02 (9H, s), 0.26 (6H, s); 13C NMR (75 MHz, 
CDCl3): δ 159.9, 137.6, 119.9, 111.0, 25.8, 18.4, −4.2. The spectroscopic data 
matched that reported in the literature.305 
 
 
 
N
H
NBr
NH2
OTBS
B(OH)2
Chapter 6 
 127 
5-bromo-1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-1H-benzo[d]imidazol-2-amine 
(41a) 
 
This compound was prepared following a literature procedure.237 To a solution of 39 
(106 mg, 0.50 mmol) in MeOH (5 mL) was added (4-((tert-
butyldimethylsilyl)oxy)phenyl)boronic acid 40 (139 mg, 0.55 mmol), followed by the 
addition of Cu(OAc)2 at RT. and the resulting mixture was stirred at RT for 12 h. 
After completion monitored by TLC, the solvent was removed under reduced pressure 
and the crude product was purified by flash chromatography (CH2Cl2/MeOH 200:1 → 
50:1) to give the product as an off-white solid (71 mg, 34%); m.p. 198−199 °C; Rf 
(CH2Cl2/MeOH 20:1): 0.45; 1H NMR (300 MHz, d-DMSO): δ 7.34−7.32 (3H, m), 
7.04 (2H, d, J = 7.8 Hz), 6.99 (1H, d, J = 8.1 Hz), 6.72 (1H, d, J = 8.1 Hz), 6.43 (2H, 
br.s), 0.99 (9H, s), 0.26 (6H, s); 13C NMR (75 MHz, CDCl3): δ 156.5, 154.2, 142.6, 
134.1, 128.1, 126.9, 122.9, 121.7, 118.8, 114.8, 109.5, 25.6, 18.2, −4.4; HRMS 
(ESI+) Calc. for C19H24N3OSiBr [M + H]+ 418.0945/420.0924, found 
418.0941/420.0922. IR (neat, cm-1):  3359, 3060, 2955, 2856, 1654, 1510, 1268, 
915, 840, 802, 519. 
 
6-bromo-1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-1H-benzo[d]imidazol-2-amine 
(41b) 
 
Pale pink solid (106 mg, 51%); m.p. 194−196 °C; Rf (CH2Cl2/MeOH 20:1): 0.40; 1H 
NMR (300 MHz, d-DMSO): δ 7.34 (2H, d, J = 8.1 Hz), 7.15−7.10 (2H, m), 7.05 (2H, 
d, J = 8.1 Hz), 6.84 (1H, s), 6.36 (2H, s), 1.00 (9H, s), 0.27 (6H, s); 13C NMR (75 
MHz, CDCl3): δ 156.6, 128.1, 128.0, 126.8, 125.1, 122.9, 121.8, 117.1, 112.7, 111.5, 
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109.6, 25.6, 18.2, −4.3. HRMS (ESI+) Calc. for C19H24N3OSiBr [M + H]+ 
418.0945/420.0924, found 418.0942/420.0922. IR (neat, cm-1):  3467, 2954, 2928, 
2856, 1644, 1607, 1508, 1255, 908, 837, 804, 513.  
 
General procedure G for the deprotection of TBS ethers 
 
The compounds were prepared following a literature procedure.256 To a solution of 
TBS-protected substrate (1.0 equiv.) in THF (0.05 M) was added TBAF (1 M, 2.0 
equiv.). The resulting mixture was stirred at RT for 30 min. After completion 
monitored by TLC, the solvent was removed in vacuo. 
 
4-(2-amino-6-bromo-1H-benzo[d]imidazol-1-yl)phenol (37) 
 
This compound was prepared according to general procedure G by treating 41b 
(41.8 mg, 0.1 mmol) with TBAF (0.2 mL, 0.2 mmol). The crude product was purified 
by flash chromatography (CH2Cl2/MeOH 100:1 → 20:1) to give the product as a pale 
pink solid (29.3 mg, 93%). The spectroscopic data matched that shown as above. 
 
4-(2-amino-1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-1H-benzo[d]imidazol-6-
yl)phenol (42) 
 
This compound was prepared according to general procedure F by treating 41b 
(41.8 mg, 0.1 mmol) and (4-hydroxyphenyl)boronic acid (16.6 mg, 0.12 mmol) in 
1,4-dioxane at 110 °C. The crude product was purified by flash chromatography 
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(CH2Cl2: MeOH = 50:1 → 20:1) to afford the product as an off-white solid (24 mg, 
55%). m.p. 217−219 °C; Rf (CH2Cl2/MeOH 15:1): 0.35; 1H NMR (400 MHz, d-
MeOD): δ 7.51−7.49 (3H, m), 7.32 (2H, d, J = 8.8 Hz), 7.21 (1H, d, J = 8.4 Hz), 7.04 
(2H, d, J = 8.4 Hz), 6.92−6.90 (3H, m), 1.04 (9H, s), 0.25 (6H, s); 13C NMR (100 
MHz, d-MeOD): δ 159.6, 156.3, 156.0, 142.6, 136.9, 136.7, 135.7, 129.6, 129.1, 
127.0, 121.3, 120.3, 117.9, 113.9, 109.5, 26.2, 19.1, −4.3; HRMS (ESI+) Calc. for 
C25H29N3O2Si [M + H]+ 432.2102, found 432.2099. IR (neat, cm-1):  3483, 3327, 
2953, 2925, 2854, 1631, 1606, 1513, 1470, 1253, 911, 837, 801, 779. 
 
4,4'-(2-amino-1H-benzo[d]imidazole-1,6-diyl)diphenol (29) 
 
This compound was prepared according to general procedure G by treating 42 (21.6 
mg, 0.05 mmol) and TBAF (0.1 mL, 0.1 mmol). The residue was purified by flash 
chromatography (CH2Cl2/MeOH 50:1 → 10:1) to give the product as a pale yellow 
solid (15 mg, 95%). The spectroscopic data matched that shown as above. 
 
General procedure H for condensation reactions  
 
The compounds ware prepared following a literature procedure.306-307 To a solution 
of halogenated pyridine substrate (1.0 equiv.) in dry toluene (0.05 M) was added n-
BuLi (1.1 equiv., 2.5 M in hexane) dropwise at −78 °C, and the resulting mixture was 
stirred for 30 min. N, N-dimethylacetamide or DMF (1.5 equiv.) was added dropwise 
and the mixture was stirred for another 30 min. After completion, the reaction was 
quenched with sat. NH4Cl (aq.) and extracted with ethyl acetate (3 x 15 mL). The 
organic layer was dried over MgSO4 and concentrated in vacuo. 
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1-(5-bromopyridin-2-yl)ethan-1-one (46a) 
 
This compound was prepared according to general procedure H by treating 2,5-
dibromopyridine 45 (237 mg, 1 mmol) with N, N-dimethylacetamide (44 µL, 1.5 
mmol) in dry toluene. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1) to give the product as a white solid (160 mg, 80%); Rf 
(hexane/ethyl acetate 8:1): 0.45; 1H NMR (300 MHz, CDCl3): δ 8.70 (1H, s), 
7.95−7.88 (2H, m), 2.66 (3H, s); 13C NMR (75 MHz, CDCl3): δ 199.2, 151.9, 150.2, 
139.6, 125.4, 123.0, 25.8. The spectroscopic data matched that reported in the 
literature.306 
 
5-bromopicolinaldehyde (46b). 
 
This compound was prepared according to general procedure H by treating 2,5-
dibromopyridine 45 (237 mg, 1 mmol) with DMF (115 µL, 1.5 mmol) in dry toluene. 
The crude product was purified by flash chromatography (hexane/ethyl acetate 10:1) 
to give the product as an off-brown solid (149 mg, 80%); Rf (hexane/ethyl acetate 
8:1): 0.45; 1H NMR (400 MHz, CDCl3): δ 10.03 (1H, s), 8.85 (1H, dd, J = 0.8, 2.0 
Hz), 8.02 (1H, ddd, J = 0.8, 2.0, 8.0 Hz), 7.85 (1H, dd, J = 0.8, 8.0 Hz); 13C NMR 
(100 MHz, CDCl3): δ 192.4, 151.7, 151.3, 140.0, 126.3, 122.8. The spectroscopic data 
matched that reported in the literature.308 
 
General procedure I for benzyl protection  
 
The compounds were prepared following a literature procedure.309 To a solution of 
hydroxyaryl substrate (1.0 equiv., 1 mmol) in DMF (0.05 M) was added K2CO3 (1.5 
equiv., 1.5 mmol), followed by the dropwise addition of benzyl bromide (1.2 equiv., 
1.2 mmol) at RT, and the mixture was stirred at RT for 12 h. After completion 
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monitored by TLC, the solvent was removed under reduced pressure, and the residue 
was washed with H2O (30 mL) and extracted with ethyl acetate (3 x 20 mL), the 
organic layers were dried over MgSO4 and concentrated in vacuo.  
 
Methyl 4-(benzyloxy)benzoate (47a) 
 
This compound was prepared according to general procedure I by treating methyl 4-
hydroxybenzoate (1.52 g, 0.01 mol) with K2CO3 (2.07 g, 0.015 mol) and benzyl 
bromide (1.42 ml, 0.012 mol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 → 5:1) to give the product as a white 
solid (2.37 g, 98%); Rf (hexane/ethyl acetate 4:1): 0.50; 1H NMR (300 MHz, CDCl3): 
δ 8.01 (2H, d, J = 8.1 Hz), 7.43−7.34 (5H, m), 6.98 (2H, d, J = 8.1 Hz), 5.08 (2H, s), 
3.87 (3H, s); 13C NMR (75 MHz, CDCl3): δ 166.7, 162.5, 136.3, 131.6, 128.6, 128.2, 
127.5, 122.8, 114.5, 70.0, 51.8. The spectroscopic data matched that reported in the 
literature.310 
 
4-(benzyloxy)benzaldehyde (47b) 
 
The compounds were prepared according to general procedure I by treating 4-
hydroxybenzaldehyde (1.22 g, 0.01 mol) with K2CO3 (2.07 g, 0.015 mol) and benzyl 
bromide (1.42 ml, 0.012 mol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 → 5:1) to give the product as a white 
solid (1.97 g, 93%). Rf (hexane/ethyl acetate 4:1): 0.35; 1H NMR (300 MHz, CDCl3): 
δ 9.89 (1H, s), 7.84 (2H, d, J = 7.8 Hz), 7.43−7.35 (5H, m), 7.08 (2H, d, J = 7.8 Hz), 
5.15 (2H, s); 13C NMR (75 MHz, CDCl3): δ 190.9, 163.8, 136.0, 132.1, 130.2, 128.8, 
128.4, 127.6, 115.3, 70.4. The spectroscopic data matched that reported in the 
literature.311 
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1-(4-(benzyloxy)phenyl)ethan-1-one (47c) 
 
This compound was prepared according to general procedure I by treating 1-(4-
hydroxyphenyl)ethan-1-one (1.36 g, 0.01 mol) with K2CO3 (2.07 g, 0.015 mol) and 
benzyl bromide (1.42 ml, 0.012 mol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 → 5:1) to give the product as a white 
solid (2.17 g, 96%); Rf (hexane/ethyl acetate 4:1): 0.50; 1H NMR (400 MHz, CDCl3): 
δ 7.94 (2H, dd, J = 2.0, 6.8 Hz), 7.45−7.33 (5H, m), 7.01 (2H, dd, J = 2.0, 6.8 Hz), 
5.12 (2H, s), 2.55 (3H, s); 13C NMR (100 MHz, CDCl3): δ 196.8, 162.7, 136.3, 130.7, 
130.6, 128.7, 128.3, 127.5, 114.6, 70.2, 26.4. The spectroscopic data matched that 
reported in the literature.312 
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General procedure J for aldol condensation 
 
Table 18. Conditions for screening aldol condensation reactions.238-239 
 
 
 
Base Solvent Temperature Product 
t-BuOK THF 25 to 70 °C  48b (85%) 
NaOMe MeOH 25 to 70 °C  48b (80%) 
LDAa THF - 78 to 25 °C  complex mixture 
aLDA was freshly made from n-BuLi (1.0 equiv.) and N,N-diisopropylethylamine (1.2 equiv.) at 
−78 °C. 
 
LDA formation: To a solution of N,N-diisopropylethylamine (1.3 equiv.) in dry THF 
was added n-BuLi (1.2 equiv.) dropwise at −78 °C. After addition, the resulting 
mixture was stirred for 30 min for using. 
 
To a solution of base (0.6 mmol) in solvent (10 mL) was added 27a (110 mg, 0.55 
mmol) at 25 °C or −78 °C, and the resulting mixture was stirred for 30 min. To the 
mixture above was added a solution of 28a (121 mg, 0.5 mmol) in the corresponding 
solvent (0.1 M) dropwise, after addition, the resulting mixture was slowly warmed up 
to 70 °C or 25 °C. The reactions were monitored by TLC for 48 hours. 
 
 
 
N
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4-(benzyloxy)benzoic acid (48b) 
 
This byproduct was prepared according to general procedure J. After 1 h, the 
mixture was cooled to RT and poured into aq. H3PO4 (1%, 10 mL), the off-white 
precipitate was obtained and filtered, washed by cold water and dried under reduced 
pressure to give the product as a white solid without further purification (97 mg, 
85%); Rf (hexane/ethyl acetate 4:1): 0.25; 1H NMR (400 MHz, d-DMSO): δ 12.64 
(1H, br.s), 7.90 (2H, d, J = 9.2 Hz), 7.48−7.33 (5H, m), 7.10 (2H, d, J = 9.2 Hz), 5.19 
(2H, s); 13C NMR (100 MHz, d-DMSO): δ 166.9, 161.9, 136.5, 131.3, 128.5, 128.0, 
127.8, 123.2, 114.6, 69.4. The spectroscopic data matched that reported in the 
literature.313 
 
1-(4-(benzyloxy)phenyl)-3-(5-bromopyridin-2-yl)-3-hydroxypropan-1-one (48d) 
 
This compound was prepared according to general procedure J by treating 46b (186 
mg, 1.0 mmol) with LDA (1.2 mmol) and 47c (249 mg, 1.1 mmol) in dry THF. After 
completion monitored by TLC, the reaction was quenched with sat. NH4Cl (aq.) and 
extracted with ethyl acetate (3 x 15 mL). The organic layer was dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 → 3:1) to give the product as a white 
solid (322 mg, 78%); m.p. 133−134 °C; Rf (hexane/ethyl acetate 3:1): 0.25; 1H NMR 
(400 MHz, CDCl3): δ 8.58 (1H, d, J = 2.4 Hz), 7.93 (2H, d, J = 9.0 Hz), 7.82 (1H, dd, 
J = 2.4, 8.4 Hz); 7.51 (1H, d, J = 8.0 Hz), 7.43−7.32 (5H, m), 6.99 (2H, d, J = 9.0 
Hz), 5.31 (1H, p, J = 4.0 Hz), 5.12 (2H, s), 4.31 (1H, d, J = 4.8 Hz), 3.60 (1H, dd, J = 
3.6, 17.6 Hz), 3.36 (1H, dd, J = 8.0, 17.6 Hz); 13C NMR (100 MHz, CDCl3): δ 198.6, 
163.2, 160.7, 149.7, 139.4, 136.1, 130.7, 129.9, 128.8, 128.4, 127.5, 122.1, 119.2, 
114.8, 70.3, 70.2, 45.0; HRMS (ESI+) Calc. for C21H18BrNO3 [M + Na]+ 
434.0362/436.0342, found 434.0365/436.0345. IR (neat, cm-1):  3257, 2890, 1672, 
1601, 1571, 1253, 1170, 1011, 828, 699, 543. 
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General procedure K for the oxidation of alcohols  
 
To a solution of alcohol substrate (1.0 equiv.) in CH2Cl2 (0.05 M) was added Dess-
Martin periodinane (DMP) (1.5 equiv.), and the mixture was stirred at RT for 30 min. 
After completion monitored by TLC, the mixture was quenched with sat. NaHCO3 
(aq.) (5 mL) and the resulted mixture was extracted with CH2Cl2 (3 x 10 mL), the 
organic layers were dried over MgSO4 and concentrated in vacuo.  
 
1-(4-(benzyloxy)phenyl)-3-(5-bromopyridin-2-yl)propane-1,3-dione (48a) 
 
 
This compound was prepared according to general procedure K by treating 48d (206 
mg, 0.5 mmol) with DMP (318 mg, 0.75 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 10:1 → 5:1) to give the product as a 
yellow solid (195 mg, 95%). m.p. 162−163 °C; Rf (hexane/ethyl acetate 8:1): 0.50; 1H 
NMR (400 MHz, CDCl3): δ 16.54 (1H, br.s), 8.73 (1H, d, J = 2.0 Hz), 8.04 (2H, d, J 
= 8.8 Hz), 8.01−7.96 (2H, m), 7.46−7.35 (6H, m), 7.05 (2H, d, J = 8.8 Hz), 5.15 (2H, 
s); 13C NMR (100 MHz, CDCl3): δ 186.9, 180.9, 162.8, 151.2, 150.5, 139.8, 136.3, 
129.9, 128.8, 128.4, 128.3, 127.6, 124.0, 123.2, 115.0, 93.1, 70.3; HRMS (ESI+) 
Calc. for C21H16BrNO3 [M + Na]+ 432.0206/434.0185, found 432.0205/434.0185. IR 
(neat, cm-1):  3031, 2944, 1588, 1510, 1492, 1451, 1242, 1170, 999, 826, 800, 624, 
518. 
 
General procedure L for the formation of pyrazoles 
 
R2 OH
R1 DMP, CH2Cl2, RT
R2 O
R1
N
Br
O
OBn
O
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The compounds were prepared following a literature procedure.240 To a solution of 
1,3-dione (1.0 equiv.) in MeOH (0.05 M) was added N2H4•H2O (64%, 2.0 equiv.), 
and the resulting mixture was stirred at RT for 48 h under nitrogen. After completion 
monitored by TLC, the solvent was removed under reduced pressure, and the residue 
was treated with H2O (10 mL) and extracted with ethyl acetate (3 x 10 mL). The 
combined organic layers were dried over MgSO4 and concentrated in vacuo.  
 
2-(3-(4-(benzyloxy)phenyl)-1H-pyrazol-5-yl)-5-bromopyridine (49) 
 
This compound was prepared according to general procedure L by treating 48a (150 
mg, 0.37 mmol) with N2H4•H2O (58 µL, 0.74 mmol). The crude product was purified 
by flash chromatography (hexane/ethyl acetate 5:1 → 2:1) to give the product as a 
pale yellow solid (113 mg, 75%). m.p. 241−243 °C; Rf (hexane/ethyl acetate 1:1): 
0.30; 1H NMR (400 MHz, d-DMSO): δ 13.45 (1H, br.s), 8.72 (1H, s), 8.17−8.07 (1H, 
m), 7.97−7.87 (1H, m), 7.78−7.76 (2H, m), 7.48−7.32 (5H, m), 7.16−7.11 (3H, m), 
5.16 (2H, s); 13C NMR (100 MHz, d-DMSO): δ 158.8, 151.5, 150.3, 144.1, 139.8, 
137.4, 128.9, 128.3, 128.2, 127.1, 122.3, 121.4, 119.0, 115.8, 115.5, 100.5, 69.8; 
HRMS (ESI+) Calc. for C21H16BrN3O [M + Na]+ 428.0369/430.0348, found 
428.0367/430.0346. IR (neat, cm-1):  3201, 3061, 2888, 1613, 1590, 1448, 1242, 
798, 734, 518, 498. 
 
 
General procedure M for the protection of pyrazole-N 
 
To a solution of pyrazole substrate (1.0 equiv.) in CH2Cl2 (0.05 M) was added NaH 
(60% in mineral oil, 2.0 equiv.) slowly at 0 °C, after 10 min, benzyl 
carbonobromidate (CbzBr) or TsCl (1.1 equiv.) was added, and the resulting mixture 
was allowed to warm to RT for 30 min. After completion monitored by TLC, the 
N
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HN N
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N
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mixture was quenched with H2O (5 mL) and extracted with CH2Cl2 (3 x 5 mL), the 
organic layers were dried over MgSO4 and concentrated in vacuo.  
 
Benzyl-3-(4-(benzyloxy)phenyl)-5-(5-bromopyridin-2-yl)-1H-pyrazole-1-
carboxylate (50a) 
 
This compound was prepared according to general procedure M by treating 49 (101 
mg, 0.25 mmol) with CbzBr (59 mg, 0.27 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 10:1 → 5:1) to give the product as a 
white solid (121 mg, 90%). m.p. 142−143 °C; Rf (hexane/ethyl acetate 6:1): 0.55; 1H 
NMR (300 MHz, CDCl3): δ 8.69 (1H, d, J = 2.1 Hz), 8.10 (1H, d, J = 8.7 Hz), 7.89 
(1H, dd, J = 2.1, 8.7 Hz), 7.48−7.27 (12H, m), 6.99 (1H, s), 6.96 (2H, d, J = 8.7 Hz), 
5.35 (2H, s), 5.09 (2H, s); 13C NMR (75 MHz, CDCl3): δ 159.5, 153.9, 150.7, 150.1, 
149.4, 148.6, 139.4, 136.8, 134.4, 130.6, 128.8, 128.7, 128.3, 127.8, 127.7, 127.1, 
123.3, 122.3, 121.0, 114.4, 110.0, 70.2, 69.9; HRMS (ESI+) Calc. for C29H22BrN3O3 
[M + H]+ 540.0917/542.0897, found 540.0917/542.0897. IR (neat, cm-1):  2923, 
1760, 1612, 1516, 1332, 1294, 1217, 1090, 831, 734, 697. 
 
2-(3-(4-(benzyloxy)phenyl)-1-tosyl-1H-pyrazol-5-yl)-5-bromopyridine (50b) 
 
This compound was prepared according to general procedure M by treating 49 (101 
mg, 0.25 mmol) with TsCl (52 mg, 0.27 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 10:1 → 5:1) to give the product as a 
white solid (133 mg, 95%). m.p. 152−154 °C; Rf (hexane/ethyl acetate 6:1): 0.55; 1H 
NMR (300 MHz, CDCl3): δ 8.64 (1H, d, J = 2.1 Hz), 8.06 (1H, d, J = 8.4 Hz), 7.88 
(1H, dd, J = 2.1, 8.4 Hz), 7.57 (2H, d, J = 8.4 Hz), 7.49−7.36 (7H, m), 7.18 (2H, d, J 
= 8.4 Hz), 7.03 (2H, d, J = 8.4 Hz), 6.89 (1H, s), 5.14 (2H, s), 2.36 (3H, s); 13C NMR 
(75 MHz, CDCl3): δ 159.8, 154.4, 150.4, 149.5, 149.1, 145.5, 139.3, 136.6, 134.7, 
N
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131.5, 129.6, 128.7, 128.2, 128.0, 127.6, 122.2, 121.7, 120.9, 114.2, 110.1, 70.1, 21.7; 
HRMS (ESI+) Calc. for C28H22BrN3O3S [M + Na]+ 582.0457/584.0437, found 
582.0455/584.0435. IR (neat, cm-1):  3023, 2940, 1611, 1510, 1384, 1177, 1107, 
1005, 816, 576, 545. 
 
4-(6-(3-(4-(benzyloxy)phenyl)-1-tosyl-1H-pyrazol-5-yl)pyridin-3-yl)phenol (51b) 
 
This compound was prepared according to general procedure F by treating 50b (112 
mg, 0.2 mmol) with (4-hydroxyphenyl)boronic acid (41 mg, 0.3 mmol) in 1,4-dioxane 
at 110 °C. The crude product was purified by flash chromatography (hexane/ethyl 
acetate 5:1 → 2:1) to afford the product as a white solid (97 mg, 85%). m.p. 
192−193 °C; Rf (hexane/ethyl acetate 2:1): 0.25; 1H NMR (400 MHz, CDCl3): δ 8.77 
(1H, dd, J = 0.8, 2.4 Hz), 8.20 (1H, dd, J = 0.8, 8.4 Hz), 7.90 (1H, dd, J = 2.4, 8.4 
Hz), 7.59 (2H, d, J = 8.4 Hz), 7.49−7.47 (4H, m), 7.44−7.34 (5H, m), 7.17 (2H, d, J = 
8.0 Hz), 7.03 (2H, d, J = 8.8 Hz), 6.96−6.94 (3H, m), 5.88 (1H, br.s), 5.14 (2H, s), 
2.35 (3H, s); 13C NMR (100 MHz, CDCl3): δ 159.9, 156.5, 155.3, 149.7, 148.7, 
147.3, 145.5, 136.8, 136.5, 134.9, 134.7, 131.6, 129.9, 129.8, 128.8, 128.5, 128.3, 
128.1, 127.7, 122.0, 121.3, 116.4, 114.3, 110.4, 70.3, 21.8; HRMS (ESI+) Calc. for 
C34H27N3O4S [M + Na]+ 596.1614, found 596.1613. IR (neat, cm-1):  3061, 2926, 
1608, 1378, 1242, 1174, 1112, 826, 809, 662, 591, 568, 543. 
 
4-(6-(3-(4-hydroxyphenyl)-1H-pyrazol-5-yl)pyridin-3-yl)phenol (43) 
 
To a solution of 51b (46 mg, 0.08 mmol) in MeOH was added KOH (22 mg, 0.4 
mmol) at RT, and the resulting mixture was stirred at 75 °C for 1 h. After completion 
monitored by TLC, the solvent was removed and the residue was diluted with H2O 
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and extracted with ethyl acetate (3 x 5 mL). The combined organic layers were 
washed with brine (5 mL) and dried over MgSO4 and concentrated in vacuo to get the 
crude compound without further purification. To the crude intermediate obtained 
above in MeOH (5 mL) was added Pd/C (4 mg, 10 wt. %) under nitrogen, and the 
mixture was stirred at room temperature for 5 h under 1 atm of hydrogen. After 
completion monitored by TLC, the Pd-C was filtered through Celite®, and the filtrate 
was concentrated under reduced pressure. The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 50:1 → 15:1) to give the product as a pale yellow 
solid (12 mg, 45% over two steps). m.p. 249−252 °C; Rf (CH2Cl2/MeOH 10:1): 0.25; 
1H NMR (400 MHz, d-DMSO): δ 13.30 (1H, br.s), 9.68 (1H, br.s), 8.84 (1H, s), 
8.07−8.06 (1H, m), 7.97−7.96 (1H, m), 7.67 (2H, d, J = 8.4 Hz), 7.62 (2H, d, J = 8.8 
Hz), 7.14 (1H, s), 6.91 (2H, d, J = 8.8 Hz), 6.85 (2H, d, J = 8.4 Hz); 13C NMR (100 
MHz, d-DMSO): δ 158.2, 157.9, 147.0, 134.7, 134.6, 134.4 (two overlapping signals), 
134.3, 128.3, 127.9, 127.0, 119.8, 116.5, 116.0, 100.1, 100.0; HRMS (ESI+) Calc. for 
(C20H15N3O2)2 [M + Na]+ 681.2221, found 681.2217. IR (neat, cm-1):  3292, 2921, 
2851, 1610, 1598,1449, 1247, 824, 793, 506. HPLC: 98.0% (HPLC Method A), RT: 
16.1 min. 
 
1-(benzyloxy)-4-bromobenzene (55) 
 
This compound was prepared according to general procedure I by treating 4-
bromophenol (519 mg, 3 mmol) with benzyl bromide (427 µL, 3.6 mmol). The crude 
product was purified by flash chromatography (hexane/ethyl acetate 10:1) to give the 
product as a white solid (726 mg, 92%); Rf (hexane/ethyl acetate 10:1): 0.50; 1H 
NMR (300 MHz, CDCl3): δ 7.43−7.31 (7H, m), 6.86 (2H, d, J = 9.0 Hz), 5.04 (2H, s); 
13C NMR (75 MHz, CDCl3): δ 158.0, 136.7, 132.4, 128.8, 128.3, 127.6, 116.9, 113.3, 
70.4. The spectroscopic data matched that reported in the literature.314 
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4-(4-(benzyloxy)phenyl)pyridine (56) 
 
This compound was prepared according to general procedure F by treating 55 (263 
mg, 1 mmol) with pyridin-4-ylboronic acid 54 (185 mg, 1.5 mmol) in 1,4-dioxane at 
100 °C. The crude product was purified by flash chromatography (hexane/ethyl 
acetate 10:1 → 3:1) to afford the product as a white solid (209 mg, 80%). m.p. 
136−137 °C; Rf (hexane/ethyl acetate 3:1): 0.20; 1H NMR (300 MHz, CDCl3): δ 8.62 
(2H, dd, J = 1.8, 4.5 Hz), 7.60 (2H, dd, J = 2.1, 6.9 Hz), 7.47−7.34 (7H, m), 7.08 (2H, 
dd, J = 2.1, 6.9 Hz), 5.13 (2H, s); 13C NMR (75 MHz, CDCl3): δ 159.9, 150.4, 147.9, 
136.8, 130.8, 128.8, 128.3 (two overlapping signals), 127.6, 121.2, 115.7, 70.3; 
HRMS (ESI+) Calc. for C18H15NO [M + H]+ 262.1226, found 262.1224. IR (neat, 
cm-1):  3022, 2888, 1605, 1591, 1518, 1487, 1249, 1223, 1183, 1044, 991, 808, 747, 
622, 511.   
 
4-(4-(benzyloxy)phenyl)pyridine 1-oxide (57) 
 
This compound was prepared following a literature procedure.245 To a solution 
of 56 (200 mg, 0.77 mmol) in acetic acid (10 mL) was added hydrogen peroxide (397 
µL, 3.8 mmol, 30% (w/w) in H2O) dropwise at RT, and the resulting mixture was 
heated to 70 °C and stirred for 15 h. After completion monitored by TLC, the volatiles 
were removed under reduced pressure and the residue was diluted with sat. NaHCO3 
(aq.) (10 mL) and extracted with ethyl acetate (3 x 15 mL). The combined organic 
layers were washed with brine (5 mL) and dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by flash chromatography (CH2Cl2/MeOH 
N
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ν
N
OBn
O
Chapter 6 
 141 
200:1 → 80:1) to afford the product as a white solid (171 mg, 80%). m.p. 
179−180 °C; Rf (CH2Cl2/MeOH 20:1): 0.35; 1H NMR (400 MHz, CDCl3): δ 8.22 
(2H, dd, J = 2.0, 5.2 Hz), 7.75−7.71 (4H, m), 7.48−7.32 (5H, m), 7.13 (2H, dd, J = 
2.0, 6.8 Hz), 5.18 (2H, s); 13C NMR (100 MHz, CDCl3): δ 158.9, 138.7, 136.8, 135.9, 
128.4, 128.1, 127.9, 127.7, 127.6, 122.9, 115.5, 69.3; HRMS (ESI+) Calc. for 
C18H15NO2 [M + Na]+ 300.0995, found 300.1000. IR (neat, cm-1):  3032, 3012, 
1602, 1475, 1467, 1237, 1222, 1177, 1026, 1000, 864, 827, 759, 706, 607, 533. 
 
4-(4-((tert-butyldimethylsilyl)oxy)phenyl)pyridin-2-amine (60) 
 
This compound was prepared according to general procedure F by treating 4-
bromopyridin-2-amine 59 (346 mg, 2 mmol) and boronic acid 40 (756 mg, 3 mmol) in 
1,4-dioxane at 100 °C. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1 → 3:1) to afford the product as a white solid (522 mg, 
87%). m.p. 117−119 °C; Rf (hexane/ethyl acetate 2:1): 0.20; 1H NMR (400 MHz, 
CDCl3): δ 8.08 (1H, dd, J = 0.8, 5.6 Hz), 7.47 (2H, dd, J = 2.0, 6.4 Hz), 6.90 (2H, dd, 
J = 2.0, 6.4 Hz), 6.85 (1H, dd, J = 1.6, 5.6 Hz), 6.66 (1H, dd, J = 0.8, 1.6 Hz), 4.46 
(2H, s), 1.00 (9H, s), 0.23 (6H, s); 13C NMR (100 MHz, CDCl3): δ 159.0, 156.7, 
150.0, 148.6, 131.8, 128.1, 120.6, 112.6, 105.8, 25.8, 18.4, −4.2; HRMS (ESI+) Calc. 
for C17H24N2OSi [M + H]+ 301.1731, found 301.1728. IR (neat, cm-1):  3467, 3297, 
3139, 2956, 2928, 2854, 1633, 1596, 1518, 1471, 1253, 1239, 1180, 912, 901, 835, 
821, 801, 784, 693, 666, 468. 
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General procedure N for the Sandmeyer reaction 
 
Table 19. The conditions screening for the formation of halogenated product. 
 
 
 
Halogen source Solvent Temperature Product 
CuBr MeCN 25 to 80 °C NR 
CuBr2 MeCN 25 to 80 °C NR 
CuBr/CuBr2 (1:1) MeCN 25 to 80 °C NR 
CH2I2a CH2I2 25 °C 25% 
  aCatalytic amount of HI (57%, 2 mol%) was used. 
 
To a solution of 60 (1.0 equiv.) in MeCN (0.05 M) was added isopentyl nitrite (1.5 
equiv.) and the resulting mixture was stirred at RT. After 30 min, CuBr or CuBr2 (1.2 
equiv.) was added and heated to 80 °C and monitored by TLC for 24 h. The results are 
shown in Table 19. 
 
4-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-iodopyridine (61b) 
 
This compound was prepared following a literature procedure.242 To a solution of 60 
(255 mg, 0.85 mmol) in CH2I2 (5 mL) was added isoamyl nitrite (1.75 mL, 17 mmol) 
N
OTBS
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O N
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at RT under nitrogen. After 30 min, aq. HI (57%, 2.5 µL, 0.017 mmol) was added, 
and the resulting mixture was stirred at RT for 24 h. After completion monitored by 
TLC, the mixture was poured into a mixture of NH4OH/H2O (1:1 (v/v), 50 mL) and 
extracted with CHCl3 (2 x 25 mL). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 100:1 → 40:1) to afford the product as 
colorless oil (85 mg, 25%). Rf (hexane/ethyl acetate 10:1): 0.40; 1H NMR (400 MHz, 
CDCl3): δ 8.34 (1H, dd, J = 0.4, 5.2 Hz), 7.90 (1H, dd, J = 0.8, 1.6 Hz), 7.48 (2H, dd, 
J = 2.0, 6.4 Hz), 7.42 (1H, dd, J = 1.6, 5.2 Hz), 6.93 (2H, dd, J = 2.0, 6.4 Hz), 1.00 
(9H, s), 0.23 (6H, s); 13C NMR (100 MHz, CDCl3): δ 157.5, 150.8, 150.0, 132.2, 
129.4, 128.4, 121.0, 120.8, 119.0, 25.8, 18.4, −4.2; HRMS (ESI+) Calc. for 
C17H22NOSiI [M + H]+ 412.0588, found 412.0586. IR (neat, cm-1):  2954, 2929, 
2857, 1604, 1579, 1513, 1470, 1263, 911, 828. 
 
4-(4-((tert-butyldimethylsilyl)oxy)phenyl)picolinaldehyde (52) 
 
This compound was prepared according to general procedure H by treating 61b (85 
mg, 0.2 mmol) with DMF (23 µL, 0.3 mmol) in dry toluene. The crude product was 
purified by flash chromatography (hexane/ethyl acetate 10:1) to give the product as 
pale yellow oil (31 mg, 50%); Rf (hexane/ethyl acetate 10:1): 0.45; 1H NMR (300 
MHz, CDCl3): δ 10.13 (1H, s), 8.78 (1H, d, J = 5.1 Hz), 8.16 (1H, d, J = 1.2 Hz), 7.69 
(1H, dd, J = 1.8, 5.1 Hz), 7.60 (2H, d, J = 8.7 Hz), 6.96 (2H, d, J = 8.7 Hz), 1.00 (9H, 
s), 0.24 (6H, s); 13C NMR (75 MHz, CDCl3): δ 193.8, 157.7, 153.5, 150.7, 149.4, 
129.9, 128.4, 125.0, 121.1, 119.0, 25.8, 18.4, −4.2; HRMS (ESI+) Calc. for 
C18H23NO2Si [M + Na]+ 336.1390, found 336.1338. IR (neat, cm-1):  3331, 2957, 
2927, 2858, 1714, 1604, 1515, 1462, 1263, 1037, 912, 830, 781. 
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1-(4-(benzyloxy)phenyl)-3-(4-(4-((tert-butyldimethylsilyl)oxy)phenyl)pyridin-2-
yl)-3-hydroxypropan-1-one (62) 
 
This compound was prepared according to general procedure J by treating 52 (62 
mg, 0.2 mmol) with 47c (50 mg, 0.22 mmol) and LDA (0.24 mmol) in dry THF. After 
completion monitored by TLC, the reaction was quenched with sat. NH4Cl (aq.) and 
extracted with ethyl acetate (3 x 15 mL). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 8:1) to give the product as pale yellow semi-
solid (65 mg, 60%); Rf (hexane/ethyl acetate 10:1): 0.25; 1H NMR (400 MHz, 
CDCl3): δ 8.53 (1H, dd, J = 0.4, 5.2 Hz), 7.96 (2H, d, J = 9.2 Hz), 7.76−7.75 (1H, m), 
7.56 (2H, d, J = 8.8 Hz), 7.43−7.32 (6H, m), 6.99 (2H, d, J = 9.2 Hz), 6.93 (2H, d, J = 
8.8 Hz), 5.42 (1H, dd, J = 3.6, 8.4 Hz), 5.12 (2H, s), 4.41 (1H br.s), 3.63 (1H, dd, J = 
3.6, 17.2 Hz), 3.41 (1H, dd, J = 8.4, 17.2 Hz), 1.01 (9H, s), 0.24 (6H, s); 13C NMR 
(100 MHz, CDCl3): δ 198.8, 163.1, 162.2, 157.1, 149.1, 149.0, 136.2, 131.1, 130.8, 
130.2, 128.8, 128.6, 128.4, 127.6, 120.8, 120.0, 118.0, 114.8, 70.7, 70.3, 45.6, 25.8, 
18.4, −4.2; HRMS (ESI+) Calc. for C33H37NO4Si [M + Na]+ 562.2384, found 
562.2380. IR (neat, cm-1):  3487, 2955, 2929, 2857, 1660, 1599, 1514, 1253, 1172, 
912, 900, 850, 833, 779, 613. 
 
1-(4-(benzyloxy)phenyl)-3-(4-(4-((tert-butyldimethylsilyl)oxy)phenyl)pyridin-2-
yl)propane-1,3-dione (53) 
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This compound was prepared according to general procedure K by treating 62 (54 
mg, 0.1 mmol) with DMP (64 mg, 0.15 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 5:1 → 3:1) to give the product as a 
yellow solid (40 mg, 75%). m.p. 134−135 °C; Rf (CH2Cl2/MeOH 20:1): 0.55; 1H 
NMR (400 MHz, CDCl3): δ 16.67 (1H, br.s), 8.70 (1H, d, J = 5.2 Hz), 8.35 (1H, d, J 
= 1.2 Hz), 8.08 (2H, d, J = 8.8 Hz), 7.63 (2H, d, J = 8.8 Hz), 7.60 (1H, dd, J = 2.0, 5.2 
Hz), 7.54 (1H, s), 7.46−7.33 (5H, m), 7.06 (2H, d, J = 8.8 Hz), 6.97 (2H, d, J = 8.4 
Hz), 5.15 (2H, s), 1.01 (9H, s), 0.25 (6H, s); 13C NMR (100 MHz, CDCl3): δ 187.0, 
182.0, 162.8, 157.4, 153.2, 149.7, 149.3, 136.4, 130.5, 129.9, 128.8, 128.5, 128.4 (two 
overlapping signals), 127.7, 123.4, 121.0, 119.6, 115.0, 93.3, 70.3, 25.8, 18.4, −4.2; 
HRMS (ESI+) Calc. for C33H35NO4Si [M + H]+ 538.2408, found 538.2414. IR (neat, 
cm-1):  2953, 2928, 2857, 1604, 1510, 1453, 1248, 1173, 911, 832, 805, 733, 659. 
 
2-(3-(4-(benzyloxy)phenyl)-1H-pyrazol-5-yl)-4-(4-((tert-
butyldimethylsilyl)oxy)phenyl)pyridine (63) 
 
This compound was prepared according to general procedure L by treating 53 (53.8 
mg, 0.1 mmol) and N2H4•H2O (7.8 µL, 0.2 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 50:1 → 20:1) to give the product as a pale 
yellow semi-solid (37 mg, 70%). Rf (CH2Cl2/MeOH 15:1): 0.25; 1H NMR (400 MHz, 
d-MeOD): δ 8.59 (1H, s), 8.24 (1H, s), 7.78−7.74 (4H, m), 7.62 (1H, s), 7.49−7.31 
(5H, m), 7.20 (1H, s), 7.11 (2H, d, J = 8.8 Hz), 7.03 (2H, d, J = 8.8 Hz), 5.16 (2H, s), 
1.05 (9H, s), 0.28 (6H, s); 13C NMR (100 MHz, d-MeOD): δ 160.5, 158.6, 150.7, 
150.6, 144.6, 138.6, 132.0, 130.7, 129.5 (two overlapping signals), 129.4, 129.2, 
128.9, 128.6, 128.1, 121.9, 118.6, 116.4, 102.8, 101.6, 71.1, 26.1, 19.1, −4.3; HRMS 
(ESI+) Calc. for C33H35N3O2Si [M + H]+ 534.2571, found 534.2568. IR (neat, cm-1): 
 2952, 2928, 2856, 1606, 1515, 1471, 1454, 1254, 1175, 913, 835. 
 
ν
N
HN N
OBn
OTBS
ν
Chapter 6 
 146 
4-(2-(3-(4-hydroxyphenyl)-1H-pyrazol-5-yl)pyridin-4-yl)phenol (44) 
 
To a solution of 63 (53 mg, 0.1 mmol) in MeOH was added Pd/C (5 mg, 10 wt. %) 
under nitrogen atmosphere, and the mixture was stirred at room temperature for 4 h 
under 1 atm of hydrogen. After completion monitored by TLC, the Pd-C was filtered 
through Celite®, and the filtrate was concentrated under reduced pressure to get the 
crude compound without further purification. To the crude intermediate obtained 
above in THF (3 mL) was added TBAF (0.2 mL, 0.2 mmol, 1 M in THF). The 
resulting mixture was stirred at RT for 30 min. After completion monitored by TLC, 
the solvent was removed under reduced pressure. The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 20:1 → 10:1) to give the product as an off-
white solid (18 mg, 55% over two steps). m.p. 159−161 °C; Rf (CH2Cl2/MeOH 10:1): 
0.15; 1H NMR (500 MHz, d-DMSO): δ 13.29 (1H, br.s), 9.88 (1H, br.s), 9.60 (1H, 
br.s), 8.57 (1H, d, J = 5.0 Hz), 8.16 (1H, d, J = 1.0 Hz), 7.74 (2H, d, J = 7.0 Hz), 7.67 
(2H, d, J = 8.5 Hz), 7.56 (1H, d, J = 4.0 Hz), 7.23 (1H, s), 6.93 (2H, d, J = 8.5 Hz), 
6.84 (2H, d, J = 8.5 Hz); 13C NMR (125 MHz, d-DMSO): δ 159.5, 157.9, 150.4, 
148.5, 133.0, 128.8 (two overlapping signals), 127.3, 127.2, 124.8, 123.7, 122.7, 
119.8, 116.6, 116.2, 100.6; HRMS (ESI+) Calc. for C20H15N3O2 [M + H]+ 330.1237, 
found 330.1242. IR (neat, cm-1):  2953, 2921, 2852, 1601, 1515, 1451, 1373, 1253, 
1172, 823, 799, 776, 567. HPLC: 98.4% (HPLC Method A), RT: 15.9 min. 
 
[2,2'-bipyridine] 1,1'-dioxide (66) 
 
This compound was prepared following a literature procedure.245 To a solution 
of 2,2'-bipyridine 65 (1.0 g, 6.4 mmol) in Acetic acid (15 mL) was added hydrogen 
peroxide (3.3 mL, 32 mmol, 30% (w/w) in H2O) dropwise at RT, and the resulting 
mixture was heated to 70 °C and stirred for 15 h. After completion, the cooled 
N
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mixture was added acetone (20 mL) forming a white precipitate, filtered and dried. 
The crude white solid was recrystallised from H2O to get the desired pure compound 
(1.08 g, 90%). Rf (CH2Cl2/MeOH 15:1): 0.35; 1H NMR (300 MHz, D2O): δ 8.46 (2H, 
d, J = 6.3 Hz), 7.88−7.83 (2H, m), 7.77−7.30 (4H, m); 13C NMR (75 MHz, D2O): δ 
142.3, 140.4, 132.4, 129.5, 129.1. The spectroscopic data matched that reported in the 
literature.315 
 
4,4'-dinitro-[2,2'-bipyridine] 1,1'-dioxide (67) 
 
This compound was prepared following a literature procedure.246 To a suspension 
of 66 (1.0 g, 5.3 mmol) in sulphuric acid (6 mL, 111 mmol) was added nitric acid (2.5 
mL, 44 mmol) dropwise at 0 °C, and the resulting mixture was heated to 100 °C and 
stirred for 20 h. After completion monitored by TLC, the mixture was cooled to RT 
and ice (20 mL) was added to get yellow precipitate, filtered and washed with cold 
water and dried to get the desired compound without further purification (295 mg, 
20%). Rf (CH2Cl2/MeOH 15:1): 0.40; 1H NMR (400 MHz, CDCl3): δ 8.69 (2H, d, J = 
3.2 Hz), 8.59 (2H, d, J = 7.2 Hz), 8.38 (2H, dd, J = 3.2, 7.2 Hz); 13C NMR (100 MHz, 
CDCl3): δ 142.1, 141.2, 140.5, 123.8, 122.0. The spectroscopic data matched that 
reported in the literature.315 
 
4,4'-dichloro-[2,2'-bipyridine] 1,1'-dioxide (68) 
 
This compound was prepared following a literature procedure.246 To a suspension 
of 67 (100 mg, 0.36 mmol) in acetic acid (2 mL) was added acetyl chloride (0.13 mL, 
1.8 mmol) dropwise at RT under nitrogen atmosphere, the resulting mixture was 
stirred for 2 h, and then heated to 100 °C for 12 h. After completion monitored by 
TLC, the volatile was removed under reduced pressure and the residue was treated 
with sat. NaHCO3 (aq.) (2 mL) and CH2Cl2 (5 mL), and the off-white precipitate was 
N N
O O
O2N NO2
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obtained, filtered and washed with CH2Cl2 and dried to get the desired compound 
without further purification (79 mg, 85%). Rf (CH2Cl2/MeOH 10:1): 0.20; 1H NMR 
(400 MHz, d-DMSO+TFA): δ 8.42 (2H, d, J = 6.8 Hz), 7.93 (2H, d, J = 3.2 Hz), 7.68 
(2H, dd, J = 3.2, 6.8 Hz); 13C NMR (100 MHz, d-DMSO+TFA): δ 143.0, 141.4, 
132.3, 129.6, 128.5. The spectroscopic data matched that reported in the literature.315 
 
4,4'-dichloro-2,2'-bipyridine (69) 
 
This compound was prepared following a literature procedure.246 To a suspension 
of 68 (50 mg, 0.19 mmol) in CHCl3 (5 mL) was added PCl3 (0.33 mL, 3.8 mmol) 
dropwise at RT under nitrogen atmosphere, and the resulting mixture was heated to 
65 °C and stirred for 20 h. After completion monitored by TLC, the mixture was 
poured into ice (5 mL) and solid NaOH was added to make pH = 8, and then extracted 
with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 8:1) to give the product as a white solid (41 mg, 95%); Rf 
(hexane/ethyl acetate 4:1): 0.4; 1H NMR (300 MHz, CDCl3): δ 8.55 (2H, d, J = 5.4 
Hz), 8.43 (2H, d, J = 2.1 Hz), 7.32 (2H, dd, J = 2.1, 5.4 Hz); 13C NMR (75 MHz, 
CDCl3): δ 156.5, 150.2, 145.5, 124.5, 121.9. The spectroscopic data matched that 
reported in the literature.315 
 
4,4'-([2,2'-bipyridine]-4,4'-diyl)diphenol (64) 
 
A mixture of 69 (40 mg, 0.18 mmol), (4-hydroxyphenyl)boronic acid (62 mg, 0.45 
mmol) and  aq. K2CO3 (2 M, 450 µL, 0.9 mmol) in 1,4-dioxane (5 mL) was degassed, 
and then [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (6.5 mg, 0.009 
mmol) was added. The resulting mixture was degassed and back-filled with nitrogen, 
and then heated at reflux for 4 h. After completion monitored by TLC, the reaction 
N N
Cl Cl
N N
HO OH
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mixture was concentrated under reduced pressure, and then diluted with H2O (5 mL), 
neutralised with sat. NH4Cl (aq.) and extracted with ethyl acetate (3 x 5 mL). The 
combined organic layers were washed with H2O (5 mL) and dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography 
(CH2Cl2: MeOH = 50:1 → 10:1) to afford the product as a white solid (25 mg, 40%). 
m.p. 328−330 °C; Rf (CH2Cl2/MeOH 15:1): 0.30; 1H NMR (400 MHz, d-DMSO): δ 
9.88 (2H, br.s), 8.70 (2H, d, J = 5.2 Hz), 8.64 (2H, d, J = 1.6 Hz), 7.74 (4H, d, J = 8.8 
Hz), 7.71 (2H, dd, J = 1.6, 5.2 Hz), 6.94 (4H, d, J = 8.8 Hz); 13C NMR (100 MHz, d-
DMSO): δ 158.8, 155.8, 149.8, 148.0, 128.1, 127.7, 120.7, 116.8, 116.1. HRMS 
(ESI+) Calc. for C22H16N2O2 [M + Na]+ 363.1104, found 363.1110. IR (neat, cm-1): 
 3084, 2922, 1586, 1514, 1234, 826, 567. HPLC: 96.1% (HPLC Method A), RT: 
18.7 min. 
 
2-amino-5-bromonicotinic acid (72) 
 
This compound was prepared following a literature procedure.248 To a suspension of 
2-aminonicotinic acid 71 (3.75 g, 27 mmol) in glacial acetic acid (15 mL) was added 
a solution of bromine (1.8 mL, 35 mmol) in glacial acetic acid (3 mL) and the mixture 
was stirred at RT for 20 h. After completion monitored by TLC, the resulting 
precipitate was filtered and washed with glacial acetic acid 3 times. The remaining 
solid was air dried and then recrystallised from boiling methanol to afford the product 
as white crystalline needles (5.2 g, 90%). 1H NMR (400 MHz, d-DMSO): δ 8.36 (1H, 
d, J = 2.6 Hz), 8.25 (1H, d, J = 2.6 Hz), 7.95−7.79 (2H, br.s); 13C NMR (100 MHz, d-
DMSO): δ 166.6, 156.5, 149.9, 143.8, 109.3, 103.7. The spectroscopic data matched 
that reported in the literature.248 
 
Methyl 2-amino-5-bromonicotinate (73) 
 
To a solution of 2-amino-5-bromonicotinic acid 72 (1.0 g, 4.6 mmol) in MeOH (10 
mL) was added sulphuric acid (2.0 mL, 36.8 mmol) dropwise and the mixture was 
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stirred at RT for 18 h. After completion monitored by TLC, The solvent was removed 
under reduced pressure. The residue was neutralised with sat. NaHCO3 (aq.) and 
extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo to afford the product as a white powder (1.0 g, 
94%) without further purification. m.p. 148−149 °C; Rf (CH2Cl2/MeOH 20:1): 0.55; 
1H NMR (400 MHz, d-DMSO): δ 8.24 (1H, d, J = 2.4 Hz), 8.21 (1H, d, J = 2.4 Hz), 
6.68−6.19 (2H, br.s), 3.89 (3H, s); 13C NMR (100 MHz, d-DMSO): δ 166.6, 158.0, 
154.4, 142.0, 107.5, 106.1, 52.4. HRMS (ESI+) Calc. for C7H7N2O2Br [M + H]+ 
230.9764/232.9743, found 230.9765/232.9745. IR (neat, cm-1):  3425, 3131, 2918, 
1704, 1620, 1223, 796, 526. 
 
6-bromo-4-hydroxy-1,8-naphthyridine-3-carbonitrile (74) 
 
This compound was prepared following a literature procedure.247 To a sealed tube was 
added a mixture of methyl 2-amino-5-bromonicotinate 73 (500 mg, 2.16 mmol) and 
N,N-dimethylformamide dimethyl acetal (3 mL, 21.6 mmol), and stirred at 110 °C for 
3 h. The volatiles were concentrated under reduced pressure, and the crude 
intermediate was dissolved in dry THF (30 mL), which would be used immediately in 
the following step.  
To a solution of n-BuLi (2.5 M in hexane, 1.9 mL, 4.75 mmol) in dry THF (10 mL) 
was added dry acetonitrile (248 µL, 4.75 mmol) dropwise at −78 °C under nitrogen 
atmosphere. The resulting reaction mixture was stirred at −78 °C for 20 min. To the 
resulting white suspension was added dropwise the intermediate solution described 
above, and the reaction mixture was stirred at −78 °C for 30 min, then at −40 °C for 2 
h. Acetic acid (370 µL, 6.48 mmol) was added and the resulting yellow suspension 
was warmed to RT and stirred for 10 h. After completion monitored by TLC, the 
mixture was diluted with H2O (20 mL) and extracted with ethyl acetate (3 x 15 mL). 
The combined organic layers were washed with H2O (2 x 15 mL) and brine, dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (hexane/ethyl acetate = 5:1 → 1:1) to afford the product as an orange 
solid (190 mg, 35%). 1H NMR (400 MHz, d-DMSO): δ 13.43−13.41 (1H, br.s), 8.97 
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(1H, d, J = 2.4 Hz), 8.85 (1H, s), 8.61 (1H, d, J = 2.4 Hz); 13C NMR (100 MHz, d-
DMSO): δ 174.0, 154.8, 148.6, 148.4, 136.5, 121.2, 116.5, 115.9, 95.3. The 
spectroscopic data matched that reported in the literature.247 
 
6-bromo-1,8-naphthyridin-4-ol (75) 
 
This compound was prepared following a literature procedure.247 To a sealed tube was 
added a mixture of 6-bromo-4-hydroxy-1,8-naphthyridine-3-carbonitrile 74 (100 mg, 
0.40 mmol) in aq. HCl (32%, 2 mL) and stirred at 150 °C for 3 h. After cooling to 
room temperature, the reaction mixture was neutralised with ammonia solution, 
extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed 
with H2O (2 x 10 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash chromatography (CH2Cl2: MeOH = 50:1 → 20:1) to 
afford the product as a pale yellow solid (30 mg, 33%). 1H NMR (300 MHz, d-
DMSO): δ 12.4 (1H, br.s), 8.84 (1H, s), 8.53 (1H, s), 7.98 (1H, d, J = 7.5 Hz), 6.15 
(1H, d, J = 7.5 Hz); 13C NMR (75 MHz, d-DMSO): δ 176.5, 153.6, 149.1, 140.9, 
136.3, 121.3, 114.3, 110.0. The spectroscopic data matched that reported in the 
literature.247 
 
3-bromo-5-chloro-1,8-naphthyridine (76) 
 
This compound was prepared following a literature procedure.247 To a sealed tube was 
added a mixture of 6-bromo-1,8-naphthyridin-4-ol 75 (30 mg, 0.13 mmol) in POCl3(1 
mL) and stirred at 105 °C for 3 h. After cooling to RT, the reaction mixture was 
poured into ice, and the resulting mixture was neutralised with sat. NaHCO3 (aq.) and 
extracted with ethyl acetate (3 x 5 mL). The combined organic layers were washed 
with H2O (2 x 5 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash chromatography (hexane/ethyl acetate = 5:1 → 3:1) to 
afford the product as a white solid (29 mg, 93%). 1H NMR (400 MHz, CDCl3): δ 9.16 
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(1H, d, J = 2.4 Hz), 9.02 (1H, d, J = 4.8 Hz), 8.75 (1H, d, J = 2.4 Hz), 7.61 (1H, d, J = 
4.8 Hz); 13C NMR (100 MHz, CDCl3): δ 155.8, 155.0, 153.4, 142.1, 135.3, 123.0, 
122.8, 119.5. The spectroscopic data matched that reported in the literature.247 
 
4,4'-(1,8-naphthyridine-3,5-diyl)diphenol (70) 
 
A mixture of 3-bromo-5-chloro-1,8-naphthyridine 76 (15 mg, 0.06 mmol), (4-
hydroxyphenyl)boronic acid (21 mg, 0.15 mmol) and  aq. K2CO3 (2 M, 180 µL, 0.36 
mmol) in 1,4-dioxane (1 mL) was degassed, and then PdCl2(dppf) (9 mg, 0.012 
mmol) was added. The resulting mixture was degassed and back-filled with nitrogen, 
and then stirred at 130 °C (100 W) in microwave under nitrogen atmosphere for 2 h. 
After completion monitored by TLC, the reaction mixture was concentrated under 
reduced pressure, and diluted with H2O (5 mL), neutralised with sat. NH4Cl (aq.) and 
extracted with ethyl acetate (3 x 5 mL). The combined organic layers were washed 
with H2O (5 mL), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by flash chromatography (CH2Cl2: MeOH = 50:1 → 10:1) to afford the 
product as a yellow solid (16 mg, 85%). m.p. 211−213 °C; Rf (CH2Cl2/MeOH 15:1): 
0.30; 1H NMR (400 MHz, d-DMSO): δ 9.90 (1H, s), 9.78 (1H, s), 9.38 (1H, s), 9.04 
(1H, br.s), 8.37 (1H, d, J = 2.4 Hz), 7.62 (2H, d, J = 8.4 Hz), 7.54 (1H, d, J = 4.4 Hz), 
7.48 (2H, d, J = 8.4 Hz), 7.00 (2H, d, J = 8.4 Hz), 6.92 (2H, d, J = 8.4 Hz); 13C NMR 
(100 MHz, d-DMSO): δ 158.7, 158.5, 155.4, 152.8, 152.5, 149.6, 134.2, 131.5, 130.7, 
129.0, 127.6, 127.3, 122.7, 121.1, 116.7, 116.3. HRMS (ESI+) Calc. for C20H14N2O2 
[M + Na]+ 337.0947, found 337.0950. IR (neat, cm-1):  3363, 2921, 1606, 1512, 
1265, 831, 559, 527. HPLC: 98.5% (HPLC Method A), RT: 15.5 min. 
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4,5-diiodo-1H-imidazole (79) 
 
This compound was prepared following a literature procedure.250 To a solution of 
imidazole 78 (1.11 g, 16 mmol) in NaOH (4 M, 60 mL) was added a solution of KI 
(13.3 g, 80 mmol) and I2 (8.88 g, 35 mmol) in H2O (50 mL) dropwise. The resulting 
mixture stirred at RT for 10 h. After completion monitored by TLC, the mixture was 
reduced to pH = 8 with acetic acid, and the resulting white precipitate was filtered and 
washed with cold water. The remaining solid was air dried to afford the product as a 
white creamy solid (4.1 g, 80%). m.p. 188−190 °C; Rf (hexane/ethyl acetate 1:1): 
0.15; 1H NMR (300 MHz, d-DMSO): δ 7.77 (1H, s); 13C NMR (75 MHz, d-DMSO): 
δ 141.8, 86.9. The spectroscopic data matched that reported in the literature.316  
 
4,4'-(1H-imidazole-4,5-diyl)diphenol (77) 
 
This compound was prepared following a literature procedure.251 The mixture of 4,5-
diiodo-1H-imidazole 79 (0.11 g, 0.34 mmol), (4-hydroxyphenyl)boronic acid (141 
mg, 1.02 mmol), TBAB (11 mg, 0.034 mmol), K2HPO4 (226 mg, 1.30 mmol) and 
Pd(PPh3)4 (25 mg, 6 mol%) were transferred to a microwave reactor tube equipped 
with a magnetic stirring bar, followed by the addition of a mixture solvent of 
MeOH/H2O (5 mL, 4:1), and the resulting mixture was degassed and back-filled with 
nitrogen and then stirred at 100 °C (100 W) with microwave irradiation for 60 min.  
After completion monitored by TLC, the reaction mixture was dissolved in aq. HCl 
(10%, 10 mL) and stirred vigorously. The mixture was washed with ethyl acetate (2 x 
10 mL), the combined aqueous layers were neutralised with sat. NaHCO3 (aq.) and 
extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed 
with H2O, dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash chromatography (CH2Cl2: MeOH = 50:1 → 10:1) to afford the 
product as a white solid (30 mg, 35%). Rf (CH2Cl2/MeOH 10:1): 0.25; 1H NMR (400 
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MHz, d-DMSO): δ 9.44 (2H, Br.s), 7.67 (1H, s), 7.25 (4H, d, J = 8.4 Hz), 6.72 (4H, d, 
J = 8.4 Hz); 13C NMR (100 MHz, d-DMSO): δ 156.3, 134.4, 128.6, 125.6, 124.3, 
115.2. HRMS (ESI+) Calc. for C15H12N2O2 [M + Na]+ 275.0791, found 275.0794. 
HPLC: 97.7% (HPLC Method A), RT: 13.3 min. The spectroscopic data matched that 
reported in the literature.317 
 
General procedure O for the synthesis of hydrazones 
 
The compounds were prepared following a literature procedure.252 To a solution of 
chloro-pyrazine substrate (1.0 equiv.) in ethanol (0.05 M) was added hydrazine 
monohydrate (1.1 equiv.). The resulting mixture was stirred at 80 °C for 8 h. After 
completion monitored by TLC, the reaction mixture was cooled to RT, and the 
precipitate obtained filtered, washed by ethanol and dried to get a pale yellow solid. 
To a solution of the crude intermediate (1.0 equiv.) in ethanol (0.05 M) was added 
aryl-aldehyde (1.1 equiv.), and the resulting mixture was stirred at 80 °C for 10 h. 
After completion monitored by TLC, the reaction mixture was cooled to RT, and the 
precipitate was obtained and filtered, washed by ethanol and dried to get the products. 
 
2-(2-(4-(benzyloxy)benzylidene)hydrazinyl)-6-chloropyrazine (83) 
 
This compound was prepared according to general procedure O by treating 82 (1.49 
0.01 mol) with 47b (2.33 g, 0.011 mol). Off-white solid (2.37 g, 70%). m.p. 
213−214 °C; Rf (hexane/ethyl acetate 2:1): 0.30; 1H NMR (300 MHz, d-DMSO): δ 
11.40 (1H, br.s), 8.52 (1H, s), 8.01−7.99 (2H, m), 7.66 (2H, d, J = 8.1 Hz), 7.46−7.30 
(5H, m), 7.06 (2H, d, J = 8.1 Hz), 5.14 (2H, s); 13C NMR (75 MHz, d-DMSO): δ 
159.5, 152.4, 145.5, 142.7, 136.8, 131.9, 128.6, 128.4, 128.2, 127.9, 127.7, 127.3, 
115.1, 69.3; HRMS (ESI+) Calc. for C18H15ClN4O [M + Na]+ 361.0827, found 
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361.0832. IR (neat, cm-1):  3167, 3030, 2860, 1608, 1569, 1511, 1380, 1245, 822, 
720, 508. 
 
General procedure P for the oxidative heterocyclisation 
 
The compounds were prepared following a literature procedure.253 To a solution of 
hydrazone (1.0 equiv.) in CH2Cl2 (0.05 M) was added PhI(OAc)2 (1.0 equiv.). The 
resulting mixture was stirred at RT for 12 h. After completion monitored by TLC, the 
solvent was removed under reduced pressure. 
 
3-(4-(benzyloxy)phenyl)-5-chloro-[1,2,4]triazolo[4,3-a]pyrazine (84) 
 
This compound was prepared according to general procedure P by treating 83 (2.37 
g, 7 mmol) with PhI(OAc)2 (2.25 g, 7 mmol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 1:1) to give the product as a white solid (2.00 
g, 85%). m.p. 216−217 °C; Rf (hexane/ethyl acetate 1:1): 0.30; 1H NMR (400 MHz, 
d-DMSO): δ 9.46 (1H, s), 8.06 (1H, s), 7.65 (2H, ddd, J = 2.8, 4.8, 9.6 Hz), 7.52−7.50 
(2H, m), 7.45−7.41 (2H, m), 7.39−7.34 (1H, m), 7.19 (2H, ddd, J = 2.8, 4.8, 9.6 Hz), 
5.22 (2H, s); 13C NMR (100 MHz, d-DMSO): δ 160.3, 147.8, 147.4, 143.2, 137.1, 
133.3, 129.5, 128.9, 128.4, 128.3, 122.2, 119.8, 114.4, 69.9; HRMS (ESI+) Calc. for 
C18H13ClN4O [M + Na]+ 359.0670, found 359.0668. IR (neat, cm-1): 3087, 2879, 
1607, 1453, 1233, 750, 554. 
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2-(4-(benzyloxy)phenyl)ethan-1-ol (85a) 
 
Step 1: The formation of 4-(2-hydroxyethyl)phenol. This compound was prepared 
following a literature procedure.318 To a solution of 2-(4-hydroxyphenyl)acetic acid 
(760 mg, 5 mmol) in ethanol (20 mL) was added sulfuric acid (27 µL, 0.5 mmol), and 
the resulting mixture was heated at reflux for 3 h. After completion monitored by 
TLC, the solvent was removed under reduced pressure, and the crude product was 
dissolved in dry THF (20 mL), followed by the addition of LiAlH4 (228 mg, 6 mmol) 
slowly at 0 °C, and the resulting mixture was allowed to warm to RT for 12 h. After 
completion monitored by TLC, the solution was cooled to 0 °C, and quenched by 
Na2SO4•10H2O solid and filtered through Celite®. The solvent was removed under 
reduced pressure and the residue was diluted with H2O (20 mL) and extracted with 
ethyl acetate (3 x 20 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 5:1 → 2:1) to give the product as an off-white solid (600 mg, 
87%). Rf (hexane/ethyl acetate 2:1): 0.30; 1H NMR (400 MHz, CDCl3): δ 7.10 (2H, 
dd, J = 2.0, 6.4 Hz), 6.78 (2H, dd, J = 2.0, 6.4 Hz), 4.83 (1H, br.s), 3.83 (2H, dd, J = 
6.4, 15.0 Hz), 2.80 (2H, t, J = 6.4Hz); 13C NMR (100 MHz, CDCl3): δ 154.4, 130.6, 
130.3, 115.6, 64.0, 38.4. The spectroscopic data matched that reported in the 
literature.318 
 
Step 2: The benzyl protection of 4-(2-hydroxyethyl)phenol was realised according to 
general procedure I by treating 4-(2-hydroxyethyl)phenol (600 mg, 4.3 mmol) with 
benzyl bromide (613 µL, 5.2 mmol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1→ 5:1) to give the product 67a as a white 
solid (882 mg, 90%). Rf (hexane/ethyl acetate 4:1): 0.30; 1H NMR (500 MHz, 
CDCl3): δ 7.44−7.42 (2H, m), 7.40-7.37 (2H, m), 7.33−7.31 (1H, m), 7.14 (2H, d, J = 
8.6 Hz), 6.93 (2H, d, J = 8.6 Hz), 5.05 (2H, s), 3.82 (2H, t, J = 6.5 Hz), 2.81 (2H, t, J 
= 6.5 Hz), 1.43 (1H, br.s); 13C NMR (125 MHz, CDCl3): δ 157.6, 137.2, 130.8, 
130.1, 128.7, 128.0, 127.5, 115.1, 70.1, 63.9, 38.4. The spectroscopic data matched 
that reported in the literature.309 
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2-(3-(benzyloxy)phenyl)ethan-1-ol (85b) 
 
This compound was prepared according to general procedure I by treating 3-(2-
hydroxyethyl)phenol (600 mg, 4.3 mmol) with benzyl bromide (613 µL, 5.2 mmol). 
The crude product was purified by flash chromatography (hexane/ethyl acetate 10:1→ 
5:1) to give the product as a white solid (912 mg, 93%). Rf (hexane/ethyl acetate 4:1): 
0.35; 1H NMR (300 MHz, CDCl3): δ 7.37−7.22 (5H, m), 7.18−7.13 (1H, m), 
6.79−6.74 (3H, m), 4.98 (2H, s), 3.77 (2H, t, J = 6.6 Hz), 2.76 (2H, t, J = 6.6 Hz); 13C 
NMR (75 MHz, CDCl3): δ 159.1, 140.3, 137.1, 129.7, 128.7, 128.1, 127.6, 121.8, 
115.9, 112.8, 70.1, 63.7, 39.3. The spectroscopic data matched that reported in the 
literature.319 
 
General procedure Q for the synthesis ethers  
 
To a solution of 84 (1.0 equiv.) in toluene (0.05 M) was added KOH (3.0 equiv.) and 
18-crown-6 (0.07 equiv.), followed by the addition of 85a−b (1.1 equiv.). The 
resulting mixture was stirred at 40 °C for 4 h. After completion monitored by TLC, 
the reaction mixture was washed with H2O and extracted with ethyl acetate (3 x 10 
mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo.  
 
5-(4-(benzyloxy)phenethoxy)-3-(4-(benzyloxy)phenyl)-[1,2,4]triazolo[4,3-
a]pyrazine (86a) 
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This compound was prepared according to general procedure Q by treating 84 (674 
mg, 2 mmol) with 85a (502 mg, 2.2 mmol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 1:1→ 1:1.5) to give the product as a white 
solid (772 mg, 73%). m.p. 156−158 °C; Rf (hexane/ethyl acetate 1:1): 0.15; 1H NMR 
(300 MHz, CDCl3): δ 8.94 (1H, s), 7.52 (2H, d, J = 7.8 Hz), 7.38−7.19 (10H, m), 6.97 
(2H, d, J = 7.8 Hz), 6.72 (2H, d, J = 8.1 Hz), 6.65 (2H, d, J = 8.1 Hz), 5.07 (2H, s), 
4.93 (2H, s), 4.27 (2H, t, J = 5.4 Hz), 2.77 (2H, t, J = 5.4 Hz); 13C NMR (75 MHz, 
CDCl3): δ 160.2, 157.7, 136.9, 136.4, 136.2, 132.3, 129.7, 128.7, 128.6, 128.1, 128.0, 
127.4, 120.2, 115.0, 114.2, 108.0, 106.1, 71.6, 70.1, 70.0, 33.8; HRMS (ESI+) Calc. 
for C33H28N4O3 [M + Na]+ 551.2054, found 551.2050. IR (neat, cm-1): 3033, 2951, 
2857, 1608, 1505, 1247, 830 695. 
 
5-(3-(benzyloxy)phenethoxy)-3-(4-(benzyloxy)phenyl)-[1,2,4]triazolo[4,3-
a]pyrazine (86b) 
 
This compound was prepared according to general procedure Q by treating 84 (674 
mg, 2 mmol) with 85b (502 mg, 2.2 mmol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 1:1 → 1:1.5) to give the product as a white 
solid (730 mg, 69%). m.p. 104−106 °C; Rf (hexane/ethyl acetate 1:1): 0.15; 1H NMR 
(300 MHz, CDCl3): δ 8.93 (1H, s), 7.49 (2H, d, J = 8.1 Hz), 7.35−7.18 (10H, m), 7.05 
(1H, t, J = 7.8 Hz), 6.92 (2H, d, J = 8.1 Hz), 6.75 (1H, d, J = 7.8 Hz), 6.46 (1H, s), 
6.40 (1H, d, J = 7.2 Hz), 5.01 (2H, s), 4.91 (2H, s), 4.30 (2H, t, J = 6.0 Hz), 2.81 (2H, 
t, J = 6.0 Hz); 13C NMR (75 MHz, CDCl3): δ 160.2, 159.1, 144.2, 138.1, 136.9, 
136.6, 136.5, 132.3, 129.8, 128.8, 128.7, 128.2, 128.1, 127.6, 127.5, 121.4, 120.2, 
115.8, 114.3, 112.9, 108.2, 71.2, 70.2, 70.1, 34.6; HRMS (ESI+) Calc. for 
C33H28N4O3 [M + Na]+ 551.2054, found 551.2052. IR (neat, cm-1): 3032, 2917, 
2853, 1607, 1506, 1243, 694. 
 
ν
N
N
N
N
OBn
O
OBn
ν
Chapter 6 
 159 
General procedure R for the debenzylation 
 
To a solution of benzyl protected substrates (1.0 equiv.) in MeOH (0.05 M) was 
added Pd/C (10 wt. %) under nitrogen atmosphere, and the mixture was stirred at RT 
for 2 h under 1 atm of hydrogen. After completion monitored by TLC, the Pd-C was 
filtered through Celite®, and the solvent was removed under reduced pressure.  
 
4-(5-(4-hydroxyphenethoxy)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenol (80a) 
 
This compound was prepared according to general procedure R by treating 86a (700 
mg, 1.3 mmol). The crude product was purified by flash chromatography 
(CH2Cl2/MeOH 50:1 → 10:1) to give the product as a pale yellow solid (317 mg, 
70%). m.p. 235−237 °C; Rf (CH2Cl2/MeOH 10:1): 0.25; 1H NMR (400 MHz, d-
DMSO): δ 9.90 (1H, br.s), 9.17 (1H, br.s), 8.98 (1H, s), 7.53 (2H, dd, J = 2.0, 6.4 Hz), 
7.50 (1H, s), 6.90 (2H, dd, J = 2.0, 6.8 Hz), 6.71 (2H, dd, J = 2.0, 6.4 Hz), 6.56 (2H, 
dd, J = 2.0, 6.8 Hz), 4.38 (2H, t, J = 6.4 Hz), 2.77 (2H, t, J = 6.4 Hz); 13C NMR (100 
MHz, d-DMSO): δ 158.8, 155.9, 147.2, 146.6, 143.9, 135.0, 132.3, 129.8, 127.3, 
118.4, 115.0, 114.4, 108.5, 71.7, 33.1; HRMS (ESI+) Calc. for C19H16N4O3 [M + 
Na]+ 371.1115, found 371.1112. IR (neat, cm-1):  3098, 2919, 1608, 1489, 1237, 
826. HPLC: 98.8% (HPLC Method A), RT: 16.6 min. 
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3-(2-((3-(4-hydroxyphenyl)-[1,2,4]triazolo[4,3-a]pyrazin-5-yl)oxy)ethyl)phenol 
(80b) 
 
This compound was prepared according to general procedure R by treating 86b (700 
mg, 1.3 mmol). The crude product was purified by flash chromatography 
(CH2Cl2/MeOH 50:1 → 10:1) to give the product as a pale yellow solid (303 mg, 
67%). m.p. 245−246 °C; Rf (CH2Cl2/MeOH 10:1): 0.25; 1H NMR (500 MHz, d-
DMSO): δ 9.89−9.84 (1H, br.s), 9.26 (1H, br.s), 8.99 (1H, s), 7.54 (1H, s), 7.50 (2H, 
d, J = 9.0 Hz), 6.98 (1H, t, J = 8.0 Hz), 6.86 (2H, d, J = 9.0 Hz), 6.58 (1H, d, J = 8.0 
Hz), 6.54 (1H, s), 6.34 (1H, d, J = 8.0 Hz), 4.43 (2H, t, J = 7.0 Hz), 2.80 (2H, t, J = 
7.0 Hz); 13C NMR (125 MHz, d-DMSO): δ 159.4, 158.0, 147.9, 147.3, 144.5, 139.1, 
135.7, 132.9, 129.8, 120.2, 118.9, 116.2, 115.0, 114.1, 109.3, 71.9, 34.5; HRMS 
(ESI+) Calc. for C19H16N4O3 [M + H]+ 349.1295, found 349.1295. IR (neat, cm-1):  
3102, 2956, 1608, 1510, 1439, 1242, 566. HPLC: 96.1% (HPLC Method A), RT: 
16.8 min. 
 
6-chloropyrazine-2-carboxylic acid (88) 
 
This compound was prepared following a literature procedure.254 To a solution of 
Na2WO4•2H2O (0.025 equiv., 0.24 mmol) in H2O (0.05 M) was added aq. H2O2 
(30%, 1.1 equiv., 1 mL) at RT, followed by the addition of H2SO4 (1 M) to make pH 
= 2, then pyrazine-2-carboxylic acid 87 (1.0 equiv., 8 mmol) was added, and the 
resulting suspension was stirred at 80 °C for 2 h. After completion monitored by TLC, 
the mixture was settled at RT until the precipitate was obtained, filtered and washed 
by H2O and dried under reduced pressure to get white solid compound 3-
carboxypyrazine 1-oxide without further purification. A solution of 3-
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carboxypyrazine 1-oxide (1.0 equiv., 7 mmol) in POCl3 (3 mL) in sealed tube was 
heated to 120 °C and stirred for 2 h. After completion monitored by TLC, the reaction 
mixture was cooled to RT and poured to ice water (20 mL), neutralised with sat. 
Na2CO3 (aq.) and extracted with ethyl acetate (3 x 20 mL). The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The crude product was 
recrystallised from ethanol, filtered and washed by hexane, dried to get the product as 
a white solid (880 mg, 70%). m.p. 158−160 °C; Rf (hexane/ethyl acetate 1:1): 0.25; 
1H NMR (500 MHz, d-DMSO): δ 9.13 (1H, s), 9.00 (1H, s); 13C NMR (125 MHz, d-
DMSO): δ 163.8, 148.0, 147.8, 143.7, 143.3. The spectroscopic data matched that 
reported in the literature.320 
 
3-((tert-butyldimethylsilyl)oxy)aniline (34b) 
 
This compound was prepared according to general procedure E by treating 3-
aminophenol (1.09 g, 0.01 mol), imidazole (1.60 g, 0.025 mol) and TBSCl (2.27 g, 
0.015 mol). The crude product was purified by flash chromatography (hexane/ethyl 
acetate 10:1 → 5:1) to give the product as pale yellow oil (2.07 g, 93%). Rf 
(hexane/ethyl acetate 2:1): 0.45; 1H NMR (500 MHz, CDCl3): δ 6.99 (1H, t, J = 8.0 
Hz), 6.31−6.26 (2H, m), 6.21−6.20 (1H, m), 3.46 (2H, br.s), 0.99 (9H, s), 0.20 (6H, 
s); 13C NMR (125 MHz, CDCl3): δ 156.9, 147.8,130.1, 110.7, 108.7, 107.3, 25.9, 
18.3, −4.2. The spectroscopic data matched that reported in the literature.321 
 
General procedure S for amide coupling reactions 
 
The compounds ware prepared following a literature procedure.322 To a solution of 
carboxylic acid (1.0 equiv.) in dry CH2Cl2 (0.1 M) was added oxalyl chloride (1.5 
NH2
OTBS
N
N
Cl
COOH
1) oxalyl chloride, DMF, CH2Cl2
H2N
2) TEA
OTBS N
N
Cl
NHO
OTBS
Chapter 6 
 162 
equiv.) and DMF (0.1 equiv.) at 0 °C, and the resulting mixture was allowed to warm 
to RT for 2 h. Then the volatiles were concentrated under reduced pressure, and the 
residue was dissolved in dry CH2Cl2 (0.1 M), followed by the addition of aniline (1.0 
equiv.) and triethylamine (1.1 equiv.), and the resulting mixture was stirred at RT for 
another 2 h. After completion monitored by TLC, the reaction mixture was quenched 
with H2O and extracted with CH2Cl2 (3 x 20 mL), and washed with 1% HCl solution, 
and then sat. Na2CO3 (aq.). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. 
 
N-(4-((tert-butyldimethylsilyl)oxy)phenyl)-6-chloropyrazine-2-carboxamide (89a) 
 
This compound was prepared according to general procedure S by treating 88 (316 
mg, 2 mmol) with 34a (446 mg, 2 mmol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1) to give the product as an off-white solid 
(582 mg, 80%). m.p. 115−116 °C; Rf (hexane/ethyl acetate 4:1): 0.55; 1H NMR (500 
MHz, CDCl3): δ 9.37 (1H, s), 9.30 (1H, br.s), 8.78 (1H, s), 7.59 (2H, ddd, J = 3.0, 5.5, 
10.0 Hz), 6.86 (2H, ddd, J = 3.0, 5.5, 10.0 Hz), 0.98 (9H, s), 0.20 (6H, s,); 13C NMR 
(125 MHz, CDCl3): δ 159.2, 153.1, 147.5, 147.4, 144.3, 142.3, 130.7, 121.6, 120.6, 
25.8, 18.3, −4.3; HRMS (ESI+) Calc. for C17H22ClN3O2Si [M + Na]+ 386.1062, 
found 386.1061. IR (neat, cm-1): 3374, 2950, 2930, 2855, 1686, 1591, 1261, 845. 
 
N-(3-((tert-butyldimethylsilyl)oxy)phenyl)-6-chloropyrazine-2-carboxamide (89b) 
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This compound was prepared according to general procedure S by treating 88 (316 
mg, 2 mmol) with 34b (446 mg, 2 mmol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1) to give the product as yellow oil (619 
mg, 85%). Rf (hexane/ethyl acetate 4:1): 0.55; 1H NMR (300 MHz, CDCl3): δ 9.41 
(1H, s), 9.35 (1H, br.s), 8.81 (1H, s), 7.44 (1H, s), 7.28−7.21 (2H, m), 6.70−6.68 (1H, 
m), 1.02 (9H, s), 0.26 (6H, s); 13C NMR (75 MHz, CDCl3): δ 159.4, 156.5, 147.6, 
147.5, 144.2, 142.3, 138.0, 129.9, 117.0, 113.0, 112.1, 25.8, 18.3, −4.3; HRMS 
(ESI+) Calc. for C17H22ClN3O2Si [M + Na]+ 386.1062, found 386.1060. IR (neat, cm-
1):  3374, 2954, 2929, 2857, 1686, 1598, 1534, 1166, 779. 
 
4-((tert-butyldimethylsilyl)oxy)benzaldehyde (90) 
 
This compound was prepared according to general procedure E by treating 4-
hydroxybenzaldehyde (488 mg, 4 mmol), imidazole (640 mg, 10 mmol) and TBSCl 
(906 mg, 6 mmol). The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1) to give the product as colorless oil (802 mg, 85%). Rf 
(hexane/ethyl acetate 2:1): 0.45; 1H NMR (300 MHz, CDCl3): δ 9.88 (1H, s), 7.79 
(2H, d, J = 7.8 Hz), 6.94 (2H, d, J = 7.8 Hz), 0.99 (9H, s), 0.24 (6H, s); 13C NMR (75 
MHz, CDCl3): δ 191.0, 161.6, 132.0, 130.5, 120.6, 25.7, 18.4, −4.2. The spectroscopic 
data matched that reported in the literature.323 
 
6-(2-(4-((tert-butyldimethylsilyl)oxy)benzylidene)hydrazinyl)-N-(4-((tert-
butyldimethylsilyl)oxy)phenyl)pyrazine-2-carboxamide (91a) 
 
This compound was prepared according to general procedure O by treating 89a (364 
mg, 1 mmol) with 90 (236 mg, 1 mmol). Pale yellow solid (491 mg, 85%). m.p. 
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230−232 °C; Rf (hexane/ethyl acetate 1:1): 0.60; 1H NMR (400 MHz, CDCl3): δ 9.32 
(1H, s), 8.94 (1H, s), 8.92 (1H, s), 8.31 (1H, s), 7.80 (1H, s), 7.62-7.55 (4H, m), 6.90 
(2H, dd, J = 2.0, 6.8 Hz), 6.85 (2H, dd, J = 2.0, 6.8 Hz), 1.00 (9H, s), 0.99 (9H, s), 
0.23 (6H, s), 0.20 (6H, s); 13C NMR (100 MHz, CDCl3): δ 160.9, 157.7, 152.8, 150.5, 
142.4, 141.3, 134.9, 134.8, 131.2, 128.5, 127.2, 121.4, 120.7, 120.6, 25.8 (two 
overlapping signals), 18.4, 18.3, −4.2, −4.3; HRMS (ESI+) Calc. for C30H43N5O3Si2 
[M + Na]+ 600.2797, found 600.2794. IR (neat, cm-1): 3374, 2953, 2928, 2885, 
2856, 1675, 1582, 1505, 1253, 911. 
 
6-(2-(4-((tert-butyldimethylsilyl)oxy)benzylidene)hydrazinyl)-N-(3-((tert-
butyldimethylsilyl)oxy)phenyl)pyrazine-2-carboxamide (91b) 
 
This compound was prepared according to general procedure O by treating 89b (364 
mg, 1 mmol) with 90 (236 mg, 1 mmol). Off-white solid (451 mg, 78%). m.p. 
212−214 °C; Rf (hexane/ethyl acetate 1:1): 0.60; 1H NMR (400 MHz, CDCl3): δ 9.36 
(1H, s), 8.95 (1H, s), 8.93 (1H, s), 8.27 (1H, s), 7.81 (1H, s), 7.60 (2H, d, J = 8.8 Hz), 
7.41 (1H, s), 7.23−7.22 (2H, m), 6.90 (2H, d, J = 8.8 Hz), 6.67−6.64 (1H, m), 1.01 
(9H, s), 1.00 (9H, s), 0.25 (6H, s), 0.24 (6H, s); 13C NMR (100 MHz, CDCl3): δ 
161.1, 157.7, 156.5, 150.5, 142.5, 138.6, 135.0, 132.4, 129.9, 128.5, 127.2, 120.7, 
120.1, 116.6, 112.8, 111.9, 25.8 (two overlapping signals), 18.4 (two overlapping 
signals), −4.2 (two overlapping signals); HRMS (ESI+) Calc. for C30H43N5O3Si2 [M 
+ Na]+ 600.2797, found 600.2794. IR (neat, cm-1): 3373, 2956, 2928, 2856, 1687, 
1598, 1531, 1258, 828. 
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N,3-bis(4-((tert-butyldimethylsilyl)oxy)phenyl)-[1,2,4]triazolo[4,3-a]pyrazine-5-
carboxamide (92a) 
 
This compound was prepared according to general procedure P by treating 91a (289 
mg, 0.5 mmol) with PhI(OAc)2 (161 mg, 0.5 mmol). The crude product was purified 
by flash chromatography (hexane/ethyl acetate 1:1) to give the product as a pale 
yellow solid (250 mg, 87%). m.p. 99−101 °C; Rf (hexane/ethyl acetate 1:1): 0.25; 1H 
NMR (400 MHz, CDCl3): δ 9.17 (1H, s), 9.08 (1H, s), 8.09 (1H, s), 7.43 (2H, d, J = 
8.4 Hz), 7.18 (2H, d, J = 8.8 Hz), 6.80 (2H, d, J = 8.4 Hz), 6.70 (2H, d, J = 8.8 Hz), 
0.97 (9H, s), 0.96 (9H, s), 0.17 (6H, s), 0.14 (6H, s); 13C NMR (100 MHz, CDCl3): δ 
158.2, 156.8, 153.4, 145.7, 145.6, 130.6, 130.3, 130.0, 127.9, 125.4, 121.7, 120.5, 
120.4, 119.1, 25.8, 25.7, 18.3 (two overlapping signals), −4.3, −4.4; HRMS (ESI+) 
Calc. for C30H41N5O3Si2 [M + Na]+ 598.2640, found 598.2639. IR (neat, cm-1):  
2956, 2929, 2857, 1676, 1607, 1535, 1251, 912, 778. 
 
N-(3-((tert-butyldimethylsilyl)oxy)phenyl)-3-(4-((tert-
butyldimethylsilyl)oxy)phenyl)-[1,2,4]triazolo[4,3-a]pyrazine-5-carboxamide 
(92b) 
 
This compound was prepared according to general procedure P by treating 91b (289 
mg, 0.5 mmol) with PhI(OAc)2 (161 mg, 0.5 mmol). The crude product was purified 
by flash chromatography (hexane/ethyl acetate 1:1) to give the product as a pale 
yellow solid (230 mg, 80%). m.p. 95−97 °C; Rf (hexane/ethyl acetate 1:1): 0.25; 1H 
NMR (400 MHz, CDCl3): δ 9.26 (1H, s), 9.10 (1H, s), 8.11 (1H, s), 7.42 (2H, d, J = 
N
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8.4 Hz), 7.07−7.03 (2H, m), 6.88 (1H, d, J = 8.4 Hz), 6.77 (2H, d, J = 8.4 Hz), 6.59 
(1H, dd, J = 2.4, 8.4 Hz), 0.95 (9H, s), 0.94 (9H, s), 0.16 (6H, s), 0.10 (6H, s); 13C 
NMR (100 MHz, CDCl3): δ 158.1, 156.8, 156.1, 148.4, 145.4, 145.3, 137.8, 130.7, 
129.8, 129.6, 125.3, 120.3, 118.7, 117.1, 112.7, 111.8, 25.7, 25.6, 18.2, 18.1, −4.4, 
−4.5; HRMS (ESI+) Calc. for C30H41N5O3Si2 [M + Na]+ 598.2640, found 598.2639. 
IR (neat, cm-1): 2955, 2929, 2857, 1683, 1607, 1254, 837, 778. 
 
N-3-bis(4-hydroxyphenyl)-[1,2,4]triazolo[4,3-a]pyrazine-5-carboxamide (81a) 
 
The compound was prepared according to general procedure G by treating 92a (200 
mg, 0.35 mmol) with TBAF (0.7 mL, 0.70 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 50:1 → 20:1) to give the product as a pale 
yellow solid (118 mg, 97%). m.p. 289−291 °C; Rf (CH2Cl2/MeOH 20:1): 0.20; 1H 
NMR (400 MHz, d-DMSO): δ 10.54 (1H, s), 9.80−9.79 (1H, br.s), 9.55 (1H, s), 
9.36−9.30 (1H, br.s), 8.19 (1H, s), 7.40 (2H, dd, J = 2.0, 6.8 Hz), 7.11 (2H, dd, J = 
2.0, 6.8 Hz), 6.72 (2H, dd, J = 2.0, 6.8 Hz), 6.66 (2H, dd, J = 2.0, 6.8 Hz); 13C NMR 
(100 MHz, d-DMSO): δ 159.4, 157.2, 154.7, 148.4, 146.1, 146.0, 130.2, 129.5, 125.6, 
122.2, 118.1, 115.6, 115.4, 115.2; HRMS (ESI+) Calc. for C18H13N5O3 [M + H]+ 
348.1091, found 348.1091. IR (neat, cm-1): 3184, 2920, 1668, 1512, 1276, 818. 
HPLC: 95.5% (HPLC Method A), RT: 13.6 min. 
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N-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)-[1,2,4]triazolo[4,3-a]pyrazine-5-
carboxamide (81b) 
 
The compound was prepared according to general procedure G by treating 92b (200 
mg, 0.35 mmol) with TBAF (0.7 mL, 0.70 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 50:1 → 20:1) to give the product as a pale 
yellow solid (115 mg, 95%). m.p. 239−242 °C; Rf (CH2Cl2/MeOH 20:1): 0.20; 1H 
NMR (500 MHz, d-DMSO): δ 10.68 (1H, br.s), 9.57 (1H, s), 8.22 (1H, s), 7.40 (2H, 
dd, J = 2.0, 6.5 Hz), 7.05 (1H, t, J = 8.0 Hz), 6.94 (1H, t, J = 2.0 Hz), 6.77−6.75 (1H, 
m), 6.71 (2H, dd, J = 2.0, 6.5 Hz), 6.50−6.48 (1H, m); 13C NMR (125 MHz, d-
DMSO): δ 159.6, 158.0, 157.8, 148.6, 146.4, 146.3, 139.2, 130.6, 130.2, 129.8, 125.5, 
118.1, 115.7, 112.2, 111.2, 107.6; HRMS (ESI+) Calc. for C18H13N5O3 [M + Na]+ 
370.0911, found 370.0911. IR (neat, cm-1): 3245, 2922, 2852, 1622, 1602, 1459, 
1222, 739. HPLC: 95.6% (HPLC Method A), RT: 14.6 min.  
 
2-(2-bromo-5-methoxyphenyl)-1,3-dioxolane (95) 
 
This compound was prepared following a literature procedure.324 To a solution of 2-
bromo-5-methoxybenzaldehyde 94 (1.0 g, 4.6 mmol) in toluene (15 mL) was added 
ethylene glycol (1.26 mL, 23 mmol) and p-toluenesulfonic acid (9.5 mg, 0.05 mmol), 
and the resulting mixture was heated at reflux under a Dean-Stark water separator for 
24 h. After completion monitored by TLC, the cooled mixture was diluted with ethyl 
acetate (10 mL) and washed with H2O and brine. The organic layer was dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 20:1) to give the product as colourless oil (1.1 
g, 95%); Rf (hexane/ethyl acetate 10:1): 0.35; 1H NMR (400 MHz, CDCl3): δ 7.50 
(1H, d, J = 8.8 Hz), 7.10 (1H, d, J = 2.4 Hz), 6.87 (1H, dd, J = 2.4, 8.8 Hz), 6.04 (1H, 
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s), 4.15−4.13 (2H, m), 4.06−4.04 (2H, m), 3.79 (3H, s); 13C NMR (100 MHz, 
CDCl3): δ 160.6, 128.7, 128.6, 123.4, 118.0, 113.5, 102.6, 65.4, 55.6. The 
spectroscopic data matched that reported in the literature.324 
 
N-(2-(1,3-dioxolan-2-yl)-4-methoxyphenyl)-4-methoxy-2-nitroaniline (96) 
 
This compound was prepared following a literature procedure.325 To a mixture of 
95 (518 mg, 2 mmol), 4-methoxy-2-nitroaniline (336 mg, 2 mmol), Pd(OAc)2 (45 mg, 
0.2 mmol),  Cs2CO3 (978 mg, 3 mmol) and (±)-BINAP (62.3 mg, 0.1 mmol) in 
toluene (15 mL) was purged with nitrogen, and the resulting mixture was stirred at 
120 °C for 3 h. After completion monitored by TLC, the cooled mixture was washed 
with H2O and brine. The organic layer was dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by flash chromatography (hexane/ethyl acetate 
8:1) to give the product as orange oil (616 mg, 89%); Rf (hexane/ethyl acetate 4:1): 
0.4; 1H NMR (500 MHz, CDCl3): δ 9.76 (1H, s), 7.59 (1H, d, J = 3.0 Hz), 7.38 (1H, 
d, J = 8.5 Hz), 7.35 (1H, d, J = 9.0 Hz), 7.04 (1H, dd, J = 3.0, 9.0 Hz), 6.89 (1H, d, J 
= 2.5 Hz), 6.63 (1H, dd, J = 2.5, 8.5 Hz), 5.75 (1H, s), 4.14−4.11 (2H, m), 4.00−3.98 
(2H, m), 3.78 (3H, s), 3.75 (3H, s); 13C NMR (125 MHz, CDCl3): δ 161.1, 151.7, 
140.1, 136.6, 134.2, 130.3, 125.7, 121.8, 119.0, 108.9, 108.5, 107.4, 103.3, 65.3, 56.0, 
55.5. HRMS (ESI+) Calc. for C17H18N2O6 [M + Na]+ 369.1057, found 369.1060. IR 
(neat, cm-1): 3349, 2954, 2890, 1613, 1584, 1505, 1279, 1215, 1032, 794. 
 
5-methoxy-2-((4-methoxy-2-nitrophenyl)amino)benzaldehyde (97) 
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This compound was prepared following a literature procedure.326 To a solution of 
96 (346 mg, 1 mmol) in CHCl3 (15 mL) was added TFA (459 µL, 6 mmol) dropwise, 
and the resulting mixture was stirred at RT for 30 min. After completion monitored by 
TLC, the mixture was quenched with H2O and extracted with CH2Cl2 (3 x 10 mL) and 
brine. The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by flash chromatography (hexane/ethyl acetate 
4:1) to give the product as an orange solid (272 mg, 90%); m.p. 161−163 °C; Rf 
(hexane/ethyl acetate 4:1): 0.35; 1H NMR (400 MHz, CDCl3): δ 11.17 (1H, s), 9.83 
(1H, s), 7.64 (1H, d, J = 9.2 Hz), 7.59 (1H, d, J = 3.2 Hz), 7.55 (1H, d, J = 8.8 Hz), 
7.15 (1H, dd, J = 3.2, 9.2 Hz), 6.70 (1H, d, J = 2.0 Hz), 6.52 (1H, dd, J = 2.0, 8.8 Hz), 
3.87 (3H, s), 3.80 (3H, s); 13C NMR (100 MHz, CDCl3): δ 192.0, 165.4, 154.9, 147.0, 
141.3, 139.0, 129.9, 124.6, 122.4, 116.7, 109.0, 106.3, 99.1, 56.1, 55.7. HRMS 
(ESI+) Calc. for C15H14N2O5 [M + Na]+ 325.0795, found 325.0799. IR (neat, cm-1): 
3282, 2842, 1644, 1611, 1564, 1508, 1233, 1025, 613, 567. 
 
2,8-dimethoxy-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine (98) 
 
This compound was prepared according to general procedure R by treating 97 (302 
mg, 1 mmol) with Pd/C (30 mg) and H2.  The crude product was purified by flash 
chromatography (hexane/ethyl acetate 1:1) to get the desired compound as a pale 
yellow solid (192 mg, 75%). m.p. 170−172 °C; Rf (hexane/ethyl acetate 2:1): 0.30; 1H 
NMR (400 MHz, d-DMSO): δ 7.84 (1H, br.s), 6.82 (1H, d, J = 7.6 Hz), 6.72 (1H, d, J 
= 8.8 Hz), 6.41 (1H, s), 6.29 (1H, d, J = 2.4 Hz), 6.23 (1H, s), 6.13 (1H, s), 5.58 (1H, 
br.s), 4.00 (2H, s), 3.68 (3H, s), 3.62 (3H, s); 13C NMR (100 MHz, d-DMSO): δ 
159.4, 152.9, 146.1, 141.0, 129.6, 127.5, 119.6, 119.2, 105.5, 104.5, 102.9, 102.0, 
55.4, 55.2, 50.8; HRMS (ESI+) Calc. for C15H16N2O2 [M + Na]+ 279.1104, found 
279.1109. IR (neat, cm-1): 3333, 3278, 2992, 2833, 1617, 1598, 1505, 1451, 1219, 
1036, 825, 795, 519.  
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10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-2,8-diol (93) 
 
This compound was prepared according to general procedure D by treating 98 (128 
me, 0.5 mmol) with BBr3 (3 mL, 3 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 20:1) to give the product as a brown solid 
(57 mg, 50%). m.p. 256−258 °C; Rf (CH2Cl2/MeOH 10:1): 0.40; 1H NMR (500 MHz, 
d-DMSO): δ 10.99-10.90 (1H, br.s), 9.42 (1H, br.s), 8.64 (1H, s), 7.10 (1H, d, J = 9.0 
Hz), 7.03 (1H, d, J = 8.0 Hz), 6.85 (1H, s), 6.75 (1H, d, J = 8.0 Hz), 6.50 (1H, s), 6.22 
(1H, d, J = 8.0 Hz), 4.38 (2H, s); 13C NMR (125 MHz, d-DMSO): δ 158.4, 150.0, 
143.6, 131.6, 129.8, 124.0, 121.1, 117.0, 110.0, 109.4, 106.5, 103.5, 51.8; HRMS 
(ESI+) Calc. for C13H12N2O2 [M + Na]+ 251.0791, found 251.0792. IR (neat, cm-1): 
3385, 3312, 3286, 1612, 1517, 1470, 1222, 835, 806, 524. HPLC: 97.6% (HPLC 
Method C), RT: 12.4 min. 
 
6.3 Synthesis of compounds from Chapter 3 
 
5-bromo-N-(4-((tert-butyldimethylsilyl)oxy)phenyl)pyridin-2-amine (103) 
 
To a solution of 5-bromopyridin-2-amine 102b  (1.0 equiv., 1 mmol) in MeOH (0.05 
M) was added boronic acid 40 (1.2 equiv., 1.2 mmol) at RT, followed by the addition 
of Cu(OAc)2 (0.1 equiv., 0.1 mmol). The reaction mixture was stirred for 12 h in the 
air atmosphere at RT. After completion monitored by TLC, the metal solid was 
filtered through Celite®, and the solvent was removed under reduced pressure. The 
crude product was purified by flash chromatography (hexane/ethyl acetate 10:1) to 
give the product as a white solid (227 mg, 60%). m.p. 131−132 °C; Rf (hexane/ethyl 
acetate 10:1): 0.40; 1H NMR (400 MHz, CDCl3): δ 8.16 (1H, d, J = 2.0 Hz), 7.51 
(1H, dd, J = 2.0, 8.8 Hz), 7.14 (2H, dd, J = 2.0, 6.4 Hz), 6.83 (2H, dd, J = 2.0, 6.4 
Hz), 6.60 (1H, d, J = 8.8 Hz), 6.55 (1H, s), 0.99 (9H, s), 0.20 (6H, s); 13C NMR (100 
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MHz, CDCl3): δ 155.8, 152.8, 148.4, 140.5, 133.0, 124.2, 121.0, 109.0, 108.4, 25.8, 
18.4, −4.3; HRMS (ESI+) Calc. for C17H23BrN2OSi [M + Na]+ 401.0655/403.0635, 
found 401.0659/403.0639. IR (neat, cm-1): 3244, 2947, 2855, 1605, 1525, 1251, 
904, 778. 
 
N,5-bis(4-((tert-butyldimethylsilyl)oxy)phenyl)pyridin-2-amine (104) 
 
This compound was prepared according to general procedure F by treating 103 (190 
mg, 0.5 mmol) with boronic acid 40 (189 mg, 0.75 mmol). The crude product was 
purified by flash chromatography (hexane/ethyl acetate 10:1 → 5:1) to give the 
product as a white solid (203 mg, 80%), m.p. 135−136 °C; Rf (hexane/ethyl acetate 
5:1): 0.45; 1H NMR (300 MHz, CDCl3): δ 8.26 (1H, s), 7.71 (1H, d, J = 9.0 Hz), 
7.37−7.34 (3H, m), 7.18 (2H, d, J = 8.1 Hz), 6.90 (2H, d, J = 8.1 Hz), 6.86−6.79 (3H, 
m), 1.00 (18H, s), 0.22 (6H, s), 0.21 (6H, s); 13C NMR (75 MHz, CDCl3): δ 155.6, 
155.1, 153.0, 142.9, 137.8, 132.7, 130.5, 127.5, 127.4, 124.4, 121.1, 120.8, 108.3, 
25.8 (two overlapping signals), 18.4 (two overlapping signals), −4.2 (two overlapping 
signals); HRMS (ESI+) Calc. for C29H42N2O2Si2 [M + H]+ 507.2858, found 
507.2861. IR (neat, cm-1): 3232, 2962, 2856, 1603, 1508, 1249, 911, 822, 775. 
 
4-(6-((4-hydroxyphenyl)amino)pyridin-3-yl)phenol (99a) 
 
This compound was prepared according to general procedure G by treating 104 (114 
mg, 0.2 mmol) with TBAF (0.4 mL, 0.4 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 3:1 → 1:1) to give the product as a pale 
yellow solid (53 mg, 95%). m.p. 199−200 °C; Rf (hexane/ethyl acetate 1:1): 0.30; 1H 
NMR (400 MHz, d-MeOD): δ 8.18 (1H, dd, J = 0.8, 2.8 Hz), 7.70 (1H, dd, J = 2.8, 
8.8 Hz), 7.37 (2H, ddd, J = 2.8, 4.8, 9.6 Hz), 7.21 (2H, ddd, J = 3.2, 5.6, 10.0 Hz), 
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6.84 (2H, ddd, J = 2.8, 4.8, 9.6 Hz), 6.78 (2H, ddd, J = 3.2, 5.6, 10.0 Hz), 6.74 (1H, 
dd, J = 0.8, 8.8 Hz); 13C NMR (100 MHz, d-MeOD): δ 157.9, 157.4, 154.5, 145.5, 
137.3, 134.1, 130.8, 128.4, 128.1, 124.5, 116.8, 116.7, 110.1; HRMS (ESI+) Calc. for 
C17H14N2O2 [M + H]+ 279.1128, found 279.1131. IR (neat, cm-1): 3217, 2953, 
1607, 1490, 1218, 815. HPLC: >99.9% (HPLC Method A), RT: 16.2 min. 
 
General procedure T for reductive aminations260  
 
To a solution of aldehyde (1.0 equiv.) in CF3CH2OH (0.04 M) was added amine (1.0 
equiv.), and the mixture was stirred at RT. After 30 min, NaBH(OAc)3 (1.5 equiv.) 
was added and stirred for 12 h at RT. After completion monitored by TLC, the solvent 
was removed under reduced pressure. 
 
4-(((5-bromopyridin-2-yl)amino)methyl)phenol (105) 
 
This compound was prepared according to general procedure T by treating 5-
bromopyridin-2-amine 102b (173 mg, 1 mmol) with 4-hydroxybenzaldehyde (122 
mg, 1 mmol). The crude product was purified by flash chromatography (hexane/ethyl 
acetate 5:1 → 3:1) to give the product as a white solid (190 mg, 68%). m.p. 
125−128 °C; Rf (hexane/ethyl acetate 4:1): 0.30; 1H NMR (400 MHz, d-MeOD): δ 
7.98 (1H, d, J = 2.4 Hz), 7.49 (1H, dd, J = 2.4, 8.8 Hz), 7.17 (2H, dd, J = 2.0, 6.8 Hz), 
6.75 (2H, dd, J = 2.0, 6.8 Hz), 6.48 (1H, d, J = 8.8 Hz), 4.36 (2H, s); 13C NMR (100 
MHz, d-MeOD): δ 159.0, 157.6, 148.5, 140.9, 131.3, 129.8, 116.2, 111.4, 106.9, 46.0; 
HRMS (ESI+) Calc. for C12H11BrN2O [M + Na]+ 300.9947/302.9926, found 
300.9950/302.9930. IR (neat, cm-1): 3218, 1594, 1343, 815. 
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4-(6-((4-hydroxybenzyl)amino)pyridin-3-yl)phenol (99b) 
 
This compound was prepared according to general procedure F by treating 105 (70 
mg, 0.25 mmol) with (4-hydroxyphenyl)boronic acid (52 mg, 0.375 mmol). The crude 
product was purified by flash chromatography (hexane/ethyl acetate 3:1 → 1:1) to 
give the product as a pale yellow solid (51 mg, 70%), m.p. 193−196 °C; Rf 
(hexane/ethyl acetate 1:1): 0.35; 1H NMR (300 MHz, d-MeOD): δ 8.13 (1H, s), 7.65 
(1H, d, J = 8.7 Hz), 7.34 (2H, d, J = 8.1 Hz), 7.20 (2H, d, J = 8.1 Hz), 6.85 (2H, d, J = 
8.1 Hz), 6.76 (2H, d, J = 8.1 Hz), 6.58 (1H, d, J = 8.7 Hz), 4.41 (2H, s); 13C NMR (75 
MHz, d-MeOD): δ 158.9, 157.7, 157.5, 145.2, 137.2, 131.6, 131.0, 129.7, 128.1, 
127.1, 116.7, 116.2, 109.6, 46.3; HRMS (ESI+) Calc. for (C18H16N2O2)2 [M + Na]+ 
607.2316, found 607.2321. IR (neat, cm-1): 3211, 3025, 1613, 1508, 1247, 822, 
529. HPLC: >99.9% (HPLC Method B), RT: 16.2 min. 
 
3-(4-(benzyloxy)phenyl)propanal (106) 
 
This compound was prepared in two steps. Step 1: The formation of 3-(4-
(benzyloxy)phenyl)propan-1-ol. This compound was prepared according to general 
procedure I by treating 4-(3-hydroxypropyl)phenol (608 mg, 4 mmol) with benzyl 
bromide (570 µL, 6 mmol). The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1 → 5:1) to give the intermediate as a white solid (920 mg, 
95%). Rf (hexane/ethyl acetate 4:1): 0.30; 1H NMR (400 MHz, CDCl3): δ 7.48−7.33 
(5H, m), 7.15 (2H, ddd, J = 2.8, 5.2, 9.6 Hz), 6.95 (2H, ddd, J = 2.8, 5.2, 9.6 Hz), 5.06 
(2H, s), 3.66 (2H, t, J = 6.4 Hz), 2.70−2.66 (2H, m), 2.19 (1H, s), 1.92−1.85 (2H, m); 
13C NMR (100 MHz, CDCl3): δ 157.1, 137.3, 134.3, 129.4, 128.6, 127.9, 127.5, 
114.9, 70.1, 62.1, 34.4, 31.2. The spectroscopic data matched that reported in the 
literature.327 
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Step 2: The formation of product 106. This compound was prepared according to 
general procedure K by treating 3-(4-(benzyloxy)phenyl)propan-1-ol (920 mg, 3.8 
mmol) with DMP (2.42 g, 5.7 mmol). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1) to give the product as a white solid (866 
mg, 95%). Rf (hexane/ethyl acetate 10:1): 0.50; 1H NMR (300 MHz, CDCl3): δ 9.81 
(1H, s), 7.44−7.32 (5H, m), 7.11 (2H, d, J = 8.1 Hz), 6.91 (2H, d, J = 8.1 Hz), 5.05 
(2H, s), 2.91 (2H, t, J = 7.2 Hz), 2.75 (2H, t, J = 7.2 Hz); 13C NMR (75 MHz, 
CDCl3): δ 201.9, 157.5, 137.2, 132.8, 129.4, 128.7, 128.1, 127.6, 115.1, 70.2, 45.6, 
27.4. The spectroscopic data matched that reported in the literature.328 
 
N-(3-(4-(benzyloxy)phenyl)propyl)-5-bromopyridin-2-amine (107) 
 
This compound was prepared according to general procedure T by treating 5-
bromopyridin-2-amine 102b (173 mg, 1 mmol) with aldehyde 106 (240 mg, 1 mmol). 
The crude product was purified by flash chromatography (hexane/ethyl acetate 10:1) 
to give the product as a white solid (353 mg, 89%). m.p. 97−98 °C; Rf (hexane/ethyl 
acetate 10:1): 0.40; 1H NMR (400 MHz, CDCl3): δ 8.09 (1H, d, J = 2.4 Hz), 
7.47−7.31 (6H, m), 7.10 (2H, ddd, J = 2.8, 5.2, 9.6 Hz), 6.91 (2H, ddd, J = 2.8, 5.2, 
9.6 Hz), 6.23 (1H, d, J = 8.8 Hz), 5.05 (2H, s), 4.65 (1H, br.s), 3.24 (2H, t, J = 6.4 
Hz), 2.66 (2H, t, J = 7.6 Hz), 1.91 (2H, tt, J = 7.6, 14.4 Hz); 13C NMR (100 MHz, 
CDCl3): δ 157.5, 157.3, 148.7, 139.9, 137.3, 133.9, 129.4, 128.7, 128.0, 127.6, 115.0, 
108.0, 106.8, 70.2, 41.9, 32.4, 31.2; HRMS (ESI+) Calc. for C21H21BrN2O [M + H]+ 
397.0910/399.0890, found 397.0915/399.0894. IR (neat, cm-1): 3247, 2937, 1586, 
1243, 815, 726. 
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4-(6-((3-(4-(benzyloxy)phenyl)propyl)amino)pyridin-3-yl)phenol (108) 
 
This compound was prepared according to general procedure F by treating 107 (199 
mg, 0.5 mmol) with (4-hydroxyphenyl)boronic acid (103 mg, 0.75 mmol). The crude 
product was purified by flash chromatography (hexane/ethyl acetate 10:1 → 3:1) to 
give the product as a pale yellow solid (154 mg, 75%). m.p. 138−140 °C; Rf 
(hexane/ethyl acetate 6:1): 0.30; 1H NMR (300 MHz, CDCl3): δ 8.26 (1H, s), 7.63 
(1H, d, J = 8.7 Hz), 7.44−7.34 (7H, m), 7.09 (2H, d, J = 8.1 Hz), 6.93−6.88 (4H, m), 
6.41 (1H, d, J = 8.7 Hz), 5.03 (2H, s), 4.68 (1H, br.s), 3.30−3.28 (2H, m), 2.67 (2H, t, 
J = 7.2 Hz), 1.93 (2H, tt, J = 7.2, 13.8 Hz); 13C NMR (75 MHz, CDCl3): δ 157.5, 
157.3, 155.9, 145.3, 137.3, 136.6, 133.9, 130.5, 129.5, 128.7, 128.0, 127.6 (two 
overlapping signals), 126.3, 116.2, 115.0, 106.5, 70.2, 42.0, 32.4, 31.3; HRMS 
(ESI+) Calc. for C27H26N2O2 [M + H]+ 411.2067, found 411.2071. IR (neat, cm-1): 
3409, 3029, 2928, 2856, 1606, 1501, 1232, 811, 517. 
 
4-(6-((3-(4-hydroxyphenyl)propyl)amino)pyridin-3-yl)phenol (99d) 
 
This compound was prepared according to general procedure R by treating 108 (100 
mg, 0.24 mmol) with Pd/C (10 mg) and H2. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 1:1) to give the product as a pale yellow solid 
(69 mg, 90%). m.p. 217−219 °C; Rf (hexane/ethyl acetate 1:1): 0.40; 1H NMR (400 
MHz, d-DMSO): δ 9.37 (1H, br.s), 9.11 (1H, br.s), 8.18 (1H, d, J = 2.4 Hz), 7.57 (1H, 
dd, J = 2.4, 8.8 Hz), 7.34 (2H, dd, J = 2.0, 6.4 Hz), 7.00 (2H, dd, J = 2.0, 6.4 Hz), 
6.79 (2H, dd, J = 2.0, 6.4 Hz), 6.67 (2H, dd, J = 2.0, 6.4 Hz), 6.52−6.48 (2H, m), 
N N
H
OBn
HO
ν
N N
H
OH
HO
Chapter 6 
 176 
3.25−3.20 (2H, m), 2.54 (2H, t, J = 7.6 Hz), 1.77 (2H, tt, J = 7.6, 14.8 Hz); 13C NMR 
(100 MHz, d-DMSO): δ 157.7, 156.1, 155.2, 144.7, 134.5, 131.9, 129.1 (two 
overlapping signals), 126.5, 123.7, 115.7, 115.0, 107.9, 40.5, 31.9, 31.2; HRMS 
(ESI+) Calc. for C20H20N2O2 [M + H]+ 321.1598, found 321.1601. IR (neat, cm-1): 
3403, 3150, 2922, 2852, 1609, 1508, 1450, 1234, 813. HPLC: 99.0% (HPLC Method 
B), RT: 18.3 min. 
 
5-bromo-N-(4-methoxyphenethyl)pyridin-2-amine (110) 
 
To a solution of 5-bromo-N-(4-methoxyphenethyl)pyridin-2-amine 109 (200 mg, 0.65 
mmol) in DMF (15 ml) was added K2CO3 (270 mg, 1.95 mmol) and 2-(4-
methoxyphenyl)ethan-1-amine (148 µl, 0.78 mmol), and the mixture was stirred at 
120 °C for 8 h. After completion monitored by TLC, the mixture was quenched with 
H2O and extracted with ethyl acetate (3 x 15 mL). The combined organic layers were 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 → 4:1) to give the product as a brown 
solid (125 mg, 63%). m.p. 154−156 °C; Rf (hexane/ethyl acetate 2:1): 0.40; 1H NMR 
(500 MHz, CDCl3): δ 8.09 (1H, dd, J = 0.4, 2.4 Hz), 7.44 (1H, dd, J = 2.4, 8.8 Hz), 
7.12 (2H, ddd, J = 2.0, 2.9, 8.6 Hz), 6.84 (2H, ddd, J = 2.0, 2.9, 8.6 Hz), 6.25 (1H, dd, 
J = 0.4, 8.8 Hz), 4.60 (1H, br.s), 3.78 (3H, s), 3.48 (2H, dd, J = 6.9, 12.8 Hz), 2.84 
(2H, t, J = 6.9 Hz); 13C NMR (125 MHz, CDCl3): δ 158.4, 157.3, 148.8, 139.8, 131.0, 
129.8, 114.2, 108.4, 107.0, 55.4, 43.6, 34.6; HRMS (ESI+) Calc. for C14H15N2OBr 
[M + H]+ 307.0441/309.0420, found 307.0443/309.0423. IR (neat, cm-1):  3334, 
2954, 2930, 2835, 1635, 1502, 1241, 1026, 816, 528. 
 
N-(4-methoxyphenethyl)-5-(4-methoxyphenyl)pyridin-2-amine (111) 
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This compound was prepared according to general procedure F by treating 110 (100 
mg, 0.33 mmol) with (4-methoxyphenyl)boronic acid (76 mg, 0.50 mmol) in 
toluene/ethanol 3:1 at 90 °C. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 3:1 → 1:1) to give the product as an off-white solid (99 mg, 
90%). m.p. 236−240 °C; Rf (hexane/ethyl acetate 4:1): 0.40; 1H NMR (400 MHz, 
CDCl3): δ 8.30 (1H, d, J = 2.0 Hz), 7.61 (1H, dd, J = 2.5, 8.6 Hz), 7.42 (2H, dd, J = 
2.1, 6.7 Hz), 7.16 (2H, d, J = 8.6 Hz), 6.96 (2H, dd, J = 2.1, 6.7 Hz), 6.86 (2H, dd, J = 
2.1, 6.7 Hz), 6.43 (1H, d, J = 8.6 Hz), 4.57 (1H, t, J = 5.6 Hz), 3.84 (3H, s), 3.80 (3H, 
s), 3.56 (2H, dd, J = 6.9, 12.9 Hz), 2.89 (2H, t, J = 6.9 Hz); 13C NMR (100 MHz, 
CDCl3): δ 158.8, 158.4, 157.7, 146.1, 136.0, 131.3, 129.9, 127.3, 126.1, 114.5, 114.2, 
106.8, 55.5, 55.4, 43.8, 34.9; HRMS (ESI+) Calc. for C21H22N2O2 [M + Na]+ 
357.1573, found 357.1575. IR (neat, cm-1): 3204, 2978, 2956, 1610, 1478, 1098, 
876, 789.   
 
4-(6-((4-hydroxyphenethyl)amino)pyridin-3-yl)phenol (99c) 
 
This compound was prepared according to general procedure D by treating 111 (100 
mg, 0.3 mmol) with BBr3 (1.8 mL, 1.8 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 100:1 → 40:1) to give the product as a white 
solid (54 mg, 59%). m.p. 156−158 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H NMR (500 
MHz, d-DMSO): δ 9.70 (1H, s), 9.23 (1H, s), 8.69 (1H, br s), 8.18 (1H, dd, J = 2.1, 
9.3 Hz), 8.01 (1H, s), 7.48 (2H, ddd, J = 2.0, 2.9, 8.6 Hz), 7.13 (1H, s), 7.10 (2H, d, J 
= 8.6 Hz), 6.87 (2H, ddd, J = 2.0, 2.9, 8.6 Hz), 6.71 (2H, ddd, J = 2.0, 2.9, 8.6 Hz), 
3.55 (2H, dd, J = 7.4, 11.5 Hz), 2.82 (2H, t, J = 7.4 Hz); 13C NMR (125 MHz, d-
DMSO): δ 158.2, 156.4, 151.7, 141.8, 131.9, 130.2, 128.7, 127.8, 125.5, 125.2, 116.4, 
115.6, 114.1, 43.9, 33.6; HRMS (ESI+) Calc. for C19H18N2O2 [M + Na]+ 329.1260, 
found 329.1262. IR (neat, cm-1):  3513, 3256, 3009, 1662, 1514, 833. HPLC: 
98.4% (HPLC Method A), RT: 16.5 min. 
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General procedure U for the synthesis of secondary amines  
 
The compounds were prepared following a literature procedure.329 To a solution of 
glyoxal (40% in ethanol, 0.9 equiv.) in ethanol (0.1 M) was added amine (1.1 equiv.), 
and the mixture was stirred at room temperature for 4 h. After completion monitored 
by TLC, the resulting precipitate was filtered and washed by hexane, and dried to get 
the intermediate diimine as a yellow solid without further purification. To a solution 
of diimine (1.0 equiv.) in a mixture solvent of CH2Cl2/MeOH (1:1 (v/v), 0.03 M) was 
added NaBH4 (1.0 equiv.) at 0 °C, and allowed to warm to RT for 30 min. The solvent 
was removed under reduced pressure, and H2O (10 mL) was added to afford a white 
precipitate, which was filtered and washed with hexane, recrystallised from hot 
ethanol and dried under reduced pressure to get the product without further 
purification. 
 
4,4'-(ethane-1,2-diylbis(azanediyl))diphenol (100a) 
 
This compound was prepared according to general procedure U by treating 4-
aminophenol 112a (109 mg, 1 mmol) to give the product as an off-white solid (220 
mg, 90%). m.p. 170−172 °C; Rf (CH2Cl2/MeOH 20:1): 0.35; 1H NMR (500 MHz, d-
DMSO): δ 8.38 (2H, s), 6.54 (4H, d, J = 8.8 Hz), 6.44 (4H, d, J = 8.8 Hz), 4.90 (2H, 
s), 3.09 (4H, t, J = 2.5 Hz); 13C NMR (125 MHz, d-DMSO): δ 148.3, 141.7, 115.7, 
113.5, 43.4; HRMS (ESI+) Calc. for C14H16N2O2 [M + Na]+ 267.1104, found 
267.1104. IR (neat, cm-1):  3283, 3066, 2970, 1507, 641, 533. HPLC: 96.5% 
(HPLC Method A), RT: 10.9 min. 
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4,4'-((ethane-1,2-diylbis(azanediyl))bis(ethane-2,1-diyl))diphenol (100c)  
 
This compound was prepared according to general procedure U by treating 4-(2-
aminoethyl)phenol 112b (68 mg, 0.5 mmol) to give the product as an off-white solid 
(129 mg, 86%). m.p. 205−209 °C; Rf (CH2Cl2/MeOH 20:1): 0.30; 1H NMR (500 
MHz, d-DMSO): δ 6.96 (4H, d, J = 8.1 Hz), 6.66 (4H, d, J = 8.1 Hz), 2.65−2.62 (4H, 
m), 2.55−2.52 (8H, m), NH and OH signals not observed; 13C NMR (125 MHz, d-
DMSO): δ 155.9, 130.9, 129.8, 115.5, 51.9, 49.4, 35.6; HRMS (ESI+) Calc. for 
C18H24N2O2 [M + H]+ 301.1910, found 301.1910. IR (neat, cm-1):  3179, 3019, 
2814, 1671, 1182,1131. HPLC: >99.9% (HPLC Method C), RT: 16.2 min. 
 
General procedure V for methylation of secondary amines to tertiary amines  
 
To a solution of secondary amine (1.0 equiv.) in acetic acid (0.04 M) was added 
formaldehyde (37%, 10.0 equiv.), and the mixture was stirred at RT. After 30 min, 
NaBH4 (1.0 equiv.) was added and stirred for another 30 min. The solvent was 
removed under reduced pressure and taken up in sat. Na2CO3 (aq.), extracted with 
ethyl acetate (3 x 15 mL) and the combined organic layers were dried over MgSO4 
and concentrated in vacuo.  
 
4,4'-(ethane-1,2-diylbis(methylazanediyl))diphenol (101a) 
 
This compound was prepared according to general procedure V by treating 100a (61 
mg, 0.25 mmol) with formaldehyde (37%, 249 µL, 2.5 mmol). The crude product was 
purified by flash chromatography (CH2Cl2/MeOH 100:1 → 80:1) to give the product 
as a white solid (60 mg, 88%). m.p. 174−176 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H 
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NMR (400 MHz, d-MeOD): δ 6.70−6.34 (8H, m), 3.33 (4H, s), 2.81 (6H, s), OH 
signals not observed; 13C NMR (100 MHz, d-MeOD): δ 150.6, 144.7, 116.9, 116.8, 
52.4, 40.2; HRMS (ESI+) Calc. for C16H20N2O2 [M + H]+ 273.1597, found 273.1597. 
IR (neat, cm-1):  3489, 3377, 3100, 1662, 1192, 545. HPLC: 99.7% (HPLC Method 
C), RT: 16.7 min. 
 
4,4'-((ethane-1,2-diylbis(methylazanediyl))bis(ethane-2,1-diyl))diphenol (101c) 
 
This compound was prepared according to general procedure V by treating 100c (75 
mg, 0.25 mmol) with formaldehyde (37%, 249 µL, 2.5 mmol). The crude product was 
purified by flash chromatography (CH2Cl2/MeOH 100:1 → 80:1) to give the product 
as a pale brown solid (73 mg, 89%). m.p. 229−230 °C; Rf (CH2Cl2/MeOH 20:1): 0.40; 
1H NMR (400 MHz, d-DMSO): δ 9.07 (2H, br s), 6.96 (4H, d, J = 8.4 Hz), 6.62 (4H, 
d, J = 8.4 Hz), 2.56−2.52 (4H, m), 2.48−2.43 (4H, m), 2.40 (4H, s), 2.17 (6H, s); 13C 
NMR (100 MHz, d-DMSO): δ 155.8, 131.0, 129.9, 115.4, 60.2, 55.4, 42.6, 32.6; 
HRMS (ESI+) Calc. for C20H28N2O2 [M + H]+ 329.2223, found 329.2224. IR (neat, 
cm-1): 3201, 2939, 2622, 1513, 1200, 830, 659. HPLC: 95.7% (HPLC Method A), 
RT: 12.3 min. 
 
4,4'-((ethane-1,2-diylbis(azanediyl))bis(methylene))diphenol (100b) 
 
This compound was prepared following a literature procedure.330 To a solution of 
ethylenediamine (55 µL, 0.82 mmol) in toluene (20 mL) was added 4-
hydroxybenzaldehyde 113 (200 mg, 1.64 mmol), and the mixture was stirred at 
110 °C for 20 min to form a yellow precipitate, which was filtered to get the crude 
intermediate without further purification. The obtained solid was dissolved in a 
mixture solvent of CH2Cl2/MeOH (1:1 (v/v), 20 mL) followed by the addition of 
NaBH4 (15.9 mg, 0.42 mmol) at 0 °C, and the resulting mixture was allowed to warm 
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to RT for 30 min. After completion monitored by TLC, the mixture was quenched by 
sat. NH4Cl (aq.) and extracted with ethyl acetate (3 x 15 mL), and the combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by flash chromatography (CH2Cl2/MeOH 100:1 → 80:1) to give the 
product as an off-white solid (207 mg, 93%). m.p. 139−141 °C; Rf (CH2Cl2/MeOH 
20:1): 0.35; 1H NMR (500 MHz, d-DMSO): δ 9.17 (2H, s), 7.07 (4H, d, J = 8.4 Hz), 
6.67 (4H, d, J = 8.4 Hz), 3.52 (4H, s), 2.53 (4H, s); 13C NMR (125 MHz, d-DMSO): δ 
155.9, 131.2, 128.9, 114.7, 52.5, 48.2; HRMS (ESI+) Calc. for C16H20N2O2 [M + H]+ 
273.1597, found 273.1598. IR (neat, cm-1):  3254, 3018, 2856, 1611, 1512, 876. 
HPLC: >99.9% (HPLC Method A), RT: 10.8 min. 
 
4,4'-((ethane-1,2-diylbis(methylazanediyl))bis(methylene))diphenol (101b) 
 
This compound was prepared according to general procedure V by treating 100b (68 
mg, 0.25 mmol) with formaldehyde (37%, 249 µL, 2.5 mmol). The crude product was 
purified by flash chromatography (CH2Cl2/MeOH 100:1 → 80:1) to give the product 
as a white solid (67 mg, 90%). m.p. 158−159 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H 
NMR (500 MHz, d-DMSO): δ 9.21 (2H, s), 7.03 (4H, d, J = 8.3 Hz), 6.67 (4H, d, J = 
8.3 Hz), 3.32 (4H, s), 2.42 (4H, s), 2.06 (6H, s); 13C NMR (100 MHz, d-MeOD): δ 
158.0, 132.0, 129.3, 116.1, 62.8, 54.8, 42.7; HRMS (ESI+) Calc. for C18H24N2O2 [M 
+ H]+ 301.1910, found 301.1910. IR (neat, cm-1): 3269, 3009, 1671,1126. HPLC: 
>99.9% (HPLC Method C), RT: 14.3 min. 
 
N1,N2-bis(4-methoxyphenethyl)oxalamide (115) 
 
 
This compound was prepared following a literature procedure.331 To a solution of 2-
(4-methoxyphenyl)ethan-1-amine 114 (1.03 g, 6.8 mmol) in toluene (20 mL) was 
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added diethyl oxalate (496 mg, 3.4 mmol), and the resulting mixture was heated to 
110 °C and stirred for 12 h. After completion monitored by TLC, the reaction mixture 
was cooling down, hexane was added to get white precipitate, filtered, washed by 
hexane and collected after dried under reduced pressure. The product was given 
without further purification as a white solid (1.10 g, 91%). m.p. 191−192 °C; 1H 
NMR (500 MHz, d-DMSO): δ 8.47 (2H, s), 6.89 (4H, d, J = 7.0 Hz), 6.63 (4H, d, J = 
7.0 Hz), 3.50 (6H, s), 3.10 (4H, s) (covered by solvent peak), 2.29 (4H, s); 13C NMR 
(125 MHz, d-DMSO): δ 159.8, 157.7, 130.9, 129.5, 113.7, 54.9, 40.5, 33.7; HRMS 
(ESI+) Calc. for C20H24N2O4 [M + H]+ 357.1809, found 357.1806. IR (neat, cm-1):  
3306, 1654, 1544, 1270, 1234, 1190, 742, 698. 
 
N1,N2-bis(4-methoxyphenethyl)ethane-1,2-diamine (116) 
 
This compound was prepared following a literature procedure.332 To a solution of 115 
(370 mg, 1.04 mmol) in dry THF (20 mL) was added LiAlH4 (400 mg, 10.4 mmol) at 
0 °C under nitrogen atmosphere and the resulting mixture was allowed to warm to RT 
for 30 min. After that, the reaction was heated to 70 °C and stirred another 12 h. After 
completion monitored by TLC, the reaction mixture was quenched by NaSO4•10H2O 
at 0 °C until no bubble released any more. Filtered through Celite® and washed with 
ethyl acetate. The filtrate was concentrated under reduced pressure and the crude 
product was purified by flash chromatography (CH2Cl2/MeOH 100:1 → 80:1) to give 
the product as a colorless semisolid (314 mg, 92%). 1H NMR (400 MHz, d-MeOD): δ 
7.19 (4H, d, J = 8.4 Hz), 6.92 (4H, d, J = 8.4 Hz), 3.79 (6H, s), 2.87−2.85 (4H, m), 
2.81 (4H, dd, J = 6.4 Hz, J = 16.8 Hz), 2.76 (4H, s); 13C NMR (100 MHz, d-MeOD): 
δ 159.5, 132.8, 130.6, 114.9, 55.6, 52.1, 49.3, 35.9; HRMS (ESI+) Calc. for 
C20H28N2O2 [M + H]+ 329.2224, found 329.2222. IR (neat, cm-1): 3296, 3060, 
2997, 1617, 1509, 1240, 1042, 811. 
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4,4'-((ethane-1,2-diylbis(azanediyl))bis(ethane-2,1-diyl))diphenol (100c) 
 
This compound was prepared following a literature procedure.333 A solution of 116 
(100 mg, 0.3 mmol) in aq. HBr (48%, 2 mL) was heated to 120 °C and stirred for 5 h. 
After completion monitored by TLC, the reaction mixture was diluted with H2O and 
neutralised with solid KOH until the pH was adjusted to 8, and then extracted with 
ethyl acetate (3 x 20 mL), the combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography 
(CH2Cl2/MeOH 100:1 → 80:1) to get the product as an off-white solid (72 mg, 80%). 
The spectrum data matched that shown as above. 
6.4 Synthesis of compounds from Chapter 4 
 
5-bromo-3-(4-nitrophenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (117a) 
 
This compound was prepared according to general procedure F by treating 26a (119 
mg, 0.25 mmol) with (4-nitrophenyl)boronic acid (50 mg, 0.3 mmol) in 
toluene/ethanol 3:1 at 90 °C. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 8:1 → 5:1) to give the product as pale yellow solid (92 mg, 
78%). m.p. 253−254 °C; Rf (hexane/ethyl acetate 4:1): 0.55; 1H NMR (500 MHz, 
CDCl3): δ 8.53 (1H, d, J = 2.1 Hz), 8.34 (2H, dd, J = 2.1, 6.9 Hz), 8.21 (1H, d, J = 2.1 
Hz), 8.12 (2H, dd, J = 1.7, 6.7 Hz), 8.03 (1H, s), 7.73 (2H, dd, J = 2.1, 6.9 Hz), 7.32 
(2H, d, J = 8.2 Hz), 2.40 (3H, s); 13C NMR (125 MHz, CDCl3): δ 147.3, 146.5, 146.2, 
145.8, 139.0, 134.8, 131.0, 130.1, 128.6, 127.9, 125.7, 124.7, 122.4, 117.4, 116.1, 
21.9. HRMS (ESI+) Calc. for C20H14BrN3O4S [M + Na]+ 493.9781/495.9760, found 
493.9789/495.9768. IR (neat, cm-1): 3142, 1597, 1512, 1171, 692. 
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5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (117b) 
 
This compound was prepared according to general procedure F by treating 26a (119 
mg, 0.25 mmol) with (1H-indol-5-yl)boronic acid (48 mg, 0.3 mmol) in 
toluene/ethanol 3:1 at 90 °C. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 8:1 → 5:1) to give the product as a colorless semisolid (93 mg, 
80%). Rf (hexane/ethyl acetate 5:1): 0.40; 1H NMR (500 MHz, d-MeOD): δ 8.40 (1H, 
d, J = 2.1 Hz), 8.31 (1H, d, J = 2.1 Hz), 8.03 (2H, d, J = 8.5 Hz), 7.93 (1H, s), 7.77 
(1H, d, J = 1.1 Hz), 7.49 (1H, d, J = 8.4 Hz), 7.36 (2H, d, J = 8.2 Hz), 7.33 (1H, dd, J 
= 1.7, 8.4 Hz), 7.29 (1H, d, J = 3.1 Hz), 6.52 (1H, dd, J = 0.8, 3.1 Hz), 2.36 (3H, s), 
NH signal not observed; 13C NMR (125 MHz, d-MeOD): δ 147.3, 147.2, 146.1, 
137.5, 136.4, 132.6, 130.9, 130.0, 129.0, 126.7, 125.2, 124.6, 123.7, 123.2, 122.2, 
120.4, 116.4, 112.9, 102.8, 21.6; HRMS (ESI+) Calc. for C22H16N3O2BrS [M + Na]+ 
488.0039/490.0018, found 488.0035/490.0015. IR (neat, cm-1): 3401, 2922, 1595, 
1382, 1173, 582. 
 
4-(5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzonitrile (117c) 
 
This compound was prepared according to general procedure F by treating 26a (119 
mg, 0.25 mmol) with (4-cyanophenyl)boronic acid (44 mg, 0.3 mmol) in 
toluene/ethanol 3:1 at 90 °C. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 8:1 → 5:1) to give the product as an off-white solid (96 mg, 
85%). m.p. 219−220 °C; Rf (hexane/ethyl acetate 5:1): 0.45; 1H NMR (500 MHz, 
CDCl3): δ 8.52 (1H, d, J = 2.1 Hz), 8.19 (1H, d, J = 2.1 Hz), 8.11 (2H, dd, J = 1.7, 6.7 
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Hz), 7.98 (1H, s), 7.76 (2H, dd, J = 1.9, 6.6 Hz), 7.67 (2H, dd, J = 1.9, 6.6 Hz), 7.32 
(2H, d, J = 8.2 Hz), 2.40 (3H, s); 13C NMR (125 MHz, CDCl3): δ 146.4, 146.1, 145.8, 
137.1, 134.8, 133.2, 130.9, 130.0, 128.5, 127.9, 125.4, 122.4, 118.7, 117.8, 116.0, 
111.6, 21.9; HRMS (ESI+) Calc. for C21H14BrN3O2S [M + Na]+ 473.9882/475.9862, 
found 473.9889/475.9869. IR (neat, cm-1): 2219, 1607, 1178, 591. 
 
4-(5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol (117d) 
 
This compound was prepared according to general procedure F by treating 26a (119 
mg, 0.25 mmol) with (4-hydroxyphenyl)boronic acid (41 mg, 0.3 mmol) in 
toluene/ethanol 3:1 at 90 °C. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 6:1 → 4:1) to give the product as a white solid (87 mg, 80%). 
m.p. 158−168 °C; Rf (hexane/ethyl acetate 4:1): 0.40; 1H NMR (500 MHz, CDCl3): δ 
8.47 (1H, d, J = 2.1 Hz), 8.15 (1H, d, J = 2.1 Hz), 8.07 (2H, d, J = 8.4 Hz), 7.79 (1H, 
s), 7.42 (2H, dd, J = 2.1, 6.6 Hz), 7.29 (2H, d, J = 8.2 Hz), 6.95 (2H, dd, J = 2.1, 6.6 
Hz), 2.38 (3H, s), OH signal not observed; 13C NMR (125 MHz, CDCl3): δ 155.5, 
145.7, 145.6, 145.5, 135.0, 131.0, 129.7, 128.8, 128.1, 125.1, 124.5, 123.3, 119.3, 
116.1, 115.4, 21.6; HRMS (ESI+) Calc. for C20H15N2O3BrS [M + Na]+ 
464.9879/466.9858, found 464.9876/466.9855.  IR (neat, cm-1): 3370, 1595, 1386, 
1175, 1160, 588. 
 
4-(3-(4-nitrophenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol (118a) 
 
This compound was prepared according to general procedure F by treating 117a (94 
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mg, 0.2 mmol) with (4-hydroxyphenyl)boronic acid (33 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 5:1 → 1:1) to give the product as a yellow 
solid (84 mg, 87%). m.p. 253−255 °C; Rf (hexane/ethyl acetate 2:1): 0.40; 1H NMR 
(300 MHz, d-acetone): δ 8.65 (1H, s), 8.44 (1H, s), 8.35 (3H, d, J = 7.8 Hz), 
8.20−8.15 (4H, m), 7.58 (2H, d, J = 7.9 Hz), 7.44 (2H, d, J = 7.9 Hz), 6.97 (2H, d, J = 
8.0 Hz), 2.38 (3H, s); 13C NMR (75 MHz, d-acetone): δ 158.5, 147.8, 147.3, 146.9, 
144.9, 140.5, 136.1, 134.2, 130.8, 130.0, 129.6, 129.2, 129.1, 127.2, 126.5, 125.0, 
121.4, 118.9, 116.8, 21.5; HRMS (ESI+) Calc. for C22H19N3O5S [M + Na]+ 
508.0938, found 508.0933. IR (neat, cm-1): 3132, 1594, 1517, 1232, 581. 
 
4-(3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol (118b) 
 
This compound was prepared according to general procedure F by treating 117b (93 
mg, 0.2 mmol) with (4-hydroxyphenyl)boronic acid (33 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 5:1 → 1:1) to give the product as an off-white 
solid (77 mg, 80%). m.p. 142−145 °C; Rf (hexane/ethyl acetate 2:1): 0.45; 1H NMR 
(500 MHz, CDCl3): δ 8.62 (1H, d, J = 2.1 Hz), 8.36 (1H, s), 8.22 (1H, d, J = 2.1 Hz), 
8.12 (2H, d, J = 8.4 Hz), 7.86−7.85 (2H, m), 7.49 (1H, d, J = 8.4 Hz), 7.42 (3H, dd, J 
= 2.2, 8.5 Hz), 7.29−7.27 (3H, m), 6.92 (2H, d, J = 8.5 Hz), 6.61 (1H, t, J = 2.2 Hz), 
5.46 (1H, br.s), 2.36 (3H, s); 13C NMR (125 MHz, CDCl3): δ 155.8, 146.9, 145.3, 
144.0, 135.7, 135.6, 132.7, 131.2, 129.9, 128.9, 128.6, 128.1, 127.2, 125.3, 124.3, 
122.8, 122.5, 122.2, 122.1, 119.9, 116.2, 111.9, 103.1, 21.8; HRMS (ESI+) Calc. for 
C28H21N3O3S [M + H]+ 480.1376, found 480.1373. IR (neat, cm-1): 3410, 1703, 
1611, 1318, 1230, 584. 
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4-(5-(4-hydroxyphenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzonitrile (118c) 
 
This compound was prepared according to general procedure F by treating 117c (90 
mg, 0.2 mmol) with (4-hydroxyphenyl)boronic acid (33 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 3:1 → 1:1) to give the product as an off-white 
solid (83 mg, 89%). m.p. 167−169 °C; Rf (hexane/ethyl acetate 3:1): 0.40; 1H NMR 
(500 MHz, d-DMSO): δ 9.64 (1H, s), 8.66 (1H, d, J = 2.1 Hz), 8.45 (1H, s), 8.37 (1H, 
d, J = 2.1 Hz), 8.08 (4H, dd, J = 7.2, 8.4 Hz), 7.93 (2H, d, J = 8.3 Hz), 7.60 (2H, dd, J 
= 2.0, 6.6 Hz), 7.44 (2H, d, J = 8.4 Hz), 6.87 (2H, dd, J = 2.0, 6.6 Hz), 2.34 (3H, s); 
13C NMR (125 MHz, d-DMSO): δ 157.5, 145.8, 145.8, 143.6, 137.0, 134.4, 132.9, 
132.7, 130.1, 128.6, 128.1, 127.9, 127.7, 126.3, 125.7, 120.1, 118.9, 117.9, 115.9, 
109.8, 21.1; HRMS (ESI+) Calc. for C27H19N3O3S [M + Na]+ 488.1039, found 
488.1036. IR (neat, cm-1): 3483, 2226, 1607, 1159, 578. 
 
General procedure W for the synthesis of tetrazole274 
 
To a solution of cyanated compound (1.0 equiv.) in a mixture solvent of t-BuOH/H2O 
(1:1 (v/v), 0.125 M) was added TBAF (1 M in THF, 1.0 equiv.), trimethylsilyl azide 
(10.0 equiv.), CuSO4•5H2O (0.01 equiv.) and sodium ascorbate (0.03 equiv.), and the 
mixture was stirred at 80 °C under microwave irradiation (100 W) for 2 h. After 
completion monitored by TLC, the mixture was quenched with H2O and extracted 
with ethyl acetate (3 x 10 ml), the combined organic layers were dried over MgSO4 
and concentrated in vacuo.  
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4-(3-(4-(1H-tetrazol-5-yl)phenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol 
(118d) 
 
This compound was prepared according to general procedure W by treating 118c 
(46.5 mg, 0.1 mmol) and TMSN3 (132 µL, 1 mmol). The crude product was purified 
by flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a 
white solid (42 mg, 83%). m.p. 233−235 °C; Rf (CH2Cl2/MeOH 20:1): 0.35; 1H NMR 
(500 MHz, d-MeOD): δ 8.41 (1H, d, J = 2.1 Hz), 8.12 (1H, d, J = 2.1 Hz), 8.03−8.01 
(3H, m), 7.99 (2H, d, J = 8.7 Hz), 7.71 (2H, d, J = 8.4 Hz), 7.32 (2H, dd, J = 2.0, 6.6 
Hz), 7.27 (2H, d, J = 8.2 Hz), 6.81 (2H, dd, J = 2.0, 6.6 Hz), 2.27 (3H, s), NH and OH 
signals not observed; 13C NMR (125 MHz, d-MeOD): δ 158.7, 157.3, 147.5, 147.2, 
144.7, 136.9, 136.4, 134.6, 130.9, 130.2, 129.5, 129.1, 129.0, 128.8, 127.6, 125.5, 
124.3, 122.3, 120.5, 116.9, 21.6; HRMS (ESI+) Calc. for C27H20N6O3S [M + H]+ 
509.1390, found 509.1387. IR (neat, cm-1): 3137, 2921, 2852, 1378, 1164, 582. 
 
4-(5-(4-nitrophenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol (118e) 
 
This compound was prepared according to general procedure F by treating 117d (89 
mg, 0.2 mmol) with (4-nitrophenyl)boronic acid (40 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 5:1 → 1:1) to give the product as a pale yellow 
solid (82 mg, 85%). m.p. 136−138 °C; Rf (hexane/ethyl acetate 1:1): 0.50; 1H NMR 
(500 MHz, d-MeOD): δ 8.68 (1H, d, J = 2.2 Hz), 8.38 (1H, d, J = 2.2 Hz), 8.32 (2H, 
N N
Ts
HO
N
NNHN
ν
N N
OH
O2N
Ts
Chapter 6 
 189 
dd, J = 2.1, 6.9 Hz), 8.06 (2H, d, J = 8.5 Hz), 7.94 (1H, s), 7.90 (2H, dd, J = 2.1, 7.0 
Hz), 7.53 (2H, dd, J = 2.1, 6.6 Hz), 7.37 (2H, d, J = 8.3 Hz), 6.92 (2H, dd, J = 2.1, 6.6 
Hz), 2.37 (3H, s), OH signal not observed; 13C NMR (125 MHz, d-MeOD): δ 158.7, 
148.8, 148.7, 147.2, 146.0, 144.8, 136.5, 132.1, 130.9, 130.0, 129.5, 129.0, 128.9, 
125.2, 124.5, 124.2, 123.4, 122.5, 117.0, 21.5; HRMS (ESI+) Calc. for C26H19N3O5S 
[M + H]+ 486.1118, found 486.1115. IR (neat, cm-1): 2919, 1597, 1515, 1346, 587. 
 
4-(5-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol (118f) 
 
This compound was prepared according to general procedure F by treating 117d (89 
mg, 0.2 mmol) with (1H-indol-5-yl)boronic acid (39 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 5:1 → 1:1) to give the product as a pale yellow 
solid (78 mg, 81%). m.p. 136−140 °C; Rf (hexane/ethyl acetate 2:1): 0.45; 1H NMR 
(500 MHz, d-MeOD): δ 8.60 (1H, d, J = 2.1 Hz), 8.25 (1H, d, J = 2.1 Hz), 8.03 (2H, 
d, J = 8.4 Hz), 7.85 (1H, s), 7.76 (1H, d, J = 1.2 Hz), 7.50 (2H, dd, J = 2.1, 6.6 Hz), 
7.46 (1H, d, J = 8.4 Hz), 7.34−7.32 (3H, m), 7.26 (1H, s), 6.92 (2H, dd, J = 2.1, 6.6 
Hz), 6.50−6.49 (1H, m), 2.33 (3H, s), NH and OH signals not observed; 13C NMR 
(125 MHz, d-MeOD): δ 158.6, 147.6, 147.0, 145.0, 137.4, 136.6, 136.3, 130.9, 130.3, 
130.2, 129.9, 128.8, 128.4, 126.6, 124.9, 123.5, 123.4, 122.6, 122.1, 120.2, 117.0, 
112.8, 102.7, 21.5; HRMS (ESI+) Calc. for C28H21N3O3S [M + Na]+ 502.1196, found 
502.1193. IR (neat, cm-1): 3416, 2963, 2926, 1616, 1385, 1172, 589. 
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4-(3-(4-hydroxyphenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)benzonitrile (118g) 
 
This compound was prepared according to general procedure F by treating 117d (89 
mg, 0.2 mmol) with (4-cyanophenyl)boronic acid (35 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 5:1 → 1:1) to give the product as an off-white 
solid (87 mg, 93%). m.p. 203−205 °C; Rf (hexane/ethyl acetate 3:1): 0.40; 1H NMR 
(400 MHz, CDCl3): δ 8.67 (1H, d, J = 2.2 Hz), 8.18 (1H, d, J = 2.2 Hz), 8.13 (2H, d, J 
= 8.4 Hz), 7.85 (1H, s), 7.75 (2H, dd, J = 2.0, 6.6 Hz), 7.66 (2H, dd, J = 2.0, 6.6 Hz), 
7.47 (2H, dd, J = 2.1, 6.6 Hz), 7.30 (2H, d, J = 8.1 Hz), 6.96 (2H, dd, J = 2.1, 6.6 Hz), 
2.38 (3H, s), OH signal not observed; 13C NMR (100 MHz, CDCl3): δ 155.7, 147.5, 
145.6, 144.1, 143.2, 135.4, 133.0, 131.0, 129.9, 129.1, 128.3, 128.2, 127.4, 125.0, 
123.3, 122.1, 120.3, 118.8, 116.3, 111.6, 21.8; HRMS (ESI+) Calc. for C27H19N3O3S 
[M + Na]+ 488.1039, found 488.1036. IR (neat, cm-1): 3510, 3126, 2223, 1609, 
1119, 666, 576. 
 
4-(5-(4-(1H-tetrazol-5-yl)phenyl)-1-tosyl (118h) 
 
This compound was prepared according to general procedure W by treating 118g 
(46.5 mg, 0.1 mmol) with TMSN3 (132 µL, 1 mmol). The crude product was purified 
by flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a 
white solid (41 mg, 81%). m.p. 244−245 °C; Rf (CH2Cl2/MeOH 20:1): 0.35; 1H NMR 
(300 MHz, d-DMSO): δ 9.66 (1H, br.s), 8.80 (1H, d, J = 1.8 Hz), 8.47 (1H, d, J = 1.8 
Hz), 8.16−8.01 (7H, m), 7.67 (2H, d, J = 8.5 Hz), 7.42 (2H, d, J = 8.2 Hz), 6.92 (2H, 
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d, J = 8.5 Hz), 2.33 (3H, s), NH signal not observed; 13C NMR (75 MHz, d-DMSO): 
δ 157.2, 155.1, 146.7, 145.6, 143.7, 140.1, 134.6, 131.0, 130.0, 128.8, 128.3, 127.6, 
127.5, 127.4, 123.5, 122.8, 122.5, 121.0, 120.1, 115.9, 21.1; HRMS (ESI+) Calc. for 
C27H20N6O3S [M + H]+ 509.1390, found 509.1386. IR (neat, cm-1): 3400, 3102, 
2927, 1508, 1310, 577. 
 
4-(3-(4-nitrophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol (119a) 
 
This compound was prepared according to general procedure C by treating 118a (97 
mg, 0.2 mmol) with KOH (56 mg, 1 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a yellow solid 
(62 mg, 95%). m.p. 306−316 °C; Rf (CH2Cl2/MeOH 20:1): 0.50; 1H NMR (500 MHz, 
d-DMSO): δ 12.33−12.29 (1H, br.s), 9.59−9.55 (1H, br.s), 8.54 (1H, d, J = 2.1 Hz), 
8.47 (1H, d, J = 2.1 Hz), 8.26 (2H, d, J = 1.9 Hz), 8.24 (1H, s), 8.10 (2H, d, J = 1.9 
Hz), 7.61 (2H, dd, J = 2.1, 8.6 Hz), 6.90 (2H, dd, J = 2.1, 6.6 Hz; 13C NMR (125 
MHz, d-DMSO): δ 156.9, 148.4, 144.5, 142.4, 142.2, 129.8, 129.4, 128.3, 127.5, 
126.3, 124.9, 124.3, 117.0, 115.8, 112.5; HRMS (ESI+) Calc. for C19H13N3O3 [M + 
Na]+ 354.0849, found 354.0848. IR (neat, cm-1): 3217, 3173, 3024, 2921, 1591, 
1341, 1263, 849. 
 
4-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol (119b) 
 
This compound was prepared according to general procedure C by treating 118b (48 
mg, 0.1 mmol) with KOH (28 mg, 0.5 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a yellow 
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solid (30 mg, 93%). m.p. 268−271 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H NMR (500 
MHz, d-MeOD): δ 8.40 (2H, dd, J = 1.9, 10.2 Hz), 7.85 (1H, s), 7.56 (1H, s), 7.49 
(3H, d, J = 8.6 Hz), 7.44 (1H, dd, J = 1.3, 8.4 Hz), 7.27 (1H, d, J = 3.0 Hz), 6.92 (2H, 
d, J = 8.5 Hz), 6.52 (1H, d, J = 3.0 Hz), NH and OH signals not observed; 13C NMR 
(125 MHz, d-MeOD): δ 158.0, 148.9, 142.1, 136.7, 132.1, 131.0, 130.1, 129.4, 127.4, 
127.1, 126.1, 123.9, 122.5, 120.6, 119.6, 119.1, 116.9, 112.6, 102.5; HRMS (ESI+) 
Calc. for C21H15N3O [M + H]+ 326.1288, found 326,1288. IR (neat, cm-1): 3480, 
3243, 2916, 1606, 1262, 1248, 690. HPLC: 99.1% (HPLC Method A), RT: 18.2 min. 
 
4-(3-(4-(1H-tetrazol-5-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol (119c) 
 
This compound was prepared according to general procedure C by treating 118d (51 
mg, 0.1 mmol) with KOH (28 mg, 0.5 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 50:1 → 10:1) to give the product as a pale 
yellow solid (32 mg, 90%). m.p. 282−284 °C; Rf (CH2Cl2/MeOH 20:1): 0.20; 1H 
NMR (400 MHz, d-DMSO): δ 12.08 (1H, br s), 9.51 (1H, s), 8.51 (1H, d, J = 2.0 Hz), 
8.44 (1H, d, J = 2.0 Hz), 8.11 (2H, d, J = 8.4 Hz), 8.07 (1H, d, J = 2.6 Hz), 8.04 (2H, 
d, J = 8.4 Hz), 7.60 (2H, d, J = 8.6 Hz), 6.89 (2H, d, J = 8.6 Hz), NH of tetrazole and 
OH signals not observed; 13C NMR (100 MHz, d-DMSO): δ 156.8, 155.3, 148.3, 
141.9, 137.9, 129.6, 129.3, 128.3, 127.5, 126.8, 125.6, 124.8, 121.2, 117.1, 115.8, 
113.5; HRMS (ESI+) Calc. for C20H14N6O [M + H]+ 355.1302, found 355.1302. IR 
(neat, cm-1): 3477, 3263, 3230, 2919, 1612, 1531, 1326, 1262, 1243, 836. HPLC: 
96.4% (HPLC Method A), RT: 17.1 min. 
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4-(5-(4-nitrophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol (119e) 
 
This compound was prepared according to general procedure C by treating 118e (97 
mg, 0.2 mmol) with KOH (56 mg, 1 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a yellow solid 
(62 mg, 93%). m.p. 178−180 °C; Rf (CH2Cl2/MeOH 20:1): 0.50; 1H NMR (400 MHz, 
d-DMSO): δ 11.98 (1H, s), 9.39 (1H, s), 8.68 (1H, d, J = 2.1 Hz), 8.52 (1H, d, J = 2.1 
Hz), 8.32 (2H, dd, J = 1.9, 6.9 Hz), 8.11 (2H, dd, J = 1.9, 6.9 Hz), 7.78 (1H, d, J = 2.4 
Hz), 7.60 (2H, dd, J = 2.0, 6.6 Hz), 6.87 (2H, dd, J = 2.0, 6.6 Hz; 13C NMR (100 
MHz, d-DMSO): δ 155.8, 149.1, 146.2, 145.9, 142.0, 128.0, 127.8, 126.2, 126.1, 
125.4, 124.0, 123.7, 117.5, 115.7, 115.4; HRMS (ESI+) Calc. for C19H13N3O3 [M + 
H]+ 332.1030, found 332.1032. IR (neat, cm-1): 3404, 3119, 2858, 1593, 
1336,1267. HPLC: 96.8% (HPLC Method A), RT: 23.0 min. 
 
4-(5-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol (119f) 
 
This compound was prepared according to general procedure C by treating 118f (48 
mg, 0.1 mmol) with KOH (28 mg, 0.5 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a yellow 
solid (31 mg, 94%). m.p. 241−244 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H NMR (500 
MHz, d-DMSO): δ 11.72 (1H, s), 11.13 (1H, s), 9.37 (1H, br.s), 8.53 (1H, d, J = 2.1 
Hz), 8.32 (1H, d, J = 2.1 Hz), 7.86 (1H, d, J = 1.6 Hz), 7.69 (1H, d, J = 2.4 Hz), 7.57 
(2H, dd, J = 2.1, 6.6 Hz), 7.50 (1H, d, J = 3.4 Hz), 7.45 (1H, dd, J = 1.7, 8.4 Hz), 7.38 
(1H, t, J = 2.7 Hz), 6.87 (2H, dd, J = 2.1, 6.6 Hz), 6.50 (1H, dt, J = 0.7, 2.7 Hz); 13C 
NMR (125 MHz, d-DMSO): δ 155.6, 148.0, 142.0, 135.2, 130.2, 130.1, 128.3, 127.6, 
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126.0, 125.9, 125.1, 122.9, 120.9, 118.4, 117.4, 115.7, 114.7, 111.8, 101.4; HRMS 
(ESI+) Calc. for C21H15N3O [M + H]+ 326.1288, found 326.1288. IR (neat, cm-1): 
3262, 2917, 1459, 1257, 732. HPLC: 96.5% (HPLC Method A), RT: 18.0 min. 
 
4-(5-(4-(1H-tetrazol-5-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol (119g) 
 
This compound was prepared according to general procedure C by treating 118h (51 
mg, 0.1 mmol) with KOH (28 mg, 0.5 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 50:1 → 10:1) to give the product as a pale 
yellow solid (32 mg, 90%). m.p. 301−303 °C; Rf (CH2Cl2/MeOH 20:1): 0.20; 1H 
NMR (400 MHz, d-DMSO): δ 12.06 (1H, s), 8.68 (1H, s), 8.55 (1H, s), 8.19 (2H, d, J 
= 6.3 Hz), 8.05 (2H, d, J = 6.3 Hz), 7.78 (1H, s), 7.61 (2H, d, J = 6.5 Hz), 6.88 (2H, d, 
J = 6.5 Hz), NH of tetrazole and OH signals not observed; 13C NMR (100 MHz, d-
DMSO): δ 155.8, 148.8, 141.7, 141.5, 127.8, 127.7, 127.6, 127.4, 127.4, 127.3, 125.6, 
125.5, 123.4, 117.4, 115.7, 115.2; HRMS (ESI+) Calc. for C20H14N6O [M + H]+ 
355.1302, found 355.1301. IR (neat, cm-1): 3330, 2921, 1455, 829, 518. HPLC: 
95.8% (HPLC Method A), RT: 17.1 min. 
 
General procedure X for reduction of nitro compounds 
 
To a solution of nitro substrate (1.0 equiv.) in aq. HCl (3 M, 0.03 M) was added iron 
powder (10.0 equiv.), and the reaction was heated to 110 °C for 3 h. After completion 
monitored by TLC, the mixture was cooling down and neutralised with sat. NaHCO3 
(aq.), and extracted with ethyl acetate (3 x 10 mL), and the combined organic layers 
were dried over MgSO4 and concentrated in vacuo.  
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4-(3-(4-aminophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol (119d) 
 
 
This compound was prepared according to general procedure X by treating 119a (50 
mg, 0.15 mmol) with Fe (84 mg, 1.5 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 20:1) to give the product as a pale yellow 
solid (38 mg, 84%). m.p. 113−115 °C; Rf (CH2Cl2/MeOH 20:1): 0.40; 1H NMR (500 
MHz, d-DMSO): δ 9.47 (1H, s), 8.39 (1H, d, J = 1.7 Hz), 7.75 (1H, d, J = 1.7 Hz), 
7.47 (2H, d, J = 8.4 Hz), 7.36 (2H, d, J = 8.3 Hz), 6.86 (1H, s), 6.80 (1H, d, J = 8.3 
Hz), 6.61 (2H, d, J = 8.4 Hz), 6.09−6.08 (2H, m), OH signal not observed; 13C NMR 
(125 MHz, d-DMSO): δ 156.2, 148.5, 148.4, 141.8, 129.9, 128.2, 128.1, 127.1, 126.6, 
124.4, 123.4, 118.0, 116.3, 115.2, 115.0; HRMS (ESI+) Calc. for C19H15N3O [M + 
H]+ 302.1288, found 302.1290. IR (neat, cm-1): 3481, 3444, 3359, 3338, 2918, 
1552, 1231, 794. HPLC: 96.0% (HPLC Method A), RT: 14.4 min. 
 
4-(5-(4-aminophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol (119h) 
 
This compound was prepared according to general procedure X by treating 119e (50 
mg, 0.15 mmol) with Fe (84 mg, 1.5 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 40:1) to give the product as a pale yellow 
solid (32 mg, 70%). m.p. 216−220 °C; Rf (CH2Cl2/MeOH 20:1): 0.30; 1H NMR (400 
MHz, d-DMSO): δ 11.66 (1H, s), 9.34 (1H, s), 8.41 (1H, d, J = 2.1 Hz), 8.19 (1H, d, J 
= 2.1 Hz), 7.65 (1H, d, J = 2.1 Hz), 7.54 (2H, dd, J = 2.1, 6.6 Hz), 7.40 (2H, dd, J = 
1.9, 6.6 Hz), 6.85 (2H, dd, J = 2.1, 6.6 Hz), 6.67 (2H, dd, J = 1.9, 6.6 Hz), 5.15 (2H, 
s); 13C NMR (100 MHz, d-DMSO): δ 155.6, 147.9, 147.8, 141.1, 129.2, 127.6, 127.5, 
N NH
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126.4, 125.9, 123.8, 122.8, 117.4, 115.7, 114.6, 114.4; HRMS (ESI+) Calc. for 
C19H15N3O [M + H]+ 302.1288, found 302.1288. IR (neat, cm-1): 3351, 3234, 
3024, 2870, 1610, 1542, 1478, 1260, 821, 530. HPLC: >99.9% (HPLC Method A), 
RT: 13.7 min. 
 
N-(4-(3-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)acetamide 
(120a) 
 
To a solution of 119h (50 mg, 0.17 mmol) in acetic acid (5 ml) was added acetic 
anhydride (24 µl, 0.25 mmol), and the reaction was heated to 110 °C for 5 h. After 
completion monitored by TLC, the mixture was cooling and neutralised with sat. 
Na2CO3 (aq.), and extracted with ethyl acetate (3 x 10 mL), and the combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product 
as a plae yellow solid (45 mg, 77%). m.p. 272−275 °C; Rf (CH2Cl2/MeOH 20:1): 
0.35; 1H NMR (300 MHz, d-DMSO): δ 11.78 (1H, s), 10.02 (1H, s), 9.42 (1H, s), 
8.51 (1H, s), 8.31 (1H, s), 7.69−7.68 (5H, m), 7.56 (2H, d, J = 8.0 Hz), 6.86 (2H, d, J 
= 8.0 Hz), 2.07 (3H, s); 13C NMR (75 MHz, d-DMSO): δ 168.3, 155.7, 148.3, 141.5, 
138.4, 133.7, 128.2, 127.7, 127.2, 125.7, 124.8, 123.1, 119.5, 117.4, 115.7, 114.9, 
24.0; HRMS (ESI+) Calc. for C21H17N3O2 [M + H]+ 344.1394, found 344.1396. IR 
(neat, cm-1): 3317, 3088, 2922, 1523, 1244, 886, 516. HPLC: 98.3% (HPLC 
Method A), RT: 16.3 min. 
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N-(4-(3-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-
yl)phenyl)methanesulfonamide (120b) 
 
To a solution of 119h (50 mg, 0.17 mmol) in H2O (5 ml) was added methanesulfonyl 
chloride (20 µl, 0.25 mmol), and the mixture was stirred at room temperature for 10 h. 
After completion monitored by TLC, the mixture was extracted with ethyl acetate (3 x 
10 mL), and the combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by flash chromatography (CH2Cl2/MeOH 
100:1 → 50:1) to give the product as a pale yellow solid (41 mg, 64%). m.p. 
192−195 °C; Rf (CH2Cl2/MeOH 20:1): 0.30; 1H NMR (400 MHz, d-DMSO): δ 11.83 
(1H, d, J = 2.2 Hz), 8.51 (1H, d, J = 2.1 Hz), 8.32 (1H, d, J = 2.1 Hz), 7.74 (1H, s), 
7.72 (2H, d, J = 1.6 Hz), 7.56 (2H, d, J = 8.7 Hz), 7.31 (2H, d, J = 8.7 Hz), 6.85 (2H, 
d, J = 8.7 Hz), 5.76 (1H, s), 3.01 (3H, s), OH signal not observed; 13C NMR (100 
MHz, d-DMSO): δ 156.1, 148.8, 142.0, 137.9, 135.1, 128.4, 128.1, 126.1, 125.5, 
123.6, 120.8, 117.8, 116.2, 115.3, 109.0, 55.4; HRMS (ESI+) Calc. for C20H17N3O3S 
[M + H]+ 380.1063, found 380.1067. IR (neat, cm-1): 3401, 2920, 2893, 1610, 
1520, 1152. HPLC: 95.9% (HPLC Method A), RT: 17.5 min. 
 
1-(4-(3-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)urea (120c) 
 
To a mixture of 119h (50 mg, 0.17 mmol), citric acid (326 mg, 1.70 mmol), mannitol 
(310 mg, 1.70 mmol) and urea (153 mg, 2.55 mmol) was added I2 (4.3 mg, 0.017 
mmol), and the reaction was heated to 80 °C for 6 h. After completion monitored by 
TLC, the mixture was cooling, and H2O (10 ml) was added and extracted with ethyl 
acetate (3 x 10 mL), and the combined organic layers were dried over MgSO4 and 
ν
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concentrated in vacuo. The crude product was purified by flash chromatography 
(CH2Cl2/MeOH 50:1 → 10:1) to give the product as a pale yellow solid (41 mg, 
70%). m.p. 236−239 °C; Rf (CH2Cl2/MeOH 20:1): 0.25; 1H NMR (500 MHz, d-
DMSO): δ 11.75 (1H, s), 9.37 (1H, s), 8.66 (1H, s), 8.49 (1H, d, J = 2.0 Hz), 8.28 
(1H, d, J = 2.0 Hz), 7.69 (1H, d, J = 1.4 Hz), 7.61 (2H, d, J = 8.6 Hz), 7.56 (2H, d, J = 
8.5 Hz), 7.51 (2H, d, J = 8.6 Hz), 6.86 (2H, d, J = 8.6 Hz), 5.87 (2H, s); 13C NMR 
(125 MHz, d-DMSO): δ 156.1, 155.8, 148.3, 141.5, 139.8, 131.9, 128.5, 127.8, 127.3, 
125.9, 124.7, 123.1, 118.3, 117.5, 115.8, 114.9; HRMS (ESI+) Calc. for C20H16N4O2 
[M + H]+ 345.1346, found 345.1345. IR (neat, cm-1): 2954, 2921, 2852, 1535, 
1242, 813. HPLC: >98.3% (HPLC Method A), RT: 13.3 min. 
 
5-bromo-3-(4-methoxyphenyl)-1-tosyl-1H-indole (117e) 
 
This compound was prepared according to general procedure F by treating 26b (238 
mg, 0.5 mmol) with (4-methoxyphenyl)boronic acid (91 mg, 0.6 mmol) in 
toluene/ethanol 3:1 at 90 °C. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1 → 6:1) to give the product as a white solid (212 mg, 93%). 
m.p. 114−116 °C; Rf (hexane/ethyl acetate 5:1): 0.55; 1H NMR (300 MHz, CDCl3): δ 
7.92 (1H, d, J = 8.4 Hz), 7.84 (1H, s), 7.77 (2H, d, J = 7.4 Hz), 7.61 (1H, s), 
7.48−7.43 (3H, m), 7.24 (2H, d, J = 8.3 Hz), 7.00 (2H, d, J = 7.4 Hz), 3.86 (3H, s), 
2.35 (3H, s); 13C NMR (75 MHz, CDCl3): δ 159.5, 145.4, 135.1, 134.3, 131.4, 130.1, 
129.1, 127.8, 127.0, 124.8, 123.5, 123.3, 117.3, 116.8, 115.4, 114.6, 55.5, 21.7; APCI 
Calc. for C22H15N2O2BrS [M + H]+, 456.0264/458.0243, found 456.0260/458.0234. 
IR (neat, cm-1): 2926, 1614, 1250, 1175, 587. 
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4-(5-bromo-1-tosyl-1H-indol-3-yl)benzonitrile (117f) 
 
This compound was prepared according to general procedure F by treating 26b (238 
mg, 0.5 mmol) with (4-cyanophenyl)boronic acid (88 mg, 0.6 mmol) in 
toluene/ethanol 3:1 at 90 °C. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 8:1 → 6:1) to give the product as an off-white solid (212 mg, 
94%). m.p. 187−188 °C; Rf (hexane/ethyl acetate 6:1): 0.45; 1H NMR (500 MHz, 
CDCl3): δ 7.92 (1H, d, J = 8.8 Hz), 7.82 (2H, d, J = 11.5 Hz), 7.79 (2H, d, J = 4.8 
Hz), 7.73 (2H, d, J = 8.0 Hz), 7.65 (2H, d, J = 8.1 Hz), 7.46 (1H, d, J = 8.8 Hz), 7.26 
(2H, d, J = 8.0 Hz), 2.35 (3H, s); 13C NMR (125 MHz, CDCl3): δ 145.8, 137.3, 134.7, 
134.1, 132.9, 130.3, 130.0, 128.3, 128.2, 127.0, 125.2, 122.8, 121.3, 118.7, 117.7, 
115.4, 111.2, 21.7; APCI Calc. for C22H15N2O2BrS [M + H]+, 451.0110/453.0090, 
found 451.0112/453.0091. IR (neat, cm-1): 3122, 2224, 1610, 1448, 1145, 534. 
 
3-(4-methoxyphenyl)-1-tosyl-1H,1'H-5,5'-biindole (118i) 
 
This compound was prepared according to general procedure F by treating 117e (91 
mg, 0.2 mmol) with (1H-indol-5-yl)boronic acid (39 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 5:1 → 3:1) to give the product as a pale brown 
solid (86 mg, 87%). m.p. 163−164 °C; Rf (hexane/ethyl acetate 3:1): 0.55; 1H NMR 
(300 MHz, CDCl3): δ 8.28 (1H, s), 8.09 (1H, d, J = 8.5 Hz), 7.94 (1H, s), 7.88 (1H, s), 
7.83 (2H, d, J = 7.7 Hz), 7.67 (1H, s), 7.55−7.42 (5H, m), 7.25−7.21 (2H, m), 6.95 
(2H, d, J = 7.9 Hz), 6.61 (1H, s), 3.83 (3H, s), 2.34 (3H, s), NH signal not observed; 
N
Br
Ts
CN
ν
N
O
Ts
HN
Chapter 6 
 200 
13C NMR (125 MHz, CDCl3): δ 159.0, 144.9, 136.7, 135.3, 134.6, 134.1, 130.6, 
129.9, 128.4, 128.3, 126.9, 125.6, 125.0, 124.6, 124.1, 123.6, 123.0, 122.6, 120.1, 
118.6, 114.2, 114.0, 111.5, 102.9, 55.4, 21.6; HRMS (ESI+) Calc. for C30H24N2O3S 
[M + H]+ 493.1580, found 493.1584. IR (neat, cm-1): 3416, 2927, 2835, 1608, 
1168, 584. 
 
4-(5-(4-methoxyphenyl)-1-tosyl-1H-indol-3-yl)benzonitrile (118j) 
 
This compound was prepared according to general procedure F by treating 117f (92 
mg, 0.2 mmol) with (4-methoxyphenyl)boronic acid (36 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 5:1 → 3:1) to give the product as a white solid 
(86 mg, 90%). m.p. 220−221 °C; Rf (hexane/ethyl acetate 4:1): 0.40; 1H NMR (400 
MHz, CDCl3): δ 8.09 (1H, d, J = 8.6 Hz), 7.85 (2H, d, J = 8.4 Hz), 7.83 (1H, d, J = 
1.7 Hz), 7.79 (1H, s), 7.77−7.72 (4H, m), 7.58 (1H, dd, J = 1.7, 8.6 Hz), 7.50 (2H, dd, 
J = 2.1, 6.7 Hz), 7.28−7.26 (2H, m), 6.98 (2H, dd, J = 2.1, 6.7 Hz), 3.85 (3H, s), 2.36 
(3H, s); 13C NMR (100 MHz, CDCl3): δ 159.4, 145.6, 138.2, 137.5, 135.2, 134.6, 
133.7, 132.9, 130.2, 129.0, 128.6, 128.5, 127.1, 124.9, 124.7, 122.3, 118.9, 118.0, 
114.5, 114.3, 111.1, 55.5, 21.8; APCI Calc. for C29H22N2O3S [M + H]+, 479.1424, 
found 479.1419. IR (neat, cm-1): 2934, 2835, 2222, 1609, 1246, 672, 577. 
 
3-(4-(1H-tetrazol-5-yl)phenyl)-5-(4-methoxyphenyl)-1-tosyl-1H-indole (118k)  
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This compound was prepared according to general procedure W by treating 118j (60 
mg, 0.12 mmol) and TMSN3 (159 µL, 1.2 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 3:1 → 1:1) to give the product as an off-
white solid (46 mg, 74%). m.p. 199−200 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H NMR 
(500 MHz, d-DMSO): δ 8.26 (1H, s), 8.17 (2H, d, J = 8.2 Hz), 8.07 (1H, d, J = 8.7 
Hz), 8.04 (2H, d, J = 8.2 Hz), 8.00−7.99 (3H, m), 7.66 (1H, dd, J = 1.5, 8.7 Hz), 7.64 
(2H, d, J = 8.7 Hz), 7.41 (2H, d, J = 8.4Hz), 7.01 (2H, d, J = 8.7 Hz), 3.78 (3H, s), 
2.32 (3H, s), NH signal not observed; 13C NMR (125 MHz, d-DMSO): δ 159.3, 
155.8, 146.2, 136.9, 135.5, 134.4, 134.3, 133.1, 130.8, 129.2, 129.0, 128.7, 128.0, 
127.4, 125.7, 124.6, 123.9, 122.7, 118.2, 114.8, 114.3, 55.6, 21.5; HRMS (ESI+) 
Calc. for C29H23N5O3S [M + Na]+ 544.1414, found 544.1416. IR (neat, cm-1): 
2924, 2853, 1610, 1458, 1173, 839, 585. 
 
3-(4-methoxyphenyl)-1H,1'H-5,5'-biindole (119i) 
 
This compound was prepared according to general procedure C by treating 118i (60 
mg, 0.12 mmol) with KOH (34 mg, 0.6 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 3:1 → 1:1) to give the product as an off-
white solid (38 mg, 94%). m.p. 193−195 °C; Rf (hexane/ethyl acetate 1:1): 0.40; 1H 
NMR (500 MHz, CDCl3): δ 8.15−8.12 (3H, m), 7.92 (1H, s), 7.65 (2H, d, J = 8.2 Hz), 
7.55 (2H, dd, J = 8.4, 19.8 Hz), 7.45 (2H, t, J = 8.8 Hz), 7.29 (1H, d, J = 1.8 Hz), 7.22 
(1H, t, J = 2.3 Hz), 7.03 (2H, d, J = 8.2 Hz), 6.62 (1H, d, J = 1.0 Hz), 3.87 (3H, s); 
13C NMR (125 MHz, CDCl3): δ 158.2, 135.8, 135.3, 135.0, 134.9, 128.8, 128.5, 
128.3, 126.5, 124.8, 122.9, 122.6, 121.8, 119.5, 118.4, 118.3, 114.4, 111.6, 111.2, 
103.0, 55.5; HRMS (ESI+) Calc. for (C23H18N2O)2 [M + Na]+ 699.2731, found 
699.2734. IR (neat, cm-1): 3405, 2964, 1606, 1475, 1269, 837. 
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3-(4-(1H-tetrazol-5-yl)phenyl)-5-(4-methoxyphenyl)-1H-indole (119j) 
 
This compound was prepared according to general procedure C by treating 118k (60 
mg, 0.11 mmol) with KOH (31 mg, 0.55 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as an off-
white solid (36 mg, 89%). m.p. 247−249 °C; Rf (CH2Cl2/MeOH 20:1): 0.30; 1H NMR 
(500 MHz, d-DMSO): δ 11.57 (1H, d, J = 1.2 Hz), 8.10 (2H, d, J = 8.2 Hz), 8.08 (1H, 
s), 7.99 (2H, d, J = 8.2 Hz), 7.90 (1H, d, J = 2.5 Hz), 7.65 (2H, d, J = 8.7 Hz), 7.53 
(1H, d, J = 8.5 Hz), 7.43 (1H, dd, J = 1.2, 8.5 Hz), 7.03 (2H, d, J = 8.7 Hz), 3.80 (3H, 
s), NH signal not observed; 13C NMR (125 MHz, d-DMSO): δ 158.8, 155.9, 139.4, 
136.9, 135.0, 133.1, 128.6, 128.1, 127.6, 126.0, 125.9, 121.7, 121.4, 117.2, 115.7, 
114.9, 113.1, 55.8; HRMS (ESI+) Calc. for C22H17N5O [M + Na]+ 390.1325, found 
390.1328. IR (neat, cm-1): 3412, 2928, 1612, 1244, 836. 
 
4-(1H,1'H-[5,5'-biindol]-3-yl)phenol (120d) 
 
This compound was prepared according to general procedure D by treating 119i (34 
mg, 0.1 mmol) with BBr3 (1 mL, 1 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a pale yellow 
solid (23 mg, 70%). m.p. 177−179 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H NMR (400 
MHz, d-DMSO): δ 11.18 (1H, s), 11.06 (1H, s), 9.30 (1H, s), 7.96 (1H, s), 7.79 (1H, 
s), 7.53−7.51 (3H, m), 7.47 (1H, s), 7.45−7.42 (2H, m), 7.40 (1H, dd, J = 1.7, 8.4 Hz), 
7.35 (1H, t, J = 2.7 Hz), 6.87 (2H, dd, J = 2.0, 6.6 Hz), 6.48 (1H, t, J = 2.1 Hz); 13C 
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NMR (100 MHz, d-DMSO): δ 155.3, 135.7, 134.9, 133.7, 133.3, 128.3, 127.8, 126.7, 
125.7 (3), 125.7 (0), 122.6, 121.1, 120.9, 118.0, 116.8, 116.2, 115.6, 112.0, 111.5, 
101.3; HRMS (ESI+) Calc. for C22H16N2O [M + H]+ 325.1335, found 325.1333. IR 
(neat, cm-1): 3392, 2921, 1500, 798. HPLC: 97.4% (HPLC Method A), RT: 24.1 
min. 
 
4-(3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indol-5-yl)phenol (120e) 
 
This compound was prepared according to general procedure D by treating 119j (37 
mg, 0.1 mmol) with BBr3 (1 mL, 1 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 50:1 → 10:1) to give the product as a white solid 
(24 mg, 67%). m.p. 285−286 °C; Rf (CH2Cl2/MeOH 20:1): 0.20; 1H NMR (500 MHz, 
d-DMSO): δ 11.43 (1H, s), 8.05 (2H, d, J = 8.2 Hz), 8.01 (1H, s), 7.74 (2H, d, J = 8.2 
Hz), 7.71 (1H, d, J = 2.1 Hz), 7.50 (2H, d, J = 8.6 Hz), 7.47 (1H, s), 7.37 (1H, d, J = 
8.4 Hz), 6.86 (2H, d, J = 8.4 Hz), NH of tetrazole and OH signals not observed; 13C 
NMR (125 MHz, d-DMSO): δ 160.7, 156.5, 136.1, 134.5, 132.8, 132.6, 129.8, 127.9, 
126.6, 126.4, 125.7, 124.0, 120.7, 116.5, 116.2, 115.8, 112.3; HRMS (ESI+) Calc. for 
C21H15N5O [M + Na]+ 376.1169, found 376.1172. IR (neat, cm-1): 3160, 2918, 
2852, 1606, 1220, 758. HPLC: 95.7% (HPLC Method A), RT: 21.1 min. 
 
5-bromo-1-tosyl-1H-indole-3-carbonitrile (117g)279  
 
To a solution of 5-bromo-1H-indole 25b (500 mg, 2.56 mmol) in MeCN (30 ml) was 
added chlorosulfonylisocyanate (245 µL, 2.82 mmol) dropwise at 0 °C. The reaction 
mixture was stirred at 0 °C for another 2 h, then triethylamine (372 µL, 2.69 mmol) 
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was added dropwise over 10 min. The reaction mixture was allowed to warm to RT 
for 12 h. After completion monitored by TLC, the mixture was poured into ice-water 
mixture (50 ml), and the aqueous layer was extracted with ethyl acetate (3 x 20 ml). 
The combined organic layers were dried over MgSO4 and concentrated in vacuo. The 
obtained crude intermediate was treated with TsCl (570 mg, 3.0 mmol) according to 
step 2 in general procedure A without further purification. The crude product was 
purified by flash chromatography (hexane/ethyl acetate 10:1 → 8:1) to give the 
product as an off-white solid (864 mg, 90% over two steps). m.p. 174−175 °C; Rf 
(hexane/ethyl acetate 8:1): 0.50; 1H NMR (500 MHz, CDCl3): δ 8.08 (1H, s), 7.87 
(1H, d, J = 8.9 Hz), 7.83 (1H, d, J = 1.7 Hz), 7.80 (2H, dd, J = 1.7, 6.7 Hz), 7.53 (1H, 
dd, J = 1.9, 8.9 Hz), 7.32 (2H, d, J = 8.1 Hz), 2.39 (3H, s); 13C NMR (125 MHz, 
CDCl3): δ 146.9, 134.2, 134.0, 132.6, 130.6, 130.1, 129.8, 127.3, 123.2, 118.7, 115.3, 
112.9, 93.1, 21.8; HRMS (ESI+) Calc. for C16H11N2O2BrS [M + Na]+ 
396.9617/398.9596, found 396.9619/398.9598. IR (neat, cm-1): 3132, 2230, 1399, 
1190, 582.  
 
5-(4-methoxyphenyl)-1-tosyl-1H-indole-3-carbonitrile (118l) 
 
This compound was prepared according to general procedure F by treating 117g 
(100 mg, 0.27 mmol) with (4-methoxyphenyl)boronic acid (49 mg, 0.32 mmol) in 
toluene/ethanol 3:1 at 110 °C. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 8:1 → 4:1) to give the product as a white solid 
(100 mg, 92%). m.p. 144−145 °C; Rf (hexane/ethyl acetate 6:1): 0.55; 1H NMR (300 
MHz, CDCl3): δ 8.09 (1H, s), 8.01 (1H, d, J = 8.7 Hz), 7.86 (1H, s), 7.82 (2H, d, J = 
6.5 Hz), 7.62 (1H, d, J = 8.7 Hz), 7.52 (2H, d, J = 8.1 Hz), 7.31 (2H, d, J = 8.0 Hz), 
6.99 (2H, d, J = 8.1 Hz), 3.86 (3H, s), 2.39 (3H, s); 13C NMR (75 MHz, CDCl3): δ 
159.6, 146.5, 138.3, 134.3, 133.6, 132.8, 130.6, 129.1, 128.5, 127.4, 126.0, 118.0, 
115.0, 114.6, 114.1, 113.7, 94.0, 55.5, 21.8; HRMS (ESI+) Calc. for C23H18N2O3S 
[M + H]+ 403.1111, found 403.1107. IR (neat, cm-1): 3141, 2937, 2227, 1383, 
1173, 577. 
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5-(4-methoxyphenyl)-3-(1H-tetrazol-5-yl)-1-tosyl-1H-indole (118m) 
 
This compound was prepared according to general procedure W by treating 118l (84 
mg, 0.2 mmol) with TMSN3 (264 µL, 2 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 3:1 → 1:1) to give the product as a white 
solid (69 mg, 77%). m.p. 121−123 °C; Rf (hexane/ethyl acetate 1:1): 0.35; 1H NMR 
(300 MHz, CDCl3): δ 8.47 (1H, s), 8.38 (1H, s), 7.97 (1H, d, J = 8.7 Hz), 7.79 (2H, d, 
J = 8.0 Hz), 7.54 (1H, d, J = 8.7 Hz), 7.46 (2H, d, J = 8.2 Hz), 7.14 (2H, d, J = 8.0 
Hz), 6.88 (2H, d, J = 8.2 Hz), 3.77 (3H, s), 2.24 (3H, s), NH signal not observed; 13C 
NMR (75 MHz, CDCl3): δ 158.9, 150.0, 146.2, 136.7, 133.5, 133.1, 132.2, 130.5, 
128.1, 127.8, 127.4, 127.0, 124.7, 118.9, 114.4, 113.7, 107.0, 55.1, 21.0; HRMS 
(ESI+) Calc. for C23H19N5O3S [M + Na]+ 468.1101, found 468.1103. IR (neat, cm-1): 
3112, 2936, 1610, 1174, 584. 
 
5-(4-methoxyphenyl)-3-(1H-tetrazol-5-yl)-1H-indole (119k) 
 
This compound was prepared according to general procedure C by treating 118m 
(89 mg, 0.2 mmol) with KOH (56 mg, 1 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a white 
solid (56 mg, 96%). m.p. 253−254 °C; Rf (CH2Cl2/MeOH 20:1): 0.40; 1H NMR (500 
MHz, d-DMSO): δ 11.88 (1H, s), 8.40 (1H, d, J = 1.4 Hz), 8.10 (1H, d, J = 2.8 Hz), 
7.64 (2H, dd, J = 3.0, 11.8 Hz), 7.59 (1H, d, J = 8.2 Hz), 7.50 (1H, dd, J = 1.7, 8.5 
Hz), 7.05 (2H, dd, J = 3.0, 11.8 Hz), 3.80 (3H, s); 13C NMR (125 MHz, d-DMSO): δ 
158.4, 151.4, 135.7, 133.9, 133.3, 128.0, 127.7, 125.1, 121.9, 117.7, 114.4, 112.7, 
99.9, 55.2; HRMS (ESI+) Calc. for C16H13N5O [M + Na]+ 314.1012, found 
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314.1016. IR (neat, cm-1): 3299, 2836, 1626, 800. 
 
4-(3-(1H-tetrazol-5-yl)-1H-indol-5-yl)phenol (120f) 
 
This compound was prepared according to general procedure D by treating 119k (58 
mg, 0.2 mmol) with BBr3 (1.2 mL, 1.2 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 50:1 → 10:1) to give the product as a white 
solid (39 mg, 70%). m.p. 225−227 °C; Rf (CH2Cl2/MeOH 20:1): 0.20; 1H NMR (400 
MHz, d-DMSO): δ 11.84 (1H, s), 9.48 (1H, s), 8.37 (1H, s), 8.07 (1H, d, J = 2.8 Hz), 
7.57−7.52 (3H, m), 7.47 (1H, dd, J = 1.6, 8.5 Hz), 6.88 (2H, d, J = 8.6 Hz), NH of 
tetrazole signal not observed; 13C NMR (100 MHz, d-DMSO): δ 156.9, 152.1, 135.9, 
133.9, 132.7, 128.3, 127.8, 125.5, 122.0, 117.9, 116.1, 113.0, 100.6; HRMS (ESI+) 
Calc. for C15H11N5O [M + Na]+ 300.0856, found 300.0854. IR (neat, cm-1): 3568, 
3370, 3177, 2901, 2850, 1599, 1473, 1211, 806. HPLC: 97.7% (HPLC Method A), 
RT: 18.3 min. 
 
5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridine (121) 
 
This compound was prepared according to step 2 in general procedure A by treating 
25a (197 mg, 1.0 mmol) with TsCl (228 mg, 1.2 mmol). The crude product was 
purified by flash chromatography (hexane/ethyl acetate 20:1 → 10:1) to give the 
product as a white solid (316 mg, 90%). m.p. 140−141 °C; Rf (hexane/ethyl acetate 
12:1): 0.50; 1H NMR (300 MHz, CDCl3): δ 8.41 (1H, d, J = 2.1 Hz), 8.05 (2H, d, J = 
8.2 Hz), 7.87 (1H, d, J = 2.1 Hz), 7.73 (1H, d, J = 4.0 Hz), 7.23 (2H, d, J = 8.2Hz), 
6.51 (1H, d, J = 4.0 Hz), 2.29 (3H, s); 13C NMR (75 MHz, CDCl3): δ 145.3, 145.1, 
145.0, 134.8, 131.5, 129.5, 127.8, 127.7, 124.2, 114.9, 104.4, 21.4; HRMS (ESI+) 
Calc. for C14H11N2O2BrS [M + Na]+ 372.9617/374.9596, found 372.9619/374.9599. 
IR (neat, cm-1): 1592, 1438, 1153, 664. 
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1-tosyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (122) 
 
This compound was prepared following a literature procedure.281 To a solution of 121 
(1.0 equvi, 500 mg), Pd(OAc)2 (5 mol%, 16 mg), dppf (10 mol%, 79 mg) and i-
Pr2NEt (5.0 equiv., 1.24 mL) in DMF (0.05 M) was added acetic-formic anhydride 
(5.0 equiv., 626 mg) which was freshly prepared by treating the Ac2O (5.0 equiv., 673 
µL) with formic acid (5.0 equiv., 251 µL) at 65 °C for 30 min,334 the resulting mixture 
was heated to 110 °C for 5 h. After completion monitored by TLC, the reaction 
mixture was cooled to RT and diluted with ethyl acetate (30 mL) and quenched with 
aq. KOH (20%, 10 mL) to adjust pH = 9, the aqueous layer was collected and 
acidified by aq. HCl (32%) to adjust pH 4−6, and the corresponding acid was 
precipitated and filtered to get the product as a white powder (374 mg, 83%) without 
further purification. m.p. 175−176 °C; Rf (hexane/ethyl acetate 1:1): 0.25; 1H NMR 
(300 MHz, d-DMSO): δ 13.28 (1H, s), 8.88 (1H, d, J = 2.0 Hz), 8.56 (1H, d, J = 2.0 
Hz), 8.03−8.00 (3H, m), 7.42 (2H, d, J = 8.2 Hz), 6.93 (1H, d, J = 4.0 Hz), 2.33 (3H, 
s); 13C NMR (75 MHz, d-DMSO): δ 166.3, 148.2, 145.9 (two overlapping signals), 
134.3, 131.6, 130.1, 128.3, 127.6, 122.4, 122.1, 106.5, 21.1; HRMS (ESI+) Calc. for 
C15H12N2O4S [M + Na]+ 339.0410, found 339.0409. IR (neat, cm-1): 3146, 3102, 
2854, 1680, 1528, 1192, 669, 589. 
 
General procedure Y for amide coupling reactions by utilising coupling reagent 
 
To a solution of carboxylic acid (1.0 equiv.) in DMSO (0.05 M) was added HBTU 
(1.2 equiv.) under nitrogen at 0 °C, followed by the addition of i-Pr2NEt (2.5 equiv.) 
and aniline (1.1 equiv.). The reaction mixture was allowed to warm to RT for 2 h. 
after completion monitored by TLC, the mixture was extracted with ethyl acetate (3 x 
10 mL) and H2O (15 mL), and the combined organic layers were dried over MgSO4 
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and concentrated in vacuo.  
 
N-(4-((tert-butyldimethylsilyl)oxy)phenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine-5-
carboxamide (123a) 
 
This compound was prepared according to general procedure Y by treating 122 (158 
mg, 0.5 mmol) with 34a (123 mg, 0.55 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 5:1 → 3:1) to give the product as a white 
solid (159 mg, 61%). m.p. 190−192 °C; Rf (hexane/ethyl acetate 2:1): 0.35; 1H NMR 
(300 MHz, CDCl3): δ 8.81 (1H, d, J = 2.1 Hz), 8.26 (1H, d, J = 2.1 Hz), 8.06−8.03 
(3H, m), 7.72 (1H, d, J = 4.0 Hz), 7.48 (2H, d, J = 8.8 Hz), 7.26 (2H, d, J = 8.1 Hz), 
6.82 (2H, dd, J = 2.1, 6.7 Hz), 6.55 (1H, d, J = 4.0 Hz), 2.36 (3H, s), 0.98 (9H, s), 
0.19 (6H, s); 13C NMR (75 MHz, CDCl3): δ 164.5, 152.9, 148.3, 145.8, 143.7, 135.1, 
131.5, 129.9, 129.1, 128.3, 127.9, 126.7, 122.4, 122.1, 120.6, 105.6, 25.8, 21.8, 18.3, 
−4.3; HRMS (ESI+) Calc. for C27H31N3O4SSi [M + Na]+ 544.1697, found 544.1693. 
IR (neat, cm-1): 3363, 2954, 2855, 1672, 1508, 1155, 997. 
 
N-(3-((tert-butyldimethylsilyl)oxy)phenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine-5-
carboxamide (123b) 
 
This compound was prepared according to general procedure Y by treating 122 (158 
mg, 0.5 mmol) with 34b (123 mg, 0.55 mmol). The crude product was purified by 
flash chromatography (hexane/ethyl acetate 5:1 → 3:1) to give the product as a white 
solid (206 mg, 79%). m.p. 105−107 °C; Rf (hexane/ethyl acetate 2:1): 0.35; 1H NMR 
(300 MHz, CDCl3): δ 8.82 (1H, d, J = 1.7 Hz), 8.62 (1H, s), 8.22 (1H, d, J = 1.7 Hz), 
8.06 (2H, d, J = 8.2 Hz), 7.65 (1H, d, J = 4.0 Hz), 7.41−7.39 (1H, m), 7.28−7.25 (3H, 
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m), 7.18 (1H, t, J = 8.0 Hz), 6.67−6.65 (1H, m), 6.46 (1H, d, J = 4.0 Hz), 2.38 (3H, s), 
1.00 (9H, s), 0.23 (6H, s); 13C NMR (75 MHz, CDCl3): δ 164.9, 156.2, 148.0, 145.7, 
144.0, 139.1, 134.8, 129.8, 129.6, 128.9, 128.1, 127.5, 126.6, 122.0, 116.4, 113.2, 
112.3, 105.5, 25.7, 21.6, 18.2, −4.4; HRMS (ESI+) Calc. for C27H31N3O4SSi [M + 
Na]+ 544.1697, found 544.1694.  IR (neat, cm-1): 2952, 2929, 2857, 1596, 1374, 
1191, 838, 578. 
 
N-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (124a) 
 
This compound was prepared according to general procedure C by treating 123a 
(104 mg, 0.2 mmol) with KOH (56 mg, 1 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 50:1 → 30:1) to give the product, including 
TBS deprotection, as a pale yellow solid (49 mg, 96%). m.p. 295−297 °C; Rf 
(hexane/ethyl acetate 1:1): 0.20; 1H NMR (300 MHz, d-DMSO): δ 11.94 (1H, s), 
10.04 (1H, s), 9.24 (1H, s), 8.81 (1H, s), 8.53 (1H, s), 7.57−7.54(3H, m), 6.75 (2H, d, 
J = 8.4 Hz), 6.59 (1H, d, J = 3.0 Hz); 13C NMR (75 MHz, d-DMSO): δ 164.7, 153.6, 
149.5, 142.7, 130.9, 127.8, 127.6, 122.9, 122.2, 118.7, 115.0, 100.9; HRMS (ESI+) 
Calc. for C14H11N3O2 [M + Na]+ 276.0743, found 276.0742. IR (neat, cm-1): 3334, 
3114, 2863, 1636, 1535, 1235, 752. 
 
N-(3-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (124b) 
 
This compound was prepared according to general procedure C by treating 123b 
(104 mg, 0.2 mmol) with KOH (56 mg, 1 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 50:1 → 30:1) to give the product, including 
TBS deprotection, as a pale yellow solid (48 mg, 94%). m.p. 290−295 °C; Rf 
(hexane/ethyl acetate 1:1): 0.20; 1H NMR (400 MHz, d-DMSO): δ 11.95 (1H, s), 
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10.13 (1H, s), 9.38 (1H, s), 8.80 (1H, d, J = 2.2 Hz), 8.54 (1H, d, J = 1.8 Hz), 7.59 
(1H, dd, J = 2.5, 3.4 Hz), 7.39 (1H, t, J = 2.1 Hz), 7.20−7.17 (1H, m), 7.11 (1H, t, J = 
8.0 Hz), 6.60 (1H, dd, J = 1.8, 3.4 Hz), 6.50 (1H, ddd, J = 1.0, 2.4, 8.0 Hz); 13C NMR 
(100 MHz, d-DMSO): δ 165.7, 158.0, 150.1, 143.3, 140.9, 129.7, 128.5, 128.2, 123.3, 
119.1, 111.5, 111.1, 107.9, 101.5; HRMS (ESI+) Calc. for C14H11N3O2 [M + Na]+ 
276.0743, found 276.0741. IR (neat, cm-1): 3343, 3283, 3135, 2882, 1619, 1597, 
1441, 1212, 760. 
 
General procedure Z for iodination 
 
To a solution of 124a−b (1.0 equiv.) in dry DMF (0.05 M) was added KOH (5.0 
equiv.) under nitrogen atmosphere at RT, after 10 min, a solution of I2 (1.2 equiv.) in 
DMF (0.6 M) was added dropwise, and the resulting mixture was stirred at RT for 2 
h. After completion monitored by TLC, the reaction was quenched with sat. Na2S2O3 
(aq.), and extracted with ethyl acetate (3 x 10 mL), the organic layers were dried over 
MgSO4 and concentrated in vacuo. 
 
N-(4-hydroxyphenyl)-3-iodo-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (125a) 
 
This compound was prepared according to general procedure Z by treating 124a (51 
mg, 0.2 mmol) with I2 (61 mg, 0.24 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 50:1) to give the product as a white solid (65 mg, 
86%). m.p. 209−211 °C; Rf (CH2Cl2/MeOH 50:1): 0.20; 1H NMR (400 MHz, d-
DMSO): δ 12.46−12.32 (1H, br.s), 10.17 (1H, s), 9.30−9.21 (1H, br.s), 8.83 (1H, d, J 
= 2.1 Hz), 8.29 (1H, d, J = 2.1 Hz), 7.83 (1H, s), 7.55 (2H, dd, J = 2.1, 6.8 Hz), 6.75 
(2H, dd, J = 2.1, 6.8 Hz); 13C NMR (100 MHz, d-DMSO): δ 164.1, 153.7, 149.2, 
143.9, 132.1, 130.7, 127.7, 123.7, 122.4, 121.1, 115.0, 55.7; HRMS (ESI+) Calc. for 
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C14H10N3O2I [M + Na]+ 401.9710, found 401.9708. IR (neat, cm-1): 3276, 3108, 
2921, 1534, 1292, 1167. 
 
N-(3-hydroxyphenyl)-3-iodo-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (125b) 
 
This compound was prepared according to general procedure Z by treating 124b (51 
mg, 0.2 mmol) with I2 (61 mg, 0.24 mmol). The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 50:1) to give the product as a white solid (61 mg, 
80%). m.p. 205−208 °C; Rf (CH2Cl2/MeOH 50:1): 0.20; 1H NMR (300 MHz, d-
DMSO): δ 12.40 (1H, br.s), 10.26 (1H, s), 9.41 (1H, br.s), 8.84 (1H, d, J = 1.8 Hz), 
8.30 (1H, d, J = 1.8 Hz), 7.85 (1H, s), 7.39−7.38 (1H, m), 7.20−7.10 (2H, m), 6.52 
(1H, d, J = 7.6 Hz); 13C NMR (75 MHz, d-DMSO): δ 164.6, 157.5, 149.3, 144.1, 
140.2, 132.2, 129.2, 127.9, 123.6, 121.1, 111.2, 110.8, 107.6, 55.8; HRMS (ESI+) 
Calc. for C14H10N3O2I [M + Na]+ 401.9710, found 401.9709. IR (neat, cm-1): 3103, 
3068, 2981, 2851, 1553, 1272, 773, 683. 
 
N,3-bis(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (126a) 
 
This compound was prepared according to general procedure F by treating 125a (25 
mg, 0.1 mmol) with (4-hydroxyphenyl)boronic acid (17 mg, 0.12 mmol) in 
toluene/ethanol 3:1 at 100 °C. The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 50:1→ 10:1) to give the product as a pale yellow 
solid (22 mg, 65%). m.p. 210−212 °C; Rf (CH2Cl2/MeOH 20:1): 0.30; 1H NMR (500 
MHz, d-DMSO): δ 12.04 (1H, s), 10.11 (1H, s), 9.42 (1H, br.s), 9.25 (1H, br.s), 8.82 
(1H, d, J = 2.0 Hz), 8.73 (1H, d, J = 2.0 Hz), 7.78 (1H, s), 7.57 (2H, d, J = 8.6 Hz), 
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7.53 (2H, d, J = 8.9 Hz), 6.88 (2H, d, J = 8.6 Hz), 6.75 (2H, d, J = 8.9 Hz); 13C NMR 
(125 MHz, d-DMSO): δ 164.7, 156.0, 153.6, 150.0, 143.0, 130.7, 127.8, 127.2, 127.0, 
125.3, 123.7, 122.9, 122.4, 116.4, 115.7, 115.0; HRMS (ESI+) Calc. for C20H15N3O3 
[M + Na]+ 368.1004, found 368.1006. IR (neat, cm-1): 3334, 3011, 1636, 1535, 
1235. HPLC: 98.8% (HPLC Method A), RT: 16.8 min. 
 
N-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-5-
carboxamide (126b) 
 
This compound was prepared according to general procedure F by treating 125b (25 
mg, 0.1 mmol) with (4-hydroxyphenyl)boronic acid (17 mg, 0.12 mmol) in 
toluene/ethanol 3:1 at 100 °C. The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 50:1 → 10:1) to give the product as a pale yellow 
solid (21 mg, 60%). m.p. 197−200 °C; Rf (CH2Cl2/MeOH 20:1): 0.30; 1H NMR (500 
MHz, d-DMSO): δ 12.04 (1H, s), 10.18 (1H, s), 9.39 (2H, br.s), 8.80 (1H, d, J = 2.0 
Hz), 8.71 (1H, d, J = 2.0 Hz), 7.76 (1H, s), 7.56 (2H, ddd, J = 2.0, 2.9, 6.6 Hz), 7.34 
(1H, t, J = 2.1 Hz), 7.17−7.15 (1H, s), 7.10 (1H, t, J = 8.0 Hz), 6.87 (2H, ddd, J = 2.0, 
2.9, 6.6 Hz), 6.50−6.48 (1H, m); 13C NMR (125 MHz, d-DMSO): δ 165.2, 157.5, 
156.0, 150.0, 143.1, 140.3, 129.2, 127.9, 127.2, 125.2, 123.7, 122.9, 116.3, 115.8, 
115.7, 111.2, 110.7, 107.5; HRMS (ESI+) Calc. for C20H15N3O3 [M + Na]+ 
368.1004, found 368.1006. IR (neat, cm-1): 3214, 2920, 2851, 1609, 1494, 1312. 
HPLC: 97.8% (HPLC Method A), RT: 17.7 min. 
 
5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (127) 
 
To a solution of 25a (1 g, 5.0 mmol) in dry CH2Cl2 (0.1 M) was added AlCl3 (1.67 g, 
12.5 mmol) at 0 °C under nitrogen atmosphere. After 10 min, trichloroacetyl chloride 
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(670 µL, 6 mmol) was added dropwise, and the resulting mixture was allowed to 
warm to RT for 2 h. After completion monitored by TLC, the reaction was quenched 
with cold water (20 mL), and extracted with CH2Cl2 (3 x 10 mL), the organic layers 
were dried over MgSO4 and concentrated in vacuo. The crude intermediate was 
treated with aq. NaOH (3 M, 30 mL), and stirred at RT for 3 h. After completion 
monitored by TLC, the resulting mixture was added aq. HCl (32%) dropwise at 0 °C 
to adjust pH = 4−6, and the resulting precipitate was filtered and washed by H2O and 
hexane, dried in vacuo to give the product as a pale yellow solid (856 mg, 70% over 
two steps). Rf (CH2Cl2/MeOH 50:1): 0.25; 1H NMR (500 MHz, d-DMSO): δ 12.65 
(1H, s), 12.40 (1H, s), 8.41 (1H, d, J = 2.8 Hz), 8.39 (1H, d, J = 2.8 Hz), 8.20 (1H, d, 
J = 3.7 Hz); 13C NMR (125 MHz, d-DMSO): δ 164.9, 147.1, 143.8, 134.2, 130.5, 
120.0, 112.8, 106.0. HRMS (ESI+) Calc. for C8H5N2O2Br [M + H]+ 
240.9607/242.9587, found 240.9606/242.9585. The spectroscopic data matched that 
reported in the literature.335  
 
 
5-bromo-N-(4-((tert-butyldimethylsilyl)oxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-
carboxamide (128a) 
 
This compound was prepared according to general procedure Y by treating 127 (120 
mg, 0.5 mmol) with 34a (123 mg, 0.55 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a pale 
yellow solid (156 mg, 70%). m.p. 270−272 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H 
NMR (500 MHz, d-DMSO): δ 12.47 (1H, br.s), 9.76 (1H, s), 8.61 (1H, d, J = 2.9 Hz), 
8.43 (1H, d, J = 1.7 Hz), 8.38 (1H, d, J = 2.9 Hz), 7.60 (2H, dd, J = 3.2, 11.3 Hz), 
6.83 (2H, ddd, J = 2.6, 4.2, 6.8 Hz), 0.96 (9H, s), 0.19 (6H, s); 13C NMR (125 MHz, 
d-DMSO): δ 161.8, 150.7, 146.8, 143.7, 133.0, 131.1, 130.3, 121.5, 120.4, 120.0, 
112.4, 109.1, 25.6, 17.9, −4.5; HRMS (ESI+) Calc. for C20H24N3O2BrSi [M + Na]+ 
N NH
O NH
Br
OTBS
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468.0713/470.0693, found 468.0711/470.0690. IR (neat, cm-1): 2924, 2853, 1614, 
1508, 1291.  
 
5-bromo-N-(3-((tert-butyldimethylsilyl)oxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-
carboxamide (128b) 
 
This compound was prepared according to general procedure Y by treating 127 (120 
mg, 0.5 mmol) with 34b (123 mg, 0.55 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 100:1 → 50:1) to give the product as a pale 
yellow solid (167 mg, 75%). m.p. 234−235 °C; Rf (CH2Cl2/MeOH 20:1): 0.45; 1H 
NMR (300 MHz, d-DMSO): δ 12.52 (1H, s), 9.80 (1H, s), 8.63 (1H, d, J = 2.1 Hz), 
8.48 (1H, s), 8.39 (1H, d, J = 2.1 Hz), 7.41-7.40 (1H, m), 7.36 (1H, d, J = 8.2 Hz), 
7.19 (1H, t, J = 8.0 Hz), 6.54 (1H, dd, J = 1.4, 8.0 Hz), 0.97 (9H, s), 0.21 (6H, s); 13C 
NMR (75 MHz, d-DMSO): δ 162.1, 155.2, 146.9, 143.8, 140.5, 131.1, 130.7, 129.4, 
120.5, 114.4, 112.9, 112.5, 111.3, 109.0, 25.5, 17.9, −4.5; HRMS (ESI+) Calc. for 
C20H24N3O2BrSi [M + Na]+ 468.0713/470.0693, found 468.0710/470.0690. IR (neat, 
cm-1): 3362, 3091, 2927, 1637, 1536, 837. 
 
N-(4-((tert-butyldimethylsilyl)oxy)phenyl)-5-(4-hydroxyphenyl)-1H-pyrrolo[2,3-
b]pyridine-3-carboxamide (129a) 
 
This compound was prepared according to general procedure F by treating 128a (89 
mg, 0.2 mmol) with (4-hydroxyphenyl)boronic acid (33 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 100 °C. The crude product was purified by flash 
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chromatography (CH2Cl2/MeOH 50:1 → 20:1) to give the product as a pale yellow 
solid (58 mg, 63%). m.p. 274−275 °C; Rf (CH2Cl2/MeOH 20:1): 0.35; 1H NMR (400 
MHz, d-DMSO): δ 12.24−12.23 (1H, br.s), 9.73 (1H, s), 9.55 (1H, s), 8.60 (1H, d, J = 
2.2 Hz), 8.52 (1H, d, J = 2.2 Hz), 8.38 (1H, d, J = 3.0 Hz), 7.62 (2H, dd, J = 2.2, 6.8 
Hz), 7.52 (2H, dd, J = 2.0, 6.6 Hz), 6.89 (2H, dd, J = 2.0, 6.6 Hz), 6.83 (2H, dd, J = 
2.2, 6.8 Hz), 0.96 (9H, s), 0.18 (6H, s); 13C NMR (100 MHz, d-DMSO): δ 162.4, 
156.9, 150.6, 147.6, 142.3, 133.3, 129.9, 129.4, 129.3, 128.1, 126.4, 121.5, 119.7, 
118.7, 115.9, 109.5, 25.6, 17.9, −4.5; HRMS (ESI+) Calc. for C26H29N3O3Si [M + 
Na]+ 482.1870, found 482.1867. IR (neat, cm-1): 3231, 2954, 1508, 1262. 
 
N-(3-((tert-butyldimethylsilyl)oxy)phenyl)-5-(4-hydroxyphenyl)-1H-pyrrolo[2,3-
b]pyridine-3-carboxamide (129b) 
 
This compound was prepared according to general procedure F by treating 128b (89 
mg, 0.2 mmol) with (4-hydroxyphenyl)boronic acid (33 mg, 0.24 mmol) in 
toluene/ethanol 3:1 at 100 °C. The crude product was purified by flash 
chromatography (CH2Cl2/MeOH 50:1 → 20:1) to give the product as a pale yellow 
solid (56 mg, 61%). m.p. 242−244 °C; Rf (CH2Cl2/MeOH 20:1): 0.35; 1H NMR (400 
MHz, d-DMSO): δ 12.29 (1H, s), 9.76 (1H, s), 9.55 (1H, s), 8.59 (1H, d, J = 2.2 Hz), 
8.53 (1H, d, J = 2.3 Hz), 8.43 (1H, d, J = 2.9 Hz), 7.53 (2H, d, J = 8.6 Hz), 7.42 (1H, 
t, J = 2.1 Hz), 7.40−7.38 (1H, m), 7.20 (1H, t, J = 8.1 Hz), 6.90 (2H, d, J = 8.6 Hz), 
6.56−6.54 (1H, m), 0.98 (9H, s), 0.23 (6H, s); 13C NMR (100 MHz, d-DMSO): δ 
162.6, 156.9, 155.2, 147.6, 142.4, 140.8, 130.0, 129.7, 129.4, 129.3, 128.1, 126.4, 
118.7, 115.9, 114.2, 112.9, 111.2, 109.4, 25.6, 17.9, −4.5; HRMS (ESI+) Calc. for 
C26H29N3O3Si [M + Na]+ 482.1870, found 482.1866. IR (neat, cm-1): 3392, 2953, 
2851, 1588, 1203, 830. 
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N,5-bis(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (130a) 
 
 
This compound was prepared according to general procedure G by treating 129a (46 
mg, 0.1 mmol) with TBAF (0.2 mL, 0.2 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 20:1 → 10:1) to give the product as a pale 
yellow solid (32 mg, 93%). m.p. 225−227 °C; Rf (CH2Cl2/MeOH 10:1): 0.30; 1H 
NMR (400 MHz, d-DMSO): δ 12.21−12.20 (1H, br.s), 9.64 (1H, s), 9.54 (1H, s), 9.17 
(1H, s), 8.60 (1H, d, J = 2.2 Hz), 8.51 (1H, d, J = 2.2 Hz), 8.38 (1H, d, J = 2.8 Hz), 
7.52 (4H, d, J = 8.6 Hz), 6.89 (2H, d, J = 8.6 Hz), 6.74 (2H, d, J = 8.8 Hz); 13C NMR 
(100 MHz, d-DMSO): δ 162.3, 156.9, 153.2, 147.6, 142.2, 131.0, 129.9, 129.5, 129.1, 
128.1, 126.4, 121.9, 118.8, 115.9, 115.0, 109.6; HRMS (ESI+) Calc. for C20H15N3O3 
[M + Na]+ 368.1006, found 368.1006. IR (neat, cm-1): 3090, 2960, 2873, 1511, 
820. HPLC: 99.7% (HPLC Method A), RT: 16.3 min. 
 
N-(3-hydroxyphenyl)-5-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-
carboxamide (130b) 
 
This compound was prepared according to general procedure G by treating 129b (46 
mg, 0.1 mmol) with TBAF (0.2 mL, 0.2 mmol). The crude product was purified by 
flash chromatography (CH2Cl2/MeOH 20:1 → 10:1) to give the product as a pale 
yellow solid (33 mg, 95%). m.p. 280−284 °C; Rf (CH2Cl2/MeOH 10:1): 0.30; 1H 
NMR (400 MHz, d-DMSO): δ 12.25 (1H, d, J = 2.5 Hz), 9.70 (1H, s), 9.55 (1H, s), 
9.34 (1H, s), 8.60 (1H, d, J = 2.3 Hz), 8.52 (1H, d, J = 2.3 Hz), 8.43 (1H, d, J = 2.9 
N NH
O NHHO
OH
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Hz), 7.52 (2H, dd, J = 2.0, 6.6 Hz), 7.37 (1H, t, J = 2.0 Hz), 7.15 (dt, 1H, J = 1.1, 8.0 
Hz), 7.10 (1H, t, J = 8.0 Hz), 6.90 (2H, dd, J = 2.0, 6.6 Hz), 6.48−6.45 (1H, m); 13C 
NMR (100 MHz, d-DMSO): δ 162.6, 157.5, 157.0, 147.6, 142.4, 140.6, 130.0, 129.6, 
129.5, 129.2, 128.1, 126.4, 118.8, 116.0, 110.6, 110.1, 109.5, 107.0; HRMS (ESI+) 
Calc. for C20H15N3O3 [M + Na]+ 368.1006, found 368.1005. IR (neat, cm-1): 3393, 
3091, 2921, 1639, 1365. HPLC: 99.5% (HPLC Method A), RT: 17.4 min. 
 
6.5 Biology evaluation 
 
All chemicals were obtained from Sigma Aldrich (St. Louis, MO, USA). Primary 
antibodies against DYRK1A (#8765), DYRK1B (#2703), DYRK2 (#8143) and p38α 
(#9218), secondary anti-rabbit (#7074) and anti-mouse (#7076) HRP-linked 
antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). 
EGFR (#sc03) and β-actin (#A5441) antibodies were obtained from Santa Cruz 
Biotechnology (Dallas, TX, USA) and Sigma Aldrich (St. Louis, MO, USA), 
respectively. CLK1 antibody (#ab209681) was purchased from Abcam (Cambridge, 
UK).   EGF was purchased from Life Technologies (Carlsbad, CA, USA).  
 
6.5.1 Kinase inhibition assay 
 
Active DYRK1A, DYRK1B, DYRK2 and CLK1 (all Life Technologies) were 
assayed in Tris buffer (50 mM Tris-HCl, pH 7.5) containing 0.1 mM EGTA, 15 mM 
DTT, MgAc/ATP cocktail (0.5 mM HEPES pH 7.4; 10 mM Mg(CH3COO)2; 0.1 mM 
ATP), [γ-32P]-ATP 100−300 cpm/pmol and test compounds diluted in deionised 
water. As substrate, Woodtide (50 µM, Genscript) was used in DYRK1A, DYRK1B 
and DYRK2 activity assays, and RS repeat peptide [KKGRSRSRSRSRSR] (20 µM, 
Genscript) was used in CLK1 activity assays. The reaction was initiated with 1 ng/µL 
DYRK1A or 0.5 ng/µL DYRK1B, DYRK2 and CLK1. The reaction mixture was 
incubated at 30 °C for 10 min (DYRK1A) or 40 min (DYRK1B, DYRK2, CLK1) 
Reaction was stopped by pipetting 10 µL of the reaction mixture onto P81 paper 
(Reaction Biology) and washing with 0.75% w/v H3PO4 and acetone. P81 papers were 
transferred to sample bags containing Optiphase Supermix scintillation cocktail 
ν
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(Perkin Elmer) and radioactivity (cpm) was measured with MicroBeta Trilux 2 
counter (Perkin Elmer). Compounds that inhibited DYRK1A activity by more than 
50% at 10 µM were tested in an eight-point serial dilution at a Log3 scale. Data were 
normalised to controls (set as 100% activity) and IC50 values calculated by non-linear 
regression analysis using GraphPad Prism 6.0 (GraphPad, La Jolla, CA, USA). IC50 
values represent mean ± SEM from 3 independent experiments performed in 
triplicate. 
 
6.5.2 Cell culture 
 
U251 and A172 cell lines were obtained from the European Collection of Cell 
Cultures (EACC, Salisbury, UK) through Cell Bank Australia in 2014. Cells were 
cultured in DMEM medium supplemented with 10% FBS and Antibiotic-Antimycotic 
(both Life Technologies) at 37 °C and 5% CO2. Primary glioblastoma cell lines (RN1, 
JK2, WK1, SJH1) were derived from glioblastoma specimens, characterised as 
described291-292 and cultured in KnockOut DMEM/F-12 basal medium supplemented 
with StemPro NSC SFM supplement, 2 mM GlutaMAX-ICTS, 20 ng/mL EGF, 10 
ng/mL FGF-β and Antibiotic-Antimycotic solution (all Life Technologies) as 
adherent cells on flasks coated with MatriGel Matrix (BD Falcon). The protocols 
were approved by the Human Ethics Committee of the University of Sydney 
(HREC2013/131) and the Human Ethics Committee of the Royal Brisbane & 
Women’s Hospital (RBWH 2004/161). All cell cultures were routinely tested for 
mycoplasma infection and the cumulative length of culturing did not exceed 10 
passages. 
 
6.5.2.1 Cell viability assay 
 
U251, A172, RN1, WK1 (2 x 103 cells/well) and JK2, SJH1 (4 x 103 cells/well) were 
seeded in 96-well plate and treated on the following day with vehicle or test 
compounds (0.001−50 µM) for 3 days (U251, A172, RN1, JK2) or 5 days (WK1, 
SJH1). 10 µL of Cell-Titer Blue reagent (Promega, WI, USA) was added to each well 
and incubated at 37 °C for 4 h. Fluorescence was measured with Tecan M200 PRO+ 
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microplate reader (Tecan, Switzerland) at 585 nm. Data were normalised to controls 
(set as 100% viability) and EC50 values calculated by non-linear regression analysis 
using GraphPad Prism 6.0 (GraphPad, La Jolla, CA, USA). EC50 values represent 
mean ± SEM from 3 independent experiments performed in triplicate.  
 
6.5.2.2 Clonogenic survival 
 
RN1 (2 x 103 cells/well) and U251 (0.5 x103 cells/well) were seeded onto 6-well 
plates and treated on the following day with vehicle or test compounds (0.01−5 µM). 
Cells were grown for 12 days, fixed with 50% methanol and stained with Toluidine 
Blue (Sigma Aldrich). Colonies were counted using the ImageJ software (Colony 
Area function). Data were normalised to controls (set as 100% survival) and EC50 
values calculated by non-linear regression analysis using GraphPad Prism 6.0 
(GraphPad, La Jolla, CA, USA). EC50 values represent mean ± SEM from 3 
independent experiments performed in duplicate. One-way ANOVA, followed by 
Dunnett’s multiple comparison test (GraphPad Prism 6.0) was used to determine 
statistical significance. P < 0.05 was considered as significant.  
 
6.5.2.3 Migration and invasion assays 
 
U251 (1.7 x 103 cells/well), A172 (1.5 x 103 cells/well) and RN1 (2.0 x 103 cells/well) 
were seeded onto ImageLock 96-well plates (IncuCyte). For RN1 cells, the plates 
were pre-coated with MatriGel Matrix (BD Falcon). After 24 h, each well was 
scratched using the WoundMaker (IncuCyte) and washed with Dulbecco’s PBS 
(Sigma Aldrich). Migration assays were performed in 1% FBS in DMEM (A172, 
U251) or 0.2% neural supplement in StemPro NSC SFM (RN1) containing test 
compounds or DMSO (control). For the invasion assays, 45 µL of MatriGel Matrix 
and 5 µL of 10x inhibitor (or DMSO) were added to each well and allowed to solidify 
at 37 °C for 30−60 min. Once the Matrigel Matrix was set, cells were treated with test 
compounds or DMSO in 1% FBS in DMEM (A172, U251). The plates were imaged 
over 72 h (IncuCyte) and the relative wound density (RWD, defined as the cumulative 
increase of wound confluence as a percentage over time) was analysed with IncuCyte 
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Zoom software. Velocity (µm/h) was calculated between 0−20 h, where the RWD 
curves were steep and their slopes constant, following the Wound Healing Data 
analysis (ibidi GmbH, Version 1.2; http://tinyurl.com/gv6ehvo).  
 
6.5.2.4 Transient DYRK1A knockdown and EGFR degradation assays 
 
U251 (7−9 x105 cells/well) were plated on 6-well plates and incubated overnight or 
until 60−70% confluence. Cells were washed with PBS and treated with transfection 
medium containing 10 nM siRNA-DYRK1A (5’ – CCGUAAACUUCAUAACAUUtt 
– 3’) or 10 nM siRNA-Ctr (both Ambion Silencer Select) diluted in RNAiMAX®, 
Opti-MEM® and serum free DMEM (all Life Technologies), according to 
manufacturer’s instructions. Cells were incubated in the transfection medium for 
12−16 h and then starved overnight in serum free DMEM. For the EGFR degradation 
assay, starved cells were incubated with cycoheximide (2 µg/mL, 2 h) and treated 
with EGF (100 ng/mL). Cells were lysed at indicated time points with lysis buffer (1 
M Tris, 0.5 M EDTA, 5 M NaCl, 1 M MgCl2, Triton X-100, 0.5 M NaF, 10 % v/v 
glycerol, 1 mM PMSF, 1mM Na3VO4) supplemented with protease inhibitor cocktail 
(Roche), the protein concentration in lysates was determined with the BCA Protein 
Assay Kit (Life Technologies) and samples were analysed by Western blotting.  
 
6.5.4.2.1 EGFR degradation assay upon drug treatment 
 
U251 (3 x 105 cells/well) were seeded onto 6-well plates and starved in serum free 
DMEM overnight. Starved cells were incubated with test compounds (2.5 µM) or 
DMSO (control), treated with cycloheximide (30 µg/mL; 1 h) and EGF (100 ng/mL) 
for indicated time points. Cells were lysed with lysis buffer (as above), protein 
concentration was determined with the BCA Protein Assay Kit (Life Technologies) 
and samples were analysed by Western blotting.  
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6.5.4.2.2 Cellular thermal shift assay 
 
U251 (8 x 106 cells/plate) were seeded onto 100 mm Petri dishes and incubated 
overnight. Cells were treated with test compound (10 µM) or DMSO for 1 h, 
harvested, washed with PBS and resuspended in PBS containing protease inhibitor 
cocktail (Roche). Cell suspensions were divided into 100 µL aliquots in 0.2 mL PCR 
tubes. Each tube was heated at indicated temperatures (40−70 °C) for 3 min using the 
Veriti thermal cycler (Life Technologies) followed by 3 min cooling at 25 ºC, and 
then snap-frozen using liquid nitrogen.  
 
For the ITDRF assay, U251 (8 x 106 cells/plate) were seeded onto 100 mm Petri 
dishes and incubated overnight. Cells were treated with test compound (0−20 µM) or 
DMSO for 1 h, harvested, washed with PBS and re-suspended in PBS containing 
protease inhibitor cocktail (Roche). Cell suspensions were divided into 100 µL 
aliquots in 0.2 mL PCR tubes and heated at 54 °C for 3 min using the Veriti Thermal 
Cycler (Life Technologies) followed by 3 min cooling at 25 ºC, and then snap-frozen 
using liquid nitrogen. The heat-treated cells were lysed by 3 freeze-thaw cycles using 
liquid nitrogen and 37 ºC water bath. Cell lysates were centrifuged at 15,000 rpm for 
20 min at 4 ºC. Clear supernatants were removed, subjected protein quantification 
using the BCA Protein Assay Kit (Life Technologies, following manufacturer’s 
instruction) and analysed by Western blotting. 
 
6.5.3 Western blotting 
 
Cell lysates (20−60 µg) or CETSA samples (30 µg) were resolved on 8% or 4−12% 
SDS-PAGE gels and transferred onto PVDF membranes (both Life Technologies). 
Membranes were blocked with 5% (w/v) skim milk or 15% (w/v) BSA in TBST and 
incubated with primary antibody overnight at 4 °C. After washing with TBST, 
membranes were incubated with their respective secondary antibody for 1 h at room 
temperature. Detection was performed with Immobilon Western HRP Substrate 
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Luminol-Peroxidase reagent (MerckMillipore) and the ChemiDoc MP System 
(BioRad).  
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Appendix - Selected spectra 
 
4,4'-(ethane-1,2-diylbis(azanediyl))diphenol (100a) 
1H NMR (500 MHz, d-DMSO), 13C NMR (125 MHz, d-DMSO), HPLC (Method A) 
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N-(4-(3-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)acetamide 
(120a) 
1H NMR (300 MHz, d-DMSO), 13C NMR (75 MHz, d-DMSO), HPLC (Method A) 
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N,3-bis(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (126a) 
1H NMR (500 MHz, d-DMSO), 13C NMR (125 MHz, d-DMSO), HPLC (Method A) 
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N,5-bis(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (130a) 
1H NMR (400 MHz, d-DMSO), 13C NMR (100 MHz, d-DMSO), HPLC (Method A) 
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